AUTHOR INDEX

Aapro M, *see* Nabholtz JM
Abad A, *see* Monzó M
Abbott LZ, *see* Graziano SL
Abboud CN, *see* Rapoport AP
Abdul-Karim FW, *see* Rose PG
Abeling NGGM, *see* Ahmed FY
Abeloff MD, *see* Shipp MA
Abemayor E, *see* Gritz ER
Ablin A, *see* Marina NM
Abou-Elella AA, Weisenburger DD, Vose JM, Kollath JP, Lynch JC, Bast MA, Bierman PJ, Greiner TC, Chan WC, Armitage JO. Primary Mediastinal Large B-Cell Lymphoma: A Clinicopathologic Study of 43 Patients From the Nebraska Lymphoma Study Group, 784
Abrahamsen AF, *see* Loge JH
Abrams J, Aisner J, Cirrincione C, Berry DA, Muss HB, Cooper MR, Henderson IC, Panasci L, Kirshner J, Ellerton J, Norton L. Dose-Response Trial of Megestrol Acetate in Advanced Breast Cancer: Cancer and Leukemia Group B Phase III Study 8741, 64
Abrams J, *see* Atkins MB
Abramson N, *see* Fisher B
Abreo FW, *see* Nathan C-AO
Abromowitch MA, *see* Baker KS
Abu-Saad HH, *see* de Wit R
Achterrath W, *see* Vanhoefer U
Ackland S, *see* Bishop JF
Acuña JR, *see* Acuña LR
Acuña LR, Langhi M, Pérez J, Acuña JR, Machiavelli M, Lacava J, Vallejo C, Romero A, Fasce H, Ortiz E, Grasso S, Amato S, Rodríguez R, Barbieri M, Leone B. Vinorelbine and Paclitaxel as First-Line Chemotherapy in Metastatic Breast Cancer, 74
Adak S, *see* Colevas AD
Adami HO, *see* Liljegren G
Adamo V, *see* Crinò L
Adeleine P, *see* Francois Y
Adelson MD, *see* Thigpen JT
Adjei AA, *see* Go RS
Adkins D, Brown R, Goodnough L, Khoury H, DiPersio J. Purine Analog Regimens for Allogeneic Transplant? (correspondence), 1958
Adkins D, Brown R, Trinkaus K, Maziarz R, Luedke S, Freytes C, Needles B, Wienski D, Fracasso P, Pluard T, Moriconi W, Ryan T, Hoelzer K, Safdar S, Rearden T, Rodriguez G, Khoury H, Vij R, DiPersio J. Outcomes of High-Dose Chemotherapy and Autologous Stem-Cell Transplantation in Stage IIIB Inflammatory Breast Cancer, 2006
Adkins D, *see* Brown RA
Adler LP, *see* Rose PG
Affronti ML, *see* Rizzieri DA
Afting M, *see* Engelhardt M
Agarwala SS, *see* Chapman PB
Agelidou A, *see* Georgoulias V
Agura E, *see* Jones SE
Agus DB, *see* Moskowitz CH
A'Hern RP, *see* Bonnefoi H
Ahlner-Elmqvist M, *see* Bjordal K
Ahmed FY, Johnston SJ, Cassidy J, O'Kelly T, Binnie N, Murray GI, van Gennip AH, Abeling NGGM, Knight S, McLeod HL. Eniluracil Treatment Completely Inactivates Dihydropyrimidine Dehydrogenase in Colorectal Tumors, 2439
Aisner J, *see* Abrams J
— *see* Belani CP
Aiza G, *see* Tortola S
Ajani J, *see* Rubin J
Ajani JA, Mansfield PF, Lynch PM, Pisters PW, Feig B, Dumas P, Evans DB, Raijman I, Hargraves K, Curley S, Ota DM. Enhanced Staging and All Chemotherapy Preoperatively in Patients with Potentially Resectable Gastric Carcinoma, 2403
Akazawa K, *see* Maehara Y
Aki H, *see* Ozguroglu M
Akporiaye ET, *see* Galanis E
Akslen LA, *see* Salvesen HB
Alakl M, *see* Chan S
— *see* Nabholtz JM
Alberola V, *see* Cardenal F
— *see* Monzó M
Alberti D, *see* Robins HI
Albertini P, *see* Zinzani PL
Alberts DS. A Unifying Vision of Cancer Therapy for the 21st Century, 13-21(Supp.)
Albitar M, *see* Thomas DA
Albrecht TL, Blanchard C, Ruckdeschel JC, Coovert M, Strongbow R. Strategic Physician Communication and Oncology Clinical Trials, 3324
Albright AL, *see* Zeltzer PM
Albright R, *see* Yung WKA
Aledo A, *see* Gorlick R
Aleksandrovic J, *see* Jeremic B
Allen JC, *see* Packer RJ
— *see* Zeltzer PM
Allred DC, *see* Chang J
— *see* Diab SG
— *see* Harvey JM
Alonso S, *see* Hidalgo M
Alvarez RD, *see* Thigpen JT
Alyea E, *see* Friedberg JW
Alyea EP, *see* Sehn LH
Amato S, *see* Acuña LR
American College of Radiology Task Force on Breast Cancer, Bassett LW, Cardenosa G, D'Orsi CJ, Dempsey PJ, Dershaw DD, Destouet JM, Evans WP III, Feig SA, Hendrick RE, Jackson VP, Kopans DB, Linver MN, Mendelson EB, Monsees B, Racenstein MJ, Sickles EA, Stelling CB, Warren L. Risk of Risk-Based Mammography Screening, Ages 40 to 49 (correspondence), 730
American Society of Clinical Oncology, *see* Hensley ML
Ames F, *see* Buzdar AU
Ames FC, *see* Kuerer HM
Amess J, *see* Apostolidis J
Amistá P, *see* Brandes AA
Ammassari A, *see* Antinori A
Amrein P, *see* Colevas AD
Amshey SR, *see* Carey LA
Amsterdam A, *see* Motzer RJ
Anagnostopoulos A, *see* Papadimitriou CA
Anagnostopoulos I, *see* Diehl V
— *see* Marafioti T
Andejeski Y, *see* Ritchey AK
Anderson JR, *see* Nathwani BN
— *see* Pappo AS
— *see* Smith MA
— *see* Wolden SL
Anderson S, *see* Fisher B

Anderson SJ, *see* Smith RE
André M, Henry-Amar M, Pico J-L, Brice P, Blaise D, Kuentz M, Coiffier B, Colombat P, Cahn J-Y, Attal M, Fleury J, Milpied N, Nedellec G, Biron P, Tilly H, Jouet J-P, Gisselbrecht C for the Société Francaise de Greffe de Moelle. Comparison of High-Dose Therapy and Autologous Stem-Cell Transplantation With Conventional Therapy for Hodgkin's Disease Induction Failure: A Case-Control Study, 222
André T, Bensmaine MA, Louvet C, François E, Lucas V, Desseigne F, Beerblock K, Bouché O, Carola E, Merrouche Y, Morvan F, Dupont-André G, de Gramont A. Multicenter Phase II Study of Bimonthly High-Dose Leucovorin, Fluorouracil Infusion, and Oxaliplatin for Metastatic Colorectal Cancer Resistant to the Same Leucovorin and Fluorouracil Regimen, 3560
Andreeff M, *see* Beran M
— *see* Kantarjian HM
Andrews J, *see* Rapoport AP
Andrieu JM, Yilmaz U, Colonna P. MOPP Versus ABVD and Low-Dose Versus High-Dose Irradiation in Hodgkin's Disease at Intermediate and Advanced Stages: Analysis of a Meta-Analysis by Clinicians (correspondence), 730
Androulakis N, Kourousis C, Dimopoulos MA, Samelis G, Kakolyris S, Tsavaris N, Genatas K, Aravantinos G, Papadimitriou C, Karabekios S, Stathopoulos GP, Georgoulias V. Treatment of Pancreatic Cancer With Docetaxel and Granulocyte Colony-Stimulating Factor: A Multicenter Phase II Study, 1779
Androulakis N, *see* Georgoulias V
— *see* Kouroussis C
Andrulis IL, *see* Ginsberg JP
— *see* Phillips K-A
Ang KK, *see* Garden AS
Angiolini C, *see* Esposito M
Anguiano A, *see* Espinoza F
Ansari R, *see* Einhorn L
Anthony L, *see* Rubin J
Antin JH, *see* Porter DL
— *see* Sehn LH
Antinori A, De Rossi G, Ammassari A, Cingolani A, Murri R, Di Giuda D, De Luca A, Pierconti F, Tartaglione T, Scerrati M, Larocca LM, Ortona L. Value of Combined Approach With Thallium-201 Single-Photon Emission Computed Tomography and Epstein-Barr Virus DNA Polymerase Chain Reaction in CSF for the Diagnosis of AIDS-Related Primary CNS Lymphoma, 554
Antman KH. Critique of the High-Dose Chemotherapy Studies in Breast Cancer: A Positive Look at the Data, 30-34(Supp.)
Antman KH, *see* Elias A
— *see* Grann VR
— *see* Shipp MA
Antón A, *see* Cardenal F
Antonelli G, *see* Aschele C
Antoniou F, *see* Pectasides D
Apostolidis J, Foran JM, Johnson PWM, Norton A, Amess J, Matthews J, Bradburn M, Lister TA, Rohatiner AZS. Patterns of Outcome Following Recurrence After Myeloablative Therapy With Autologous Bone Marrow Transplantation for Follicular Lymphoma, 216
Apostolopoulou F, *see* Georgoulias V
Aravantinos G, *see* Androulakis N
Arber DA, *see* Schwartz RE
Archimandritis SC, *see* Koukourakis MI
Arcusa À, *see* Cirera L
Aristei C, *see* Aversa F
Ariyoshi Y, *see* Furuse K
Arkhipov A, *see* Jones S
Armand J-P, *see* Ducreux M
Armitage JO, *see* Abou-Elella AA
— *see* Baker KS
— *see* Cheson BD
— *see* Lazarus HM
— *see* Nathwani BN
— *see* Shipp MA
Arnold A, *see* Khoo K
Aromasin Study Group, *see* Jones S
Arribas R, *see* Tortola S
Artal A, *see* Cardenal F
Arthur D, *see* Smith MA
Arzoomanian RZ, *see* Robins HI
Aschele C, Debernardis D, Casazza S, Antonelli G, Tunesi G, Baldo C, Lionetto R, Maley F, Sobrero A. Immunohistochemical Quantitation of Thymidylate Synthase Expression in Colorectal Cancer Metastases Predicts for Clinical Outcome to Fluorouracil-Based Chemotherapy, 1760
Ascierto PA, *see* Palmieri G
Ashley D, *see* Friedman HS
Ashley SE, *see* Chang J
Asmar L, *see* Buzdar AU
— *see* Vassilopoulou-Sellin R
Aspropotamitis A, *see* Pectasides D
Assersohn L, *see* Chang J
Aster JC. Lymphocyte-Predominant Hodgkin's Disease: How Little Therapy Is Enough? (editorial), 744
Astolfi M, *see* Corradini P
Astudillo J, *see* Monzó M
Ater JL, *see* Copeland DR
Athanassiou A, *see* Pectasides D
Atkins JH, *see* Smith RE
Atkins JN, *see* Fisher B
— *see* Mamounas E
— *see* Wolmark N
Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, Paradise C, Kunkel L, Rosenberg SA. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993, 2105
Atkinson R, *see* Vasey PA
Attal M, *see* André M
Atzpodien J, *see* Franzke A
Aversa F, Terenzi A, Carotti A, Felicini R, Jacucci R, Zei T, Latini P, Aristei C, Santucci A, Martelli MP, Cunningham I, Reisner Y, Martelli MF. Improved Outcome With T-Cell-Depleted Bone Marrow Transplantation for Acute Leukemia, 1545
Ayash L, *see* Elias A
Ayers D, *see* Gelmon KA
Ayoub J, Jean-François R, Cormier Y, Meyer D, Ying Y, Major P, Desjardins C, Bradley WEC. Placebo-Controlled Trial of 13-*cis*-Retinoic Acid Activity on Retinoic Acid Receptor-Beta Expression in a Population at High Risk: Implications for Chemoprevention of Lung Cancer, 3546
Azarnia N, *see* Shapiro CL
— *see* Valero V

Baas P, *see* Theuws JCM
Baba H, *see* Maehara Y
Babic B, *see* Michael M
Babin-Boilletot A, *see* Tabone M-D
Bachelot T, *see* Ray-Coquard I
Bachinsky ME, *see* Hesketh PJ
Bacigalupo A, *see* Corradini P
Bacik J, *see* Dodd PM
— *see* Motzer RJ
Badia A, *see* Cirera L
Baekelandt M, Kristensen GB, Nesland JM, Tropé CG, Holm R. Clinical Significance of Apoptosis-Related Factors *p53, Mdm2,* and *Bcl-2* in Advanced Ovarian Cancer, 2061
Baer MR, *see* Byrd JC
Baez L, *see* Smith RE
Bagiella E, *see* Petrylak DP
Bahir R, *see* Glantz MJ
Baillot A, *see* Berthold F
Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, Herr H, Higgins G, Boyle MG. Long-Term Survival in Metastatic Transitional-Cell Carcinoma and Prognostic Factors Predicting Outcome of Therapy, 3173
Bajorin DF, *see* Dodd PM
Baker KS, Gordon BG, Gross TG, Abromowitch MA, Lyden ER, Lynch JC, Vose JM, Armitage JO, Coccia PF, Bierman PJ. Autologous Hematopoietic Stem-Cell Transplantation for Relapsed or Refractory Hodgkin's Disease in Children and Adolescents, 825
Baker SD, *see* Eckhardt SG
— *see* Hammond LA
Balch CM, *see* Gershenwald JE
Baldini EH, Goldberg J, Jenner C, Manola JB, Demetri GD, Fletcher CDM, Singer S. Long-Term Outcomes After Function-Sparing Surgery Without Radiotherapy for Soft Tissue Sarcoma of the Extremities and Trunk, 3252
Baldo C, *see* Aschele C
Balil A, *see* Cirera L
Balla-Mekias S, *see* Delanian S
Ballatori E, *see* Roila F
Ballestrero A, Ferrando F, Garuti A, Basta P, Gonella R, Stura P, Mela GS, Sessarego M, Gobbi M, Patrone F. Comparative Effects of Three Cytokine Regimens After High-Dose Cyclophosphamide: Granulocyte Colony-Stimulating Factor, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF), and Sequential Interleukin-3 and GM-CSF, 1296
Ballo MT, Zagars GK, Pollack A, Pisters PWT, Pollock RA. Desmoid Tumor: Prognostic Factors and Outcome After Surgery, Radiation Therapy, or Combined Surgery and Radiation Therapy, 158
Bally MB, *see* Gelmon KA
Balog J, *see* Petrylak DP
Balsham A, *see* Einhorn L
Bamberg M, Kortmann R-D, Calaminus G, Becker G, Meisner C, Harms D, Göbel U. Radiation Therapy for Intracranial Germinoma: Results of the German Cooperative Prospective Trials MAKEI 83/86/89, 2585
Bangala C, *see* Gennari A
Barakat RR. Screening for Endometrial Cancer in the Patient Receiving Tamoxifen for Breast Cancer (editorial), 1967
Baranzelli MC, Kramar A, Bouffet E, Quintana E, Rubie H, Edan C, Patte C. Prognostic Factors in Children With Localized Malignant Nonseminomatous Germ Cell Tumors, 1212
Barbieri M, *see* Acuña LR
Barbui T, *see* Foran JM
Barclay J, *see* Esserman L
Barichello M, *see* Boccardo F
Barista I. Biphosphonates and the Flare Phenomenon (correspondence), 1326
Barlogie B, *see* Vesole DH
Barnadas A, *see* Monzó M
Barnes MJ, *see* Jacobs TW
Barneto I, *see* Cardenal F
Barnett M, *see* Macpherson N
Barni S, *see* Crinò L
Barosi G. Myelofibrosis With Myeloid Metaplasia: Diagnostic Definition and Prognostic Classification for Clinical Studies and Treatment Guidelines, 2954
Barr FG, *see* Ginsberg JP
Barreca A, *see* Decensi A
Barrett J, *see* Cheson BD
— *see* Childs RW
Bartels CCM, *see* Verhoog LC
Bartlett J, *see* Clarke K
Bartolazzi A, *see* Gasbarri A
Barton D, *see* Bonnefoi H
Barton J, *see* Colevas AD
Baselga J, *see* Hudis C
Bashford J, *see* Basser RL
Bass EB, *see* Rizzo JD
Basser RL, Bik To L, Collins JP, Begley CG, Keefe D, Cebon J, Bashford J, Durrant S, Szer J, Kotasek D, Juttner CA, Russell I, Maher DW, Olver I, Sheridan WP, Fox RM, Green MD. Multicycle High-Dose Chemotherapy and Filgrastim-Mobilized Peripheral-Blood Progenitor Cells in Women With High-Risk Stage II or III Breast Cancer: Five-Year Follow-Up, 82
Basser RL, *see* Clarke K
Basset LW, *see* American College of Radiology Task Force on Breast Cancer
Bast MA, *see* Abou-Elella AA
Basta P, *see* Ballestrero A
Batchelor T, *see* Glantz MJ
— *see* Henson JW
Batist G, *see* Gelmon K
Batiste-Alentorn E, *see* Cirera L
Battaglia M, *see* Boccardo F
Baty J, *see* Mortimer JE
Batzios S, *see* Pectasides D
Bauer J, *see* Fokkema E
Bauknecht T, *see* du Bois A
Baulieux J, *see* Francois Y
Bean JM, *see* Carter DL
Bear HD, *see* Mamounas E
—*see* Wolmark N
Beard CJ, *see* D'Amico AV
Bearden J, *see* Murray N
Bearden JD, *see* Smith RE
Beardsley GP, *see* Gorlick R
Beaupre DM, Kurzrock R. *RAS* and Leukemia: From Basic Mechanisms to Gene-Directed Therapy, 1071
Becette V, *see* Bouchet C
Becker G, *see* Bamberg M
Beckwith JB, *see* Breslow NE
Bedrosian C, *see* Rapoport AP

Beerblock K, *see* André T
Begg CB, *see* Chapman PB
Begley CG, *see* Basser RL
Begovic M, *see* Fisher B
Begrich M, *see* Heussel CP
Behm FG, *see* Pui C-H
— *see* Rubnitz JE
Behnisch W, *see* Schneider DT
Behrendt MD, *see* Nouwen JL
Beijnen JH, *see* Herben VMM
— *see* Kroep JR
Beinfield M, *see* Turner BC
Beitler J. Tamoxifen and Sexuality: Let's Listen to the Data Speak (correspondence), 3689
Beker A, *see* Debrix I
Bekkenk MW, Vermeer MH, Geerts M-L, Noordijk EM, Heule F, van Voorst Vader PC, van Vloten WA, Meijer CJLM, Willemze R. Treatment of Multifocal Primary Cutaneous B-Cell Lymphoma: A Clinical Follow-Up Study of 29 Patients, 2471
Belani CP, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Capozzoli MJ, Aisner J, Egorin MJ. Phase I Trial, Including Pharmacokinetic and Pharmacodynamic Correlations, of Combination Paclitaxel and Carboplatin in Patients With Metastatic Non-Small-Cell Lung Cancer, 676
Belhadj K, *see* Decaudin D
Belin TR, *see* Ganz PA
Belinson J, *see* Markman M
Bell DW, *see* Nichols KE
Belldegrun A, *see* Cangiano T
Belldegrun A, Tsui K-H, deKernion JB, Smith RB. Efficacy of Nephron-Sparing Surgery for Renal Cell Carcinoma: Analysis Based on the New 1997 Tumor-Node-Metastasis Staging System, 2868
Belldegrun AS, *see* Figlin RA
Belli M, *see* Frasci G
Belt RJ, *see* Royce ME
Ben-Izhack O, *see* Siegelmann-Danieli N
Bendandi M, *see* Zinzani PL
Benjamin RS, *see* Fleming JB
Benner A, *see* Deichmann M
Bennett CL, *see* Scullion B
Bennett CL, Somerfield MR. In reply (correspondence), 3360
Bennett CL, Weeks JA, Somerfield MR, Feinglass J, Smith TJ, Health Services Research Committee of ASCO, 3676
Bennett K, *see* Moore MJ
Bensmaine MA, *see* André T
Benson AB III, *see* Desch CE
Benson M, *see* Petrylak DP
Beran M, Estey E, O'Brien S, Cortes J, Koller CA, Giles FJ, Kornblau S, Andreeff M, Vey N, Pierce SR, Hayes K, Wong GC, Keating M, Kantarjian H. Topotecan and Cytarabine Is an Active Combination Regimen in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia, 2819
Beran M, *see* Kantarjian HM
Berdel WE, *see* Thomas M
Berg W, *see* Motzer RJ
Bergaglio M, *see* Esposito M
Berger MS, *see* Chang SM
Bergerat JP, *see* Escudier B
Bergh J, *see* Liljegren G
Bergman M, *see* Salminen E
Bergman W, *see* Kefford RF
Berkenblit R, *see* Wadler S
Berman RS, *see* Fleming JB
Bernard S, *see* van Deventer H
Bernard SA, *see* Blackstock AW
Bernhard J, Thurlimann B, Schmitz SFH, Castiglione-Gertsch M, Cavalli F, Morant R, Fey MF, Bonnefoi H, Goldhirsch A, Hurny C for Swiss Group for Clinical Research. Defining Clinical Benefit in Postmenopausal Patients With Breast Cancer Under Second-Line Endocrine Treatment: Does Quality of Life Matter?, 1672
Bernier J, *see* Greiner R
Beroukas K, *see* Koukourakis MI
Berry D, *see* Rizzieri DA
Berry DA, *see* Abrams J
— *see* Bluman LG
— *see* Costanza ME
— *see* Parmigiani G
Berry DL, Theriault RL, Holmes FA, Parisi VM, Booser DJ, Singletary SE, Buzdar AU, Hortobagyi GN. Management of Breast Cancer During Pregnancy Using a Standardized Protocol, 855
Berthelsen JG, *see* Petersen PM
Berthold F, Baillot A, Hero B, Schurr P, Nerenz A, Hunneman DH, Sander J. Which Cases Are Found and Missed by Neuroblastoma Screening at 1 Year? Results From the 1992 to 1995 Study in Three Federal States of Germany, 1200
Berti F, *see* Brandes AA
Bertino JR, *see* Moskowitz CH
Bertz H, *see* Engelhardt M
Besmaine A, *see* Wasserman E
Bessell E, *see* Cullen MH
Bessho F, *see* Kawa K
Beusenberg FD, *see* Herben VMM
Bexon A, *see* Ducreux M
Beyer J, *see* Bokemeyer C
Bezjak A, *see* Loblaw DA
Bezwoda WR, *see* Nabholtz JM
Bhattacharya-Chatterjee, *see* Foon KA
Bianco A, *see* Comella P
Bianco R, *see* Crinò L
Bielack SS, Kempf-Bielack B, Heise U, Schwenzer D, Winkler K for the Cooperative German-Austrian-Swiss Osteosarcoma Study Group. Combined Modality Treatment for Osteosarcoma Occurring as a Second Malignant Disease, 1164
Bieri S, *see* Weber DC
Bierman PJ, *see* Abou-Elella AA
— *see* Baker KS
— *see* Lazarus HM
Biesma B, *see* Groen HJM
— *see* Tjan-Heijnen VCG
Bigner DD, *see* Friedman HS
Bik To L, *see* Basser RL
Bilancia D, *see* Comella P
— *see* Frasci G
Billingham LJ, *see* Cullen MH
Binkley SM, *see* Kuerer HM
Binnie N, *see* Ahmed FY
Biörklund A, *see* Bjordal K
Birch R, *see* Schulman KA
Biron P, *see* André M
— *see* Ray-Coquard I
Birt A, *see* Vasey PA

Bishop JAN, *see* Kefford RF
Bishop JF, Dewar J, Toner GC, Smith J, Tattersall MHN, Olver IN, Ackland S, Kennedy I, Goldstein D, Gurney H, Walpole E, Levi J, Stephenson J, Canetta R for the Taxol Investigational Trials Group, Australia/New Zealand. Initial Paclitaxel Improves Outcome Compared with CMFP Combination Chemotherapy as Front-Line Therapy in Untreated Metastatic Breast Cancer, 2355
Bishop PC, Wilson WH, Pearson D, Janik J, Jaffe ES, Elwood PC. CNS Involvement in Primary Mediastinal Large B-Cell Lymphoma, 2479
Bizakis JG, *see* Koukourakis MI
Bjordal K, Hammerlid E, Ahlner-Elmqvist M, de Graeff A, Boysen M, Evensen JF, Biörklund A, de Leeuw JRJ, Fayers PM, Jannert M, Westin T, Kaasa S for the European Organization for Research and Treatment of Cancer Quality of Life Study Group. Quality of Life in Head and Neck Cancer Patients: Validation of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-H&N35, 1008
Blackstein M, *see* Gelmon K
Blackstock AW, Bernard SA, Richards F, Eagle KS, Case LD, Poole ME, Savage PD, Tepper JE. Phase I Trial of Twice-Weekly Gemcitabine and Concurrent Radiation in Patients With Advanced Pancreatic Cancer, 2208
Blackstock AW, Tepper JE. In reply (correspondence), 3692
Blaise D, *see* André M
Blake P, *see* Bonnefoi H
Blanchard C, *see* Albrecht TL
Blanchette C, *see* Hébert-Croteau N
Blatter J, *see* Thödtmann R
Blay JY, *see* Ray-Coquard I
Blessing JA, *see* Rose PG
Blikstad I, *see* Kressner U
Bliss JM, *see* Wils JA
Blohmer J-U, *see* von Minckwitz G
Bloomfield CD, *see* Byrd JC
— *see* Harris NL
Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger H-U, Brown CS, Griffin T. Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer, 485
Bluman LG, Rimer BK, Berry DA, Borstelmann N, Iglehart JD, Regan K, Schildkraut J, Winer EP. Attitudes, Knowledge, and Risk Perceptions of Women With Breast and/or Ovarian Cancer Considering Testing for *BRCA1* and *BRCA2*, 1040
Boadas J, *see* Castells A
Boasberg PD, *see* O'Day SJ
Boccadoro M, *see* Corradini P
Boccardo F, Rubagotti A, Barichello M, Battaglia M, Carmignani G, Comeri G, Conti G, Cruciani G, Dammino S, Delliponti U, Ditonno P, Ferraris V, Lilliu S, Montefiore F, Portoghese F, Spano G for Italian Prostate Cancer Project. Bicalutamide Monotherapy Versus Flutamide Plus Goserelin in Prostate Cancer Patients: Results of an Italian Prostate Cancer Project Study, 2027
Bock M, *see* Deichmann M
Bodrogi I, *see* Chan S
Boecker W, *see* Poremba C
Boeker K, *see* Schlitt HJ
Boente M, *see* Schilder RJ
Boersma LJ, *see* Theuws JCM
Boisdron-Celle M, *see* Gamelin E
Boix L, *see* Castells A
Bok B, *see* Véra P
Bokemeyer C, Gerl A, Schöffski P, Harstrick A, Niederle N, Beyer J, Casper J, Schmoll HJ, Kanz L. Gemcitabine in Patients With Relapsed or Cisplatin-Refractory Testicular Cancer, 512
Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll H-J, Einhorn L, Kanz L, Nichols C. First-Line High-Dose Chemotherapy Compared With Standard-Dose PEB/VIP Chemotherapy in Patients With Advanced Germ Cell Tumors: A Multivariate and Matched-Pair Analysis, 3450
Boku N, Ohtsu A, Shimada Y, Shirao K, Seki S, Saito H, Sakata Y, Hyodo I. Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer, 319
Boku N, *see* Ohtsu A
Bolan C, *see* Murray CK
Boleda M, *see* Cirera L
Bolla M, *see* Greiner R
Bolt-de Vries J, *see* Meijer-van Gelder ME
Bonadonna G, *see* Fossâ A
—*see* Tondini C
Bonanni B, *see* Decensi A
Bonduelle M, *see* Goelen G
Bonetti F, *see* Zecca M
Bonetti F, Zecca M, Pession A, Messina C, Montagna D, Lanino E, Fagioli F, Santoro N, Prete A, Cesaro S, Rondelli R, Giorgiani G, De Stefano P, Locatelli F for the Italian Association for Pediatric Hematology and Oncology – Bone Marrow Transplantation Group. Total-Body Irradiation and Melphalan Is a Safe and Effective Conditioning Regimen for Autologous Bone Marrow Transplantation in Children With Acute Myeloid Leukemia in First Remission, 3729
Bonnay M, *see* Ducreux M
Bonnefoi H, A'Hern RP, Fisher C, Macfarlane V, Barton D, Blake P, Shepherd JH, Gore ME. Natural History of Stage IV Epithelial Ovarian Cancer, 767
Bonnefoi H, Gore ME. In reply (correspondence), 3002
Bonnefoi H, *see* Bernhard J
Bonner JA, Sloan JA, Shanahan TG, Brooks BJ, Marks RS, Krook JE, Gerstner JB, Maksymiuk A, Levitt R, Mailliard JA, Tazelaar HD, Hillman S, Jett JR. Phase III Comparison of Twice-Daily Split-Course Irradiation Versus Once-Daily Irradiation for Patients with Limited Stage Small-Cell Lung Carcinoma, 2681
Bonnin F, *see* Véra P
Bookman MA, *see* Schilder RJ
Booser D, *see* Valero V
Booser DJ, *see* Berry DL
— *see* Buzdar AU
Boraas M, *see* Fowble B
Bormans G, *see* Flamen P
Bornhövd EC, Schmid-Wendtner M-H, Volkenandt M, Wendtner C-M, Sander CA. Malignant Skin Lesions; Case 2: Lymphoepithelioma-Like Carcinoma of the Skin, 3853
Borowitz MJ, *see* Rubnitz JE
Borstelmann N, *see* Bluman LG
Bosch F, *see* Terol M-J
Bosquée L, *see* Leyvraz S
Bostick PJ, Morton DL, Turner RR, Huynh KT, Wang H-J, Elashoff R, Essner R, Hoon DSB. Prognostic Significance of Occult Metastases Detected by Sentinel Lymphadenectomy and Reverse

Transcriptase – Polymerase Chain Reaction in Early-Stage Melanoma Patients, 3238
Bostwick DG, *see* Neumann RM
Bouché O, *see* André T
Boucher L, *see* Mortimer JE
Bouchet C, Hacène K, Martin P-M, Becette V, Tubiana-Hulin M, Lasry S, Oglobine J, Spyratos F. Dissemination Risk Index Based on Plasminogen Activator System Components in Primary Breast Cancer, 3048
Bouffet E, *see* Baranzelli MC
Boulad F, Steinherz P, Reyes B, Heller G, Gillio AP, Small TN, Brochstein JA, Kernan NA, O'Reilly RJ. Allogeneic Bone Marrow Transplantation Versus Chemotherapy for the Treatment of Childhood Acute Lymphoblastic Leukemia in Second Remission: A Single-Institution Study, 197
Bouleuc C, *see* Debrix I
Bouros D, *see* Georgoulias V
Bouvet N, *see* Martelli H
Bow EJ, Kilpatrick MG, Clinch JJ. Totally Implantable Venous Access Ports Systems for Patients Receiving Chemotherapy for Solid Tissue Malignancies: A Randomized Controlled Clinical Trial Examining the Safety, Efficacy, Costs, and Impact on Quality of Life, 1267
Bowman LC, *see* Furman WL
Boyd C, Zhang-Salomons JY, Groome PA, Mackillop WJ. Association Between Community Income and Cancer Survival in Ontario, Canada, and the United States, 2244
Boyett JM, *see* Fouladi M
— *see* Gajjar A
— *see* Packer RJ
— *see* Pui C-H
— *see* Zeltzer PM
Boyle MG, *see* Bajorin DF
— *see* Dodd PM
Boysen M, *see* Bjordal K
Bozik ME, *see* Chang SM
Brabant G, *see* Franzke A
Brada M, *see* Yung WKA
Bradburn M, *see* Apostolidis J
Bradley AJ, Carrington BM, Lawrance JAL, Ryder WDJ, Radford JA. Assessment and Significance of Mediastinal Bulk in Hodgkin's Disease: Comparison Between Computed Tomography and Chest Radiography, 2493
Bradley WEC, *see* Ayoub J
Brady F, *see* Harte RJA
Brady MF, *see* Thigpen JT
Brämswig J, *see* Schellong G
Bramwell VHC, Steward WP, Nooij M, Whelan J, Craft AW, Grimer RJ, Taminau AHM, Cannon SR, Malcolm AJ, Hogendoorn PCW, Uscinska B, Kirkpatrick AL, Machin D, Van Glabbeke MM. Neoadjuvant Chemotherapy With Doxorubicin and Cisplatin in Malignant Fibrous Histiocytoma of Bone: A European Osteosarcoma Intergroup Study, 3260
Brandes AA, Ermani M, Turazzi S, Scelzi E, Berti F, Amistá P, Rotilio A, Licata C, Fiorentino MV. Procarbazine and High-Dose Tamoxifen as a Second-Line Regimen in Recurrent High-Grade Gliomas: A Phase II Study, 645
Brandes L, *see* Khoo K
Bready B, *see* Royce ME
Breitfeld PP, *see* Pappo AS
Brekelmans CTM, *see* Verhoog LC
Breneman JC, *see* Wolden SL
Breslow NE, Partin AW, Lee BR, Guthrie KA, Beckwith JB, Green DM. Nuclear Morphometry and Prognosis in Favorable Histology Wilms' Tumor: A Prospective Reevaluation, 2123
Bresnahan J, *see* Gill PS
Brewer M, Gershenson DM, Herzog CE, Mitchell MF, Silva EG, Wharton JT. Outcome and Reproductive Function After Chemotherapy for Ovarian Dysgerminoma, 2670
Brice P, *see* André M
— *see* Decaudin D
Bridgewater JA, Nelstrop AE, Rustin GJS, Gore ME, McGuire WP, Hoskins WJ. Comparison of Standard and CA-125 Response Criteria in Patients With Epithelial Ovarian Cancer Treated With Platinum or Paclitaxel, 501
Brisson J, *see* Hébert-Croteau N
Broadwater G, *see* Carter DL
— *see* Rizzieri DA
Brochstein JA, *see* Boulad F
Broder G, *see* Hensley ML
Brooks BJ, *see* Bonner JA
Brossart P, *see* Brugger W
Brosteanu O, *see* Andrieu JM
Brousse N, *see* Decaudin D
Browman GP. Essence of Evidence-Based Medicine: A Case Report, 169
Browman GP. Science, Language, Intuition, and the Many Meanings of Quality of Life (editorial), 1651
Brown AM, *see* Smith RE
Brown CS, *see* Blum JL
Brown G, *see* Harte RJA
Brown J, *see* Velikova G
Brown MA, *see* Gill PS
Brown R, *see* Adkins D
Brown RA, Adkins D, Khoury H, Vij R, Goodnough LT, Shenoy S, DiPersio JF. Long-Term Follow-Up of High-Risk Allogeneic Peripheral-Blood Stem-Cell Transplant Recipients: Graft-Versus-Host Disease and Transplant-Related Mortality, 806
Bruce J, *see* Nemunaitis J
Bruera E. In reply (correspondence), 730
Bruera E, *see* Nekolaichuk CL
Brugger W, Bühring H-J, Grünebach F, Vogel W, Kaul S, Müller R, Brümmendorf TH, Ziegler BL, Rappold I, Brossart P, Scheding S, Kanz L. Expression of MUC-1 Epitopes in Normal Bone Marrow: Implications for the Detection of Micrometastatic Tumor Cells, 1535
Brümmendorf TH, *see* Brugger W
Brunat-Mentigny M, *see* Tabone M-D
Bruner J, *see* Yung WKA
Bruzzi P, *see* Gennari A
Bryant B, *see* Highley MS
Bryce C, *see* Gelmon K
Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G. Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group, 3461
Buchanan GR, *see* Ritchey AK
Buchholz TA, *see* Kuerer HM
— *see* Thames HD

Büchler MW, *see* Zhu Z
Büchner T, *see* Hiddemann W
Buck M, *see* Byrne MJ
Buckner JC, Peethambaram PP, Smithson WA, Groover RV, Schomberg PJ, Kimmel DW, Raffel C, O'Fallon JR, Neglia J, Shaw EG. Phase II Trial of Primary Chemotherapy Followed by Reduced-Dose Radiation for CNS Germ Cell Tumors, 933
Budach V, *see* Stuschke M
Buer J, *see* Franzke A
Buesa J, *see* Van Glabbeke M
Buffa R, *see* Pruneri G
Bührer C, *see* Reich S
Bühring H-J, *see* Brugger W
Bui BN, *see* Ravaud A
Bukowski R, *see* Rubin J
Bukowski RM, *see* Figlin RA
Buksmaui S, *see* Fosså A
Bundy BN, *see* Whitney CW
Bunston T, *see* Loblaw DA
Burch PA, Loprinzi CL. Prostate-Specific Antigen Decline After Withdrawal of Low-Dose Megestrol Acetate (correspondence), 1086
Burge C, *see* Gelmon KA
Bürger H, *see* Poremba C
Burger H-U, *see* Blum JL
Burger HU, *see* Villalona-Calero MA
Burgess MA, *see* Fleming JB
Burris HA, *see* Villalona-Calero MA
Butow P. In reply (correspondence), 3857
Butow PN, Coates AS, Dunn SM. Psychosocial Predictors of Survival in Metastatic Melanoma, 2256
Butts C, *see* Rusthoven JJ
Buyse M, Carlson RW, Piedbois P. Meta-Analysis of Published Results Are Unreliable (correspondence), 1644
Buzdar AU, *see* Berry DL
— *see* Blum JL
— *see* Kuerer HM
— *see* Valero V
Buzdar AU, Singletary SE, Theriault RL, Booser DJ, Valero V, Ibrahim N, Smith TL, Asmar L, Frye D, Manuel N, Kau S-W, McNeese M, Strom E, Hunt K, Ames F, Hortobagyi GN. Prospective Evaluation of Paclitaxel Versus Combination Chemotherapy With Fluorouracil, Doxorubicin, and Cyclophosphamide as Neoadjuvant Therapy in Patients With Operable Breast Cancer, 3412
Buzzi F, *see* Chan S
Byding S, *see* Kressner U
Byers RM, *see* Garden AS
Byram D, *see* Wirth A
Byrd JC, Dodge RK, Carroll A, Baer MR, Edwards C, Stamberg J, Qumsiyeh M, Moore JO, Mayer RJ, Davey F, Schiffer CA, Bloomfield CD. Patients With t(8;21)(q22;q22) and Acute Myeloid Leukemia Have Superior Failure-Free and Overall Survival When Repetitive Cycles of High-Dose Cytarabine Are Administered, 3767
Byrd JC, *see* Murray CK
Byrd JC, Waselenko JK, Maneatis TJ, Murphy T, Ward FT, Monahan BP, Sipe MA, Donegan S, White CA. Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor Clearance, 791
Byrne M, *see* Clarke K
Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BWS. Cisplatin and Gemcitabine Treatment for Malignant Mesothelioma: A Phase II Study, 25
Byrne MJ, Dewar J, van Hazel G. In reply (correspondence), 2625

Cabanillas F, *see* Cheson BD
Cabanillas FF, *see* Thomas DA
Cabriales S, *see* Gill PS
Cahn J-Y, *see* André M
Cain AM, *see* Marina NM
— *see* Spunt SL
Calaminus G, *see* Bamberg M
Calandri C, *see* Crinò L
Calderone L, *see* Mercadante S
Caligaris-Cappio F, Hamblin TJ. B-Cell Chronic Lymphocytic Leukemia: A Bird of a Different Feather, 399
Callans LS, *see* Reynolds C
Callender DL, *see* Garden AS
Camitta BM, *see* Rubnitz JE
Camoriano JK, *see* Loprinzi CL
Campo E, *see* Terol M-J
Cancer and Leukemia Group B, *see* Costanza ME
Canellos GP. Clinical Research Saves Money: Reflections on High-Dose Therapy of Breast Cancer (editorial), 1965
Canellos GP, *see* Cheson BD
Canetta R, *see* Bishop JF
Cangiano T, Liao J, Naitoh J, Dorey F, Figlin R, Belldegrun A. Sarcomatoid Renal Cell Carcinoma: Biologic Behavior, Prognosis, and Response to Combined Surgical Resection and Immunotherapy, 523
Canning C, *see* Sehn LH
Cannistra SA. Back to the Future: Multiagent Chemotherapy in Ovarian Cancer Revisited (editorial), 741
Cannon M, *see* O'Day SJ
Cannon SR, *see* Bramwell VHC
Cantonetti AM, *see* Zinzani PL
Capellà G, *see* Castells A
Capella G, *see* Tortola S
Caponigro F, *see* Iaffaioli RV
Capozzoli MJ, *see* Belani CP
Carbone DP, *see* Johnson DH
Carboni N, *see* Pruneri G
Cardenal F, López-Cabrerizo MP, Antón A, Alberola V, Massuti B, Carrato A, Barneto I, Lomas M, García M, Lianes P, Montalar J, Vadell C, González-Larriba JL, Nguyen B, Artal A, Rosell R. Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non-Small-Cell Lung Cancer, 12
Cardenosa G, *see* American College of Radiology Task Force on Breast Cancer
Cardona T, *see* Cirera L
Carducci M, *see* Bubley GJ
Carella AM, *see* Sweetenham JW
Carey LA, Kim NW, Goodman S, Marks J, Henderson G, Umbricht CB, Dome JS, Dooley W, Amshey SR, Sukumar S. Telomerase Activity and Prognosis in Primary Breast Cancers, 3075
Carli M, Colombatti R, Oberlin O, Stevens M, Masiero L, Frascella E, Koscielniak E, Treuner J, Pinkerton CR. High-Dose Melphalan With Autologous Stem-Cell Rescue in Metastatic Rhabdomyosarcoma, 2796
Carlson RW, *see* Buyse M

Carmack CL, *see* Gritz ER
Carmichael J, *see* von Pawel J
Carmignani G, *see* Boccardo F
Carney D, *see* Waldron D
Carola E, *see* André T
Carotti A, *see* Aversa F
Carpagnano F, *see* Comella P
— *see* Frasci G
Carrato A, *see* Cardenal F
Carrington BM, *see* Bradley AJ
Carroll A, *see* Byrd JC
Carroll AJ, *see* Rubnitz JE
Carroll G, *see* Shipp MA
Carter DL, Marks LB, Bean JM, Broadwater G, Hussein A, Vredenburgh JJ, Peters WP, Prosnitz LR. Impact of Consolidation Radiotherapy in Patients With Advanced Breast Cancer Treated With High-Dose Chemotherapy and Autologous Bone Marrow Rescue, 887
Carter W, *see* Cheson BD
Casak S, *see* Chantada GL
Casazza S, *see* Aschele C
Case LD, *see* Blackstock AW
Casella G, *see* Pignata S
Casper J, *see* Bokemeyer C
Cassel WA, Olkowski ZL, Murray DR. Immunotherapy in Malignant Melanoma (correspondence), 1958
Cassella A, *see* Stevenson JP
Cassidy J, *see* Ahmed FY
Cassileth BR. Complementary and Alternative Cancer Medicine, 44-52(Supp.)
Castellano D, *see* Hidalgo M
Castellino R, *see* Cheson BD
Castello G, *see* Palmieri G
Castells A, Puig P, Móra J, Boadas J, Boix L, Urgell E, Solé M, Capellà G, Lluís F, Fernández-Cruz L, Navarro S, Farré A. K-*ras* Mutations in DNA Extracted From the Plasma of Patients With Pancreatic Carcinoma: Diagnostic Utility and Prognostic Significance, 578
Castiglione-Gertsch M, *see* Bernhard J
Castleberry RP, *see* Marina NM
Casuccio A, *see* Mercadante S
Catalano PJ, *see* Smith MA
Catchatourian R, *see* Vesole DH
Caty A, *see* Escudier B
Cavalli F, *see* Bernhard J
— *see* Nathwani BN
Cebon J, *see* Basser RL
Ceribelli A, *see* Crinò L
Cesana BM, *see* Pruneri G
Cesaro S, *see* Bonetti F
— *see* Zecca M
Chadwick D, *see* Herman EH
Chakraborty M, *see* Foon KA
Chamberlain D, *see* Michael M
Chamberlain M, *see* Glantz MJ
Champlin R, *see* Khouri I
Chan J, *see* Liu G
Chan RJ, *see* Ganjoo KN
Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil MG, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, Mancha RG, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J for the 303 Study Group. Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer, 2341
Chan WC, *see* Abou-Elella AA
Chan YL, *see* Yeo W
Chandra A, Eilender D. Uncommon Site of Presentation of Hematologic Malignancies; Case1: Localized Primary Non-Hodgkin's Lymphoma of the Patella, 1640
Chang AY, *see* Clamon G
Chang G, *see* Nichols KE
Chang J, Powles TJ, Allred DC, Ashley SE, Clark GM, Makris A, Assersohn L, Gregory RK, Osborne CK, Dowsett M. Biologic Markers as Predictors of Clinical Outcome From Systemic Therapy for Primary Operable Breast Cancer, 3058
Chang M, *see* Parson SK
Chang SM, Kuhn JG, Robins HI, Schold SC, Spence AM, Berger MS, Mehta MP, Bozik ME, Pollack I, Schiff D, Gilbert M, Rankin C, Prados MD. Phase II Study of Phenylacetate in Patients With Recurrent Malignant Glioma: A North American Brain Tumor Consortium Report, 984
Chang SM, *see* Yung WKA
Chantada GL, Fandiño A, Mato G, Casak S. Phase II Window of Idarubicin in Children With Extraocular Retinoblastoma, 1847
Chao M, *see* Wirth A
Chao NJ, *see* Rizzieri DA
Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma, 2745
Chatterjee SK, *see* Foon KA
Chaudri HA, Trunet PF. Letrozole: Updated Duration of Response, 3859
Chauvergne J, *see* Lhommé C
Cheang MS, *see* Kobrinsky NL
Chen M-H, *see* D'Amico AV
Chen NP, *see* Fleming JB
Chen T, *see* Chute JP
Cheng DKL, *see* Wong LC
Cheng S-C, *see* Fleming JB
Cher L, *see* Clarke K
Chernenko G, *see* Tang S-C
Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-López A, Hagenbeek A, Cabanillas F, Klippensten D, Hiddemann W, Castellino R, Harris NL, Armitage JO, Carter W, Hoppe R, Canellos GP. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas, 1244
Cheson BD, Vena DA, Barrett J, Freidlin B. Second Malignancies as a Consequence of Nucleoside Analog Therapy for Chronic Lymphoid Leukemias, 2554
Chetiyawardana AD, *see* Cullen MH
— *see* Fosså SD
Cheung ANY, *see* Wong LC
Cheung N-KV, *see* Kushner BH
Chevallier B, *see* Lhommé C
Chevreau C, *see* Escudier B
— *see* Ray-Coquard I
Chèze S, *see* Decaudin D
Childs B, *see* Moskowitz CH

Childs RW, Clave E, Tisdale J, Plante M, Hensel N, Barrett J. Successful Treatment of Metastatic Renal Cell Carcinoma With a Nonmyeloablative Allogeneic Peripheral-Blood Progenitor-Cell Transplant: Evidence for a Graft-Versus-Tumor Effect, 2044
Chim CS, Ma SK, Lom CK, Liang R. Two Uncommon Lymphomas; Case 2: Signet Ring Lymphoma of the Bone Marrow, 728
Chim CS, Ooi GC, Shek TWH, Liang R, Kwong YL. Lethal Midline Granuloma Revisited: Nasal T/Natural-Killer Cell Lymphoma, 1322
Chin K, *see* Ohtsu A
Chinnery LW, *see* Gralla RJ
Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG for the American Society of Clinical Oncology Working Group on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene. American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene, 1939
Chlebowski RT, McTiernan A. Elements of Informed Consent for Hormone Replacement Therapy in Patients With Diagnosed Breast Cancer, 130
Choy DTK, *see* Wong LC
Christensen BJ, *see* Loprinzi CL
Chrysson NG, *see* von Pawel J
Chu P, *see* Schwartz RE
Chung CS, *see* Green DM
Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty Years of Phase III Trials for Patients With Extensive-Stage Small-Cell Lung Cancer: Perceptible Progress, 1794
Cid M-C, *see* Terol M-J
Cingolani A, *see* Antinori A
Cioffi R, *see* Comella P
— *see* Frasci G
Cirera L, Balil A, Batiste-Alentorn E, Tusquets I, Cardona T, Arcusa À, Jolis L, Saigí E, Guasch I, Badia A, Boleda M. Randomized Clinical Trial of Adjuvant Mitomycin Plus Tegafur in Patients With Resected Stage III Gastric Cancer, 3810
Cirrincione C, *see* Abrams J
Cirrincionne C, *see* Costanza ME
Clamon G, Herndon J, Cooper R, Chang AY, Rosenman J, Green MR. Radiosensitization With Carboplatin for Patients With Unresectable Stage III Non-Small-Cell Lung Cancer: A Phase III Trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group, 4
Clark GM, *see* Chang J
— *see* Diab SG
— *see* Harvey JM
— *see* Jatoi L
Clark PI, *see* von Pawel J
Clark-Snow R, *see* Gralla RJ
Clarke K, Basser RL, Underhill C, Mitchell P, Bartlett J, Cher L, Findlay M, Dalley D, Pell M, Byrne M, Geldard H, Hill JS, Maher D, Fox RM, Green MD, Kaye AH. KRN8602 (MX2-Hydrochloride): An Active New Agent for the Treatment of Recurrent High-Grade Glioma, 2579
Clarke-Pearson DL, *see* Whitney CW
Clarridge BR, *see* Wolfe J
Clave E, *see* Childs RW
Clayman GL, *see* Garden AS
Clinch JJ, *see* Bow EJ
Cloughsey T, *see* Friedman HS
Coady-Lyons N, *see* Moskowitz CH
Coates AS, *see* Butow PN
Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease, 2639
Coccia PF, *see* Baker KS
Cohen BH, *see* Packer RJ
Cohen GI, *see* Hensley ML
Cohen H, *see* Hochster H
Cohen HI, *see* Siegelmann-Danieli N
Cohen JD, *see* Robins HI
Cohen L, *see* Hack TF
— *see* Marina NM
Cohen R, *see* Tolcher AW
Coiffier B, *see* André M
— *see* Cheson BD
— *see* Decaudin D
— *see* Foran JM
— *see* Shipp MA
Cokgor I, *see* Friedman HS
Cole BF, *see* Parson SK
Coleman CN, Mitchell JB. Clinical Radiosensitization: Why It Does and Does Not Work (editorial), 1
Coleman CN, *see* D'Amico AV
Coleman JJ III, *see* Wagner JD
Coleman R, *see* Vasey PA
Colevas AD, Norris CM, Tishler RB, Fried MP, Gomolin HI, Amrein P, Nixon A, Lamb C, Costello R, Barton J, Read R, Adak S, Posner MR. Phase II Trial of Docetaxel, Cisplatin, Fluorouracil, and Leucovorin as Induction for Squamous Cell Carcinoma of the Head and Neck, 3503
Collins JP, *see* Basser RL
Collyar DE, *see* Chlebowski RT
Colombat P, *see* André M
Colombatti R, *see* Carli M
Colome MI, *see* Gershenwald JE
Colonna P, *see* Andrieu JM
Colvin OM, *see* Friedman HS
Comella G, *see* Comella P
— *see* Frasci G
Comella P, Frasci G, Panza N, Manzione L, Lorusso V, Di Rienzo G, Cioffi R, De Cataldis G, Maiorino L, Bilancia D, Nicolella G, Natale M, Carpagnano F, Pacilio C, De Lena M, Bianco M, Comella G. Cisplatin, Gemcitabine, and Vinorelbine Combination Therapy in Advanced Non-Small-Cell Lung Cancer: A Phase II Randomized Study of the Southern Italy Cooperative Oncology Group, 1526
Comella P, *see* Frasci G
Comerford T. Efficacy of Controlled-Release Oxycodone (correspondence), 730
Comeri G, *see* Boccardo F
Comis R, *see* McCaskill-Stevens W
Conaway M, *see* Kantoff PW
Confalonieri C, *see* Fossati R
Coniglio D, *see* Rizzieri DA
Conners JM, *see* Macpherson N
Connolly CK, *see* Cullen MH
Connors JM, *see* Cheson BD
— *see* Porter DL
Conolly M, *see* Sabbatini P

Conroy T, Guillemin F. Quality of Life in Advanced Colorectal Cancer (correspondence), 1644
Consonni A, *see* Jones S
Constine L, *see* Rapoport AP
Conte PF, *see* Gennari A
Conti G, *see* Boccardo F
Contu A, *see* Frasci G
Cook JE, *see* Cullen MH
Coombes G, *see* Wils JA
Coombes RC, *see* Slade MJ
— *see* Wils JA
Cooper B, *see* Jones S
Cooper MR, *see* Abrams J
Cooper R, *see* Clamon G
Cooperative German-Austrian-Swiss Osteosarcoma Study Group, *see* Bielack SS
Coovert M, *see* Albrecht TL
Copeland DR, deMoor C, Moore BD III, Ater JL. Neurocognitive Development of Children After a Cerebellar Tumor in Infancy: A Longitudinal Study, 3476
Cormier Y, *see* Ayoub J
Cormio G, *see* Pignata S
Corradini P, Voena C, Tarella C, Astolfi M, Ladetto M, Palumbo A, Van Lint MT, Bacigalupo A, Santoro A, Musso M, Majolino I, Boccadoro M, Pileri A. Molecular and Clinical Remissions in Multiple Myeloma: Role of Autologous and Allogeneic Transplantation of Hematopoietic Cells, 208
Corry J, *see* Wirth A
Cortazar P, Johnson BE. Review of the Efficacy of Individualized Chemotherapy Selected by In Vitro Drug Sensitivity Testing for Patients With Cancer, 1625
Cortes-Funes H, *see* Hidalgo M
Cortes J, *see* Beran M
— *see* Kantarjian HM
— *see* Thomas DA
Coscarelli A, *see* Gritz ER
Costa A, *see* Decensi A
Costa SD, *see* von Minckwitz G
Costagliola G, *see* Iaffaioli RV
Costantino JP, *see* Day R
Costanza ME, Weiss RB, Henderson IC, Norton L, Berry DA, Cirrincionne C, Winer E, Wood WC, Frei E III, McIntyre OR, Schilsky RL, for the Cancer and Leukemia Group B. Safety and Efficacy of Using a Single Agent or Phase II Agent Before Instituting Standard Combination Chemotherapy in Previously Untreated Metastatic Breast Cancer Patients: Report of a Randomized Study—Cancer and Leukemia Group B 8642, 1397
Costello R, *see* Colevas AD
Costello S, *see* Theriault RL
Cowens W, *see* Glantz MJ
Cox A, *see* Tjan-Heijnen VCG
Coyle D, *see* Stewart DJ
Craft AW, *see* Bramwell VHC
Cramer HM, *see* Ganjoo KN
Crawford J, *see* Devore RF
Crawford SM, *see* Vasey PA
Creagan ET, Suman VJ, Dalton RJ, Pitot HC, Long HJ, Veeder MH, Vukov AM, Rowland KM, Krook JE, Michalak JC. Phase III Clinical Trial of the Combination of Cisplatin, Dacarbazine, and Carmustine With or Without Tamoxifen in Patients With Advanced Malignant Melanoma, 1884
Crinò L, Mosconi M, Scagliotti G, Selvaggi G, Novello S, Rinaldi M, Giulia MD, Gridelli C, Rossi A, Calandri C, De Marinis F, Noseda M, Tonato M. Gemcitabine as Second-Line Treatment for Advanced Non-Small-Cell Lung Cancer: A Phase II Trial, 2081
Crinò L, Scagliotti GV, Ricci S, De Marinis F, Rinaldi M, Gridelli C, Ceribelli A, Bianco R, Marangolo M, Di Costanzo F, Sassi M, Barni S, Ravaioli A, Adamo V, Portalone L, Cruciani G, Masotti A, Ferrara G, Gozzelino F, Tonato M. Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non-Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project, 3522
Crist WM, *see* Pappo AS
— *see* Wolden SL
Croce CM, Sozzi G, Huebner K. Role of *FHIT* in Human Cancer, 1618
Croft H, *see* Murray N
Cromer J, *see* Vesole DH
Cronin WM, *see* Day R
Cropp G, *see* Eckhardt SG
Cross NCP, *see* Slade MJ
Crotty M-L, *see* Sun L
Crowley J, *see* Livingston R
Crowley JJ, *see* Vesole DH
Crown J, *see* Chan S
— *see* Hudis C
Crown JPA, *see* Hudis C
Crowther D, *see* Van Glabbeke M
Cruciani G, *see* Boccardo F
— *see* Crinò L
Cull A, *see* Velikova G
Cullen J, *see* Marina NM
Cullen MH, Billingham LJ, Woodroffe CM, Chetiyawardana AD, Gower NH, Joshi R, Ferry DR, Rudd RM, Spiro SG, Cook JE, Trask C, Bessell E, Connolly CK, Tobias J, Souhami RL. Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non-Small-Cell Lung Cancer: Effects on Survival and Quality of Life, 3188
Cullen MH, *see* Foran JM
— *see* Fosså SD
Cummings FJ, *see* Recht A
Cunningham D, *see* Popescu RA
— *see* Sweetenham JW
Cunningham I, *see* Aversa F
Curbow BA, *see* Fogarty LA
Curley S, *see* Ajani JA
Curran WJ Jr, *see* Prados MD
Currie V, *see* Hudis C
Curry BJ, Myers K, Hersey P. MART-1 Is Expressed Less Frequently on Circulating Melanoma Cells in Patients Who Develop Distant Compared With Locoregional Metastases, 2562
Curtis RE, *see* Rowlings PA
Cushing B, *see* Marina NM
Cutler C, Gragoudas ES. Choroidal Metastases; Case 2: Lung Cancer, 3356
Cutler C, *see* Piccone MR
Cuvier C, *see* Wasserman E
Cvitkovic E, *see* Wasserman E
Czerniecki BJ, *see* Reynolds C

Czuczman MS, Grillo-López AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Klippenstein D, Dallaire B, Varns C. Treatment of Patients With Low-Grade-B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy, 268

Dagovic A, *see* Jeremic B
Dahmen G, *see* Verhoog LC
Dahrouge S, *see* Stewart DJ
Dahut W, *see* Bubley GJ
Dakhil SR, *see* Royce ME
Daliani D, *see* Bubley GJ
Dallaire B, *see* Czuczman MS
Dallaire BK, *see* de Jonge MJA
Dalley D, *see* Clarke K
Dalton RJ, *see* Creagan ET
D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen M-H, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Coleman CN. Pretreatment Nomogram for Prostate-Specific Antigen Recurrence After Radical Prostatectomy or External-Beam Radiation Therapy for Clinically Localized Prostate Cancer, 168
Damle S, *see* Wadler S
Dammino S, *see* Boccardo F
Dancey J, *see* Rusthoven JJ
Dandona P, *see* Rubin J
Danesi R, *see* Gennari A
Danhauser-Riedl S, *see* Jung C!
Daniel PT, *see* Sturm I
Daniels ER, *see* Wolfe J
Daponte A, *see* Palmieri G
Darling ML, *see* Liu G
Das R, *see* Foon KA
Datta MW, *see* Jänne PA
Daugaard G, *see* Petersen PM
Daugherty CK. Impact of Therapeutic Research on Informed Consent and the Ethics of Clinical Trials: A Medical Oncology Perspective, 1601
Davey F, *see* Byrd JC
Davidson D, *see* Wagner JD
Davidson JA, *see* Byrne MJ
Davidson NE, *see* Recht A
— *see* Smith TJ
Davila E, *see* Fisher B
— *see* Smith RE
Davis J, *see* Vasey PA
Davis S, *see* Wirth A
Davis TA, White CA, Grillo-López AJ, Velásquez WS, Link B, Maloney DG, Dillman RO, Williams ME, Mohrbacher A, Weaver R, Dowden S, Levy R. Single-Agent Monoclonal Antibody Efficacy in Bulky Non-Hodgkin's Lymphoma: Results of a Phase II Trial of Rituximab, 1851
Dawson N, *see* Bubley GJ
Dawson NA. In reply (correspondence), 1644
Day R, Ganz PA, Costantino JP, Cronin WM, Wickerham DL, Fisher B. Health-Related Quality of Life and Tamoxifen in Breast Cancer Prevention: A Report From the National Surgical Adjuvant Breast and Bowel Project P-1 Study, 2659
de Alava E, *see* Ginsberg JP
De Benedetti A, *see* Nathan C-AO
De Cataldis G, *see* Comella P
de Graeff A, *see* Bjordal K
de Gramont A, *see* André T
De Gréve J, *see* Goelen G
de Jonge MJA, Punt CJA, Gelderblom AH, Loos WJ, van Beurden V, Planting ASTh. van der Burg MEL, van Maanen LWGM, Dallaire BK, Verweij J, Wagener DJT, Sparreboom A. Phase I and Pharmacologic Study of Oral (PEG-1000) 9-Aminocamptothecin in Adult Patients With Solid Tumors, 2219
de Klerk NH, *see* Byrne MJ
de Leeuw JRJ, *see* Bjordal K
De Lena M, *see* Comella P
—*see* Frasci G
De Leyn PR, *see* Stroobants SG
De Luca A, *see* Antinori A
de Marie S, *see* Nouwen JL
De Marinis F, *see* Crinò L
De Marino V, *see* Iaffaioli RV
de Moor C, *see* Gritz ER
De Rossi G, *see* Antinori A
De Stefano P, *see* Bonetti F
de Takats PG, *see* Foran JM
De Vadder N, *see* Flamen P
de Vries EGE, *see* Wymenga ANM
de Wit R, van Dam F, Abu-Saad HH, Loonstra S, Zandbelt L, van Buuren A, van der Heijden K, Leenhouts G. Empirical Comparison of Commonly Used Measures to Evaluate Pain Treatment in Cancer Patients With Chronic Pain, 1280
Debernardis D, *see* Aschele C
Debrix I, Bouleuc C, Liote H, Milleron B, Beker A. Impact of American Society of Clinical Oncology Guidelines for Clinical Use of Colony-Stimulating Factors (correspondence), 3360
DeCataldis, *see* Frasci G
Decaudin D, Lepage E, Brousse N, Brice P, Harousseau J-L, Belhadj K, Tilly H, Michaux L, Chèze S, Coiffier B, Solal-Céligny P. Low-Grade Stage III-IV Follicular Lymphoma: Multivariate Analysis of Prognostic Factors in 484 Patients – A Study of the Groupe d'Etude des Lymphomes de l'Adulte, 2499
Decensi A, Gandini S, Guerrieri-Gonzaga A, Johansson H, Manetti L, Bonanni B, Sandri MT, Barreca A, Costa A, Robertson C, Lien EA. Effect of Blood Tamoxifen Concentrations on Surrogate Biomarkers in a Trial of Dose Reduction in Healthy Women, 2633
DeCillis A, *see* Fisher B
Dedhar C, *see* Gelmon KA
Deeg J, *see* Rowlings PA
DeFusco PA, *see* Smith RE
DeGroff J, *see* Ilson DH
Deichmann M, Benner A, Bock M, Jäckel a, Uhl K, Waldmann V, Näher H. S100-Beta, Melanoma-Inhibiting Activity, and Lactate Dehydrogenase Discriminate Progressive From Nonprogressive American Joint Committee on Cancer Stage IV Melanoma, 1891
deKernion JB, *see* Belldegrun A
Del Favero A, *see* Roila F
Del Mastro L, *see* Esposito M
Del Prete F, *see* Gasbarri A
Del Tacca M, *see* Gennari A
Delanian S, Balla-Mekias S, Lefaix J-L. Striking Regression of Chronic Radiotherapy Damage in a Clinical Trial of Combined Pentoxifylline and Tocopherol, 3283
Delliponti U, *see* Boccardo F

DelPrete S, *see* Hesketh PJ
Delva R, *see* Gamelin E
Demedts MG, *see* Stroobants SG
Demetri GD, *see* Baldini EH
Demir G, *see* Ozguroglu M
Demirelli F, *see* Ozguroglu M
deMoor C, *see* Copeland DR
Dempsey PJ, *see* American College of Radiology Task Force on Breast Cancer
Deneffe GJ, *see* Stroobants SG
Denekamp J, *see* Greiner R
Dent S, *see* Khoo K
Depenbrock H, *see* Thödtmann R
Depierre A, *see* von Pawel J
Depisch D, *see* Scheithauer W
Dershaw DD, *see* American College of Radiology Task Force on Breast Cancer
Desch CE, Benson AB III, Smith TJ, Flynn PJ, Krause C, Loprinzi CL, Minsky BD, Petrelli NJ, Pfister DG, Somerfield MR. Recommended Colorectal Cancer Surveillance Guidelines by the American Society of Clinical Oncology, 1312
Deschênes L, *see* Hébert-Croteau N
—*see* Nabholtz JM
Desjardins C, *see* Ayoub J
Desmond KA, *see* Ganz PA
Desseigne F, *see* André T
Destouet JM, *see* American College of Radiology Task Force on Breast Cancer
Destro AN, *see* Chapman PB
Devilee P, *see* Verhoog LC
Devore RF, Johnson DH, Crawford J, Garst J, Dimery IW, Eckardt J, Eckhardt SG, Elfring GL, Schaaf LJ, Hanover CK, Miller LL. Phase II Study of Irinotecan Plus Cisplatin in Patients With Advanced Non-Small-Cell Lung Cancer, 2710
Dewar J, *see* Bishop JF
—*see* Byrne MJ
Dhingra K, *see* Kuerer HM
Di Costanzo F, *see* Crinò L
Di Finizio D, *see* Pruneri G
Di Giuda D, *see* Antinori A
Di Rienzo G, *see* Comella P
di Salle E, *see* Jones S
Di Vagno G, *see* Pignata S
Diab AR, *see* Gelmon KA
Diab SG, Clark GM, Osborne CK, Libby A, Allred DC, Elledge RM. Tumor Characteristics and Clinical Outcome of Tubular and Mucinous Breast Carcinomas, 1442
Diakomanolis E, *see* Papadimitriou CA
Diallo R, *see* Poremba C
Diaz-Puente M, *see* Hidalgo M
Diebold J, *see* Harris NL
— *see* Nathwani BN
Diederichs C, *see* Schirrmeister H
Diehl V, Sextro M, Franklin J, Hansmann M-L, Harris N, Jaffe E, Poppema S, Harris M, Franssila K, van Krieken J, Marafioti T, Anagnostopoulos I, Stein H. Clinical Presentation, Course, and Prognostic Factors in Lymphocyte-Predominant Hodgkin's Disease and Lymphocyte-Rich Classical Hodgkin's Disease: Report From the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease, 776
Dieras V, *see* Lhommé C
Diller L, *see* Nichols KE
Dillman RO, *see* Davis TA
Dillon P, *see* Love CDB
Dimery IW, *see* Devore RF
Dimitri P, *see* Iaffaioli RV
Dimitrov N, *see* Jones SE
Dimitrov NV, *see* Wolmark N
diMola FF, *see* Zhu Z
Dimopoulos M-A, *see* Georgoulias V
Dimopoulos MA, *see* Androulakis N
—*see* Papadimitriou CA
Ding C, *see* Sabbatini P
DiPaola RS, Rafi MM, Vyas V, Toppmeyer D, Rubin E, Patel J, Goodin S, Medina M, Medina P, Zamek R, Zhang C, White E, Gupta E, Hait WN. Phase I Clinical and Pharmacologic Study of 13-*cis*-Retinoic Acid, Interferon Alfa, and Paclitaxel in Patients With Prostate Cancer and Other Advanced Malignancies, 2213
DiPersio J, *see* Adkins D
DiPersio JF, *see* Brown RA
Dirlam NL, *see* Hesketh PJ
Ditonno P, *see* Boccardo F
Dixon JM, *see* Love CDB
Dockhorn-Dworniczak B, *see* Poremba C
Dockhorn-Dworniczak BH, *see* Ginsberg JP
Dodd PM, McCaffrey JA, Herr H, Mazumdar M, Bacik J, Higgins G, Boyle MG, Scher HI, Bajorin DF. Outcome of Postchemotherapy Surgery After Treatment With Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Patients With Unresectable or Metastatic Transitional Cell Carcinoma, 2546
Dodd PM, *see* Bajorin DF
Dodge RK, *see* Byrd JC
Dome JS, *see* Carey LA
Donaldson SS, *see* Suryanarayan K
— *see* Wolden SL
Donati S, *see* Gennari A
Donegan S, *see* Byrd JC
Donohue JH, *see* Reynolds C
Dooley W, *see* Carey LA
Doppman JL, *see* Yu F
Dorey F, *see* Cangiano T
Dörffel W, *see* Schellong G
Dörken B, *see* Sturm I
Dorr A, *see* Nemunaitis J
Dorr FA, *see* Stevenson JP
D'Orsi CJ, *see* American College of Radiology Task Force on Breast Cancer
Douillard JY, *see* Escudier B
Douma J, *see* Nabholtz JM
Dowden S, *see* Davis TA
Downing JR, *see* Rubnitz JE
Dowsett M, *see* Chang J
Doyle E, *see* Herben VMM
Drachenberg MR, *see* Nathwani BN
Dranitsaris G, *see* Leung PP
Drbal J, *see* Nabholtz JM
Drengler R, *see* Eckhardt SG

Drengler RL, Kuhn JG, Schaaf LJ, Rodriguez GI, Villalona-Calero MA, Hammond LA, Stephenson JA Jr, Hodges S, Kraynak MA, Staton BA, Elfring GL, Locker PK, Miller LL, Von Hoff DD, Rothenberg ML. Phase I and Pharmacokinetic Trial of Oral Irinotecan Administered Daily for 5 Days Every 3 Weeks in Patients With Solid Tumors, 685
Drengler RL, *see* Villalona-Calero MA
du Bois A, Lück HJ, Bauknecht T, Meier W, Richter B, Kuhn W, Quaas J, Pfisterer J. First-Line Chemotherapy With Epirubicin, Paclitaxel, and Carboplatin for Advanced Ovarian Cancer: A Phase I/II Study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group, 46
Du Pen AR, *see* Du Pen SL
Du Pen SL, Du Pen AR, Polissar N, Hansberry J, Kraybill BM, Stillman M, Panke J, Everly R, Syrjala K. Implementing Guidelines for Cancer Pain Management: Results of a Randomized Controlled Clinical Trial, 361
Duarte R, *see* Chan S
Duchesne GM, *see* Fosså SD
Ducreux M, Ychou M, Seitz J-F, Bonnay M, Bexon A, Armand J-P, Mahjoubi M, Méry-Mignard D, Rougier P. Irinotecan Combined With Bolus Fluorouracil, Continuous Infusion Fluorouracil, and High-Dose Leucovorin Every Two Weeks (LV5FU2 Regimen): A Clinical Dose-Finding and Pharmacokinetic Study in Patients With Pretreated Metastatic Colorectal Cancer, 2901
Duerst R, *see* Rapoport AP
Duffy KM, *see* Porter DL
Dugan M, *see* Hammond LA
— *see* Yung WKA
Dugan W, *see* Einhorn L
Dumas P, *see* Ajani JA
Dumez H, *see* Thödtmann R
Dumontet C, Sikic BI. Mechanisms of Action of and Resistance to Antitubulin Agents: Microtubule Dynamics, Drug Transport, and Cell Death, 1061
Duncan L, *see* Jones SE
Dunn SM, *see* Butow PN
Dünser M, *see* Kemmler G
Dupont-André G
see André T
see Wasserman E
Dupont P, *see* Flamen P
Dupont PJ, *see* Stroobants SG
Durrant S, *see* Basser RL
Dussek J, *see* Highley MS
Dutcher JP, *see* Atkins MB
Duval M, *see* Véra P
Duvic M, *see* Kurzrock R

Eagle KS, *see* Blackstock AW
Eberhardt W, *see* Stuschke M
Eberly S, *see* Rapoport AP
Eckardt J, *see* Devore RF
Eckardt JR, *see* Eckhardt SG
— *see* Hammond LA
Eckhardt SG, Rizzo J, Sweeney KR, Cropp G, Baker SD, Kraynak MA, Kuhn JG, Villalona-Calero MA, Hammond L, Weiss G, Thurman A, Smith L, Drengler R, Eckardt JR, Moczygemba J, Hannah AL, Von Hoff DD, Rowinsky EK. Phase I and Pharmacologic Study of the Tyrosine Kinase Inhibitor SU101 in Patients With Advanced Solid Tumors, 1095
Eckhardt SG, *see* Devore RF
— *see* Hammond LA
— *see* Nemunaitis J
— *see* Villalona-Calero MA
Edan C, *see* Baranzelli MC
Edenfield WJ, *see* Murray CK
Edgerton SM, *see* Thor AD
Edmonson J, *see* Galanis E
Edwards C, *see* Byrd JC
Edwards S, *see* O'Day SJ
Eggleton SPH, *see* Vasey PA
Egorin MJ, *see* Belani CP
— *see* Sparano JA
Eiermann W, *see* von Minckwitz G
Eifel PJ. Concurrent Chemotherapy and Radiation: A Major Advance for Women With Cervical Cancer (editorial), 1334
Eilender D, *see* Chandra A
Einhorn JH, *see* Rosenberg SA
Einhorn L, Ross E, Balsham A, Loehrer P, Ramsey H, Sprandio J, Entmacher M, Dugan W, Ansari R, Monaco F, Hanna M, Roth B. Vinblastine Versus Vinblastine Plus Oral Estramustine Phosphate for Patients With Hormone-Refractory Prostate Cancer: A Hoosier Oncology Group and Fox Chase Network Phase III Trial, 3160
Einhorn L, *see* Bokemeyer C
Einhorn LH, *see* Chapman PB
— *see* Ganjoo KN
Einhorn LH, Stender MJ, Williams SD. Phase II Trial of Gemcitabine in Refractory Germ Cell Tumors, 509
Eisbruch A, Robertson JM, Johnston CM, Tworek J, Reynolds KR, Roberts JA, Lawrence TS. Bromodeoxyuridine Alternating With Radiation for Advanced Uterine Cervix Cancer: A Phase I and Drug Incorporation Study, 31
Eisen A, *see* Gelmon KA
Eisenberg P, *see* Jones S
Eisenberger M, *see* Bubley GJ
Eisenhauer E, *see* Gelmon K
— *see* Khoo K
— *see* Rusthoven JJ
Ekeberg Ø, *see* Loge JH
Ekholm E, *see* Salminen E
Elashoff R, *see* Bostick PJ
Elfring GL, *see* Devore RF
— *see* Drengler RL
— *see* Friedman HS
Elias A, Ibrahim J, Skarin AT, Wheeler C, McCauley M, Ayash L, Richardson P, Schnipper L, Antman KH, Frei E III. Dose-Intensive Therapy for Limited-Stage Small-Cell Lung Cancer: Long-Term Outcome, 1175
Elkordy M, *see* Rizzieri DA
Elledge RM, *see* Diab SG
Ellerton J, *see* Abrams J
Ellis GK, Gralow JR, Pierce HI, Williams MA, Livingston RB. Infusional Paclitaxel and Weekly Vinorelbine Chemotherapy With Concurrent Filgrastim for Metastatic Breast Cancer: High Complete Response Rate in a Phase I-II Study of Doxorubicin-Treated Patients, 1407
Elmaleh M, *see* Véra P
Elsner K, *see* Schirrmeister H
Elson P, *see* Markman M
Elwood PC, *see* Bishop PC

ELYPSE 1 Study Group, *see* Ray-Coquard I
Emanuel EJ, *see* Wolfe J
Embree L, *see* Gelmon KA
Emi Y, *see* Maehara Y
Emmanouilides C, *see* Witzig TE
Eng C. *RET* Proto-Oncogene in the Development of Human Cancer, 380
Engelhard H, *see* Kleinberg L
Engelhardt M, Bertz H, Afting M, Waller CF, Finke J. High-Versus Standard-Dose Filgrastim (rhG-CSF) for Mobilization of Peripheral-Blood Progenitor Cells From Allogeneic Donors and CD34$^+$ Immunoselection, 2160
Engstrom C, *see* Belani CP
Ennis M, *see* Goodwin PJ
Entmacher M, *see* Einhorn L
Enzinger P, *see* Ilson DH
Eriksson B, *see* Wymenga ANM
Erkmen K, *see* Belani CP
Ermani M, *see* Brandes AA
Ernst DS, *see* Osoba D
Ernstoff MS, *see* Chapman PB
Ervin T, *see* Shapiro CL
Escudier B, Chevreau C, Lasset C, Douillard JY, Ravaud A, Fabbro M, Caty A, Rossi JF, Viens P, Bergerat JP, Savary J, Négrier S for the Groupe Français d'Immunothérapie. Cytokines in Metastatic Renal Cell Carcinoma: Is It Useful to Switch to Interleukin-2 or Interferon After Failure of a First Treatment?, 2039
Esper P, *see* Smith DC
Espina BM, *see* Gill PS
Espinoza F, Anguiano A. The HercepTest Assay: Another Perspective (correspondence), 2293
Esposito M, Venturini M, Vannozzi MO, Tolino G, Lunardi G, Garrone O, Angiolini C, Viale M, Bergaglio M, Del Mastro L, Rosso R. Comparative Effects of Paclitaxel and Docetaxel on the Metabolism and Pharmacokinetics of Epirubicin in Breast Cancer Patients, 1132
Esserman L, Hylton N, Yassa L, Barclay J, Frankel S, Sickles E. Utility of Magnetic Resonance Imaging in the Management of Breast Cancer: Evidence for Improved Preoperative Staging, 110
Essner R, *see* Bostick PJ
— *see* O'Day SJ
Estey E, *see* Beran M
— *see* Murray CK
Etoh T, *see* Kawa K
Etter MA, *see* Rapoport AP
European Organization for Research and Treatment of Cancer Quality of Life Study Group, *see* Bjordal K
Evans DB, *see* Ajani JA
Evans WE, *see* Pui C-H
Evans WK, *see* Stewart DJ
Evans WP III, *see* American College of Radiology Task Force on Breast Cancer
Evensen JF, *see* Bjordal K
Evensen SA, *see* Hjermstad MJ
Everly R, *see* Du Pen SL
Ewer M, *see* Valero V

Fabbro M, *see* Escudier B
Facchini G, *see* Iaffaioli RV
Faderl, S
— *see* Thomas DA
Fagioli F, *see* Bonetti F
Fairclough DL, *see* Wolfe J
Falkson CI, *see* Sparano JA
Falkson G, *see* Recht A
Falkson HC, *see* Recht A
Fandiño A, *see* Chantada GL
Fargeot P, *see* Lhommé C
Farley DR, *see* Reynolds C
Farré A, *see* Castells A
Fasce H, *see* Acuña LR
Fattorossi A, *see* Pierelli L
Faulhaber PF, *see* Rose PG
Favre C, *see* Zecca M
Fawzy NW, *see* O'Day SJ
Fayers PM, *see* Bjordal K
— *see* Hjermstad MJ
Fazzari M, *see* Bajorin DF
Fehrenbacher L, *see* Cobleigh MA
— *see* Fisher B
— *see* Jones S
Feierabend C, *see* Robins HI
Feig B, *see* Ajani JA
Feig BW, *see* Fleming JB
pFeig SA, *see* American College of Radiology Task Force on Breast Cancer
Feigal E, *see* Chute JP
Feinglass J, *see* Bennett CL
Felicini R, *see* Aversa F
Felip E, *see* Monzó M
Fennelly D, *see* Hudis C
Fernández-Cruz L, *see* Castells A
Ferrando F, *see* Ballestrero A
Ferrans VJ, *see* Herman EH
Ferrante G, *see* Iaffaioli RV
Ferrara G, *see* Crinò L
Ferrara J, *see* Motzer RJ
Ferrari E, *see* Pignata S
Ferraris V, *see* Boccardo F
Ferraro A, *see* Iaffaioli RV
Ferreri AJM, *see* Tondini C
Ferry DR, *see* Cullen MH
Festen J, *see* Tjan-Heijnen VCG
Feusner JH, *see* Reaman GH
Fey MF, *see* Bernhard J
Fiasse RH, *see* Wymenga ANM
Fields SZ, *see* von Pawel J
Figg WD, *see* Bubley GJ
Figlin R, *see* Cangiano T
Figlin RA, Thompson JA, Bukowski RM, Vogelzang NJ, Novick AC, Lange P, Steinberg GD, Belldegrun AS. Multicenter, Randomized, Phase III Trial of CD8$^+$ Tumor-Infiltrating Lymphocytes in Combination With Recombinant Interleukin-2 in Metastatic Renal Cell Carcinoma, 2521
Filippa D, *see* Moskowitz CH
Findlay M, *see* Clarke K
Fine R, *see* Petrylak DP
Finke J, *see* Engelhardt M
Finlay JL, *see* Zeltzer PM
Fiorentino MV, *see* Brandes AA
Fiorentino R, *see* Pignata S
Fischer B, *see* Heussel CP

Fisher B, Anderson S, DeCillis A, Atkins JN, Fehrenbacher L, Henry PH, Romond EH, Lanier KS, Davila E, Kardinal CG, Laufman L, Pierce HI, Abramson N, Keller AM, Hamm JT, Wickerham DL, Begovic M, Tan-Chiu E, Tian W, Wolmark N. Further Evaluation of Intensified and Increased Total Dose of Cyclophosphamide for the Treatment of Primary Breast Cancer: Findings From National Surgical Adjuvant Breast and Bowel Project B-25, 3374

Fisher B. National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial: A Reflective Commentary, 1632

Fisher B, *see* Day R
— *see* Gelmon K
— *see* Khoo K
— *see* Rusthoven JJ
— *see* Wolmark N

Fisher C, *see* Bonnefoi H

Fisher ER, *see* Wolmark N

Fisher RI, *see* Atkins MB
— *see* Cheson BD

Flamant F, *see* Martelli H

Flamen P, Stroobants S, Van Cutsem E, Dupont P, Bormans G, De Vadder N, Penninckx F, Van Hoe L, Mortelmans L. Additional Value of Whole-Body Positron Emission Tomography With Fluorine-18-2-Fluoro-2-deoxy-D-glucose in Recurrent Colorectal Cancer, 894

Flandrin G, *see* Harris NL

Fleming JB, Berman RS, Cheng S-C, Chen NP, Hunt KK, Feig BW, Respondek PM, Yasko AW, Pollack A, Patel SR, Burgess MA, Papadopoulos NE, Plager C, Zagars G, Benjamin RS, Pollock RE, Pisters PWT. Long-Term Outcome of Patients With American Joint Committee on Cancer Stage IIB Extremity Soft Tissue Sarcomas, 2772

Fletcher BD, Glicksman AS, Gieser P. Interobserver Variability in the Detection of Cervical-Thoracic Hodgkin's Disease by Computed Tomography, 2153

Flether CDM, *see* Baldini EH

Fleury J, *see* André M

Flombaum CD, Meyers PA. High-Dose Leucovorin as Sole Therapy for Methotrexate Toxicity, 1589

Flynn PJ, *see* Desch CE

Foekens JA, *see* Meijer-van Gelder ME

Fogarty LA, Curbow BA, Wingard JR, McDonnell K, Somerfield MR. Can 40 Seconds of Compassion Reduce Patient Anxiety?, 371

Fogt F, *see* Poremba C

Fokkema E, Groen HJM, Bauer J, Uges DRA, Weil C, Smith IE. Phase II Study of Oral Platinum Drug JM216 as First-Line Treatment in Patients With Small-Cell Lung Cancer, 3822

Fokkema E, *see* Groen HJM

Fonatsch C, *see* Hiddemann W

Fondurulia J, *see* D'Amico AV

Fonseca GA, *see* Valero V

Fonseca R, *see* Rajkumar SV

Font A, *see* Monzó M

Fontaine C, *see* Wils JA

Foon KA, John WJ, Chakraborty M, Das R, Teitelbaum A, Garrison J, Kashala O, Chatterjee SK, Bhattacharya-Chatterjee M. Clinical and Immune Responses in Resected Colon Cancer Patients Treated With Anti-Idiotype Monoclonal Antibody Vaccine That Mimics the Carcinoembryonic Antigen, 2889

Foran JM, Oscier D, Orchard J, Johnson SA, Tighe M, Cullen MH, de Takats PG, Kraus C, Klein M, Lister TA. Pharmacokinetic Study of Single Doses of Oral Fludarabine Phosphate in Patients With "Low-Grade" Non-Hodgkin's Lymphoma and B-Cell Chronic Lymphocytic Leukemia, 1574

Foran JM, Rohatiner AZS, Coiffier B, Barbui T, Johnson SA, Hiddemann W, Radford JA, Norton AJ, Tollerfield SM, Wilson MP, Lister TA. Multicenter Phase II Study of Fludarabine Phosphate for Patients With Newly Diagnosed Lymphoplasmacytoid Lymphoma, Waldenström's Macroglobulinemia, and Mantle-Cell Lymphoma, 546

Foran JM, *see* Apostolidis J

Forman D, *see* Velikova G

Fornier M, *see* Hudis C

Forral K, *see* Hammond LA

Forscher C, *see* Galanis E

Fortin A, Larochelle M, Laverdiére J, Lavertu S, Tremblay D. Local Failure Is Responsible for the Decrease in Survival for Patients With Breast Cancer Treated With Conservative Surgery and Postoperative Radiotherapy, 101

Fortuna G, *see* Pignata S

Foshag LJ, *see* O'Day SJ

Foss H-D, *see* Marafioti T

Fossâ A, Santoro A, Hiddemann W, Truemper L, Niederie N, Buksmaui S, Bonadonna G, Seeber S, Nowrousian MR. Gemcitabine as a Single Agent in the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma, 3786

Fossâ SD, Horwich A. In reply (correspondence), 3002

Fossâ SD, Horwich A, Russell JM, Roberts JT, Cullen MH, Hodson NJ, Jones WG, Yosef H, Duchesne GM, Owen JR, Grosch EJ, Chetiyawardana AD, Reed NS, Widmer B, Stenning SP for the Medical Council Testicular Tumor Working Party. Optimal Planning Target Volume for Stage I Testicular Seminoma: A Medical Research Council Randomized Trial, 1146

Fossati R, Confalonieri C, Torri V, Liberati A. In reply (correspondence), 1644

Fossella FV, *see* Glisson BS

Fouladi M, Gajjar A, Boyett JM, Walter AW, Thompson SJ, Merchant TE, Jenkins JJ, Langston JW, Liu A, Kun LE, Heideman RL. Comparison of CSF Cytology and Spinal Magnetic Resonance Imaging in the Detection of Leptomeningeal Disease in Pediatric Medulloblastoma or Primitive Neuroectodermal Tumor, 3234

Fouladi M, *see* Gajjar A

Fountzilas G, *see* Papadimitriou CA

Fournier P, *see* O'Day SJ

Fowble B, Hanlon A, Freedman G, Patchefsky A, Kessler H, Nicolaou N, Hoffman J, Sigurdson E, Boraas M, Goldstein L. Postmenopausal Hormone Replacement Therapy: Effect on Diagnosis and Outcome in Early-Stage Invasive Breast Cancer Treated With Conservative Surgery and Radiation, 1680

Fowble BL, *see* Recht A

Fowler WC Jr, *see* Whitney CW

Fox KC, *see* Piccone MR

Fox NJ, *see* Glisson BS

Fox RM, *see* Basser RL
— *see* Clarke K

Fracasso P, *see* Adkins D

François E, *see* André T

Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean J-P, Partensky C, Souquet JC, Adeleine P, Gerard J-P. Influence of the Interval Between Preoperative Radiation Therapy and Surgery on Downstaging and on the Rate of Sphincter-Sparing Surgery for Rectal Cancer: The Lyon R90-01 Randomized Trial, 2396

Frank R, *see* Moskowitz CH

Frankel S, *see* Esserman L
Franklin J, *see* Diehl V
Franklin S, *see* Nathan C-AO
Franssila K, *see* Diehl V
Franzke A, Peest D, Probst-Kepper M, Buer J, Kirchner GI, Brabant G, Kirchner H, Ganser A, Atzpodien J. Autoimmunity Resulting From Cytokine Treatment Predicts Long-Term Survival in Patients With Metastatic Renal Cell Cancer, 529
Frascella E, *see* Carli M
Frasci G, Panza N, Comella P, Nicolella GP, Natale M, Manzione L, Bilancia D, Cioffi R, Maiorino L, DeCataldis G, Belli M, Micillo E, Mascia V, Massidda B, Lorusso V, De Lena M, Carpagnano F, Contu A, Pusceddu G, Comella G for the Southern Italy Cooperative Oncology Group. Cisplatin, Gemcitabine, and Paclitaxel in Locally Advanced or Metastatic Non-Small-Cell Lung Cancer: A Phase I-II Study, 2316
Frasci G, *see* Comella P
Freedman AS, *see* Friedberg JW
Freedman G, *see* Fowble B
Frei E III. C. Gordon Zubrod, MD *(In Memoriam)*, 1331
Frei E III, *see* Costanza ME
— *see* Elias A
Freidlin B, *see* Bubley GJ
— *see* Cheson BD
— *see* Smith MA
Freitag L, *see* Thomas M
Freytes C, *see* Adkins D
Frezza P, *see* Pignata S
Fridrik M, *see* Jakesz R
Fried MP, *see* Colevas AD
Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer RJ, Freedman AS. Outcome in Patients With Myelodysplastic Syndrome After Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma, 3128
Friedland D, *see* Stevenson JP
Friedman AH, *see* Friedman HS
— *see* Yung WKA
Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, Parry M, Houghton PJ, Lovell S, Rasheed K, Cloughsey T, Stewart ES, Colvin OM, Provenzale JM, McLendon RE, Bigner DD, Cokgor I, Haglund M, Rich J, Ashley D, Malczyn J, Elfring GL, Miller LL. Irinotecan Therapy in Adults With Recurrent or Progressive Malignant Glioma, 1516
Friedman HS, *see* Yung WKA
Friedrichs K, *see* Chan S
Friess H, *see* Zhu Z
Frink B, *see* Rizzo JD
Frost M, *see* Poremba C
Fry D, *see* Sparano JA
Frye D, *see* Buzdar AU
Fujimura S, *see* Sato G
Fujisawa T, Iizasa T, Saitoh Y, Sekine Y, Motohashi S, Yasukawa T, Shibuya K, Hiroshima K, Ohwada H. Smoking Before Surgery Predicts Poor Lung-Term Survival in Patients With Stage I Non-Small-Cell Lung Carcinomas, 2086
Fujiwara Y. Current Status of Oral Anticancer Drugs in Japan, 3360
Fuks Z, *see* Zelefsky MJ
Fukuoka M, *see* Furuse K
Fukuse T, *see* Tanaka F
Fuller AJ Jr, *see* Penson RT
Fumoleau P, *see* Lhommé C
Furman WL, Stewart CF, Poquette CA, Pratt CB, Santana VM, Zamboni WC, Bowman LC, Ma MK, Hoffer FA, Meyer WH, Pappo AS, Walter AW, Houghton PJ. Direct Translation of a Protracted Irinotecan Schedule From a Xenograft Model to a Phase I Trial in Children, 1815
Furuse K, Fukuoka M, Kawahara M, Nishikawa H, Takada Y, Kudoh S, Katagami N, Ariyoshi Y for the West Japan Lung Cancer Group. Phase III Study of Concurrent Versus Sequential Thoracic Radiotherapy in Combination With Mitomycin, Vindesine, and Cisplatin in Unresectable Stage III Non-Small-Cell Lung Cancer, 2692
Furuse K, Kawahara M, Nishiwaki Y, Fukuoka M, Takada M, Miyashita M, Ohashi Y. Phase I/II Study of Vinorelbine, Mitomycin, and cisplatin for Stage IIIB or IV Non-Small-Cell Lung Cancer, 3195

Gadner H, *see* Koscielniak E
Gafà R, *see* Lanza G
Gafni A, *see* Whelan T
Gail MH, Rimer BK. In reply (correspondence), 730
Gajewski JL, *see* Lazarus HM
Gajjar A, Fouladi M, Walter AW, Thompson SJ, Reardon DA, Merchant TE, Jenkins JJ, Liu A, Boyett JM, Kun LE, Heideman RL. Comparison of Lumbar and Shunt Cerebrospinal Fluid Specimens for Cytologic Detection of Leptomeningeal Disease in Pediatric Patients With Brain Tumors, 1825
Gajjar A, *see* Fouladi M
— *see* Pui C-H
— *see* Walter AW
Gajjar AJ, *see* Woo MH
Galanis E, Hersh EM, Stopeck AT, Gonzalez R, Purch P, Spier C, Akporiaye ET, Rinehart JJ, Edmonson J, Sobol RE, Forscher C, Sondak VK, Lewis BD, Unger EC, O'Driscoll M, Selk L, Rubin J. Immunotherapy of Advanced Malignancy by Direct Gene Transfer of an Interleukin-2 DNA/DMRIE/DOPE Lipid Complex: Phase I/II Experience, 3313
Gale D, *see* Richards JM
Gale RP, *see* Lazarus HM
Galieni P, *see* Zinzani PL
Gallagher M, *see* Stevenson JP
Gallo C, *see* Pignata S
Gallo J, *see* Schilder RJ
Gamble GP, *see* Graziano SL
Gamelin E, Boisdron-Celle M, Guérin-Meyer V, Delva R, Lortholary A, Genevieve F, Larra F, Ifrah N, Robert J. Correlation Between Uracil and Dihydrouracil Plasma Ratio, Fluorouracil (5-FU) Pharmacokinetic Parameters, and Tolerance in Patients With Advanced Colorectal Cancer: A Potential Interest for Predicting 5-FU Toxicity and Determining Optimal 5-FU Dosage, 1105
Gammon G, *see* O'Day SJ
Gandara D, *see* Murray N
Gandini S, *see* Decensi A
Ganjoo KN, Chan RJ, Sharma M, Einhorn LH. Positron Emission Tomography Scans in the Evaluation of Postchemotherapy Residual Masses in Patients With Seminoma, 3457
Ganjoo KN, Loyal JA, Cramer HM, Leohrer PJ. Lung Cancer Presenting With Solitary Bone Metastases; Case 1: Metastatic Adenocarcinoma to the Patella, 2995
Ganser A, *see* Franzke A

Ganz PA, Desmond KA, Belin TR, Meyerowitz BE, Rowland JH. Predictors of Sexual Health in Women After a Breast Cancer Diagnosis, 2371
Ganz Pa, *see* Day R
Ganz PA, *see* Mandelblatt JS
García M, *see* Cardenal F
Garden AS, Glisson BS, Ang KK, Morrison WH, Lippman SM, Byers RM, Geara F, Clayman GL, Shin DM, Callender DL, Khuri FR, Goepfert H, Hong WK, Peters LJ. Phase I/II Trial of Radiation With Chemotherapy "Boost" for Advanced Squamous Cell Carcinomas of the Head and Neck: Toxicities and Responses, 2390
Gariépy G, *see* Hébert-Croteau N
Garrison J, *see* Foon KA
Garrison L, *see* Jones SE
Garrone O, *see* Esposito M
Garst J, *see* Devore RF
Garuti A, *see* Ballestrero A
Gasbarri A, Martegani MP, Del Prete F, Lucante T, Natali PG, Bartolazzi A. Galectin-3 and CD44v6 Isoforms in the Preoperative Evaluation of Thyroid Nodules, 3494
Gascoyne RD, *see* Macpherson N
Gaudin P, *see* Zelefsky MJ
Gaynon PS, *see* Reaman GH
— *see* Sun L
Geara F, *see* Garden AS
Geary R, *see* Nemunaitis J
pppGeerts M-L, *see* Bekkenk MW
Geisler HE. Optimal Cytoreduction in Stage IV Ovarian Carcinoma (correspondence), 3002
Gelber RD, *see* Parson SK
Gelber S, *see* Parson SK
Geldard H, *see* Clarke K
Gelderblom AH, *see* de Jonge MJA
Gelmon K, Eisenhauer E, Bryce C, Tolcher A, Mayer L, Tomlinson E, Zee B, Blackstein M, Tomiak E, Yau J, Batist G, Fisher B, Iglesias J. Randomized Phase II Study of High-Dose Paclitaxel With or Without Amifostine in Patients With Metastatic Breast Cancer, 30338
Gelmon KA, *see* Tolcher AW
Gelmon KA, Tolcher A, Diab AR, Bally MB, Embree L, Hudon N, Dedhar C, Ayers D, Eisen A, Melosky B, Burge C, Logan P, Mayer LD. Phase I Study of Liposomal Vincristine, 697
Genatas K, *see* Androulakis N
Gendron K, *see* Piccone MR
Genevieve F, *see* Gamelin E
Gennari A, Salvadori B, Donati S, Bangala C, Orlandini C, Danesi R, Del Tacca M, Bruzzi P, Conte PF. Cardiotoxicity of Epirubicin/Paclitaxel-Containing Regimens: Role of Cardiac Risk Factors, 3596
Genot JY, *see* Nabholtz JM
Gentile M, *see* Iaffaioli RV
Gentilini P, *see* Zinzani PL
Georgoulias V, Kouroussis C, Androulakis N, Kakolyris S, Dimopoulos M-A, Papadakis E, Bouros D, Apostolopoulou F, Papadimitriou C, Agelidou A, Hatzakis K, Kalbakis K, Kotsakis A, Vardakis N, Vlachonicolis J. Front-Line Treatment of Advanced Non-Small-Cell Lung Cancer With Docetaxel and Gemcitabine: A Multicenter Phase II Trial, 914
Georgoulias V, *see* Androulakis N
— *see* Kouroussis C
Gerard J-P, *see* Francois Y
Gerber M, *see* Kleinberg L
Gerl A, *see* Bokemeyer C
German-Austrian Pediatric Hodgkin's Disease Study Group, *see* Schellong G
Gershenson DM, *see* Brewer M
— *see* Rose PG
Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng C-H, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-Institutional Melanoma Lymphatic Mapping Experience: The Prognostic Value of Sentinel Lymph Node Status in 612 Stage I or II Melanoma Patients, 976
Gerstner JB, *see* Bonner JA
Gertz MA, Lacy MQ, Lust JA, Greipp PR, Witzig TE, Kyle RA. Prospective Randomized Trial of Melphalan and Prednisone Versus Vincristine, Carmustine, Melphalan, Cyclophosphamide, and Prednisone in the Treatment of Primary Systemic Amyloidosis, 262
Gertz MA, *see* Rajkumar SV
Gesme D, *see* Stovall E
Geyer JR, *see* Zeltzer PM
Gherlinzoni F, *see* Zinzani PL
Giaccone G. In reply (correspondence), 730
Giaccone G, *see* Kroep JR
Giannakoulis N, *see* Papadimitriou CA
Giardini R, *see* Tondini C
Giatromanolaki A, *see* Koukourakis MI
Gibril F, *see* Yu F
Gieser P, *see* Fletcher BD
— *see* Pratt CB
Gika D, *see* Papadimitriou CA
Gil MG, *see* Chan S
Gilbert C, *see* Rizzieri DA
Gilbert M, *see* Chang SM
Giles FJ
see Beran M
see Kantarjian HM
Gilewski T, *see* Hudis C
Gill DP, *see* Gralla RJ
Gill PS, Tulpule A, Espina BM, Cabriales S, Bresnahan J, Ilaw M, Louie S, Gustafson NF, Brown MA, Orcutt C, Winograd B, Scadden DT. Paclitaxel Is Safe and Effective in the Treatment of Advanced AIDS-Related Kaposi's Sarcoma, 1876
Giller R, *see* Marina NM
Gillio AP, *see* Boulad F
Ginsberg JP, de Alava E, Ladanyi M, Wexler LH, Kovar H, Paulussen M, Zoubek A, Dockhorn-Dworniczak BH, Juergens H, Wunder JS, Andrulis IL, Malik R, Sorensen PHB, Womer RB, Barr FG. *EWS-FLI1* and *EWS-ERG* Gene Fusions Are Associated With Similar Clinical Phenotypes in Ewing's Sarcoma, 1809
Giorgiani G, *see* Bonetti F
— *see* Zecca M
Giralt S, *see* Kantarjian HM
Girschikofsky M, *see* Zach O
Gisselbrecht C, *see* André M
Giulia MD, *see* Crinò L
Given FT, *see* Thigpen JT
Giwercman A, *see* Petersen PM
Glantz MJ, LaFollette S, Jaeckle KA, Shapiro W, Swinnen L, Rozental JR, Phuphanich S, Rogers LR, Gutheil JC, Batchelor T, Lyter D, Chamberlain M, Maria BL, Schiffer C, Bashir R, Thomas D,

Cowens W, Howell SB. Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous Meningitis, 3110
Glass AG, *see* Wolmark N
Glass J, *see* Nathan C-AO
Glassman J, *see* Groeger JS
Glassman JR, *see* Moskowitz CH
Glatting G, *see* Schirrmeister H
Glazer PM, *see* Turner BC
Gleason MJ, *see* Wong ET
Glicksman AS, *see* Fletcher BD
Glimelius B, *see* Kressner U
Glisson BS, Kurie JM, Perez-Soler R, Fox NJ, Murphy WK, Fossella FV, Lee JS, Ross MB, Nyberg DA, Pisters KMW, Shin DM, Hong WK. Cisplatin, Etoposide, and Paclitaxel in the Treatment of Patients With Extensive Small-Cell Lung, 2309
Glisson BS, *see* Garden AS
Glück S, *see* Theriault RL
Gnant M, *see* Jakesz R
Go RS, Adjei AA. Review of the Comparative Pharmacology and Clinical Activity of Cisplatin and Carboplatin, 409
Gobbi M, *see* Ballestrero A
Göoel U, *see* Bamberg M
— *see* Schneider DT
Godzinski J, *see* Martelli H
Goebel F-D, *see* Jung Ch
Goebel SU, *see* Yu F
Goelen G, Rigo A, Bonduelle M, De Gréve. Moral Concerns of Different Types of Patients in Clinical *BRCA1/2* Gene Mutation Testing, 1595
Goepfert H, *see* Garden AS
Goldberg J, *see* Baldini EH
Goldhirsch A, *see* Bernhard J
Goldstein D, *see* Bishop JF
Goldstein L, *see* Fowble B
Goldstone AH, *see* Perry AR
— *see* Sweetenham JW
Goldwasser F, *see* Wasserman E
Goldwein J, *see* Packer RJ
Gollub M, *see* Ilson DH
Gomolin HI, *see* Colevas AD
Gonella R, *see* Ballestrero A
Gonzalez G, *see* Ilson DH
González I, *see* Tortola S
González-Larriba JL
see Cardenal F
see Monzó M
Gonzalez R, *see* Galanis E
Goodin S, *see* DiPaola RS
Goodman PA, *see* Sun L
Goodman S, *see* Carey LA
Goodnough L, *see* Adkins D
Goodnough LT, *see* Brown RA
Goodwin JW, *see* Murray N
Goodwin PJ, Ennis M, Pritchard KI, McCready D, Koo J, Sidlofsky S, Trudeau M, Hood N, Redwood S. Adjuvant Treatment and Onset of Menopause Predict Weight Gain After Breast Cancer Diagnosis, 120
Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of Menopause During the First Year After Breast Cancer Diagnosis, 2365
Goodwin PJ, *see* Phillips K-A
Goodwin W, *see* Royce ME
Gordon BG, *see* Baker KS
Gordon L, *see* Czuczman MS
Gordon LI, *see* Witzig TE
Gore ME, *see* Bonnefoi H
— *see* Bridgewater JA
Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH, Meyers PA. Expression of HER2/*erb*B-2 Correlates With Survival in Osteosarcoma, 2781
Goss P, *see* Hack TF
Goss PE, Winer EP, Tannock IF, Schwartz LH on behalf of the North American Vorozole Study Group. Randomized Phase III Trial Comparing the New Potent and Selective Third-Generation Aromatase Inhibitor Vorozole With Megestrol Acetate in Postmenopausal Advanced Breast Cancer Patients, 52
Gould A, *see* Velikova G
Gower NH, *see* Cullen MH
Gown AM, *see* Jacobs TW
Goy A, *see* Moskowitz CH
Gozzelino F, *see* Crinò L
Graber HU, *see* Zhu Z
Gradishar WJ, *see* Hensley ML
— *see* Sparano JA
Grafton C, *see* Murray N
Gragoudas ES, *see* Cutler C
— *see* Piccone MR
Graham J, *see* Vasey PA
Gralla R, *see* von Pawel J
Gralla RJ, Osoba D, Kris M, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG, American Society of Clinical Oncology. Recommendations for the Use of Antiemetics: Evidence-Based, Clinical Practice Guidelines, 2971
Gralla RJ, *see* Hesketh PJ
Gralow JR, *see* Ellis GK
Grandjean J-P, *see* Francois Y
Grann A, *see* Zelefsky MJ
Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI. Benefits and Costs of Screening Ashkenazi Jewish Women for *BRCA1* and *BRCA2*, 494
Grann VR, Whang W, Jacobson JS, Heitjan DF, Antman KH, Neugut AI. In reply (correspondence), 1958
Grant CS, *see* Reynolds C
Grasso S, *see* Acuña LR
Gravalos C, *see* Hidalgo M
Gravina A, *see* Iaffaioli RV
Gray R, *see* Recht A
— *see* Royce ME
Graziano SL, Gamble GP, Newman NB, Abbott LZ, Rooney M, Mookherjee S, Lamb ML, Kohman LJ, Poiesz BJ. Prognostic Significance of K-*ras* Codon 12 Mutations in Patients With Resected Stage I and II Non-Small-Cell Lung Cancer, 668
Green D, *see* Pratt CB
Green DM, Hyland A, Chung CS, Zevon MA, Hall BC. Cancer and Cardiac Mortality Among 15-Year Survivors of Cancer Diagnosed During Childhood or Adolescence, 3207
Green DM, *see* Breslow NE
— *see* Hensley ML
Green MD, *see* Basser RL
— *see* Clarke K

Green MR, *see* Clamon G
Greene GF, *see* Pisters LL
Greenwald C, *see* Marina NM
Gregg R, *see* Rusthoven JJ
Greggi R, *see* Pierelli L
Gregory RK, *see* Chang J
Gregory SA, *see* Venugopal P
Greil R, *see* Kemmler G
Greiner R, Bolla M, Storme G, Hulshof M, Bernier J, Denekamp J, Rojas AM, Pierart M, van Glabbeke M, Mirimanoff RO. Accelerated Radiotherapy, Carbogen, and Nicotinamide in Glioblastoma Multiforme: Report of European Organization for Research and Treatment of Cancer Trial 22933, 3143
Greiner TC, *see* Abou-Elella AA
Greipp PR, *see* Gertz MA
— *see* Rajkumar SV
Greten TF, Jaffee EM. Cancer Vaccines, 1047
Gribben JG, *see* Friedberg JW
Gridelli C, *see* Crinò L
Grier HE, *see* Pappo AS
Grier HE. Soft Tissue Sarcoma: Apples, Oranges, and Passion Fruit (editorial), 3695
Griffin T, *see* Blum JL
— *see* Villalona-Calero MA
Grillo-López A, *see* Cheson BD
Grillo-López AJ, *see* Czuczman MS
— *see* Davis TA
— *see* Witzig TE
Grimer RJ, *see* Bramwell VHC
Gritz ER, Carmack CL, de Moor C, Coscarelli A, Schacherer CW, Meyers EG, Abemayor E. First Year After Head and Neck Cancer: Quality of Life, 352
Groeger JS, White P Jr, Nierman DM, Glassman J, Shi W, Horak D, Price K. Outcome for Cancer Patients Requiring Mechanical Ventilation, 991
Groen HJM, Fokkema E, Biesma B, Kwa B, van Putten JWG, Postmus PE, Smit EF. Paclitaxel and Carboplatin in the Treatment of Small-Cell Lung Cancer Patients Resistant to Cyclophosphamide, Doxorubicin, and Etoposide: A Non-Cross-Resistant Schedule, 927
Groen HJM, *see* Fokkema E
Groome PA, *see* Boyd C
Groover RV, *see* Buckner JC
Grosch EJ, *see* Fosså SD
Groshen S, *see* Gralla RJ
Gross M, *see* Jung Ch
Gross TG, *see* Baker KS
Grossman JS, Kroener J. Misleading Title and Abstract in Recent Granulocyte-Macrophage Colony-Stimulating Factor Trial (correspondence), 1644
Grossman SA, *see* Kleinberg L
Groupe Français d'Immunothérapie, *see* Escudier B
Gruia G, *see* Herben VMM
Grunberg S, *see* Gralla RJ
Grunberg SM, Sofferman R, Roland T, Shubel S. Complications of Chemotherapy:1. Hemialopecia Due to Regional Chemotherapy, 430
Grünebach F, *see* Brugger W
Grunfeld E, *see* Smith TJ
Guardigni L, *see* Zinzani PL
Guasch I, *see* Cirera L
Guérin-Meyer V, *see* Gamelin E
Guerrieri-Gonzaga A, *see* Decensi A
Guhlmann A, *see* Schirrmeister H
Guillemin F, *see* Conroy T
Gumbs AA, *see* Turner BC
Guo M, *see* O'Day SJ
Gupta E, *see* DiPaola RS
Gurney H, *see* Bishop JF
Gustafson NF, *see* Gill PS
Gutheil J, *see* Witzig TE
Gutheil JC, *see* Glantz MJ
Guthrie KA, *see* Breslow NE

Haber DA. Breast Cancer in Carriers of *BRCA1* and *BRCA2* Mutations: Tackling a Molecular and Clinical Conundrum (editorial), 3367
Haber DA, *see* Nichols KE
Hacène K, *see* Bouchet C
Hack TF, Cohen L, Katz J, Robson LS, Goss P. Physical and Psychological Morbidity After Axillary Lymph Node Dissection for Breast Cancer, 143
Haffty BG, *see* Turner BC
Hagemeister FB, *see* Thomas DA
Hagenbeek A, *see* Cheson BD
— *see* Shipp MA
Haglund M, *see* Friedman HS
Haider K, *see* Jakesz R
— *see* Scheithauer W
Haie-Meder C, *see* Martelli H
Hait WN, *see* DiPaola RS
Hak LJ, *see* Woo MH
Halabi S, *see* Bubley GJ
— *see* Kantoff PW
Halikia A, *see* Pectasides D
Hall BC, *see* Green DM
Halley DJJ, *see* Verhoog LC
Hamblin TJ, *see* Caligaris-Cappio F
Hamm JT, *see* Fisher B
Hammerlid E, *see* Bjordal K
Hammond L, *see* Eckhardt SG
Hammond LA, Eckardt JR, Baker SD, Eckhardt SG, Dugan M, Forral K, Reidenberg P, Statkevich P, Weiss GR, Rinaldi DA, Von Hoff DD, Rowinsky EK. Phase I and Pharmacokinetic Study of Temozolomide on a Daily-for-5-Days Schedule in Patients With Advanced Solid Malignancies, 2604
Hammond LA, *see* Drengler RL
Hanauske A-R, *see* Thödtmann R
Hanlon A, *see* Fowble B
Hanna M, *see* Einhorn L
Hannah AL, *see* Eckhardt SG
Hannigan EV, *see* Whitney CW
Hanover CK, *see* Devore RF
Hansberry J, *see* Du Pen SL
Hansen SW, *see* Petersen PM
Hansmann M-L, *see* Diehl V
Haraf D, *see* List MA
Haraf DJ, Kies M, Rademaker AW, Stenson K, Mittal B, Pelzer H, Wenig B, Witt ME, Sulzen L, Weichselbaum RR, Vokes EE. Radiation Therapy With Concomitant Hydroxyurea and Fluorouracil in Stage II and III Head and Neck Cancer, 638
Hargraves K, *see* Ajani JA
Harms D, *see* Bamberg M
— *see* Koscielniak E

Harousseau J-L, *see* Decaudin D
Harper PG, *see* Highley MS
Harrington DP. The Tea Leaves of Small Trials (editorial), 1336
Harris M, *see* Diehl V
Harris N, *see* Diehl V
Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, Lister TA, Bloomfield CD. World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues: Report of the Clinical Advisory Committee Meeting – Airlie House, Virginia, November 1997, 3835
Harris NL, *see* Cheson BD
— *see* Nathwani BN
Harrison PL, *see* Pui C-H
— *see* Woo MH
Harrold E, *see* Turner BC
Hars V, *see* Kantoff PW
Harstrick A, *see* Bokemeyer C
— *see* Vanhoefer U
Hart GAM, *see* Theuws JCM
Harte RJA, Matthews JC, O'Reilly SM, Tilsley DWO, Osman S, Brown G, Luthra SJ, Brady F, Jones T, Price PM. Tumor, Normal Tissue, and Plasma Pharmacokinetic Studies of Fluorouracil Biomodulation With *N*-Phosphonacetyl-L-aspartate, Folinic Acid, and Interferon Alfa, 1580
Hartmann JT, *see* Bokemeyer C
Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen Receptor Status by Immunohistochemistry Is Superior to the Ligand-Binding Assay for Predicting Response to Adjuvant Endocrine Therapy in Breast Cancer, 1474
Hasenclever D, *see* Andrieu JM
Hatzakis K, *see* Georgoulias V
Hatzidaki D, *see* Kouroussis C
Hauptmann S, *see* Sturm I
Hausmaninger H, *see* Jakesz R
Hawkins D, *see* Pappo AS
Hawkins E, *see* Marina NM
Hawkins M, *see* Atkins MB
Hawkins MJ, *see* Marshall JL
Hayashi I, *see* Okamoto H
Hayes DF, *see* Shapiro CL
Hayes JT, *see* Wagner JD
Hayes K, *see* Beran M
Haynes H, *see* Wadler S
Healey D, *see* Tolcher AW
Healey JH, *see* Gorlick R
Health Services Research Committee of ASCO, *see* Bennett CL
Hearn S, *see* Herben VMM
Hébert-Croteau N, Brisson J, Latreille J, Gariépy G, Blanchette C, Deschênes L. Time Trends in Systemic Adjuvant Treatment for Node-Negative Breast Cancer, 1458
Hedge S, *see* Nichols KE
Hedrick EE, *see* Moskowitz CH
Heerema NA, *see* Reaman GH
Heffernan M, *see* Theriault RL
Hehenwarter W, *see* Zach O
Heideman RL, *see* Fouladi M
— *see* Gajjar A
— *see* Walter AW
Heifetz S, *see* Marina NM
Heinecke A, *see* Hiddemann W
Heinzer H, Mir TS, Huland E, Huland H. Subjective and Objective Prospective, Long-Term Analysis of Quality of Life During Inhaled Interleukin-2 Immunotherapy, 3612
Heise U, *see* Bielack SS
Heitjan D, *see* Petrylak DP
Heitjan DF, *see* Grann VR
Hejna M, *see* Scheithauer W
Helidonis ES, *see* Koukourakis MI
Heller B, Kane J, Penetrante R, Weber T, Rodriguez-Bigas M, Petrelli N. Large Bowel Adenocarcinoma Metastases Presenting as Appendicitis, 2623
Heller G, *see* Boulad F
— *see* Gorlick R
Hellman S. In reply (correspondence), 3689
Hellman S. The Key and the Lamppost (editorial), 3007
Henderson G, *see* Carey LA
Henderson IC, *see* Abrams J
— *see* Costanza ME
Hendrick RE, *see* American College of Radiology Task Force on Breast Cancer
Henry-Amar M, *see* André M
Henry PH, *see* Fisher B
Hensel N, *see* Childs RW
Hensley ML, Schuchter LM, Lindley C, Meropol NJ, Cohen GI, Broder G, Gradishar WJ, Green DM, Langdon RJ Jr, Mitchell RB, Negrin R, Szatrowski TP, Thigpen JT, Von Hoff D, Wasserman TH, Winer EP, Pfister DG for the American Society of Clinical Oncology. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants, 3333
Henson JW, Yang J, Batchelor T. Intraocular Methotrexate Level After High-Dose Intravenous Infusion (correspondence), 1326
Henze G, *see* Koscielniak E
— *see* Reich S
Herben VMM, Panday VRN, Richel DJ, Schellens JHM, van der Vange N, Rosing H, Beusenberg FD, Hearn S, Doyle E, Beijnen JH, ten Bokkel Huinink WW. Phase I and Pharmacologic Study of the Combination of Paclitaxel, Cisplatin, and Topotecan Administered Intravenously Every 21 Days as First-Line Therapy in Patients With Advanced Ovarian Cancer, 747
Herben VMM, Panday VRN, Richel DJ, Schellens JHM, van der Vange N, Rosing H, Beusenberg FD, Hearn S, Doyle E, Beijnen JH, ten Bokkel Huinink WW. Phase I and Pharmacologic Study of the Combination of Paclitaxel, Cisplatin, and Topotecan Administered Intravenously Every 21 Days as First-Line Therapy in Patients With Advanced Ovarian Cancer, 747
Herben VMM, Schellens JHM, Swart M, Gruia G, Vernillet L, Beijnen JH, ten Bokkel Huinink WW. Phase I and Pharmacokinetic Study of Irinotecan Administered as Low-Dose, Continuous Intravenous Infusion Over 14 Days in Patients With Malignant Solid Tumors, 1897
Herben VMM, van Gijn R, Schellens JHM, Schot M, Lieverst J, Hillebrand MJX, Schoemaker NE, Porro MG, Beijnen JH, ten Bokkel Huinink WW. Phase I and Pharmacokinetic Study of Daily Times 5 Short Intravenous Infusion Schedule of 9-Aminocamptothecin in a Colloidal Dispersion Formulation in Patients With Advanced Solid Tumors, 1906
Herbst M, *see* Koscielniak E
Herman EH, Zhang J, Lipshultz SE, Rifai N, Chadwick D, Takeda K, Yu Z-X, Ferrans VJ. Correlation Between Serum Levels of Cardiac

Troponin-T and the Severity of the Chronic Cardiomyopathy Induced by Doxorubicin, 2237
Hermans R, *see* Mancuso AA
Herndon J, *see* Clamon G
Hero B, *see* Berthold F
Herr H, *see* Bajorin DF
— *see* Dodd PM
Herrmann R, *see* Serke S
Hersey P, *see* Curry BJ
Hersh EM, *see* Galanis E
Herzog CE, *see* Brewer M
Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, Dirlam NL, Stack CB, Silberman SL. Randomized Phase II Study of the Neurokinin 1 Receptor Antagonist CJ-11,974 in the Control of Cisplatin-Induced Emesis, 338
Hesketh PJ. In reply (correspondence), 1644, 1958
Hesketh PJ, *see* Gralla RJ
Hess KR, *see* Wong ET
Heule F, *see* Bekkenk MW
Heussel CP. In reply (correspondence), 3856
Heussel CP, Kauczor H-U, Heussel GE, Fischer B, Begrich M, Mildenberger P, Thelen M. Pneumonia in Febrile Neutropenic Patients and in Bone Marrow and Blood Stem-Cell Transplant Recipients: Use of High-Resolution Computed Tomography, 796
Heussel GE, *see* Heussel CP
Heyn R, *see* Smith MA
Hidalgo M, Castellano D, Paz-Ares L, Gravalos C, Diaz-Puente M, Hitt R, Alonso S, Cortes-Funes H. Phase I-II Study of Gemcitabine and Fluorouracil as a Continuous Infusion in Patients With Pancreatic Cancer, 585
Hiddemann W, Kern W, Schoch C, Fonatsch C, Heinecke A, Wörmann B, Büchner T. Management of Acute Myeloid Leukemia in Elderly Patients, 3569
Hiddemann W, *see* Cheson BD
— *see* Foran JM
— *see* Fosså A
Hietanen P, *see* Pyrhönen S
Higgins G, *see* Bajorin DF
— *see* Dodd PM
Highley MS, Underhill CR, Parnis FX, Karapetis C, Rankin E, Dussek J, Bryant B, Rowland C, Hodson N, Hughes J, Harper PG. Treatment of Invasive Thymoma With Single-Agent Ifosfamide, 2737
Hilgenfeld E, *see* Schneider DT
Hill GJ. Institutional Review Board Review of Research Reported in the *Journal of Clinical Oncology* (correspondence), 2625
Hill JS, *see* Clarke K
Hillebrand MJX, *see* Herben VMM
Hillebrand T, *see* Sturm I
Hillman S, *see* Bonner JA
Hilsenbeck SG, *see* Jatoi I
Hiponia D, *see* Belani CP
Hiroshima K, *see* Fujisawa T
Hitt R, *see* Hidalgo M
Hjermstad MJ, Evensen SA, Kvaløy SO, Fayers PM, Kaasa S. Health-Related Quality of Life 1 Year After Allogeneic or Autologous Stem-Cell Transplantation: A Prospective Study, 706
Ho J, *see* Michael M
Hochster H, Wadler S, Runowicz C, Liebes L, Cohen H, Wallach R, Sorich J, Taubes B, Speyer J for the New York Gynecologic Oncology Group. Activity and Pharmacodynamics of 21-Day Topotecan Infusion in Patients With Ovarian Cancer Previously Treated With Platinum-Based Chemotherapy, 2553
Hodges S, *see* Drengler RL
Hodson N, *see* Highley MS
Hodson NJ, *see* Fosså SD
Hoelzer K, *see* Adkins D
Hoff PM, *see* Royce ME
Hoffer FA, *see* Furman WL
Hoffman J, *see* Fowble B
Hogendoorn PCW, *see* Bramwell VHC
Hollister T, *see* Zelefsky MJ
Holm R, *see* Baekelandt M
Holmberg L, *see* Liljegren G
Holmes EJ, *see* Reaman GH
Holmes FA, *see* Berry DL
Holmlund J, *see* Stevenson JP
Holmlund JT, *see* Nemunaitis J
Holzner B, *see* Kemmler G
Homesley HD, *see* Thigpen JT
Hong J-H, *see* Tseng C-J
Hong WK, *see* Garden AS
— *see* Glisson BS
Honig S, *see* Jones S
Honna T, *see* Kawa K
Honnebier MB, *see* Wong JH
Hood N, *see* Goodwin PJ
Hoon DSB, *see* Bostick PJ
Hop WCJ, *see* Nouwen JL
Hoppe R, *see* Cheson BD
Horak D, *see* Groeger JS
Horak I, *see* Sabbatini P
Horning SJ, *see* Cheson BD
Horowitz MM, *see* Lazarus HM
— *see* Rowlings PA
Horsman D, *see* Macpherson N
Hortobagyi GN. High-Dose Chemotherapy for Primary Breast Cancer: Facts Versus Anecdotes, 25(Supp.)
Hortobagyi,GN
— *see* Kuerer HM
—*see* Berry DL
— *see* Buzdar AU
— *see* Theriault RL
— *see* Valero V
— *see* Vassilopoulou-Sellin R
Horwich A, *see* Fosså SD
Hoskins WJ, *see* Bridgewater JA
Houghton AN, *see* Chapman PB
Houghton PJ, *see* Friedman HS
— *see* Furman WL
Howard RS, *see* Murray CK
Howell SB, *see* Glantz MJ
Howell SJ, Radford JA, Ryder WDJ, Shalet SM. Testicular Function After Cytotoxic Chemotherapy: Evidence of Leydig Cell Insufficiency, 1493
Hsueh S, *see* Tseng C-J
Hu P, *see* Sparano JA
Huan S, *see* Moore MJ
Huang Y, *see* Ilson DH

Hudes G, *see* Bubley GJ
Hudes G. Signaling Inhibitors in the Clinic: New Agents and New Challenges (editorial), 1093
Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas KS, Yao TJ, Norton L. 5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women With High-Risk Node-Positive Breast Cancer: A Phase II Study, 1118
Hudis C, Seidman A, Baselga J, Raptis G, Lebwohl D, Gilewski T, Moynahan M, Sklarin N, Fennelly D, Crown JPA, Surbone A, Uhlenhopp M, Riedel E, Yao TJ, Norton L. Sequential Dose-Dense Doxorubicin, Paclitaxel, and Cyclophosphamide for Resectable High-Risk Breast Cancer: Feasibility and Efficacy, 93
Hudon N, *see* Gelmon KA
Huebner K, *see* Croce CM
Hughes J, *see* Highley MS
Huhn D, *see* Marafioti T
— *see* Serke S
Huhtala S, *see* Salminen E
Huland E, *see* Heinzer H
Huland H, *see* Heinzer H
Hulshof M, *see* Greiner R
Humblet Y, *see* Leyvraz S
Hummel M, *see* Marafioti T
Hunneman DH, *see* Berthold F
Hunt K, *see* Buzdar AU
Hunt KK, *see* Fleming JB
— *see* Kuerer HM
— *see* McMasters KM
Hunt YS, *see* Spunt SL
Hunte S, *see* Moskowitz CH
Hupperets PSGJ, *see* Nabholtz JM
Hurny C, *see* Bernhard J
Hurst HC, *see* Pandha HS
Hussain M, *see* Bubley GJ
Hussein A, *see* Carter DL
— *see* Rizzieri DA
Hutchins G, *see* Wagner JD
Hutchison RE, *see* Suryanarayan K
Huvos AG, *see* Gorlick R
Huynh KT, *see* Bostick PJ
Hwu P, *see* Rosenberg SA
Hyland A, *see* Green DM
Hylton N, *see* Esserman L
Hyman W, *see* Jones SE
Hyodo I, *see* Boku N

Iaffaioli RV, Tortoriello A, Facchini G, Caponigro F, Gentile M, Marzano N, Gravina A, Dimitri P, Costagliola G, Ferraro A, Ferrante G, De Marino V, Illiano A. Phase I-II Study of Gemcitabine and Carboplatin in Stage IIIB-IV Non-Small-Cell Lung Cancer, 921
Ibrahim J, *see* Elias A
Ibrahim N, *see* Buzdar AU
Ifrah N, *see* Gamelin E
Iglehart JD, *see* Bluman LG
— *see* Parmigiani G
Iglesias J, *see* Gelmon K
— *see* Rusthoven JJ
Iizasa T, *see* Fujisawa T
Ilaw M, *see* Gill PS
Illiano A, *see* Iaffaioli RV
Ilson DH, Saltz L, Enzinger P, Huang Y, Kornblith A, Gollub M, O'Reilly E, Schwartz G, DeGroff J, Gonzalez G, Kelsen DP. Phase II Trial of Weekly Irinotecan Plus Cisplatin in Advanced Esphageal Cancer, 3270
Imbriaco M, *see* Sabbatini P
Inganäs M, *see* Kressner U
Ingle JN, *see* Roche PC
International Collaborative Cancer Group, *see* Wils JA
International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. Efficacy of Adjuvant Fluorouracil and Folinic Acid in B2 Colon Cancer, 1356
Iodice F, *see* Pignata S
Isaacs C, *see* Tolcher AW
Ishikura S, *see* Ohtsu A
Ishioka C, *see* Nichols KE
Isobe H, *see* Okamoto H
Italian Association for Pediatric Hematology and Oncology – Bone Marrow Transplantation Group, *see* Bonetti F
Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation. Monitoring Treatment and Survival in Chronic Myeloid Leukemia, 1858
Italian Prostate Cancer Project, *see* Boccardo F
Iversen OE, *see* Salvesen HB
Iwafuchi M, *see* Kawa K
Izbicki JR, *see* Kubuschok B

Jäckel A, *see* Deichmann M
Jackisch C, *see* von Minckwitz G
Jackson VP, *see* American College of Radiology Task Force on Breast Cancer
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Comparison of Fluorescence In Situ Hybridization and Immunohistochemistry for the Evaluation of *HER-2/neu* in Breast Cancer, 1974
Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in Determining *HER-2/neu* Status of Breast Cancer Using the United States Food and Drug Administration-Approved Scoring System, 1983
Jacobs TW, Schnitt SJ, Gown AM, Yaziji H. In reply (correspondence), 3691
Jacobsen MB, *see* Wymenga ANM
Jacobson E, *see* Robins HI
Jacobson JS, *see* Grann VR
Jacucci R, *see* Aversa F
Jaeckle KA, *see* Glantz MJ
— *see* Wong ET
Jaffe E, *see* Diehl V
Jaffe ES, *see* Bishop PC
— *see* Harris NL
— *see* Rowlings PA
Jaffee EM, *see* Greten TF
Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R, Stierer M, Fridrik M, Mlineritsch B, Steindorfer P, Mittlböck M, Steger G and the Austrian Breast Cancer Study Group. Randomized Trial of Low-Dose Chemotherapy Added to Tamoxifen in Patients With Receptor-Positive and Lymph Node-Positive Breast Cancer, 1701
Jaklitsch MT, *see* Liu G
Jallow H, *see* Friedberg JW
James K, *see* Murray N
Janakiraman N, *see* Witzig TE

Janik J, *see* Bishop PC
Jänne PA, Datta MW, Johnson BE. Lung Cancer Presenting With Solitary Bone Metastases; Case 2: Acrometastasis as an Initial Presentation of Non-Small-Cell Lung Carcinoma, 2995
Jannert M, *see* Bjordal K
Japan Clinical Oncology Group – Lung Cancer Study Group, *see* Okamoto H
Jatoi I, Hilsenbeck SG, Clark GM, Osborne CK. Significance of Axillary Lymph Node Metastasis in Primary Breast Cancer, 2334
Jean-François R, *see* Ayoub J
Jenkins JJ, *see* Fouladi M
— *see* Gajjar A
— *see* Pratt CB
— *see* Spunt SL
Jenner C, *see* Baldini EH
Jensen RT, *see* Yu F
Jeremic B, Shibamoto Y, Nikolic N, Milicic B, Milisavljevic S, Dagovic A, Aleksandrovic J, Radosavljevic-Asic G. Role of Radiation Therapy in the Combined-Modality Treatment of Patients With Extensive Disease Small-Cell Lung Cancer: A Randomized Study, 2092
Jerian S, Keegan P. Cardiotoxicity Associated With Paclitaxel/Trastuzumab Combination Therapy (correspondence), 1644
Jett JR, *see* Bonner JA
Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS. Declining Rates of Extracapsular Extension After Radical Prostatectomy: Evidence for Continued Stage Migration, 3167
Johansson H, *see* Decensi A
John WJ, *see* Foon KA
Johnsen HE, *see* Serke S
Johnson BE, *see* Chute JP
— *see* Cortazar P
— *see* Jänne PA
Johnson DB, *see* Vesole DH
Johnson DH, Carbone DP. Increased Dose-Intensity in Small-Cell Lung Cancer: A Failed Strategy? (editorial), 2297
Johnson DH, *see* Devore RF
Johnson PWM, *see* Apostolidis J
Johnson RD, *see* Thödtmann R
Johnson S, *see* Schilder RJ
Johnson SA, *see* Foran JM
Johnson TD, *see* O'Day SJ
Johnston CM, *see* Eisbruch A
Johnston SJ, *see* Ahmed FY
Johnstone HS, *see* Reaman GH
Jolis L, *see* Cirera L
Jonas C, *see* Czuczman MS
Jones J, *see* Mamounas E
— *see* Wolmark N
Jones R, *see* Rizzieri DA
Jones S, Vogel C, Arkhipov A, Fehrenbacher L, Eisenberg P, Cooper B, Honig S, Polli A, Whaley F, di Salle E, Tiffany J, Consonni A, Miller L for the Aromasin Study Group. Multicenter, Phase II Trial of Exemestane as Third-Line Hormonal Therapy of Postmenopausal Woman With Metastatic Breast Cancer, 3418
Jones SE, Khandelwal P, McIntyre K, Mennel R, Orr D, Kirby R, Agura E, Duncan L, Hyman W, roque T, regan D, Schuster M, Dimitrov N, Garrison L, Lange M. Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Hematopoietic Growth Factor PIXY321 After Moderate-Dose Fluorouracil, Doxorubicin, and Cyclophosphamide in Stage II and III Breast Cancer, 3025
Jones SE, *see* Blum JL
Jones T, *see* Harte RJA
Jones WG, *see* Fosså SD
Jordan VC. Tamoxifen: Too Much of a Good Thing? (editorial), 2629
Joshi R, *see* Cullen MH
Jouet J-P, *see* André M
Judge T, *see* Petrylak DP
Juergens H, *see* Ginsberg JP
Jung Ch, Gross M, Kronawitter U, Danhauser-Riedl S, Goebel F-D, Schlondorff D. Two Uncommon Lymphomas; Case 1: Abdominal Burkitt's Lymphoma, 726
Junker K, *see* Thomas M
Junor EJ, *see* Vasey PA
Juran BD, *see* Sun L
Jurcic J, *see* Moskowitz CH
Jürgens H, *see* Koscielniak E
Juttner CA, *see* Basser RL
Juusela H, *see* Pyrhönen S

Kaasa S, *see* Bjordal K
— *see* Hjermstad MJ
— *see* Loge JH
Kabashima A, *see* Maehara Y
Kahn KL, *see* Mandelblatt JS
Kakeji Y, *see* Maehara Y
Kaklamani E, *see* Kaklamani VG
Kaklamani VG, Linos A, Kaklamani E, Markaki I, Koumantaki Y, Mantzoros CS. Dietary Fat and Carbohydrates Are Independently Associated With Circulating Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor – Binding Protein 3 Concentrations in Healthy Adults, 3291
Kaklamani VG, Linos A, Kaklamani E, Markaki I, Mantzoros C. Age, Sex, and Smoking Are Predictors of Circulating Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor-Binding Protein 3, 813
Kakolyris S, *see* Androulakis N
— *see* Georgoulias V
— *see* Kouroussis C
Kalantaridou A, *see* Pectasides D
Kalbakis K, *see* Georgoulias V
Kaleya R, *see* Wadler S
Kalifa C, *see* Tabone M-D
Kalla S, *see* Wasserman E
Kane J, *see* Heller B
Kaneko K, *see* Ohtsu A
Kaneko M, *see* Kawa K
Kantarjian H, *see* Beran M
— *see* Thomas DA
Kantarjian HM, O'Brian S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M. Treatment of Philadelphia Chromosome-Positive Early Chronic Phase Chronic Myelogenous Leukemia With Daily Doses of Interferon Alpha and Low-Dose Cytarabine, 284
Kantoff PW, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer EP, Vogelzang NJ. Hydrocortisone With or Without Mitoxantrone in Men With Hormone-Refractory Prostate Cancer: Results of the Cancer and Leukemia Group B 9182 Study, 2506
Kantoff PW, *see* Oh WK
Kanz L, *see* Bokemeyer C
— *see* Brugger W
Kaplan I, *see* D'Amico AV

Kaplan R, *see* Bubley GJ
Karabekios S, *see* Androulakis N
Karapetis C, *see* Highley MS
Kardinal CG, *see* Fisher B
Karkavitsas N, *see* Koukourakis MI
Karvounis N, *see* Pectasides D
Kashala O, *see* Foon KA
Kasparu H, *see* Zach O
Katagami N, *see* Furuse K
Katschinski DM, *see* Robins HI
Katsogridakis K, *see* Kouroussis C
Kattan MW, Wheeler TM, Scardino PT. Postoperative Nomogram for Disease Recurrence After Radical Prostatectomy for Prostate Cancer, 1499
Katz J, *see* Hack TF
Kau S-W, *see* Buzdar AU
Kauczor H-U, *see* Heussel CP
Kaufman DS, *see* Shipley WU
Kaufmann M, *see* von Minckwitz G
Kaul S, *see* Brugger W
Kawa K, Ohnuma N, Kaneko M, Yamamoto K, Etoh T, Mugishima H, Ohhira M, Yokoyama J, Bessho F, Honna T, Yoshizawa J, Nakada K, Iwafuchi M, Nozaki T, Mimaya J, Sawada T, Nakamura T, Miyata H, Yamato K, Tsuchida Y. Long-Term Survivors of Advanced Neuroblastoma With *MYCN* Amplification: A Report of 19 Patients Surviving Disease-Free for More Than 66 Months, 3216
Kawahara M, *see* Furuse K
Kawano Y, *see* Tanaka F
Kaye AH, *see* Clarke K
Kaye SB, *see* Vasey PA
Kearney M, *see* Waldron D
Kearns CM, *see* Belani CP
Keating A, *see* Lazarus HM
Keating J, *see* Shapiro CL
Keating M, *see* Beran M
Keating MJ, *see* Kantarjian HM
Keating MJ, *see* Thomas DA
Keefe D, *see* Basser RL
Keegan P, *see* Jerian S
Keeney GL, *see* Reynolds C
Kefford RF, Bishop JAN, Bergman W, Tucker MA, Melanoma Genetics Consortium. Counseling and DNA Testing for Individuals Perceived to Be Genetically Predisposed to Melanoma: A Consensus Statement of the Melanoma Genetics Consortium, 3245
Keller AM, *see* Fisher B
Kellokumpu-Lehtinen P-L, *see* Pyrhönen S
Kelly WK, *see* Sabbatini P
Kelsen DP, *see* Ilson DH
Kemmler G, Holzner B, Kopp M, Dünser M, Margreiter R, Greil R, Sperner-Unterweger B. Comparison of Two Quality-of-Life Instruments for Cancer Patients: The Functional Assessment of Cancer Therapy-General and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, 2932
Kempf-Bielack B, *see* Bielack SS
Kennedy A, *see* Markman M
Kennedy I, *see* Bishop JF
— *see* Theriault RL
Kerby T, *see* Friedman HS
Kern W, *see* Hiddemann W
Kernan NA, *see* Boulad F
Kessler H, *see* Fowble B
Khalifa M, *see* Tang S-C
Khandelwal P, *see* Jones SE
Khayat A, *see* Smith MA
Khokha R, *see* Michael M
Khoo K, Brandes L, Reyno L, Arnold A, Dent S, Vandenberg T, Lebwohl D, Fisher B, Eisenhauer E. Phase II Trial of N,N-Diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and Doxorubicin Chemotherapy in Metastatic Breast Cancer: A National Cancer Institute of Canada Clinical Trials Group Study, 3431
Khouri I, Champlin R. In reply (correspondence), 1958
Khoury H, *see* Adkins D
— *see* Brown RA
Khuri FR, *see* Garden AS
Kies M, *see* Haraf DJ
— *see* List MA
Kiffer J, *see* Wirth A
Kilpatrick MG, *see* Bow EJ
Kim NW, *see* Carey LA
Kimmel DW, *see* Buckner JC
Kindsfather S, *see* Schilder RJ
Kingma DW, *see* Rowlings PA
Kirby R, *see* Jones SE
Kirchner GI, *see* Franzke A
Kirchner H, *see* Franzke A
Kirkbride P, *see* Gralla RJ
Kirkpatrick AL, *see* Bramwell VHC
Kirkwood JM, *see* Chapman PB
Kirshner J, *see* Abrams J
— *see* Kantoff PW
Kivelä T. Trilateral Retinoblastoma: A Meta-Analysis of Hereditary Retinoblastoma Associated With Primary Ectopic Intracranial Retinoblastoma, 1829
Klasa R, *see* Macpherson N
Klein EA, *see* Jhaveri FM
Klein JP, *see* Lazarus HM
Klein M, *see* Foran JM
Klein MJ, *see* Vassilopoulou-Sellin R
Kleinberg L, Grossman SA, Piantadosi S, Pearlman J, Engelhard H, Lesser G, Ruffer J, Gerber M. New Approaches to Brain Tumor Therapy Central Nervous System Consortium. Phase I Trial to Determine the Safety, Pharmacodynamics, and Pharmacokinetics of RSR13, a Novel Radioenhancer, in Newly Diagnosed Glioblastoma Multiforme, 2593
Kleisbauer JP, *see* von Pawel J
Klijn JGM, *see* Meijer-van Gelder ME
— *see* Verhoog LC
Klingebiel T, *see* Koscielniak E
Klinke F, *see* Thomas M
Klippenstein D, *see* Czuczman MS
Klippensten D, *see* Cheson BD
Kluytmans JAJW, *see* Nouwen JL
Knapp D, *see* Mortimer JE
Knapp DL, *see* Mortimer JE
Knell ER, Presant CA. Re-evaluation of Benefits of *BRCA1/2* Testing (correspondence), 1958
Knietig R, *see* Koscielniak E
Knight RD, *see* Theriault RL
Knight S, *see* Ahmed FY

Knox K, *see* Scullion B
Kobrinsky NL, Sjolander DE, Cheang MS, Levitt R, Steen PD. Granulocyte-Macrophage Colony-Stimulating Factor Treatment Before Doxorubicin and Cyclophosphamide Chemotherapy Priming in Women With Early-Stage Breast Cancer, 3426
Kobylecky A, *see* Whelan T
Koeller JM, *see* Gralla RJ
Koh L-P, *see* Lim L-C
Kohman LJ, *see* Graziano SL
Kohne C-H, *see* Sturm I
Köhne C-H, *see* Vanhoefer U
Kohnoe S, *see* Maehara Y
Koike K, *see* Sato G
Kolb R, *see* Jakesz R
Kollath JP, *see* Abou-Elella AA
Koller C, *see* Kantarjian HM
Koller CA, *see* Beran M
Kollmannsberger C, *see* Bokemeyer C
Koo J, *see* Goodwin PJ
Kopans DB, *see* American College of Radiology Task Force on Breast Cancer
Kopp M, *see* Kemmler G
Korc M, *see* Zhu Z
Korec S, *see* Chan S
Körholz D, *see* Schellong G
Kornblau S
see Beran M
see Kantarjian HM
Kornblith A, *see* Ilson DH
Kornek GV, *see* Scheithauer W
Kortmann R-D, *see* Bamberg M
Koscielniak E, Harms D, Henze G, Jürgens H, Gadner H, Herbst M, Klingebiel T, Schmidt BF, Morgan M, Knietig R, Treuner J. Results of Treatment for Soft Tissue Sarcoma in Childhood and Adolescence: A Final Report of the German Cooperative Soft Tissue Sarcoma Study CWS-86, 3706
Koscielniak E, *see* Carli M
Kotasek D, *see* Basser RL
Kotsakis A, *see* Georgoulias V
Kotsakis T, *see* Kouroussis C
Kotzerke J, *see* Schirrmeister H
Koukouraki S, *see* Koukourakis MI
Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, Bizakis JG, Retalis G, Karkavitasas N, Helidonis ES. Liposomal Doxorubicin and Conventionally Fractionated Radiotherapy in the Treatment of Locally Advanced Non-Small-Cell Lung Cancer and Head and Neck Cancer, 3512
Koumantaki Y, *see* Kaklamani VG
Kouriefs C, *see* Mokbel K
Kourousis C, *see* Androulakis N
Kouroussis C, Androulakis N, Kakolyris S, Souglakos J, Kotsakis T, Mavroudis D, Katsogridakis K, Vardakis N, Hatzidaki D, Samonis G, Vlachonikolis J, Georgoulias V. Dose-Escalation Study of Docetaxel in Combination With Mitoxantrone as First-Line Treatment in Patients With Metastatic Breast Cancer, 862
Kouroussis C, *see* Georgoulias V
Kovar H, *see* Ginsberg JP
Krailo M, *see* Marina NM
— *see* Smith MA
Krakowski Y, *see* Lhommé C
Kramar A, *see* Baranzelli MC
Kramer K, *see* Kushner BH
Kramer S, *see* Prados MD
Kraus C, *see* Foran JM
Krause C, *see* Desch CE
Kraut M, *see* Murray N
Krawczak G, *see* Weckermann D
Kraybill BM, *see* Du Pen SL
Kraynak M, *see* Nemunaitis J
— *see* Villalona-Calero MA
Kraynak MA, *see* Drengler RL
— *see* Eckhardt SG
Krebs JB, *see* von Pawel J
Kreienberg R, *see* Schirrmeister H
Kremer LCM, Tiel-van Buul MMC, Ubbink MC, Offringa M, Ottenkamp J, Valdés Olmos R, Voûte PA. Indium-111-Antimyosin Scintigraphy in the Early Detection of Heart Damage After Anthracycline Therapy in Children, 1208
Kremer Z-F, *see* Sabbatini P
Kressner U, Inganäs M, Byding S, Blikstad I, Påhlman L, Glimelius B, Lindmark G. Prognostic Value of *p53* Genetic Changes in Colorectal Cancer, 593
Krieger O, *see* Zach O
Kris MG, *see* Gralla RJ
Kristedja TS, *see* O'Day SJ
Kristensen GB, *see* Baekelandt M
Kroener J, *see* Grossman JS
Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJA, van Groeningen CJ, Postmus PE, Pinedo HM, Peters GJ. Gemcitabine and Paclitaxel: Pharmacokinetic and Pharmacodynamic Interactions in Patients With Non-Small-Cell Lung Cancer, 2190
Kronawitter U, *see* Jung Ch
Krook JE, *see* Bonner JA
— *see* Creagan ET
— *see* Loprinzi CL
Krumm S, *see* Rizzo JD
Kubicka S, *see* Schlitt HJ
Kubilis P, *see* Mancuso AA
Kubista E, *see* Jakesz R
Kubuschok B, Passlick B, Izbicki JR, Thetter O, Pantel K. Disseminated Tumor Cells in Lymph Nodes as a Determinant for Survival in Surgically Resected Non-Small-Cell Lung Center, 19
Kudoh S, *see* Furuse K
Kuentz M, *see* André M
Kuerer HM, Newman LA, Smith TL, Ames FC, Hunt KK, Dhingra K, Theriault RL, Singh G, Binkley SM, Sneige N, Buchholz TA, Ross MI, McNeese MD, Buzdar AU, Hortobagyi GN, Singletary SE. Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy, 460
Kugler JW, *see* Loprinzi CL
Kuhn JG, *see* Chang SM
— *see* Drengler RL
— *see* Eckhardt SG
Kühn T, *see* Schirrmeister H
Kuhn W, *see* du Bois A
Kulp B, *see* Markman M
Kumano N, *see* Sato G

Kun LE, *see* Fouladi M
— *see* Gajjar A
— *see* Walter AW
Kunkel L, *see* Atkins MB
Kuntz KM, *see* Ng AK
Kupelian PA, *see* Jhaveri FM
Kurie JM, *see* Glisson BS
Kurita Y, *see* Okamoto H
Kurtz JM, *see* Weber DC
Kurzrock R, Pilat S, Duvic M. Pentostatin Therapy of T-Cell Lymphomas With Cutaneous Manifestations, 3117
Kurzrock R, *see* Beaupre DM
Kushner BH, Cheung N-KV, LaQuaglia MP. In reply (correspondence), 2625
Kushner BH, Kramer K, Cheung N-KV. Oral Etoposide for Refractory and Relapsed Neuroblastoma, 3221
Kuter I, *see* Blum JL
Kutluk MT. Use of Bisphosphonates in Hypercalcemia Associated With Childhood Cancer (correspondence), 1958
Kvaløy SO, *see* Hjermstad MJ
Kwa B, *see* Groen HJM
Kwa SLS, *see* Theuws JCM
Kwasny W, *see* Scheithauer W
Kwoh TJ, *see* Nemunaitis J
— *see* Stevenson JP
Kwong YL, *see* Chim CS
— *see* Liang R
Kyle RA, *see* Gertz MA
— *see* Rajkumar SV
Kyritsis AP, *see* Wong ET

LaCasce A, *see* Friedberg JW
Lacava J, *see* Acuña LR
Lacy MQ, *see* Gertz MA
— *see* Rajkumar SV
Ladanyi M, *see* Ginsberg JP
Ladetto M, *see* Corradini P
Ladner RD, *see* Wadler S
LaFollette S, *see* Glantz MJ
Laidlaw C, *see* Wirth A
Lamb C, *see* Colevas AD
Lamb ML, *see* Graziano SL
Laméris JS, *see* Nouwen JL
Land VJ, *see* Smith MA
Lane SR, *see* von Pawel J
Langdon RJ Jr, *see* Hensley ML
Lange A, *see* Leyvraz S
Lange BJ, *see* Reaman GH
Lange M, *see* Jones SE
Lange P, *see* Figlin RA
Langhi M, *see* Acuña LR
Langleben A, *see* Murray N
Langston JW, *see* Fouladi M
Lanier KS, *see* Fisher B
Lanino E, *see* Bonetti F
Lanza G, Gafà R, Matteuzzi M, Santini A. Medullary-Type Poorly Differentiated Adenocarcinoma of the Large Bowel: A Distinct Clinicopathologic Entity Characterized by Microsatellite Instability and Improved Survival, 2429
LaQuaglia MP, *see* Kushner BH
Larocca LM, *see* Antinori A
Larochelle M, *see* Fortin A
Larra F, *see* Gamelin E
Larson SM, *see* Sabbatini P
Lasry S, *see* Bouchet C
Lasset C, *see* Escudier B
Latini P, *see* Aversa F
Latreille J, *see* Hébert-Croteau N
Lau GKK, *see* Liang R
Lauer SJ, *see* Marina NM
— *see* Ritchey AK
Laufer MR. Reproductive Issues for Cancer Patients/Survivors (editorial), 2631
Laufman L, *see* Fisher B
Laverdiére J, *see* Fortin A
Lavertu S, *see* Fortin A
Lawrance JAL, *see* Bradley AJ
Lawrence TS, *see* Eisbruch A
Lawton TJ, *see* Reynolds C
Lawyer J, *see* Friedman HS
Lazarus HM, Rowlings PA, Zhang M-J, Vose JM, Armitage JO, Bierman PJ, Gajewski JL, Gale RP, Keating A, Klein JP, Miller CB, Phillips GL, Reece DE, Sobocinski KA, van Besien K, Horowitz MM. Autotransplants for Hodgkin's Disease in Patients Never Achieving Remission: A Report From the Autologous Blood and Marrow Transplant Registry, 534
Le Cesne A, *see* Ray-Coquard I
Lebesque JV, *see* Theuws JCM
Lebwohl D, *see* Hudis C
— *see* Khoo K
Leco K, *see* Michael M
Lee BR, *see* Breslow NE
Lee EJ, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, Dodge RK, Smith R, Baer M, Schiffer CA. Parallel Phase I Studies of Daunorubicin Given With Cytarabine and Etoposide With or Without the Multidrug Resistance Modulator PSC-833 in Previously Untreated Patients 60 Years of Age or Older With Acute Myeloid Leukemia: Results of Cancer and Leukemia Group B Study 9420, 2831
Lee JE, *see* Gershenwald JE
Lee JJ, *see* Gershenwald JE
Lee JS, *see* Glisson BS
— *see* Monzó M
Lee LW, *see* Valero V
Lee S, *see* Sehn LH
Leenhouts G, *see* de Wit R
Lefaix J-L, *see* Delanian S
Leff R, *see* Theriault RL
Lehtonen T, *see* Pyrhönen S
Leibel S, *see* Prados MD
Leibel SA, *see* Zelefsky MJ
Lembersky BC, *see* Smith RE
Lemoine NR, *see* Pandha HS
Lentz M-A, *see* Lhommé C
Leohrer PJ, *see* Ganjoo KN
Leonard DGB, *see* Porter DL
Leonard M, *see* Reaman GH
Leonard RCF, *see* Love CDB
Leone B, *see* Acuña LR
Leone G, *see* Pierelli L
Lepage E, *see* Decaudin D
Leris ACA, *see* Mokbel K
Lesack D, *see* Macpherson N

Leslie WT, *see* Venugopal P
Lesser G, *see* Kleinberg L
Lestingi T, *see* Richards JM
Leung PP, Tannock IF, Oza AM, Puodziunas A, Dranitsaris G. Cost-Utility Analysis of Chemotherapy Using Paclitaxel, Docetaxel, or Vinorelbine for Patients With Anthracycline-Resistant Breast Cancer, 3082
Leuven Lung Cancer Group, *see* Stroobants SG
Levi J, *see* Bishop JF
Levin HS, *see* Jhaveri FM
Levin VA, *see* Wong ET
— *see* Yung WKA
Levine M, *see* Whelan T
Levitt R, *see* Bonner JA
— *see* Kobrinsky NL
Levitz S, *see* Nichols KE
Levy R. Karnofsky Lecture: Immunotherapy of Lymphoma, 7-13(Supp.)
Levy R, *see* Davis TA
Lewis BD, *see* Galanis E
Leyvraz S, Perey L, Rosti G, Lange A, Pampallona S, Peters R, Humblet Y, Bosquée L, Pasini F, Marangolo M. Multiple Courses of High-Dose Ifosfamide, Carboplatin, and Etoposide With Peripheral-Blood Progenitor Cells and Filgrastim for Small-Cell Lung Cancer: A Feasibility Study by the European Group for Blood and Marrow Transplantation, 3531
Lhommé C, Fumoleau P, Fargeot P, Krakowski Y, dieras V, Chauvergne J, Vennin P, Rebattu P, Roche H, Misset J-L, Lentz M-A, Van Glabbeke M, Matthieu-Boué A, Mignard D, Chevallier B. Results of a European Organization for Research and Treatment of Cancer/Early Clinical Studies Group Phase II Trial of First-Line Irinotecan in Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Cervix, 3136
Li FP. Cancer Control in Susceptible Groups: Opportunities and Challenges, 719
Li H, *see* Zeltzer PM
Li M, *see* Tanaka F
Lianes P, *see* Cardenal F
Liang R, Lau GKK, Kwong YL. Chemotherapy and Bone Marrow Transplantation for Cancer Patients Who Are Also Chronic Hepatitis B Carriers: A Review of the Problem, 394
Liang R, *see* Chim CS
Liao J, *see* Cangiano T
Liao S-Y, *see* Whitney CW
Libby A, *see* Diab SG
Liberati A, *see* Fossati R
Licata C, *see* Brandes AA
Lichter, AS. Presidential Address, 2-6(Supp.)
Lieberman G, *see* Cobleigh MA
Liebes L, *see* Hochster H
— *see* Sparano JA
Lien EA, *see* Decensi A
Liesveld JL, *see* Rapoport AP
Lieverst J, *see* Herben VMM
Liew K, *see* Wirth A
Liljegren G, Holmberg L, Bergh J, Lindgren A, Tabár L, Nordgren H, Adami HO, and the Uppsala-Örebro Breast Cancer Study Group. 10-Year Results After Sector Resection With or Without Postoperative Radiotherapy for Stage I Breast Cancer: A Randomized Trial, 2326
Lilliu S, *see* Boccardo F
Lim L-C, Koh L-P. Tan P. Fatal Cytokine Release Syndrome With Chimeric Anti-CD20 Monoclonal Antibody Rituximab in a 71-Year-Old Patients With Chronic Lymphocytic Leukemia (correspondence), 1958
Lin J-D, *see* Tseng C-J
Linch DC, *see* Sweetenham JW
Linder T, *see* Rapoport AP
Lindgren A, *see* Liljegren G
Lindley C, *see* Hensley ML
Lindmark G, *see* Kressner U
Ling CC, *see* Zelefsky MJ
Link B, *see* Davis TA
Link MP, *see* Rubnitz JE
— *see* Suryanarayan K
Linos A, *see* Kaklamani VG
Linver MN, *see* American College of Radiology Task Force on Breast Cancer
Lionetto R, *see* Aschele C
Liote H, *see* Debrix I
Lipp J, *see* Rapoport AP
Lippman SM, *see* Garden AS
Lipshultz SE, *see* Herman EH
Lipton A, *see* Theriault RL
List MA, Siston A, Haraf D, Schumm P, Kies M, Stenson K, Vokes EE. Quality of Life and Performance in Advanced Head and Neck Cancer Patients on Concomitant Chemoradiotherapy: A Prospective Examination, 1020
Lister TA, *see* Apostolidis J
— *see* Cheson BD
— *see* Foran JM
— *see* Harris NL
Litwin MS, McGuigan KA. Accuracy of Recall in Health-Related Quality-of-Life Assessment Among Men Treated for Prostate Cancer, 2882
Litwin S, *see* Schilder RJ
Litzow MR, *see* Rajkumar SV
Liu A, *see* Fouladi M
see Gajjar A
Liu G, Darling MLR, Chan J, Jaklitsch MT, Skarin AT. Gynecomastia in a Patient With Lung Cancer, 1956
Liu S, *see* Thor AD
OLivingston RB, Crowley J. Commentary on PBT-1 Study of High-Dose Consolidation Versus Standard Therapy in Metastatic Breast Cancer, 22-24(Supp.)
Livingston RB, *see* Ellis GK
— *see* Murray N
Lluís F, *see* Castells A
Loblaw DA, Bezjak A, Bunston T. Development and Testing of a Visit-Specific Patients Satisfaction Questionnaire: The Princess Margaret Hospital Satisfaction With Doctor Questionnaire, 1931
LoBuglio AF, *see* Czuczman MS
Locatelli F, *see* Bonetti F
— *see* Zecca M
Locker PK, *see* Drengler RL
Loeffler M, Brosteanu O, Hasenclever D. In reply (correspondence), 730
Loeffler M, *see* Shipp MA
Loehrer P, *see* Einhorn L
Loehrer PJ Sr, *see* Thomas CR Jr
Loesch DM, *see* Miller KD
Logan P, *see* Gelmon KA

Loge JH, Abrahamsen AF, Ekeberg Ø, Kaasa S. Hodgkin's Disease Survivors More Fatigued Than the General Population, 253
Lokiec F, *see* Wasserman E
Lom CK, *see* Chim CS
Lomas M, *see* Cardenal F
Long GD, *see* Rizzieri DA
Long HJ, *see* Creagan ET
Look MP, *see* Meijer-van Gelder ME
Loonstra S, *see* de Wit R
Loos WJ, *see* de Jonge MJA
López-Cabrerizo MP, *see* Cardenal F
López-Guillermo A, *see* Terol M-J
Loprinzi C, *see* Sloan J
Loprinzi CL, Kugler JW, Sloan JA, Mailliard JA, Krook JE, Wilwerding MB, Rowland KM Jr, Camoriano JK, Novotny PJ, Christensen BJ. Randomized Comparison of Megestrol Acetate Versus Dexamethasone Versus Fluoxymesterone for the Treatment of Cancer Anorexia/Cachexia, 3299
Loprinzi CL, *see* Burch PA
— *see* Desch CE
Lorenz M, *see* Sturm I
Lorenzo JC, *see* Monzó M
Lortholary A, *see* Gamelin E
LoRusso PM, *see* Blum JL
Lorusso V, *see* Comella P
— *see* Frasci G
Lotze MT, *see* Atkins MB
Louie D, *see* Moskowitz CH
Louie S, *see* Gill PS
Louvet C, *see* André T
Love C, *see* Wagner JD
Love CDB, Muir BB, Scrimgeour JB, Leonard RCF, Dillon P, Dixon JM. Investigating of Endometrial Abnormalities in Asymptomatic Women Treated With Tamoxifen and an Evaluation of the Role of Endometrial Screening, 2050
Lovell S, *see* Friedman HS
Loyal JA, *see* Ganjoo KN
Lucante T, *see* Gasbarri A
Lucas JB, Horwitz SM, Horning SJ. Gemcitabine Is Active in Relapsed Hodgkin's Disease (correspondence), 2625
Lucas V, *see* André T
Lück HJ, *see* du Bois A
Luedke S, *see* Adkins D
Lunardi G, *see* Esposito M
Lust JA, *see* Gertz MA
Luthra SJ, *see* Harte RJA
Lutz D, *see* Zach O
Lyden ER, *see* Baker KS
Lymphoma Working Party of the European Group for Blood and Marrow Transplantation, *see* Sweetenham JW
Lynch JC, *see* Abou-Elella AA
— *see* Baker KS
Lynch PM, *see* Ajani JA
Lyter D, *see* Glantz MJ

Ma MK, *see* Furman WL
Ma SK, *see* Chim CS
Macarthur RB, *see* Petrylak DP
Macfarlane V, *see* Bonnefoi H
Macha HN, *see* Thomas M
Machiavelli M, *see* Acuña LR
Machin D, *see* Bramwell VHC
Mackay B, *see* Valero V
Mackillop WJ, *see* Boyd C
MacLennan KA, *see* Nathwani BN
Macpherson N, Lesack D, Klasa R, Horsman D, Conners JM, Barnett M, Gascoyne RD. Small Noncleaved, Non-Burkitt's (Burkitt-Like) Lymphoma: Cytogenetics Predict Outcome and Reflect Clinical Presentation, 1558
Maehara Y, Kakeji Y, Kabashima A, Emi Y, Watanabe A, Akazawa K, Baba H, Kohnoe S, Sugimachi K. Role of Transforming Growth Factor-ß1 in Invasion and Metastasis in Gastric Carcinoma, 607
Maestre J, *see* Monzó M
Maffeo A, *see* Pignata S
Magagnoli M, *see* Zinzani PL
Maguire AM, *see* Piccone MR
Maguire TO, *see* Nekolaichuk CL
Maher D, *see* Clarke K
Maher DW, *see* Basser RL
Mahjoubi M, *see* Ducreux M
— *see* Wasserman E
Mahmoud H, *see* Rubnitz JE
Mahmoud HH, *see* Tabone M-D
Maia DM. Immunohistochemical Assays for *HER2* Overexpression (correspondence), 1644
Maibach R, *see* Schmid H-P
Mailliard JA, *see* Bonner JA
— *see* Loprinzi CL
Maiorino L, *see* Comella P
— *see* Frasci G
Majolino I, *see* Corradini P
Major P, *see* Ayoub J
Makris A, *see* Chang J
Maksymiuk A, *see* Bonner JA
Malcolm AJ, *see* Bramwell VHC
Malczyn J, *see* Friedman HS
Maley F, *see* Aschele C
Malfetano JH, *see* Whitney CW
Malik R, *see* Ginsberg JP
Malkowicz SB, *see* D'Amico AV
Maloney DG, *see* Davis TA
Mamounas E, *see* Wolmark N
Mamounas E, Wienand S, Wolmark N, Bear HD, Atkins JN, Song K, Jones J, Rockette H. Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes' B Versus Dukes' C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04), 1349
Mamounas EP, *see* Smith RE
Mancha RG, *see* Chan S
Mancuso AA, Mukherji SK, Schmalfuss I, Mendenhall W, Parsons J, Pameijer F, Hermans R, Kubilis P. Preradiotherapy Computed Tomography as a Predictor of Local Control in Supraglottic Carcinoma, 631
Mancuso S, *see* Pierelli L
Mandel NM, *see* Ozguroglu M
Mandelblatt JS, Ganz PA, Kahn KL. Proposed Agenda for the Measurement of Quality-of-Care Outcomes in Oncology Practice, 2614
Maneatis TJ, *see* Byrd JC
Manetta A, *see* Thigpen JT
Manetti L, *see* Decensi A
Manfreda D, *see* Jakesz R

Mann G, *see* Schellong G
Mann KP, *see* Murray CK
Manns MP, *see* Schlitt HJ
Manola JB, *see* Baldini EH
Mansfield PF, *see* Ajani JA
— *see* Gershenwald JE
Mantzoros C, *see* Kaklamani VG
Mantzoros CS, *see* Kaklamani VG
Manuel N, *see* Buzdar AU
Manzione L, *see* Comella P
— *see* Frasci G
Marafioti T, Hummel M, Anagnostopoulos I, Foss H-D, Huhn D, Stein H. Classical Hodgkin's Disease and Follicular Lymphoma Originating From the Same Germinal Center B Cell, 3804
Marafioti T, *see* Diehl V
ppMarangolo M, *see* Crinò L
— *see* Leyvraz S
Marcuello E, *see* Tortola S
Marcus AC, *see* McCaskill-Stevens W
Marcus R, *see* Pratt CB
— *see* Sweetenham JW
Margolin K, *see* Atkins MB
Margreiter R, *see* Kemmler G
Maria BL, *see* Glantz MJ
Marina NM, Cushing B, Giller R, Cohen L, Lauer SJ, Ablin A, Weetman R, Cullen J, Rogers P, Vinocur C, Stolar C, Rescorla F, Hawkins E, Heifetz S, Rao PV, Krailo M, Castleberry RP. Complete Surgical Excision Is Effective Treatment for Children With Immature Teratomas With or Without Malignant Elements: A Pediatric Oncology Group/Children's Cancer Group Intergroup Study, 2137
Marina NM, Pappo AS, Parham DM, Cain AM, Rao BN, Poquette CA, Pratt CB, Greenwald C, Meyer WH. Chemotherapy Dose-Intensification for Pediatric Patients With Ewing's Family of Tumors and Desmoplastic Small Round-Cell Tumors: A Feasibility Study at St. Jude Children's Research Hospital, 180
Marincola FM, *see* Rosenberg SA
Maris JM, Matthay KK. Molecular Biology of Neuroblastoma, 2264
Markaki I, *see* Kaklamani VG
Markman M, Kennedy A, Webster K, Elson P, Peterson G, Kulp B, Belinson J. Clinical Features of Hypersensitivity Reactions to Carboplatin, 1141
Marks J, *see* Carey LA
Marks LB, *see* Carter DL
Marks RS, *see* Bonner JA
Marshall JL, Hawkins MJ, Tsang KY, Richmond E, Pedicano JE, Zhu M, Schlom J. Phase I Study in Cancer Patients of a Replication-Defective Avipox Recombinant Vaccine That Expresses Human Carcinoembryonic Antigen, 332
Martegani MP, *see* Gasbarri A
Martelli H, Oberlin O, Rey A, Godzinski J, Spicer RD, Bouvet N, Haie-Meder C, Terrier-Lacombe M-J, Sanchez de Toledo J, Spooner D, Sommelet D, Flamant F, Stevens MCG. Conservative Treatment for Girls With Nonmetastatic Rhabdomyosarcoma of the Genital Tract: A Report From the Study Committee of the International Society of Pediatric Oncology, 2117
Martelli M, *see* Zinzani PL
Martelli MF, *see* Aversa F
Martelli MP, *see* Aversa F
Martín C, *see* Monzó M
Martin L-A, *see* Pandha HS
Martin MA, *see* O'Day SJ
Martin P-M, *see* Bouchet C
Martino R. Computed Tomography in Febrile Neutropenia (correspondence), 3856
Marty M, *see* Wasserman E
— *see* Wils JA
Marzano N, *see* Iaffaioli RV
Maschek H, *see* Schlitt HJ
Mascia V, *see* Frasci G
Masiero L, *see* Carli M
Masotti A, *see* Crinò L
Massidda B, *see* Frasci G
Massuti B, *see* Cardenal F
Masutani M, *see* Okamoto H
Matloff E, *see* Turner BC
Mato G, *see* Chantada GL
Matteuzzi M, *see* Lanza G
Matthay KK. In reply (correspondence), 2625
Matthay KK, *see* Maris JM
Matthews J, *see* Apostolidis J
Matthews JC, *see* Harte RJA
Matthieu-Boué A, *see* Lhommé C
Mauch P, *see* Nichols KE
Mauch PM, *see* Friedberg JW
— *see* Ng AK
Maugard C, *see* Ray-Coquard I
Maurer H, *see* Pratt CB
Mavroudis D, *see* Kouroussis C
Mayer L, *see* Gelmon K
Mayer LD, *see* Gelmon KA
Mayer RJ, *see* Byrd JC
Maziarz R, *see* Adkins D
Mazumdar M, *see* Bajorin DF
— *see* Dodd PM
— *see* Motzer RJ
Mazzarino I, *see* Zecca M
McCaffrey JA, *see* Bajorin DF
— *see* Dodd PM
McCaskill-Stevens W, Hawk ET, Flynn PJ, Lippman SM. National Cancer Institute-Supported Cancer Chemoprevention Research: Coming of Age, 53-62(Supp.)
McCaskill-Stevens W, Pinto H, Marcus AC, Comis R, Morgan R, Plomer K, Schoentgen S. Recruiting Minority Cancer Patients Into Cancer Clinical Trials: A Pilot Project Involving the Eastern Cooperative Oncology Group and the National Medical Association, 1029
McCaskill-Stevens W, *see* Miller KD
McCauley M, *see* Elias A
McCready D, *see* Goodwin PJ
— *see* Whelan T
McDonnell K, *see* Fogarty LA
McGarigle C, *see* Porter DL
McGarry W, *see* Royce ME
McGehee R, *see* Rose PG
McGuigan KA, *see* Litwin MS
McGuire-Cullen P, *see* Zeltzer PM
McGuire WP, *see* Bridgewater JA
McIntyre K, *see* Jones SE
McIntyre OR, *see* Costanza ME
McLendon RE, *see* Friedman HS
McLeod HL, *see* Ahmed FY
McLeod RS, *see* Temple LKF

McMasters KM, Hunt KK. Neoadjuvant Chemotherapy, Locally Advanced Breast Cancer, and Quality of Life (editorial), 441
McNeese M, *see* Buzdar AU
— *see* Vassilopoulou-Sellin R
McNeese MD, *see* Kuerer HM
McTiernan A, *see* Chlebowski RT
Medical Research Council Testicular Tumor Working Party, *see* Fosså SD
Medina M, *see* DiPaola RS
Medina P, *see* DiPaola RS
Mehta M, *see* Robins HI
Mehta MP, *see* Chang SM
Mehta N, *see* Richards JM
Meier W, *see* du Bois A
Meijer CJLM, *see* Bekkenk MW
Meijer-van Gelder ME, Look MP, Bolt-de Vries J, Peters HA, Klijn JGM, Foekens JA. Breast-Conserving Therapy: Proteases as Risk Factors in Relation to Survival After Local Relapse, 1449
Meijers-Heijboer EJ, *see* Verhoog LC
Meisner C
see Bamberg M
see Bokemeyer C
Mela GS, *see* Ballestrero A
Melanoma Cooperative Group, *see* Palmieri G
Melanoma Genetics Consortium, *see* Kefford RF
Mellars K, *see* Theriault RL
Melnychuk D, *see* Nabholtz JM
Melosky B, *see* Gelmon KA
Mendelson EB, *see* American College of Radiology Task Force on Breast Cancer
Mendenhall W, *see* Mancuso AA
Mendoza S, *see* Sparano JA
Menichella G, *see* Pierelli L
Menker H, *see* Stuschke M
Mennel R, *see* Jones SE
Mercadante S, Casuccio A, Calderone L. Rapid Switching From Morphine to Methadone in Cancer Patients With Poor Response to Morphine, 3307
Merchant TE, *see* Fouladi M
— *see* Gajjar A
— *see* Spunt SL
Mermet J, *see* Ray-Coquard I
Meropol NJ, *see* Hensley ML
Merrouche Y, *see* André T
Méry-Mignard D, *see* Ducreux M
— *see* Wasserman E
Messer P, *see* Schirrmeister H
Messina C, *see* Bonetti F
Metzner B, *see* Bokemeyer C
Meyer D, *see* Ayoub J
Meyer WH, *see* Furman WL
— *see* Marina NM
Meyerowitz BE, *see* Ganz PA
Meyers EG, *see* Gritz ER
Meyers ML, *see* Chapman PB
Meyers PA, *see* Flombaum CD
— *see* Gorlick R
Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, Leco K, Chamberlain D, Sheperd FA. Expression and Prognostic Significance of Metalloproteinases and Their Tissue Inhibitors in Patients With Small-Cell Lung Cancer, 1802
Michalak JC, *see* Creagan ET
Michaux L, *see* Decaudin D
Micillo E, *see* Frasci G
Mick R, *see* Reynolds C
Mignard D, *see* Lhommé C
Mildenberger P, *see* Heussel CP
Milicic B, *see* Jeremic B
Milisavljevic S, *see* Jeremic B
Millenson MM, *see* Schilder RJ
Miller CB, *see* Lazarus HM
Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R, Sledge GW Jr. Combination Versus Sequential Doxorubicin and Docetaxel as Primary Chemotherapy for Breast Cancer: A Randomized Pilot Trial of the Hoosier Oncology Group, 3033
Miller L, *see* Jones S
Miller LL, *see* Devore RF
— *see* Drengler RL
— *see* Friedman HS
Milleron B, *see* Debrix I
Milpied N, *see* André M
Milstein JM, *see* Zeltzer PM
Mimaya J, *see* Kawa K
Minami Y, *see* Sato G
Minsky BD, *see* Desch CE
Mir TS, *see* Heinzer H
Miralbell R, *see* Weber DC
Miraldi F, *see* Rose PG
Mirimanoff RO, *see* Greiner R
Mirsky D, *see* Whelan T
Miser J, *see* Smith MA
Misset J-L
see Lhommé C
see Wasserman E
Mitchell EP, *see* Stevenson JP
Mitchell JB, *see* Coleman CN
Mitchell MF, *see* Brewer M
Mitchell P, *see* Clarke K
Mitchell PLR and Pinkerton CR. Granulocyte-Macrophage Colony-Stimulating Factor in Established Febrile Neutropenia (correspondence), 3002
Mitchell RB, *see* Hensley ML
Mittal B, *see* Haraf DJ
Mittlböck M, *see* Jakesz R
Miura Y, *see* Takagi S
Miyahara R, *see* Tanaka F
Miyashita M, *see* Furuse K
Miyata H, *see* Kawa K
Miyata Y, *see* Ohtsu A
Mlineritsch B, *see* Jakesz R
Mock V, *see* Rizzo JD
Moczygemba J, *see* Eckhardt SG
— *see* Villalona-Calero MA
Mogan M, *see* Koscielniak E
Mohrbacher A, *see* Davis TA
Mokbel K, Williams NJ, Leris ACA, Kouriefs C. Telomerase Activity in Fine-Needle Aspirates of Breast Lesions (correspondence), 3856
Molica S, *see* Zinzani PL
Molino A, *see* Nabholtz JM
Monaco F, *see* Einhorn L
— *see* Miller KD

Monahan BP, *see* Byrd JC
Monia B, *see* Stevenson JP
Monsees B, *see* American College of Radiology Task Force on Breast Cancer
Montagna D, *see* Bonetti F
Montalar J, *see* Cardenal F
Montefiore F, *see* Boccardo F
Montserrat E, *see* Shipp MA
— *see* Terol M-J
Monzó M, Rosell R, Felip E, Astudillo J, Sánchez JJ, Maestre J, Martín C, Font A, Barnadas A, Abad A. A Novel Anti-Apoptosis Gene: Re-expression of Survivin Messenger RNA as a Prognosis Marker in Non-Small-Cell Lung Cancers, 2100
Monzó M, Rosell R, Sánchez JJ, Lee JS, O'Brate A, González-Larriba JL, Alberola V, Lorenzo JC, Núñez L, Ro JY, Martín C. Paclitaxel Resistance in Non-Small-Cell Lung Cancer Associated With Beta-Tubulin Gene Mutations, 1786
Mookherjee S, *see* Graziano SL
Moore BD III, *see* Copeland DR
Moore II DH, *see* Thor AD
Moore JO, *see* Byrd JC
Moore MJ, Winquist EW, Murray N, Tannock IF, Huan S, Bennett K, Walsh W, Seymour L. Gemcitabine Plus Cisplatin, an Active Regimen in Advanced Urothelial Cancer: A Phase II Trial of the National Cancer Institute of Canada Clinical Trials Group, 2876
Móra J, *see* Castells A
Morant R, *see* Bernhard J
Morgan R, *see* McCaskill-Stevens W
Mori K, *see* Okamoto H
Moriarty M, *see* Waldron D
Moriconi W, *see* Adkins D
Morrison WH, *see* Garden AS
Morrow GR, *see* Gralla RJ
Mortelmans L, *see* Flamen P
Mortelmans LA, *see* Stroobants SG
Mortimer JE, Boucher L, Baty J, Knapp DL, Ryan E, Rowland JH. Effect of Tamoxifen on Sexual Functioning in Patients With Breast Cancer, 1488
Mortimer JE, Knapp D. In reply (correspondence), 3690
Morton DL, *see* Bostick PJ
— *see* O'Day SJ
Morvan F, *see* André T
— *see* Wils JA
Mosconi M, *see* Crinò L
Moskowitz CH, Bertino JR, Glassman JR, Hedrick EE, Hunte S, Coady-Lyons N, Agus DB, Goy A, Jurcic J, Noy A, O'Brien J, Portlock CS, Straus DS, Childs B, Frank R, Yohalom J, Filippa D, Louie D, Nimer SD, Zelenetz AD. Ifosfamide, Carboplatin, and Etoposide: A Highly Effective Cytoreduction and Peripheral-Blood Progenitor-Cell Mobilization Regimen for Transplant-Eligible Patients With Non-Hodgkin's Lymphoma, 3776
Motohashi S, *see* Fujisawa T
Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma, 2530
Moulopoulos LA, *see* Papadimitriou CA
Mouridsen H, *see* Van Glabbeke M
Moynahan M, *see* Hudis C
Mugishima H, *see* Kawa K
Muir BB, *see* Love CDB
Mukherji SK, *see* Mancuso AA
Mulhern RK, *see* Walter AW
Muller-Hermelink HK, *see* Harris NL
Müller-Hermelink HK, *see* Nathwani BN
Müller P, *see* Weckermann D
Müller R, *see* Brugger W
Müller R-D, *see* Stuschke M
Muller SH, *see* Theuws JCM
Muraszko K, *see* Packer RJ
Murawsky M, *see* Chan S
— *see* Nabholtz JM
Murgo A, *see* Wadler S
Muro K, *see* Ohtsu A
Murphy S, *see* Thomas DA
Murphy SB, *see* Suryanarayan K
Murphy T, *see* Byrd JC
Murphy WK, *see* Glisson BS
Murray CK, Estey E, Paietta E, Howard RS, Edenfield WJ, Pierce S, Mann KP, Bolan C, Byrd JC. CD56 Expression in Acute Promyelocytic Leukemia: A Possible Indicator of Poor Treatment Outcome?, 293
Murray DR, *see* Cassel WA
Murray E, *see* Chan S
Murray GI, *see* Ahmed FY
Murray N, Livingston RB, Shepherd FA, James K, Zee B, Langleben A, Kraut M, Bearden J, Goodwin JW, Grafton C, Turrisi A, Walde D, Croft H, Osoba D, Ottaway J, Gandara D. Randomized Study of CODE Versus Alternating CAV/EP for Extensive-Stage Small-Cell Lung Cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group, 2300
Murray N, *see* Moore MJ
Murri R, *see* Antinori A
Musk AW, *see* Byrne MJ
Muss HB, *see* Abrams J
— *see* Smith TJ
Musso M, *see* Corradini P
Muto M, *see* Ohtsu A
Myers C, *see* Bubley GJ
Myers K, *see* Curry BJ

Nabholtz JM, Senn HJ, Bezwoda WR, Melnychuk D, Deschênes L, Douma J, Vandenberg TA, Rapoport B, Rosso R, Trillet-Lenoir V, Drbal J, Molino A, Nortier JWR, Richel DJ, Nagykalnai T, Siedlecki P, Wilking N, Genot JY, Hupperets PSGJ, Pannuti F, Skarlos D, Tomiak EM, Murawsky M, Alakl M, Riva A, Aapro M for the 304 Study Group. Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing Chemotherapy, 1413
Nachman J, *see* Sun L
Nadler LM, *see* Friedberg JW
Nagykalnai T, *see* Nabholtz JM
Näher H, *see* Deichmann M
Naimark D, *see* Temple LKF
Naitoh J, *see* Cangiano T
Nakada K, *see* Kawa K
Nakamura A, *see* Ohtsu A
Nakamura T, *see* Kawa K
Nakata K, *see* Okamoto H
Namiki TS, *see* Wong JH

Nanfro JJ. Phase I Trial Dosing of Gemcitabine and Concurrent Involved Field Irradiation in Patients With Localized Pancreatic Carcinomas (correspondence), 3692
Nashan B, *see* Schlitt HJ
Nassar R, *see* Nathan C-AO
Natale M, *see* Comella P
— *see* Frasci G
Natali PG, *see* Gasbarri A
Nathan C-AO, Franklin S, Abreo FW, Nassar R, De Benedetti A, Glass J. Analysis of Surgical Margins With the Molecular Marker eIF4E: A Prognostic Factor in Patients With Head and Neck Cancer, 2909
Nathwani BN, Anderson JR, Armitage JO, Cavalli F, Diebold J, Drachenberg MR, Harris NL, MacLennan KA, Müller-Hermelink HK, Ullrich FA, Weisenburger DD for the Non-Hodgkin's Lymphoma Classification Project. Marginal Zone B-Cell Lymphoma: A Clinical Comparison of Nodal and Mucosa-Associated Lymphoid Tissue Types, 2486
National Cancer Institute of Canada Clinical Trials Group, *see* Rusthoven JJ
Navara C, *see* Sun L
Navari RM. Use of Placebos in Delayed-Emesis Studies (correspondence), 1644
Navarro S, *see* Castells A
Nedellec G, *see* André M
Needles B, *see* Adkins D
Neff J, *see* Pratt CB
Neglia J, *see* Buckner JC
Négrier S, *see* Escudier B
Negrin R, *see* Hensley ML
Neipp M, *see* Schlitt HJ
Nekolaichuk CL, Maguire TO, Suarez-Almazor M, Rogers WT, Bruera E. Assessing the Reliability of Patient, Nurse, and Family Caregiver Symptom Ratings in Hospitalized Advanced Cancer Patients, 3621
Nelson DF, *see* Prados MD
Nelstrop AE, *see* Bridgewater JA
Nemoz CJ, *see* Francois Y
Nemunaitis J, Holmlund JT, Kraynak M, Richards D, Bruce J, Ognoskie N, Kwoh TJ, Geary R, Dorr A, Von Hoff D, Eckhardt SG. Phase I Evaluation of ISIS 3521, and Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients With Advanced Cancer, 3586
Nerenz A, *see* Berthold F
Neri A, *see* Pruneri G
Nesland JM, *see* Baekelandt M
Neuberg D, *see* Friedberg JW
— *see* Nichols KE
Neugut AI, *see* Grann VR
Neumaier B, *see* Schirrmeister H
Neumann RM, Weaver AL, Spotts BE, Bostwick DG. Predicting Cancer Progression in Patients With Stage T1 Bladder Carcinoma, 3182
Neville AJ, *see* Osoba D
New York Gynecologic Oncology Group, *see* Hochster H
Newman LA, *see* Kuerer HM
Newman NB, *see* Graziano SL
Ng AK, Weeks JC, Mauch PM, Kuntz KM. Decision Analysis on Alternative Treatment Strategies for Favorable-Prognosis, Early-Stage Hodgkin's Disease, 3577
Ng AK, Weeks JC, Mauch PM, Kuntz KM. Laparotomy Versus No Laparotomy in the Management of Early-Stage, Favorable-Prognosis Hodgkin's Disease: A Decision Analysis, 241
Ng TY, *see* Wong LC
Ngan HYS, *see* Wong LC
Nguyen B, *see* Cardenal F
Nichols C, *see* Bokemeyer C
Nichols KE, Levitz S, Shannon KE, Wahrer DCR, Bell DW, Chang G, Hegde S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishioka C, Haber DA, Diller L. Heterozygous Germline *ATM* Mutations Do Not Contribute to Radiation-Associated Malignancies After Hodgkin's Disease, 1259
Nicholson HS, *see* Packer RJ
Nicolaou N, *see* Fowble B
Nicolella G, *see* Comella P
Nicolella GP, *see* Frasci G
Niederie N, *see* Fosså A
Niederle N, *see* Bokemeyer C
Nierman DM, *see* Groeger JS
Nikolic N, *see* Jeremic B
Nimer SD, *see* Moskowitz CH
Nishikawa H, *see* Furuse K
Nishiwaki Y, *see* Furuse K
— *see* Okamoto H
Nishiyama H, *see* Shoji A
Nixon A, *see* Colevas AD
Nixon D. Alternative and Complementary Therapies in Oncology Care, 35-37(Supp.)
Noel D, *see* Chan S
Non-Hodgkin's Lymphoma Classification Project, *see* Nathwani BN
Nooij M, *see* Bramwell VHC
Noordijk EM, *see* Bekkenk MW
Nordenskjöld B, *see* Sun X-F
Nordgren H, *see* Liljegren G
Norman A, *see* Popescu RA
Norris CM, *see* Colevas AD
North American Vorozole Study Group, *see* Goss PE
Nortier JWR, *see* Nabholtz JM
Norton A, *see* Apostolidis J
Norton AJ, *see* Foran JM
Norton L, *see* Abrams J
— *see* Costanza ME
— *see* Hudis C
Noseda M, *see* Crinò L
Nouwen JL, Wielenga JJ, van Overhagen H, Laméris JS, Kluytmans JAJW, Behrendt MD, Hop WCJ, Verbrugh HA, de Marie S. Hickman Catheter-Related Infections in Neutropenic Patients: Insertion in the Operating Theater Versus Insertion in the Radiology Suite, 1304
Novello S, *see* Crinò L
Novick AC, *see* Figlin RA
Novotny PJ, *see* Loprinzi CL
Nowrousian MR, *see* Fosså A
Noy A, *see* Moskowitz CH
Nozaki T, *see* Kawa K
Nukiwa T, *see* Sato G
Núñez L, *see* Monzó M
Nurmi M, *see* Pyrhönen S
Nüssle K, *see* Schirrmeister H
Nyberg DA, *see* Glisson BS

Öberg KE, *see* Wymenga ANM
Oberlin O, *see* Carli M
— *see* Martelli H

O'Boyle CA, *see* Waldron D
O'Brate A, *see* Monzó M
O'Brian RT, *see* Reaman GH
O'Brian S, *see* Kantarjian HM
O'Brien J, *see* Moskowitz CH
O'Brien S
see Beran M
see Thomas DA
O'Brien T, *see* Venugopal P
O'Connor J, *see* Petrylak DP
Odagiri S, *see* Shoji A
O'Day SJ, Gammon G, Boasberg PD, Martin MA, Kristedja TS, Guo M, Stern S, Edwards S, Fournier P, Weisberg M, Cannon M, Fawzy NW, Johnson TD, Essner R, Foshag LJ, Morton DL. Advantages of Concurrent Biochemotherapy Modified by Decrescendo Interleukin-2, Granulocyte Colony-Stimulating Factor, and Tamoxifen for Patients With Metastatic Melanoma, 2752
O'Driscoll M, *see* Galanis E
O'Dwyer PJ, *see* Stevenson JP
O'Fallon JR, *see* Buckner JC
Offringa M, *see* Kremer LCM
Ogden A, *see* Parson SK
Ogino T, *see* Ohtsu A
Oglobine J, *see* Bouchet C
Ognoskie N, *see* Nemunaitis J
Ogura T, *see* Shoji A
Oh W, *see* Bubley GJ
Oh WK, Kantoff PW. Treatment of Locally Advanced Prostate Cancer: Is Chemotherapy the Next Step?, 3664
Ohashi Y, *see* Furuse K
Ohhira M, *see* Kawa K
Ohkuda K, *see* Sato G
Ohnuma N, *see* Kawa K
Ohtake Y, *see* Tanaka F
Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, Satake M, Ishikura S, Ogino T, Miyata Y, Seki S, Kaneko K, Nakamura A. Definitive Chemoradiotherapy for T4 and/or M1 Lymph Node Squamous Cell Carcinoma of the Esophagus, 2915
Ohtsu A, *see* Boku N
Ohwada H, *see* Fujisawa T
Okamoto H, Watanabe K, Nishiwaki Y, Mori K, Kurita Y, Hayashi I, Masutani M, Nakata K, Tsuchiya S, Isobe H, Saijo N on behalf of the Japan Clinical Oncology Group – Lung Cancer Study Group. Phase II Study of Area Under the Plama-Concentration-Versus-Time Curve–Based Carboplatin Plus Standard-Dose Intravenous Etoposide in Elderly Patients With Small-Cell Lung Cancer, 3540
O'Kelly T, *see* Ahmed FY
Oldhafer KJ, *see* Schlitt HJ
Olkowski ZL, *see* Cassel WA
Olmos T, *see* Wils JA
Olsen M, *see* Robins HI
Olson J, *see* Yung WKA
Olsson CA, *see* Petrylak DP
Olver I, *see* Basser RL
Olver IN, *see* Bishop JF
O'Neill AM, *see* Yung WKA
Onetto N, *see* Tolcher AW
Ooi GC, *see* Chim CS
Oosterhuis JW, *see* Van Glabbeke M
Orchard J, *see* Foran JM
Orcutt C, *see* Gill PS
O'Reilly E, *see* Ilson DH
O'Reilly RJ, *see* Boulad F
O'Reilly SM, *see* Harte RJA
Orel SG, *see* Reynolds C
Orhan B. Doxorubicin Cardiotoxicity: Growing Importance (correspondence), 2293
Origasa H, *see* Takagi S
Orlandini C, *see* Gennari A
Orr D, *see* Jones SE
Ortiz E, *see* Acuña LR
Ortona L, *see* Antinori A
Osborne CK, *see* Chang J
— *see* Diab SG
— *see* Harvey JM
— *see* Jatoi L
Oscier D, *see* Foran JM
Osman S, *see* Harte RJA
Osoba D, *see* Gralla RJ
— *see* Murray N
Osoba D, Tannock I. Measuring Health-Related Quality of Life (correspondence), 2293
Osoba D, Tannock IF, Ernst S, Neville AJ. Health-Related Quality of Life in Men With Metastatic Prostate Cancer Treated With Prednisone Alone or Mitoxantrone and Prednisone, 1654
Osterwalder B, *see* Blum JL
Ota DM, *see* Ajani JA
Ottaway J, *see* Murray N
Ottenkamp J, *see* Kremer LCM
Ouldkaci M, *see* Wasserman E
Ouyang P, *see* Sabbatini P
Overberg-Schmidt US, *see* Reich S
Owen JR, *see* Fossâ SD
Oza AM, *see* Leung PP
Ozguroglu M, Aki H, Demir G, Demirelli F, Mandel NM. Unusual Manifestations of B-Cell Disorders; Case 1: Multiple Myeloma With Predominant Phalangeal Involvement, 1083
Ozols RF, *see* Schilder RJ

Pacilio C, *see* Comella P
Packer RJ, Goldwein J, Nicholson HS, Vezina LG, Allen JC, Ris MD, Muraszko K, Rorke LB, Wara WM, Cohen BH, Boyett JM. Treatment of Children With Medulloblastomas With Reduced-Dose Craniospinal Radiation Therapy and Adjuvant Chemotherapy: A Children's Cancer Group Study, 2127
Packer RJ, *see* Zeltzer PM
Packman CH, *see* Rapoport AP
Pacquement H, *see* Tabone M-D
Påhlman L, *see* Kressner U
Paietta E, *see* Murray CK
Palmer MC, *see* von Pawel J
Palmieri G, Strazzullo M, Ascierto PA, Satriano SMR, Daponte A, Castello G for the Melanoma Cooperative Group. Polymerase Chain Reaction-Based Detection of Circulating Melanoma Cells as an Effective Marker of Tumor Progression, 304
Palumbo A, *see* Corradini P
Pameijer F, *see* Mancuso AA
Pampallona S, *see* Leyvraz S
Panageas KS, *see* Chapman PB
— *see* Hudis C
Panasci L, *see* Abrams J
Panday VRN, *see* Herben VMM

Pandha HS, Martin L-A, Rigg A, Hurst HC, Stamp GWH, Sikora K, Lemoine NR. Genetic Prodrug Activation Therapy for Breast Cancer: A Phase I Clinical Trial of *erb*B-2-Directed Suicide Gene Expression, 2180
Pania N, *see* Schulman KA
Panici PB, *see* Pierelli L
Panke J, *see* Du Pen SL
Pannuti F, *see* Nabholtz JM
Pantel K, *see* Kubuschok B
Panza N, *see* Comella P
— *see* Frasci G
Pao CC, *see* Tseng C-J
Papadakis E, *see* Georgoulias V
Papadimitriou C, *see* Androulakis N
— *see* Georgoulias V
Papadimitriou CA, Sarris K, Moulopoulos LA, Fountzilas G, Anagnostopoulos A, Voulgaris Z, Gika D, Giannakoulis N, Diakomanolis E, Dimopoulos M. Phase II Trial of Paclitaxel and Cisplatin in Metastatic and Recurrent Carcinoma of the Uterine Cervix, 761
Papadopoulos NE, *see* Fleming JB
Papamichael D, Norton AJ, Foran JM, Mulatero C, Mathews J, Amess JAL, Bradburn M, Lister TA, Rohatiner AZS. Immunocytoma: A Retrospective Analysis From St Bartholomew's Hospital – 1972 to 1996, 2847
Pappo AS, Anderson JR, Crist WM, Wharam MD, Breitfeld PP, Hawkins D, Raney RB, Womer RB, Parham DM, Qualman SJ, Holcombe EG. Survival After Relapse in Children and Adolescents With Rhabdomyosarcoma: A Report From the Intergroup Rhabdomyosarcoma Study Group, 3487
Pappo AS, *see* Furman WL
— *see* Marina NM
— *see* Pratt CB
— *see* Spunt SL
Paradise C, *see* Atkins MB
Parham D, *see* Pratt CB
Parham DM, *see* Marina NM
— *see* Pappo AS
Parikh B, *see* Popescu RA
Parisi VM, *see* Berry DL
Parker E, *see* Witzig TE
Parkinson D, *see* Atkins MB
Parmigiani G, Berry DA, Winer EP, Tebaldi C, Iglehart JD, Prosnitz LR. Is Axillary Lymph Node Dissection Indicated for Early-Stage Breast Cancer? A Decision Analysis, 1465
Parnis FX, *see* Highley MS
Parry M, *see* Friedman HS
Parson SK, Gelber S, Cole BF, Ravindranath Y, Ogden A, Yeager AM, Chang M, Shuster J, Weinstein HJ, Gelber RD. Quality-Adjusted Survival After Treatment for Acute Myeloid Leukemia in Childhood: A Q-TWiST Analysis of the Pediatric Oncology Group Study 8821, 2144
Parsons J, *see* Mancuso AA
Partensky C, *see* Francois Y
Partin AW, *see* Breslow NE
Pasini F, *see* Leyvraz S
Passlick B, *see* Kubuschok B
Passweg JR, *see* Rowlings PA
Patchefsky A, *see* Fowble B
Patel J, *see* DiPaola RS
Patel SR, *see* Fleming JB
Paton V, *see* Cobleigh MA
Patrone F, *see* Ballestrero A
Patte C, *see* Baranzelli MC
Paul J, *see* Vasey PA
Paulussen M, *see* Ginsberg JP
Paz-Ares L, *see* Hidalgo M
Pazdur R, *see* Royce ME
Pearlman J, *see* Kleinberg L
Pearson D, *see* Bishop PC
Peckham M. Emmanuel van der Schueren *(In Memoriam)*, 437
Pectasides D, Aspropotamitis A, Halikia A, Visvikis A, Antoniou F, Kalantaridou A, Karvounis N, Batzios S, Athanassiou A. Combination Chemotherapy With Carboplatin, Docetaxel, and Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase II Study, 3816
Pedicano JE, *see* Marshall JL
Peest D, *see* Franzke A
Peethambaram PP, *see* Buckner JC
Peinado MA, *see* Tortola S
Pell M, *see* Clarke K
Pelzer H, *see* Haraf DJ
Pendergrass TW, *see* Reaman GH
Penetrante R, *see* Heller B
Penninckx F, *see* Flamen P
Penson RT, Skates SJ, Fuller AJ Jr, Seiden MV. Clinical Course of Stage IV Epithelial Ovarian Cancer (correspondence), 3360
Perey L, *see* Leyvraz S
Perez EA. In reply (correspondence), 1644, 2293
Perez EA, *see* Gralla RJ
Pérez J, *see* Acuña LR
Pérez-López FR, *see* Wils JA
Perez-Soler R, *see* Glisson BS
Perillo A, *see* Pierelli L
Perren T, *see* Velikova G
Perrone F, *see* Pignata S
Perrotte P, *see* Pisters LL
Perry AR, Rivlin MM, Goldstone AH. Bone Marrow Transplant Patients With Life-Threatening Organ Failure: When Should Treatment Stop?, 298
Perry MC. In reply (correspondence), 3002
Pession A, *see* Bonetti F
— *see* Zecca M
Pestalozzi BC, *see* Taverna C
Peters GJ, *see* Kroep JR
Peters HA, *see* Meijer-van Gelder ME
Peters LJ, *see* Garden AS
Peters R, *see* Leyvraz S
Peters WP, *see* Carter DL
— *see* Rizzieri DA
Petersen JP, Schellhammer PF. Should We Delay Prostate Radiotherapy? (correspondence), 1326
Petersen PM, Giwercman A, Hansen SW, Berthelsen JG, Daugaard G, Rørth M, Skakkebæk NE. Impaired Testicular Function in Patients With Carcinoma-In-Situ of the Testis, 173
Petersen PM, Skakkebæk NE, Vistisen K, Rørth M, Giwercman A. Semen Quality and Reproductive Hormones Before Orchiectomy in Men With Testicular Cancer, 941
Peterson G, *see* Markman M
Petrelli N, *see* Heller B
Petrelli NJ, *see* Desch CE
Petros WP, *see* Friedman HS
— *see* Rizzieri DA

Petrowsky H, *see* Sturm I
Petrylak DP, Macarthur RB, O'Connor J, Shelton G, Judge T, Balog J, Pfaff C, Bagiella E, Heitjan D, Fine R, Zuech N, Sawczuk I, Benson M, Olsson CA. Phase I Trial of Docetaxel With Estramustine in Androgen-Independent Prostate Cancer, 958
Petrylak DP, *see* Bubley GJ
Pfaff C, *see* Petrylak DP
Pfister DG, *see* Chlebowski RT
— *see* Desch CE
— *see* Gralla RJ
— *see* Hensley ML
Pfisterer J, *see* du Bois A
Philip T, *see* Shipp MA
Phillips GL, *see* Lazarus HM
Phillips K-A, Andrulis IL, Goodwin PJ. Breast Carcinomas Arising in Carriers of Mutations in *BRCA1* or *BRCA2:* Are They Prognostically Different?, 3653
Phuphanich S, *see* Glantz MJ
Piantadosi S, *see* Kleinberg L
Piccone MR, Maguire AM, Fox KC, Gendron K, Cutler C, Gragoudas ES. Choroidal Metastases; Case 1: Breast Cancer, 3356
Pichlmayr R, *see* Schlitt HJ
Pico J-L, *see* André M
Picus J, *see* Kantoff PW
Piedbois P, *see* Buyse M
Pienta KJ, *see* Smith DC
Pierart M, *see* Greiner R
Pierce HI, *see* Ellis GK
— *see* Fisher B
Pierce S, *see* Murray CK
— *see* Thomas DA
Pierce SR, *see* Beran M
Pierconti F, *see* Antinori A
Pierelli L, Perillo A, Greggi S, Salerno G, Panici PB, Menichella G, Fattorossi A, Leone G, Mancuso S, Scambia G. Erythropoietin Addition to Granulocyte Colony-Stimulating Factor Abrogates Life-Threatening Neutropenia and Increases Peripheral-Blood Progenitor-Cell Mobilization After Epirubicin, Paclitaxel, and Cisplatin Combination Chemotherapy: Results of a Randomized Comparison, 1288
Pignata S, Silvestro G, Ferrari E, Selvaggi L, Perrone F, Maffeo A, Frezza P, Di Vagno G, Casella G, Ricchi P, Cormio G, Gallo C, Iodice F, Romeo F, Fiorentino R, Fortuna G, Tramontana S. Phase II Study of Cisplatin and Vinorelbine as First-Line Chemotherapy in Patients With Carcinoma of the Uterine Cervix, 756
Pignataro L, *see* Pruneri G
Pilat S, *see* Kurzrock R
Pileri A, *see* Corradini P
Pinedo HM, *see* Kroep JR
Pinkerton CR, *see* Carli M
— *see* Mitchell PLR
Pintér T, *see* Chan S
Pintilie M, *see* Michael M
Pinto H, *see* McCaskill-Stevens W
Pisters KMW, *see* Glisson BS
Pisters LL, Perrotte P, Scott SM, Greene GF, von Eschenbach AC. Patient Selection for Salvage Cryotherapy for Locally Recurrent Prostate Cancer After Radiation Therapy, 2514
Pisters PW, *see* Ajani JA
Pisters PWT, *see* Ballo MT
— *see* Fleming JB
Pitot HC, *see* Creagan ET
Plager C, *see* Fleming JB
Plante M, *see* Childs RW
Planting ASTh, *see* de Jonge MJA
Plomer K, *see* McCaskill-Stevens W
Plowman PN. Glucocorticoids and Prostate Cancer in Castrate Men (correspondence), 3858
Pluard T, *see* Adkins D
Podoloff D, *see* Valero V
Poiesz BJ, *see* Graziano SL
Poletti V, *see* Zinzani PL
Polissar N, *see* Du Pen SL
Pollack A, *see* Ballo MT
— *see* Fleming JB
Pollack I, *see* Chang SM
Polli A, *see* Jones S
Pollock BH, *see* Ritchey AK
Pollock RA, *see* Ballo MT
Pollock RE, *see* Fleming JB
Pommier R, *see* Rubin J
Poole ME, *see* Blackstock AW
Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D. Adjuvant or Palliative Chemotherapy for Colorectal Cancer in Patients 70 Years or Older, 2412
Poppema S, *see* Diehl V
Poquette CA, *see* Furman WL
— *see* Marina NM
— *see* Spunt SL
Poremba C, Diallo R, Boecker W, Dockhorn-Dworniczak B. In reply (correspondence), 3856
Poremba C, Shroyer KR, Frost M, Diallo R, Fogt F, Schäfer K-L, Bürger H, Shroyer AL, Dockhorn-Dworniczak B, Boecker W. Telomerase Is a Highly Sensitive and Specific Molecular Marker in Fine-Needle Aspirates of Breast Lesions, 2020
Porro MG, *see* Herben VMM
Porta F, *see* Zecca M
Portalone L, *see* Crinò L
Porter DL, Connors JM, Van Deerlin VMD, Duffy KM, McGarigle C, Saidman SL, Leonard DGB, Antin JH. Graft-Versus-Tumor Induction With Donor Leukocyte Infusions as Primary Therapy for Patients With Malignancies, 1234
Portlock CS, *see* Moskowitz CH
Portoghese F, *see* Boccardo F
Posner MR, *see* Colevas AD
Postmus PE, *see* Groen HJM
— *see* Kroep JR
— *see* Tjan-Heijnen VCG
Pötter R, *see* Schellong G
Pöttgen C, *see* Stuschke M
Poweley E, *see* Rapoport AP
Powles TJ, *see* Chang J
Prados MD, Scott C, Curran WJ Jr, Nelson DF, Leibel S, Kramer S. Procarbazine, Lomustine, and Vincristine (PCV) Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine or PCV Adjuvant Chemotherapy, 3389
Prados MD, *see* Chang SM
— *see* Wong ET
— *see* Yung WKA

Pratt CB, Pappo AS, Gieser P, Jenkins JJ, Salzberg A, Neff J, Rao B, Green D, Thomas P, Marcus R, Parham D, Maurer H. Role of Adjuvant Chemotherapy in the Treatment of Surgically Resected Pediatric Nonrhabdomyosarcomatous Soft Tissue Sarcomas: A Pediatric Oncology Group Study, 1219
Pratt CB, *see* Furman WL
— *see* Marina NM
— *see* Spunt SL
Presant CA, *see* Knell ER
Prete A, *see* Bonetti F
— *see* Zecca M
Price K, *see* Groeger JS
Price PM, *see* Harte RJA
Pritchard KI, *see* Goodwin PJ
Probst-Kepper M, *see* Franzke A
Prosnitz LR, *see* Carter DL
— *see* Parmigiani G
Protocol 18 Aredia Breast Cancer Study Group, *see* Theriault RL
Prott F-J, *see* Schellong G
Provenzale JM, *see* Friedman HS
Pruneri G, Pignataro L, Carboni N, Buffa R, Di Finizio D, Cesana BM, Neri A. Clinical relevance of Expression of the CIP/KIP Cell-Cycle Inhibitors p21 and p27 in Laryngeal Cancer, 3150
Pui C-H, Boyett JM, Relling MV, Harrison PL, Rivera GK, Behm FG, Sandlund JT, Ribeiro RC, Rubnitz JE, Gajjar A, Evans WE. Sex Differences in Prognosis for Children With Acute Lymphoblastic Leukemia, 818
Pui C-H, Evans WE. Acute Lymphoblastic Leukemia in Infants (editorial), 438
Pui C-H, *see* Rubnitz JE
— *see* Woo MH
Puig P, *see* Castells A
Pullen DJ, *see* Rubnitz JE
Punt CJA, *see* de Jonge MJA
Puodziunas A, *see* Leung PP
Purch P, *see* Galanis E
Pusceddu G, *see* Frasci G
Pyrhönen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen P-L. Prospective Randomized Trial of Interferon Alfa-2a Plus Vinblastine Versus Vinblastine Alone in Patients With Advanced Renal Cell Cancer, 2859

Quaas J, *see* du Bois A
Qualman SJ, *see* Pappo AS
— *see* Wolden SL
Quintana E, *see* Baranzelli MC
Qumsiyeh M, *see* Byrd JC
Quong G, *see* Wirth A

Raab R, *see* Schlitt HJ
Raben A, *see* Zelefsky MJ
Racenstein MJ, *see* American College of Radiology Task Force on Breast Cancer
Rademaker AW, *see* Haraf DJ
Raderer M, *see* Scheithauer W
Radford JA, *see* Bradley AJ
— *see* Foran JM
— *see* Howell SJ
— *see* Shipp MA
Radosavljevic-Asic G, *see* Jeremic B
Raffel C, *see* Buckner JC
Rafi MM, *see* DiPaola RS
Raghaven D. Prostate Cancer Management Under Scrutiny: One Man's Meta-Analysis is Anther Man's Poisson (editorial), 3371
Raijman I, *see* Ajani JA
Raimondi SC, *see* Rubnitz JE
Rajkumar SV, Fonseca R, Lacy MQ, Witzig TE, Therneau TM, Kyle RA, Litzow MR, Gertz MA, Greipp PR. Plasmablastic Morphology Is an Independent Predictor of Poor Survival After Autologous Stem-Cell Transplantation for Multiple Myeloma, 1551
Ramanathan RK, *see* Belani CP
Rampinelli I, *see* Tondini C
Ramsey H, *see* Einhorn L
Raney RB, *see* Pappo AS
Rankin C, *see* Chang SM
Rankin E, *see* Highley MS
Rao B, *see* Pratt CB
Rao BN, *see* Marina NM
— *see* Spunt SL
Rao PV, *see* Marina NM
Rao RM, *see* Sparano JA
Rapoport AP, Watelet LFM, Linder T, Eberly S, Raubertas RF, Lipp J, Duerst R, Abboud CN, Constine L, Andrews J, Etter MA, Spear L, Powley E, Packman CH, Rowe JM, Schwertschlag U, Bedrosian C, Liesveld JL. Analysis of Factors That Correlate With Mucositis in Recipients of Autologous and Allogeneic Stem-Cell Transplants, 2446
Rapoport B, *see* Nabholtz JM
Rappold I, *see* Brugger W
Raptis G, *see* Hudis C
Rasheed K, *see* Friedman HS
Rath B, *see* Schellong G
Raubertas RF, *see* Rapoport AP
Raubitschek A, *see* Witzig TE
Ravaioli A, *see* Crinò L
Ravaud A, Bui BN. In reply (correspondence), 1644, 3002
Ravaud A, *see* Escudier B
— *see* Ray-Coquard I
Ravindranath Y, *see* Parson SK
Ray-Coquard I, Le Cesne A, Rubio MT, Mermet J, Maugard C, Ravaud A, Chevreau C, Sebban C, Bachelot t, Biron P, Blay JY, ELYPSE 1 Study Group. Risk Model for Severe Anemia Requiring Red Blood Cell Transfusion After Cytotoxic Conventional Chemotherapy Regimens, 2840
Read R, *see* Colevas AD
Reaman GH, *see* Sun L
Reaman GH, Sposto R, Sensel MG, Lange BJ, Feusner JH, Heerema NA, Leonard M, Holmes EJ, Sather HN, Pendergrass TW, Johnstone HS, O'Brian RT, Steinherz PG, Zeltzer PM, Gaynon PS, Trigg ME, Uckun FM. Treatment Outcome and Prognostic Factors for Infants With Acute Lymphoblastic Leukemia Treated on Two Consecutive Trials of the Children's Cancer Group, 445
Rearden T, *see* Adkins D
Reardon D, *see* Walter AW
Reardon DA, *see* Gajjar A
Rebattu P, *see* Lhommé C
Recht A, Gray R, Davidson NE, Fowble BL, Solin LJ, Cummings FJ, Falkson G, Falkson HC, Taylor SG IV, Tormey DC. Locoregional Failure 10 Years After Mastectomy and Adjuvant Chemotherapy With or Without Tamoxifen Without Irradiation: Experience of the Eastern Cooperative Oncology Group, 1689
Redman B, *see* Smith DC

Redwood S, *see* Goodwin PJ
Reece DE, *see* Lazarus HM
Reed E, *see* Bubley GJ
Reed JC. Dysregulation of Apoptosis in Cancer, 2941
Reed K, *see* Whelan T
Reed NS, *see* Fosså SD
— *see* Vasey PA
Regan D, *see* Jones SE
Regan K, *see* Bluman LG
Reich S, Overberg-Schmidt US, Bührer C, Henze G. Low-Dose Chemotherapy With Vinblastine and Methotrexate in Childhood Desmoid Tumors (correspondence), 1086
Reichman B, *see* Hudis C
Reid S, *see* Whelan T
Reidenberg P, *see* Hammond LA
Reigner B, *see* Villalona-Calero MA
Reintgen DS, *see* Gershenwald JE
Reisner Y, *see* Aversa F
Reiter A, *see* Schellong G
Reitsma DJ, *see* Theriault RL
Relling MV
see Pui C-H
see Woo MH
Renshaw AA, *see* D'Amico AV
Renstrup J, *see* Wymenga ANM
Rescorla F, *see* Marina NM
Reske SN, *see* Schirrmeister H
Respondek PM, *see* Fleming JB
Retalis G, *see* Koukourakis MI
Rey A, *see* Martelli H
Reyes B, *see* Boulad F
Reyes G, *see* Tortola S
Reyno L, *see* Khoo K
Reynolds C, Mick R, Donohue JH, Grant CS, Farley DR, Callans LS, Orel SG, Keeney GL, Lawton TJ, Czerniecki BJ. Sentinel Lymph Node Biopsy With Metastasis: Can Axillary Dissection Be Avoided in Some Patients With Breast Cancer?, 1720
Reynolds KR, *see* Eisbruch A
Ribeiro RC, *see* Pui C-H
Ribersani M, *see* Zinzani PL
Ricchi P, *see* Pignata S
Ricci S, *see* Crinò L
Riccio L, *see* Hudis C
Rich J, *see* Friedman HS
Richards D, *see* Nemunaitis J
Richards F, *see* Blackstock AW
Richards JM, Gale D, Mehta N, Lestingi T. Combination of Chemotherapy With Interleukin-2 and Interferon Alfa for the Treatment of Metastatic Melanoma, 651
Richardson G, *see* Chan S
Richardson MA. Research of Complementary/Alternative Medicine Therapies in Oncology: Promising but Challenging, 38-43(Supp.)
Richardson P, *see* Elias A
Richel DJ, *see* Herben VMM
— *see* Nabholtz JM
Richmond E, *see* Marshall JL
Richter B, *see* du Bois A
Riedel E, *see* Hudis C
Riepenhausen M, *see* Schellong G
Riethmüller G, *see* Weckermann D
Rifai N, *see* Herman EH
Rigg A, *see* Pandha HS
Rigo A, *see* Goelen G
Rimer BK
see Bluman LG
see Gail MH
Rinaldi DA, *see* Hammond LA
Rinaldi M, *see* Crinò L
Rinehart JJ, *see* Galanis E
Ringe B, *see* Schlitt HJ
Rintala E, *see* Pyrhönen S
Rios MB, *see* Kantarjian HM
Ris MD, *see* Packer RJ
Ritchey AK, Pollock BH, Lauer SJ, Andejeski Y, Buchanan GR. Improved Survival of Children With Isolated CNS Relapse of Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Study, 3745
Ritz J, *see* Friedberg JW
— *see* Sehn LH
Riva A, *see* Chan S
— *see* Nabholtz JM
Rivera GK, *see* Pui C-H
Rivlin MM, *see* Perry AR
Rizzieri DA, Vredenburgh JJ, Jones R, Ross M, Shpall EJ, Hussein A, Broadwater G, Berry D, Petros WP, Gilbert C, Affronti ML, Coniglio D, Rubin P, Elkordy M, Long GD, Chao NJ, Peters WP. Prognostic and Predictive Factors for Patients With Metastatic Breast Cancer Undergoing Aggressive Induction Therapy Followed by High-Dose Chemotherapy With Autologous Stem-Cell Support, 3064
Rizzo J, *see* Eckhardt SG
Rizzo JD, Vogelsang GB, Krumm S, Frink B, Mock V, Bass EB. Outpatient-Based Bone Marrow Transplantation for Hematologic Malignancies: Cost Saving or Cost Shifting?, 2811
Ro JY, *see* Monzó M
Robert J, *see* Gamelin E
Robert NJ, *see* Cobleigh MA
Roberts JA, *see* Eisbruch A
Roberts JT, *see* Fosså SD
Robertson C, *see* Decensi A
Robertson JM, *see* Eisbruch A
Robins HI, *see* Chang SM
Robins HI, Tutsch K, Katschinski DM, Jacobson E, Mehta M, Olsen M, Cohen JD, Tiggelaar CL, Arzoomanian RZ, Alberti D, Feierabend C, Wilding G. Phase I Trial of Intravenous Thymidine and Carboplatin in Patients With Advanced Cancer, 2922
Robinson BWS, *see* Byrne MJ
Robson LS, *see* Hack TF
Roche H, *see* Lhommé C
Roche PC, Ingle JN. In reply (correspondence), 2293
Roche PC, Ingle JN. Increased HER2 With U.S. Food and Drug Administration-Approved Antibody (correspondence), 434
Rockette H, *see* Mamounas E
— *see* Wolmark N
Rodrigues G, *see* Villalona-Calero MA
Rodriguez-Bigas M, *see* Heller B
Rodriguez G, *see* Adkins D
Rodriguez GI, *see* Drengler RL
Rodriguez M, *see* Rose PG
Rodríguez R, *see* Acuña LR
Rogers B, *see* Schilder RJ
Rogers LR, *see* Glantz MJ

Rogers P, *see* Marina NM
Rogers WT, *see* Nekolaichuk CL
Rohatiner AZS, *see* Apostolidis J
— *see* Foran JM
Rohrlich P, *see* Véra P
Roila F, Tonato M, Ballatori E, Del Favero A. Studies on New Antiemetic Drugs (correspondence), 1958
Rojas AM, *see* Greiner R
Roland T, *see* Grunberg SM
Romeo F, *see* Pignata S
Romero A, *see* Acuña LR
Romond EH, *see* Fisher B
Rondelli R, *see* Bonetti F
— *see* Zecca M
Ronzoni M, *see* Chan S
Rooney M, *see* Graziano SL
Roque T, *see* Jones SE
Rorke LB, *see* Packer RJ
— *see* Zeltzer PM
Rørth M, *see* Petersen PM
Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positron Emission Tomography for Evaluating Para-aortic Nodal Metastasis in Locally Advanced Cervical Cancer Before Surgical Staging: A Surgicopathologic Study, 41
Rose PG, Blessing JA, Gershenson DM, McGehee R. Paclitaxel and Cisplatin as First-Line Therapy in Recurrent or Advanced Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study, 2676
Rosell R, *see* Cardenal F
— *see* Monzó M
Rosenberg SA, *see* Atkins MB
Rosenberg SA, Yang JC, Schwartzentruber DJ, Hwu P, Marincola FM, Topalian SL, Seipp CA, Einhorn JH, White DE, Steinberg SM. Prospective Randomized Trial of the Treatment of Patients With Metastatic Melanoma Using Chemotherapy With Cisplatin, Dacarbazine, and Tamoxifen Alone or in Combination With Interleukin-2 and Interferon Alfa-2b, 968
Rosenblum N, *see* Schilder RJ
Rosenfeld SS, *see* Yung WKA
Rosenman J, *see* Clamon G
Rosenthal M. The ASCO Annual Meeting and Excess Baggage (correspondence), 3002
Rosing H
see Herben VMM
see Kroep JR
Ross E, *see* Einhorn L
Ross G, *see* von Pawel J
Ross M, *see* Rizzieri DA
Ross MB, *see* Glisson BS
Ross MI, *see* Gershenwald JE
— *see* Kuerer HM
Ross PJ, *see* Popescu RA
Rossi A, *see* Crinò L
Rossi JF, *see* Escudier B
Rosso R, *see* Esposito M
— *see* Nabholtz JM
Rosti G, *see* Leyvraz S
Roth B, *see* Bubley GJ
— *see* Einhorn L
Rothenberg ML, *see* Drengler RL
Rotilio A, *see* Brandes AA
Rougier P, *see* Ducreux M
Rowe JM, *see* Rapoport AP
Rowinsky EK, *see* Eckhardt SG
— *see* Hammond LA
— *see* Villalona-Calero MA
Rowinsky EK, Windle JJ, Von Hoff DD. Ras Protein Farnesyltransferase: A Strategic Target for Anticancer Therapeutic Development, 3631
Rowland C, *see* Highley MS
Rowland JH, *see* Ganz PA
— *see* Mortimer JE
Rowland KM, *see* Creagan ET
Rowland KM Jr, *see* Loprinzi CL
Rowlings PA, Curtis RE, Passweg JR, Deeg J, Socié G, Travis LB, Kingma DW, Jaffe ES, Sobocinski KA, Horowitz MM. Increased Incidence of Hodgkin's Disease After Allogeneic Bone Marrow Transplantation, 3122
Rowlings PA, *see* Lazarus HM
Royce ME, McGarry W, Bready B, Dakhil SR, Belt RJ, Goodwin W, Gray R, Hoff PM, Winn R, Pazdur R. Sequential Biochemical Modulation of Fluorouracil With Folinic Acid, N-Phosphonacetyl-L-Aspartic Acid, and Interferon Alfa-2a in Advanced Colorectal Cancer, 3276
Rozental JR, *see* Glantz MJ
Rubagotti A, *see* Boccardo F
Rübe C, *see* Thomas M
Rubie H, *see* Baranzelli MC
Rubin E, *see* DiPaola RS
Rubin J, Ajani J, Schirmer W, Venook AP, Bukowski R, Pommier R, Saltz L, Dandona P, Anthony L. Octreotide Acetate Long-Acting Formulation Versus Open-Label Subcutaneous Octreotide Acetate in Malignant Carcinoid Syndrome, 600
Rubin J, *see* Galanis E
Rubin P, *see* Rizzieri DA
Rubinstein L, *see* Smith MA
Rubio MT, *see* Ray-Coquard I
Rubnitz JE, Camitta BM, Mahmound H, Raimondi SC, Carroll AJ, Borowitz MJ, Shuster JJ, Link MP, Pullen DJ, Downing JR, Behm FG, Pui C-H. Childhood Acute Lymphoblastic Leukemia With the *MLL-ENL* Fusion and t(11;19)(q23;p13.3) Translocation, 191
Rubnitz JE, *see* Pui C-H
Ruckdeschel JC, *see* Albrecht TL
Rudd RM, *see* Cullen MH
Ruffer J, *see* Kleinberg L
Runowicz C, *see* Hochster H
Russell I, *see* Basser RL
Russell JM, *see* Fosså SD
Rusthoven JJ, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J for the National Cancer Institute of Canada Clinical Trials Group. Multitargeted Antifolate LY231514 as First-Line Chemotherapy for Patient With Advanced Non-Small-Cell Lung Cancer: A Phase II Study, 1194
Rustin GJS, *see* Bridgewater JA
Rustum YM, *see* Vanhoefer U
Rütten S, *see* Sun X-F
Ruutu M, *see* Pyrhönen S
Ryan E, *see* Mortimer JE
Ryan G, *see* Wirth A
Ryan T, *see* Adkins D
Ryder WDJ, *see* Bradley AJ
— *see* Howell SJ

Sabbatini P, Larson SM, Kremer A, Zhang Z-F, Sun M, Yeung H, Imbriaco M, Horak I, Conolly M, Ding C, Ouyang P, Kelly WK, Scher HI. Prognostic Significance of Extent of Disease in Bone in Patients With Androgen-Independent Prostate Cancer, 948
Sack H, *see* Stuschke M
Safdar S, *see* Adkins D
Sagawa M, *see* Sato G
Saidman SL, *see* Porter DL
Saigí E, *see* Cirera L
Saijo N, *see* Okamoto H
Saijo Y, *see* Sato G
Saito H, *see* Boku N
Saitoh Y, *see* Fujisawa T
Sakata Y, *see* Boku N
Saleh M, *see* Czuczman MS
Saleh M, *see* Tolcher AW
Salerno G, *see* Pierelli L
Salles G, *see* Shipp MA
Salmela PI, *see* Wymenga ANM
Salminen E, Bergman M, Huhtala S, Ekholm E. Docetaxel: Standard Recommended Dose of 100 mg/m^2 Is Effective But Not Feasible for Some Metastatic Breast Cancer Patients Heavily Pretreated With Chemotherapy—A Phase II Single-Center Study, 1127
Salminen E, *see* Pyrhönen S
Salmon SE, *see* Vesole DH
Saltz L, *see* Ilson DH
— *see* Rubin J
Salvadori B, *see* Gennari A
Salvaggio R, *see* Hudis C
Salvesen HB, Iversen OE, Akslen LA. Prognostic Significance of Angiogenesis, *Ki-67*, *p53*, and *p21* Expression: A Population-Based Endometrial Carcinoma Study, 1382
Salzberg A, *see* Pratt CB
Samelis G, *see* Androulakis N
Samonigg H, *see* Jakesz R
Samonis G, *see* Kouroussis C
Samur M. Prognosis of Metastatic Melanoma: Where Are the Details? (correspondence), 3857
Sanchez de Toledo J, *see* Martelli H
Sánchez JJ, *see* Monzó M
Sancho FJ, *see* Tortola S
Sander C, *see* Schmid-Wendtner M-H
Sander CA, *see* Bornhövd EC
Sander J, *see* Berthold F
Sanders K, *see* Whelan T
Sandlund JT, *see* Pui C-H
— *see* Woo MH
Sandri MT, *see* Decensi A
Sanford RA, *see* Walter AW
Santana VM, *see* Furman WL
— *see* Spunt SL
Santini A, *see* Lanza G
Santjohanser C, *see* Schirrmeister H
Santoro A, *see* Corradini P
— *see* Fosså A
— *see* Van Glabbeke M
Santoro N, *see* Bonetti F
Santucci A, *see* Aversa F
Sarris K, *see* Papadimitriou CA
Sartor O, *see* Bubley GJ
Sassi M, *see* Crinò L
Satake M, *see* Ohtsu A
Sather H, *see* Sun L
Sather HN, *see* Reaman GH
Sato G, Saijo Y, Uchiyama B, Kumano N, Sugawara S-i, Fujimura S, Sato M, Sagawa M, Ohkuda K, Koike K, Minami Y, Satoh K, Nukiwa T. Prognostic Value of Nucleolar Protein *p120* in Patients With Resected Lung Adenocarcinoma, 2721
Sato M, *see* Sato G
Satoh K, *see* Sato G
Satriano SMR, *see* Palmieri G
Sause W, *see* Whitney CW
Sauter C. Chemotherapy of Advanced Non-Small-Cell Lung Cancer: "Those Who Cannot Remember the Past Are Condemned to Repeat It" (correspondence), 730
Savage PD, *see* Blackstock AW
Savary J, *see* Escudier B
Sawada T, *see* Kawa K
Sawczuk I, *see* Petrylak DP
Saxman S, *see* Chapman PB
— *see* Wagner JD
Scadden DT, *see* Gill PS
Scagliotti G, *see* Crinò L
Scagliotti GV, *see* Crinò L
Scambia G, *see* Pierelli L
Scardino PT, *see* Kattan MW
Scelzi E, *see* Brandes AA
Scerrati M, *see* Antinori A
Schaaf LJ, *see* Devore RF
— *see* Drengler RL
— *see* Friedman HS
Schacherer CW, *see* Gritz ER
Schäfer K-L, *see* Poremba C
Schapira DV, *see* Smith TJ
Schauwecker D, *see* Wagner JD
Schechner R, *see* Wadler S
Scheding S, *see* Brugger W
Scheithauer W, Kornek GV, Raderer M, Valencak J, Weinländer G, Hejna M, Haider K, Kwasny W, Depisch D. Combined Irinotecan and Oxaliplatin Plus Granulocyte Colony-Stimulating Factor in Patients With Advanced Fluoropyrimidine/Leucovorin-Pretreated Colorectal Cancer, 902
Scheld HH, *see* Thomas M
Schellens JHM, *see* Herben VMM
Schellhammer PF, *see* Petersen JP
Schellong G, Pötter R, Brämswig J, Wagner W, Prott F-J, Dörffel W, Körholz D, Mann G, Rath B, Reiter A, Weissbach G, Riepenhausen M, Thiemann M, Schwarze E-W for the German-Austrian Pediatric Hodgkin's Disease Study Group. High Cure Rates and Reduced Long-Term Toxicity in Pediatric Hodgkin's Disease: The German-Austrian Multicenter Trial DAL-HD-90, 3736
Scher H, *see* Bubley GJ
Scher HI, *see* Bajorin DF
— *see* Dodd PM
— *see* Sabbatini P
Schiff D, *see* Chang SM
Schiffer C, *see* Glantz MJ
Schiffer CA, *see* Byrd JC
Schilder RJ, Johnson S, Gallo J, Kindsfather S, Rogers B, Bookman MA, Millenson MM, Boente M, Rosenblum N, Litwin S, Ozols RF. Phase I Trial of Multiple Cycles of High-Dose Chemother-

apy Supported by Autologous Peripheral-Blood Stem Cells, 2198
Schilder RJ, *see* Witzig TE
Schildkraut J, *see* Bluman LG
Schiller JH, *see* von Pawel J
Schilsky RL, *see* Costanza ME
Schirmer W, *see* Rubin J
Schirrmeister H, Guhlmann A, Kotzerke J, Santjohanser C, Kühn T, Kreienberg R, Messer P, Nüssle K, Elsner K, Glatting G, Träger H, Neumaier B, Diederichs C, Reske SN. Early Detection and Accurate Description of Extent of Metastatic Bone Disease in Breast Cancer With Fluoride Ion and Positron Emission Tomography, 2381
Schlimok G, *see* Weckermann D
Schlitt HJ, Neipp M, Weimann A, Oldhafer KJ, Schmoll E, Boeker K, Nashan B, Kubicka S, Maschek H, Tusch G, Raab R, Ringe B, Manns MP, Pichlmayr R. Recurrence Patterns of Hepatocellular and Fibrolamellar Carcinoma After Liver Transplantation, 324
Schlondorff D, *see* Jung Ch
Schmalfuss I, *see* Mancuso AA
Schmid H-P, Semjonow A, Maibach R. Prostate-Specific Antigen Doubling Time: A Potential Surrogate End Point in Hormone-Refractory Prostate Cancer (correspondence), 1644
Schmid-Wendtner M-H, Sander C, Volkenandt M, Wendtner C-M. Unusual Manifestations of B-Cell Disorders; Case 2: Chronic Lymphocytic Leukemia Presenting With Cutaneous Lesions, 1083
Schmid-Wendtner M-H, *see* Bornhövd EC
Schmidt BF, *see* Koscielniak E
Schmitt C, *see* Tabone M-D
Schmitz N, *see* Shipp MA
— *see* Sweetenham JW
Schmitz SFH, *see* Bernhard J
Schmoll E, *see* Schlitt HJ
Schmoll H-J, *see* Bokemeyer C
Schmoll HJ, *see* Bokemeyer C
Schneider DT, Hilgenfeld E, Schwabe D, Behnisch W, Zoubek A, Wessalowski R, Göbel U. Acute Myelogenous Leukemia After Treatment for Malignant Germ Cell Tumors in Children, 3226
Schnider D, *see* Whelan T
Schnipper L, *see* Elias A
Schnitt SJ, *see* Jacobs TW
Schoch C, *see* Hiddemann W
Schoemaker NE, *see* Herben VMM
Schoentgen S, *see* McCaskill-Stevens W
Schöffski P, *see* Bokemeyer C
Schold SC, *see* Chang SM
Scholl S, *see* Cobleigh MA
Scholm J, *see* Marshall JL
Schomberg PJ, *see* Buckner JC
Schot M, *see* Herben VMM
Schuchter LM, *see* Chapman PB
— *see* Hensley ML
Schulman KA, Birch R, Zhen B, Pania N, Weaver CH. Effect of $CD34^+$ Cell Dose on Resource Utilization in Patients After High-Dose Chemotherapy With Peripheral-Blood Stem-Cell Support, 1227
Schumm P, *see* List MA
Schurr P, *see* Berthold F
Schuster M, *see* Jones SE
Schwabe D, *see* Schneider DT
Schwartz G, *see* Ilson DH
Schwartz LH, *see* Goss PE
Schwartz RE, Chu P, Arber DA. Extranodal Follicular Dendritic Cell Tumor of the Abdominal Wall, 2290
Schwartzentruber DJ, *see* Rosenberg SA
Schwarze E-W, *see* Schellong G
Schwenzer D, *see* Bielack SS
Schwertschlag U, *see* Rapoport AP
Scott C, *see* Prados MD
Scott SM, *see* Pisters LL
Scottish Gynaecological Cancer Trials Group, *see* Vasey PA
Scrimgeour JB, *see* Love CDB
Scullion B, Knox K, Bennett CL. Quality Improvement: Carrots or Sticks? (correspondence), 3859
Seaman JJ, *see* Theriault RL
Sebban C, *see* Ray-Coquard I
Seeber S, *see* Fosså A
— *see* Stuschke M
— *see* Vanhoefer U
Seeling S. Fluorescence In Situ Hybridization Versus Immunohistochemistry: Importance of Clinical Outcome (correspondence), 3690
Sehn LH, Alyea EP, Weller E, Canning C, Lee S, Ritz J, Antin JH, Soiffer RJ. Comparative Outcomes of T-Cell-Depleted and Non-T-Cell-Depleted Allogeneic Bone Marrow Transplantation for Chronic Myelogenous Leukemia: Impact of Donor Lymphocyte Infusion, 561
Seibel N, *see* Sun L
Seiden MV, *see* Penson RT
Seidman A, *see* Hudis C
Seipp CA, *see* Rosenberg SA
Seitz J-F, *see* Ducreux M
Seki S, *see* Boku N
— *see* Ohtsu A
Sekine Y, *see* Fujisawa T
Selby PJ, *see* Velikova G
Selk L, *see* Galanis E
Selvaggi G, *see* Crinò L
Selvaggi L, *see* Pignata S
Semik M, *see* Thomas M
Semjonow A, *see* Schmid H-P
Senn HJ, *see* Nabholtz JM
Sensel M, *see* Sun L
Sensel MG, *see* Reaman GH
Seppenwoolde Y, *see* Theuws JCM
Serke S, Huhn D, Johnsen HE, Herrmann R. Detrimental Effects of Prechemotherapy Filgrastim (correspondence), 1086
Serrano J, *see* Yu F
Seshadri R, *see* Miller KD
Sessarego M, *see* Ballestrero A
Severino R, *see* Wong JH
Sextro M, *see* Diehl V
Seymour L, *see* Moore MJ
Shafman T, *see* Nichols KE
Shahab N. Bladder Preservation Trial: Radiation Therapy Oncology Group 89-03 (correspondence), 1326
Shaheta N, *see* Tang S-C
Shak S, *see* Cobleigh MA
Shalet SM, *see* Howell SJ
Shanahan TG, *see* Bonner JA
Shannon KE, *see* Nichols KE
Shapiro CL, Ervin T, Welles L, Azarnia N, Keating J, Hayes DF for the TLC D-99 Study Group. Phase II Trial of High-Dose Liposome-

Encapsulated Doxorubicin With Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer, 1435
Shapiro CL. In reply (correspondence), 2293
Shapiro W, *see* Glantz MJ
Sharma M, *see* Ganjoo KN
Shaw EG, *see* Buckner JC
Shek TWH, *see* Chim CS
Shelton G, *see* Petrylak DP
Shenoy S, *see* Brown RA
Sheperd FA, *see* Michael M
Shepherd FA
see Murray N
see von Pawel J
Shepherd JH, *see* Bonnefoi H
Sheridan WP, *see* Basser RL
Shi W, *see* Groeger JS
Shibamoto Y, *see* Jeremic B
Shibata HR, *see* Smith RE
Shibuya K, *see* Fujisawa T
Shimada Y, *see* Boku N
Shin DM, *see* Garden AS
— *see* Glisson BS
Shipley WU, Kaufman DS. In reply (correspondence), 1326
Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M, Montserrat E, Radford JA, Salles G, Schmitz N, Symann M, Armitage JO, Philip T, Coiffier B. International Consensus Conference on High-Dose Therapy With Hematopoietic Stem Cell Transplantation in Aggressive Non-Hodgkin's Lymphomas: Report of the Jury, 423
Shipp MA. In reply (correspondence), 3002
Shipp MA, *see* Cheson BD
Shirao K, *see* Boku N
Shoji A, Toda M, Suzuki K, Takahashi H, Takahashi K, Yoshiike Y, Ogura T, Watanuki Y, Nishiyama H, Odagiri S. Insufficient Effectiveness of 5-Hydroxytryptamine-3 Receptor Antagonist Due to Oral Morphine Administration in Patients With Cisplatin-Induced Emesis, 1926
Shpall A, *see* Rizzieri DA
Shroyer AL, *see* Poremba C
Shroyer KR, *see* Poremba C
Shubel S, *see* Grunberg SM
Shurin SB, *see* Zeltzer PM
Shuster J, *see* Parson SK
— *see* Smith MA
Shuster JJ, *see* Rubnitz JE
— *see* Suryanarayan K
Sickles E, *see* Esserman L
Sickles EA, *see* American College of Radiology Task Force on Breast Cancer
Sidlofsky S, *see* Goodwin PJ
Siedlecki P, *see* Nabholtz JM
Siegelmann-Danieli N, Cohen HI, Ben-Izhack O. Malignant Skin Lesions; Case 1: Nevoid Malignant Melanoma of the Breast Presenting as a Contralateral Breast Metastasis, 3850
Sigurdson E, *see* Fowble B
Sikic BI, *see* Dumontet C
Sikora K, *see* Pandha HS
Silber JH, *see* Gralla RJ
Silberman SL, *see* Hesketh PJ
Silva EG, *see* Brewer M
Silverman DHS, *see* Witzig TE
Silvestro G, *see* Pignata S
Simeone J, *see* Theriault RL
Simmonds P, *see* Chan S
Simon R, *see* Chute JP
Simons J, *see* Bubley GJ
Singer S, *see* Baldini EH
Singh G, *see* Kuerer HM
Singletary SE, *see* Berry DL
— *see* Buzdar AU
— *see* Kuerer HM
— *see* Vassilopoulou-Sellin R
Sinibaldi V, *see* Bubley GJ
Sinnett HD, *see* Slade MJ
Sipe MA, *see* Byrd JC
Siracusano L, *see* Tondini C
Sisk J, *see* Miller KD
Siston A, *see* List MA
Sjolander DE, *see* Kobrinsky NL
Skakkebæk NE, *see* Petersen PM
Skarin AT, *see* Elias A
— *see* Liu G
Skarlatos J, *see* Koukourakis MI
Skarlos D, *see* Nabholtz JM
Skates SJ, *see* Penson RT
Sklarin N, *see* Hudis C
Skolnick M, *see* Turner BC
Slade MJ, Smith BM, Sinnett HD, Cross NCP, Coombes RC. Quantitative Polymerase Chain Reaction for the Detection of Micrometastases in Patients With Breast Cancer, 870
Slamon DJ, *see* Cobleigh MA
Sledge GW Jr, *see* Miller KD
Slichenmyer W, *see* Tolcher AW
Sloan J, Loprinzi C. In reply (correspondence), 730
Sloan JA, *see* Bonner JA
— *see* Loprinzi CL
Small EJ, *see* Bubley GJ
Small TN, *see* Boulad F
Smit EF, *see* Groen HJM
— *see* Kroep JR
Smith AB, *see* Velikova G
Smith BM, *see* Slade MJ
Smith CD, *see* Thames HD
Smith DC, Esper P, Strawderman M, Redman B, Pienta KJ. Phase II Trial of Oral Estramustine, Oral Etoposide, and Intravenous Paclitaxel in Hormone-Refractory Prostate Cancer, 1664
Smith IE, *see* Fokkema E
Smith J, *see* Bishop JF
Smith L, *see* Eckhardt SG
Smith MA, Rubinstein L, Anderson JR, Arthur D, Catalano PJ, Freidlin B, Heyn R, Khayat A, Krailo M, Land VJ, Miser J, Shuster J, Vena D. Secondary Leukemia or Myelodysplastic Syndrome After Treatment With Epipodophyllotoxins, 569
Smith MR, *see* Bubley GJ
Smith RB, *see* Belldegrun A
Smith RE, Brown AM, Mamounas EP, Anderson SJ, Lembersky BC, Atkins JH, Shibata HR, Baez L, DeFusco PA, Davila E, Tipping SJ, Bearden JD, Thirlwell MP. Randomized Trial of 3-Hour Versus 24-Hour Infusion of High-Dose Paclitaxel in Patients With Metastatic or Locally Advanced Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26, 3403

Smith T, *see* Turner BC
Smith TJ, Davidson NE, Schapira DV, Grunfeld E, Muss HB, Vogel VG III, Somerfield MR for the American Society of Clinical Oncology Breast Cancer Surveillance Expert Panel. American Society of Clinical Oncology 1998 Update of Recommended Breast Cancer Surveillance Guidelines, 1080
Smith TJ, *see* Bennett CL
— *see* Desch CE
Smith TL, *see* Buzdar AU
— *see* Kantarjian HM
— *see* Kuerer HM
Smithson WA, *see* Buckner JC
Sneige N, *see* Kuerer HM
Sobocinski KA, *see* Lazarus HM
— *see* Rowlings PA
Sobol RE, *see* Galanis E
Sobrero A, *see* Aschele C
Socié G, *see* Rowlings PA
Société Francaise de Greffe de Moelle, *see* André M
Sofferman R, *see* Grunberg SM
Soiffer RJ, *see* Friedberg JW
— *see* Sehn LH
Solal-Céligny P, *see* Decaudin D
Solé M, *see* Castells A
Solin LJ, *see* Recht A
Somerfield MR, *see* Bennett CL
— *see* Chlebowski RT
— *see* Desch CE
— *see* Fogarty LA
— *see* Smith TJ
Somerfield MR. Wherefore Global Quality-of-Life Assessment? (correspondence), 730
Somers R, *see* Van Glabbeke M
Sommelet D, *see* Martelli H
Sondak BD, *see* Galanis E
Song K, *see* Mamounas E
Soong Y-K, *see* Tseng C-J
Soper JT, *see* Thigpen JT
Sorensen PHB, *see* Ginsberg JP
Sorich J, *see* Hochster H
Souglakos J, *see* Kouroussis C
Souhami RL, *see* Cullen MH
Souquet JC, *see* Francois Y
Southern Italy Cooperative Oncology Group, *see* Frasci G
Sozzi G, *see* Croce CM
Spano G, *see* Boccardo F
Sparano JA, Hu P, Rao RM, Falkson CI, Wolff AC, Wood WC. Phase II Trial of Doxorubicin and Paclitaxel Plus Granulocyte Colony-Stimulating Factor in Metastatic Breast Cancer: An Eastern Cooperative Oncology Group Study, 3828
Sparano JA, Speyer J, Gradishar WJ, Liebes L, Sridhara R, Mendoza S, Fry D, Egorin MJ. Phase I Trial of Escalating Doses of Paclitaxel Plus Doxorubicin and Dexrazoxane in Patients With Advanced Breast Cancer, 880
Sparreboom A, *see* de Jonge MJA
Spear L, *see* Rapoport AP
Spence AM, *see* Chang SM
Sperner-Unterweger B, *see* Kemmler G
Speyer J, *see* Hochster H
— *see* Sparano JA
Spicer RD, *see* Martelli H
Spier C, *see* Galanis E
Spies S, *see* Witzig TE
Spiro SG, *see* Cullen MH
Splinter TAW, *see* Tjan-Heijnen VCG
Spooner D, *see* Martelli H
Sposto R, *see* Reaman GH
Spotts BE, *see* Neumann RM
Sprandio J, *see* Einhorn L
Spunt SL, Poquette CA, Hunt YS, Cain AM, Rao BN, Merchant TE, Jenkins JJ, Santana VM, Pratt CB, Pappo AS. Prognostic Factors for Children and Adolescents With Surgically Resected Nonrhabdomyosarcoma Soft Tissue Sarcoma: An Analysis of 121 Patients Treated at St. Jude Children's Research Hospital, 3697
Spyratos F, *see* Bouchet C
Sridhara R, *see* Sparano JA
Stack CB, *see* Hesketh PJ
Stadler WM, Kuzel T, Shapiro C, Sosman J, Clark J, Vogelzang NJ. Multi-Institutional Study of the Angiogenesis Inhibitor TNP-470 in Metastatic Renal Carcinoma, 2541
Stamatis G, *see* Stuschke M
Stamberg J, *see* Byrd JC
Stamp GWH, *see* Pandha HS
Stanley P, *see* Zeltzer PM
Stathopoulos GP, *see* Androulakis N
Statkevich P, *see* Hammond LA
Staton BA, *see* Drengler RL
Stead M, *see* Velikova G
Steen PD, *see* Kobrinsky NL
Steger G, *see* Jakesz R
Stehbens JA, *see* Zeltzer PM
Stein H, *see* Diehl V
— *see* Marafioti T
Steinberg GD, *see* Figlin RA
Steinberg SM, *see* Rosenberg SA
Steindorfer P, *see* Jakesz R
Steinherz P, *see* Boulad F
Steinherz PG, *see* Reaman GH
— *see* Sun L
Stelling CB, *see* American College of Radiology Task Force on Breast Cancer
Stender MJ, *see* Einhorn LH
Stenning SP, *see* Fosså SD
Stenson K, *see* Haraf DJ
— *see* List MA
Stephenson J, *see* Bishop JF
Stephenson JA Jr, *see* Drengler RL
Stern S, *see* O'Day SJ
Stevens KR, *see* Zeltzer PM
Stevens M, *see* Carli M
Stevens MCG, *see* Martelli H
Stevenson JP, Yao K-S, Gallagher M, Friedland D, Mitchell EP, Cassella A, Monia B, Kwoh TJ, Yu R, Holmlund J, Dorr FA, O'Dwyer PJ. Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-*raf*-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A), 227
Steward WP, *see* Bramwell VHC
Stewart CF, *see* Furman WL
Stewart DJ, Dahrouge S, Coyle D, Evans WK. Costs of Treating and Preventing Nausea and Vomiting in Patients Receiving Chemotherapy, 344
Stewart DJ, *see* von Pawel J

Stewart ES, *see* Friedman HS
Stewart JF, *see* Theriault RL
Stierer M, *see* Jakesz R
Stiévenart JL, *see* Véra P
Stiff PJ, *see* Vesole DH
Stillman M, *see* Du Pen SL
Stöblen F, *see* Stuschke M
Stolar C, *see* Marina NM
Stone RM, *see* Friedberg JW
Stopeck AT, *see* Galanis E
Storm MC, *see* Woo MH
Storme G, *see* Greiner R
Stovall E, Gesme D. Coming Together to Conquer Cancer (correspondence), 730
Straus DS, *see* Moskowitz CH
Strawderman M, *see* Smith DC
Strazzullo M, *see* Palmieri G
Strom E, *see* Buzdar AU
Strongbow R, *see* Albrecht TL
Stroobants S, *see* Flamen P
Stroobants SG, Dupont PJ, De Lyn PR, Verbeken EK, Deneffe GJ, Mortelmans LA, Demedts MG, Leuven Lung Cancer Group. Prognostic Importance of the Standardized Uptake Value on ^{18}F-Flluoro-2-Deoxy-Glucose-Positron Emission Tomography Scan in Non-Small-Cell Lung Cancer: An Analysis of 125 Cases, 3201
Stüben G, *see* Stuschke M
Stura P, *see* Ballestrero A
Sturm I, Kohne C-H, Wolff G, Petrowsky H, Hillebrand T, Hauptmann S, Lorenz M, Dörken B, Daniel PT. Analysis of the *p53/BAX* Pathway in Colorectal Cancer: Low *BAX* Is a Negative Prognostic Factor in Patients With Resected Liver Metastases, 1364
Stuschke M, Eberhardt W, Pöttgen C, Stamatis G, Wilke H, Stüben G, Stöblen F, Wilhelm HH, Menker H, Teschler H, Müller R-D, Budach V, Seeber S, Sack H. Prophylactic Cranial Irradiation in Locally Advanced Non-Small-Cell Lung Cancer After Multimodality Treatment: Long-Term Follow-Up and Investigations of Late Neuropsychologic Effects, 2700
Suarez-Almazor M, *see* Nekolaichuk CL
Sugarman S, *see* Tolcher AW
Sugawara S-i, *see* Sato G
Sugimachi K, *see* Maehara Y
Sukumar S, *see* Carey LA
Sulzen L, *see* Haraf DJ
Suman VJ, *see* Creagan ET
Sun L, Goodman PA, Wood CM, Crotty M-L, Sensel M, Sather H, Navara C, Nachman J, Steinherz PG, Gaynon PS, Seibel N, Vassilev A, Juran BD, Reaman GH, Uckun FM. Expression of Aberrantly Spliced Oncogenic Ikaros Isoforms in Childhood Acute Lymphoblastic Leukemia, 3753
Sun M, *see* Sabbatini P
Sun X-F, Rütten S, Zhang H, Nordenskjöld B. Expression of the Deleted in Colorectal Cancer Gene Is Related to Prognosis in DNA Diploid and Low Proliferative Colorectal Adenocarcinoma, 1745
Surbone A, *see* Hudis C
Suryanarayan K, Shuster JJ, Donaldson SS, Hutchison RE, Murphy SB, Link MP. Treatment of Localized Primary Non-Hodgkin's Lymphoma of Bone in Children: A Pediatric Oncology, 456
Suzuki K, *see* Shoji A
Swart M, *see* Herben VMM
Sweeney KR, *see* Eckhardt SG
Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Volpe AD, Linch DC, Schmitz N, Goldstone AH, Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. High-Dose Therapy and Autologous Stem-Cell Transplantation for Adult Patients With Hodgkin's Disease Who Do Not Enter Remission After Induction Chemotherapy: Results in 175 Patients Reported to the European Group for Bone Marrow Transplantation, 3101
Swinnen L, *see* Glantz MJ
Swiss Group for Clinical Research, *see* Bernhard J
Symann M, *see* Shipp MA
Symonds RP, *see* Vasey PA
Synaeve C, *see* Verhoog LC
Syrjala K, *see* Du Pen SL
Szatrowski TP, *see* Hensley ML
Szer J, *see* Basser RL
Sznol M, *see* Atkins MB

Tabár L, *see* Liljegren G
Tabone M-D, Terrier P, Pacquement H, Brunat-Mentigny M, Schmitt C, Babin-Boilletot A, Mahmoud HH, Kalifa C. Outcome of Radiation-Related Osteosarcoma After Treatment of Childhood and Adolescent Cancer: A Study of 23 Cases, 2789
Taghipour G, *see* Sweetenham JW
Takada M, *see* Furuse K
Takada Y, *see* Furuse K
Takagi S, Tanaka O, Origasa H, Miura Y. Prognostic Significance of Magnetic Resonance Imaging of Femoral Marrow in Patients With Myelodysplastic Syndromes, 277
Takahashi H, *see* Shoji A
Takahashi K, *see* Shoji A
Takata T, *see* Tanaka F
Takeda K, *see* Herman EH
Talpaz M, *see* Kantarjian HM
Taminau AHM, *see* Bramwell VHC
Tammela T, *see* Pyrhönen S
Tan-Chiu E, *see* Fisher B
Tan P, *see* Lim L-C
Tanaka F, Kawano Y, Li M, Takata T, Miyara R, Yanagihara K, Ohtake Y, Fukuse T, Wada H. Prognostic Significance of Apoptotic Index in Completely Resected Non-Small-Cell Lung Cancer, 2728
Tanaka O, *see* Takagi S
Tang S-C, Shaheta N, Chernenko G, Khalifa M, Wang X. Expression of *BAG-1* in Invasive Breast Carcinomas, 1710
Tannock I, *see* Osoba D
Tannock IF, *see* Goss PE
— *see* Leung PP
— *see* Moore MJ
— *see* Osoba D
Tarbell NJ, *see* Nichols KE
Tarella C, *see* Corradini P
Tartaglione T, *see* Antinori A
Tattersall MHN, *see* Bishop JF
Taubes B, *see* Hochster H
Taverna C, Vogt P, Pestalozzi BC. Uncommon Sites of Presentation of Hematologic Malignancies; Case 2: Diffuse Muscle Infiltration by Granulocytic Sarcoma Seven Years After Myelomonocytic Leukemia, 1640
Taxol Investigational Trials Group, Australia/New Zealand
— *see* Bishop JF

Taylor SG IV, *see* Recht A
Tazelaar HD, *see* Bonner JA
Tebaldi C, *see* Parmigiani G
Teitelbaum A, *see* Foon KA
Temodal Brain Tumor Group, *see* Yung WKA
Temple LKF, Naimark D, McLeod RS. Decision Analysis as an Aid to Determining the Management of Early Low Rectal Cancer for the Individual Patient, 312
ten Bokkel Huinink WW, *see* Herben VMM
Tepper JE, *see* Blackstock AW
Terenzi A, *see* Aversa F
Terol M-J, López-Guillermo A, Bosch F, Villamor N, Cid M-C, Campo E, Montserrat W. Expression of Beta-Integrin Adhesion Molecules in Non-Hodgkin's Lymphoma: Correlation With Clinical and Evolutive Features, 1869
Terrier-Lacombe M-J, *see* Martelli H
Terrier P, *see* Tabone M-D
Teschler H, *see* Stuschke M
Thames HD, Buchholz TA, Smith CD. Frequency of First Metastatic Events in Breast Cancer: Implications for Sequencing of Systemic and Local-Regional Treatment, 2649
Thelen M, *see* Heussel CP
Theodoulou M, *see* Hudis C
Theriault RL, Lipton A, Hortobagyi GN, Leff R, Glück S, Stewart JF, Costello S, Kennedy I, Simeone J, Seaman JJ, Knight RD, Mellars K, Heffernan M, Reitsma DJ for the Protocol 18 Aredia Breast Cancer Study Group. Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled Trial, 846
Theriault RL, *see* Berry DL
— *see* Buzdar AU
— *see* Kuerer HM
— *see* Valero V
— *see* Vassilopoulou-Sellin R
Therneau TM, *see* Rajkumar SV
Thetter O, *see* Kubuschok B
Theuws JCM, Muller SH, Seppenwoolde Y, Kwa SLS, Boersma LJ, Hart GAM, Baas P, Lebesque JV. Effect of Radiotherapy and Chemotherapy on Pulmonary Function After Treatment for Breast Cancer and Lymphoma: A Follow-Up Study, 3091
Thiemann M, *see* Schellong G
Thigpen JT, Brady MF, Alvarez RD, Adelson MD, Homesley HD, Manetta A, Soper JT, Given FT. Oral Medroxyprogesterone Acetate in the Treatment of Advanced or Recurrent Endometrial Carcinoma: A Dose-Response Study by the Gynecologic Oncology Group, 1736
Thigpen T, *see* Hensley ML
Thirlwell MP, *see* Smith RE
Thödtmann R, Depenbrock H, Dumez H, Blatter J, Johnson RD, van Oosterom A, Hanauske A-R. Clinical and Pharmacokinetic Phase I Study of Multitargeted Antifolate (LY231514) in Combination With Cisplatin, 3009
Thomas A, *see* Turner BC
Thomas CR Jr, Wright CD, Loehrer PJ Sr. Thymoma: State of the Art, 2280
Thomas D, *see* Glantz MJ
Thomas DA, Cortes J, O'Brien S, Pierce S, Faderl S, Albitar M, Hagemeister FB, Cabanillas FF, Murphy S, Keating MJ, Kantarjian H. Hyper-CVAD Program in Burkitt's-Type Adult Acute Lymphoblastic Leukemia, 2461
Thomas GM. Is "Optimal" Radiation for Stage I Seminoma Yet Defined? (correspondence), 3002
Thomas H, *see* Vasey PA
Thomas M, Rübe C, Semik M, von Eiff M, Freitag L, Macha HN, Wagner W, Klinke F, Scheld HH, Willich N, Berdel WE, Junker K. Impact of Preoperative Bimodality Induction Including Twice-Daily Radiation on Tumor Regression and Survival in Stage III Non-Small-Cell Lung Cancer, 1185
Thomas P, *see* Pratt CB
Thompson JA, *see* Figlin RA
Thompson SJ, *see* Fouladi M
— *see* Gajjar A
Thompson W, *see* Gershenwald JE
Thor AD, Liu S, Moore II DH, Edgerton SM. Comparison of Mitotic Index, In Vitro Bromodeoxyuridine Labeling, and MIB-1 Assays to Quantitate Proliferation in Breast Cancer, 470
303 Study Group, *see* Chan S
304 Study Group, *see* Nabholtz JM
Thurlimann B, *see* Bernhard J
Thurman A, *see* Eckhardt SG
Tian W, *see* Fisher B
Tiel-van Buul MMC, *see* Kremer LCM
Tiffany J, *see* Jones S
Tiggelaar CL, *see* Robins HI
Tighe M, *see* Foran JM
Tilanus-Linthorst MMA, *see* Verhoog LC
Tilly H, *see* André M
— *see* Decaudin D
Tilsley DWO, *see* Harte RJA
Tipping SJ, *see* Smith RE
Tisdale J, *see* Childs RW
Tishler RB, *see* Colevas AD
Tjan-Heijnen VCG, Biesma B, Festen J, Splinter TAW, Cox A, Wagner DJT, Postmus PE. In reply (correspondence), 1086
TLC D-99 Study Group, *see* Shapiro CL
Tobias J, *see* Cullen MH
Toda M, *see* Shoji A
Tolcher A, *see* Gelmon KA
Tolcher AW, Sugarman S, Gelmon KA, Cohen R, Saleh M, Isaacs C, Young L, Healey D, Onetto N, Slichenmyer W. Randomized Phase II Study of BR96-Doxorubicin Conjugate in Patients With Metastatic Breast Cancer, 478
Tolino G, *see* Esposito M
Tollerfield SM, *see* Foran JM
Tom P, *see* Wong JH
Tomaszewski JE, *see* D'Amico AV
Tomiak E, *see* Gelmon K
Tomiak EM, *see* Nabholtz JM
Tomlinson E, *see* Gelmon K
Tonato M, *see* Crinò L
— *see* Roila F
Tondini C, Ferreri AJM, Siracusano L, Valagussa P, Giardini R, Rampinelli I, Bonadonna G. Diffuse Large-Cell Lymphoma of the Testis, 2854
Toner GC, *see* Bishop JF
Tong MMS, *see* Yeo W
Topalian SL, *see* Rosenberg SA
Toppmeyer D, *see* DiPaola RS
Tormey DC, *see* Recht A
Torri V, *see* Fossati R

Tortola S, Marcuello E, González I, Reyes G, Arribas R, Aiza G, Sancho FJ, Peinado MA, Capella G. *p53* and K-*Ras* Gene Mutation Correlate With Tumor Aggressiveness but Are Not of Routine Prognostic Value in Colorectal Cancer, 1375
Tortoriello A, *see* Iaffaioli RV
Träger H, *see* Schirrmeister H
Tramontana S, *see* Pignata S
Trask C, *see* Cullen MH
Travis LB, *see* Rowlings PA
Tremblay D, *see* Fortin A
Treuner J, *see* Carli M
— *see* Koscielniak E
Trigg ME, *see* Reaman GH
Trillet-Lenoir V, *see* Nabholtz JM
Trinkaus K, *see* Adkins D
Tripathy D, *see* Cobleigh MA
Tropé CG, *see* Baekelandt M
Trudeau M, *see* Goodwin PJ
Truemper L, *see* Fosså A
Trump D, *see* Kantoff PW
Trump DL, *see* Bubley GJ
Trunet PF, *see* Chaudri HA
Tsang KY, *see* Marshall JL
Tsao M, *see* Michael M
Tsavaris N, *see* Androulakis N
Tschurtschenthaler G, *see* Jakesz R
Tseng C-H, *see* Gershenwald JE
Tseng C-J, Pao CC, Lin J-D, Soong Y-K, Hong J-H, Hsueh S. Detection of Human Papillomavirus Types 16 and 18 mRNA in Peripheral Blood of Advanced Cervical Cancer Patients and Its Association With Prognosis, 1391
Tsuchida Y, *see* Kawa K
Tsuchiya S, *see* Okamoto H
Tsui K-H, *see* Belldegrun A
Tubiana-Hulin M, *see* Bouchet C
Tucker MA, *see* Kefford RF
Tulpule A, *see* Gill PS
Tulusan AH, *see* von Minckwitz G
Tunesi G, *see* Aschele C
Tura S, *see* Zinzani PL
Turazzi S, *see* Brandes AA
Turner BC, Glazer PM, Haffty BG. *BRCA1/BRCA2* in Breast-Conserving Therapy (correspondence), 3689
Turner BC, Harrold E, Matloff E, Smith T, Gumbs AA, Beinfield M, Ward B, Skolnick M, Glazer PM, Thomas A, Haffty BG. *BRCA1/BRCA2* Germline Mutations in Locally Recurrent Breast Cancer Patients After Lumpectomy and Radiation Therapy: Implications for Breast-Conserving Management in Patients With *BRCA1/BRCA2* Mutations, 3017
Turner RR, *see* Bostick PJ
Turrisi A, *see* Murray N
Tursz T, *see* Van Glabbeke M
Tusch G, *see* Schlitt HJ
Tusquets I, *see* Cirera L
Tutsch K, *see* Robins HI
Tworek J, *see* Eisbruch A

Ubbink MC, *see* Kremer LCM
Uchiyama B, *see* Sato G
Uckun FM, *see* Reaman GH
— *see* Sun L
Ueno W, *see* Hesketh PJ
Uges DRA, *see* Fokkema E
Uhl K, *see* Deichmann M
Uhlenhopp M, *see* Hudis C
Ullrich FA, *see* Nathwani BN
Umbricht CB, *see* Carey LA
Underhill C, *see* Clarke K
Underhill CR, *see* Highley MS
Unger EC, *see* Galanis E
Uppsala-Örebro Breast Cancer Study Group, *see* Liljegren G
Urgell E, *see* Castells A
Uscinska B, *see* Bramwell VHC

Vadell C, *see* Cardenal F
Valagussa P, *see* Tondini C
Valdés Olmos R, *see* Kremer LCM
Valencak J, *see* Scheithauer W
Valero V, Buzdar AU, Theriault RL, Azarnia N, Fonseca GA, Wiley J, Ewer M, Walters RS, Mackay B, Podoloff D, Booser D, Lee LW, Hortobagyi GN. Phase II Trial of Liposome-Encapsulated Doxorubicin, Cyclophosphamide, and Fluorouracil as First-Line Therapy in Patients With Metastatic Breast Cancer, 1425
Valero V, *see* Buzdar AU
Välimäki MJ, *see* Wymenga ANM
Vallejo C, *see* Acuña LR
Van Belle S, *see* Chan S
van Besien K, *see* Lazarus HM
van Beurden V, *see* de Jonge MJA
van Buuren A, *see* de Wit R
Van Cutsem E, *see* Flamen P
Van Cutsem EJDG, *see* Wymenga ANM
van Dam F, *see* de Wit R
Van Deerlin VMD, *see* Porter DL
van den Ouweland AMW, *see* Verhoog LC
van der Burg MEL, *see* de Jonge MJA
van der Heijden K, *see* de Wit R
van der Vange N, *see* Herben VMM
van Deventer H, Bernard S. Use of Gabapentin of Treat Taxane-Induced Myalgias (correspondence), 434
van Geel AN, *see* Verhoog LC
van Gennip AH, *see* Ahmed FY
van Gijn R, *see* Herben VMM
Van Glabbeke M, *see* Bramwell VHC
— *see* Lhommé C
van Glabbeke M, *see* Greiner R
Van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T. Prognostic Factors for the Outcome of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2, 185 Patients Treated With Anthracycline-Containing First-Line Regimens—A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study, 150
van Groeningen CJ, *see* Kroep JR
van Hazel G, *see* Byrne MJ
Van Hoe L, *see* Flamen P
van Krieken J, *see* Diehl V
Van Lint MT, *see* Corradini P
van Maanen LWGM, *see* de Jonge MJA
van Moorsel CJA, *see* Kroep JR
van Oosterom A, *see* Thödtmann R
van Oosterom AT, *see* Van Glabbeke M

van Overhagen H, *see* Nouwen JL
van Putten JWG, *see* Groen HJM
van Vloten WA, *see* Bekkenk MW
van Voorst Vader PC, *see* Bekkenk MW
Vandenberg T, *see* Khoo K
Vandenberg TA, *see* Nabholtz JM
Vanhoefer U, Harstrick A, Köhne C-H, Achterrath W, Rustum YM, seeber S, Wilke H. Phase I Study of a Weekly Schedule of Irinotecan, High-Dose Leucovorin, and Infusional Fluorouracil as First-Line Chemotherapy in Patients With Advanced Colorectal Cancer, 907
Vannozzi MO, *see* Esposito M
Vardakis N, *see* Georgoulias V
— *see* Kouroussis C
Vardiman J, *see* Harris NL
Varns C, *see* Czuczman MS
Vasey PA, Paul J, Birt A, Junor EJ, Reed NS, Symonds RP, Atkinson R, Graham J, Crawford SM, Coleman R, Thomas H, Davis J, Eggleton SPH, Kaye SB for the Scottish Gynaecological Cancer Trials Group. Docetaxel and Cisplatin in Combination as First-Line Chemotherapy for Advanced Epithelial Ovarian Cancer, 2069
Vassilopoulos P, *see* Wils JA
Vassilopoulou-Sellin R, Asmar L, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, Theriault RL. Estrogen Replacement Therapy After Localized Breast Cancer: Clinical Outcome of 319 Women Followed Prospectively, 1482
Veeder MH, *see* Creagan ET
Velásquez WS, *see* Davis TA
Velikova G, Wright EP, Smith AB, Cull A, Gould A, Forman D, Perren T, Stead M, Brown J, Selby PJ. Automated Collection of Quality-of-Life Data: A Comparison of Paper and Computer Touch-Screen Questionnaires, 998
Vena D, *see* Smith MA
Vena DA, *see* Cheson BD
Vennin P, *see* Lhommé C
Venook AP, *see* Rubin J
Venturini M, *see* Esposito M
Venugopal P, Leslie WT, O'Brien T, Gregory SA. CD20-Negative Relapse After ^{131}I – Anti-CD20 Therapy, 3692
Venzon DJ, *see* Yu F
Véra P, Rohrlich P, Stiévenart JL, Elmaleh M, Duval M, Bonnin F, Bok B, Vilmer E. Contribution of Single-Photon Emission Computed Tomography in the Diagnosis and Follow-Up of CNS Toxicity of a Cytarabine-Containing Regimen in Pediatric Leukemia, 2804
Verbeken EK, *see* Stroobants SG
Verbrugh HA, *see* Nouwen JL
Verdonck LF. High-Dose Therapy With Autologous Stem-Cell Transplantation in Aggressive Non-Hodgkin's Lymphoma (correspondence), 3002
Verhoog LC, Brekelmans CTM, Seynaeve C, Dahmen G, van Geel AN, Bartels CCM, Tilanus-Linthorst MMA, Wagner A, Devilee P, Halley DJJ, van den Ouweland AMW, Meijers-Heijboer EJ, Klijn JGM. Survival in Hereditary Breast Cancer Associated With Germline Mutations of *BRCA2*, 3396
Vermeer MH, *see* Bekkenk MW
Vernillet L, *see* Herben VMM
Verweij J, *see* de Jonge MJA
— *see* Van Glabbeke M
Vesole DH, Crowley JJ, Catchatourian R, Stiff PJ, Johnson DB, Cromer J, Salmon SE, Barlogie B. High-Dose Melphalan With Autotransplantation for Refractory Multiple Myeloma: Results of a Southwest Oncology Group Phase II Trial, 2173
Vey N, *see* Beran M
Vezina LG, *see* Packer RJ
Viale M, *see* Esposito M
Viens P, *see* Escudier B
Vignal J, *see* Francois Y
Vij R, *see* Adkins D
— *see* Brown RA
Villalona-Calero MA, *see* Drengler RL
— *see* Eckhardt SG
Villalona-Calero MA, Weiss GR, Burris HA, Kraynak M, Rodrigues G, Drengler RL, Eckhardt SG, Reigner B, Moczygemba J, Burger HU, Griffin T, Von Hoff DD, Rowinsky EK. Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine Capecitabine in Combination With Paclitaxel in Patients With Advanced Solid Malignancies, 1915
Villamor N, *see* Terol M-J
Vilmer E, *see* Véra P
Vinocur C, *see* Marina NM
Vissilev A, *see* Sun L
Vistisen K, *see* Petersen PM
Visvikis A, *see* Pectasides D
Vlachonicolis J, *see* Georgoulias V
Vlachonikolis J, *see* Kouroussis C
Voena C, *see* Corradini P
Vogel C, *see* Blum JL
— *see* Jones S
Vogel CL, *see* Cobleigh MA
Vogel VG III, *see* Smith TJ
Vogel W, *see* Brugger W
Vogelsang GB, *see* Rizzo JD
Vogelzang NJ. Gemcitabine and Cisplatin: Second-Line Chemotherapy for Malignant Mesothelioma? (correspondence), 2625
Vogelzang NJ, *see* Figlin RA
— *see* Kantoff PW
Vogt P, *see* Taverna C
Vokenandt M, *see* Bornhövd EC
Vokes EE, *see* Haraf DJ
— *see* List MA
Volkenandt M, *see* Schmid-Wendtner M-H
Vollmer R, *see* Bubley GJ
Volpe AD, *see* Sweetenham JW
von Eiff M, *see* Thomas M
von Eschenbach AC, *see* Pisters LL
Von Hoff D, *see* Hensley ML
— *see* Nemunaitis J
Von Hoff DD, *see* Drengler RL
— *see* Eckhardt SG
— *see* Hammond LA
— *see* Rowinsky EK
— *see* Villalona-Calero MA
von Minckwitz G, Costa SD, Eiermann W, Blohmer J-U, Tulusan AH, Jackisch C, Kaufmann M. Maximized Reduction of Primary Breast Tumor Size Using Preoperative Chemotherapy With Doxorubicin and Docetaxel, 1999
von Minckwitz G, *see* Chan S
von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A,

Carmichael J, Krebs JB, Ross G, Lane SR, Gralla R. Topotecan Versus Cyclophosphamide, Doxorubicin, and Vincristine for the Treatment of Recurrent Small-Cell Lung Cancer, 658
Voorn DA, *see* Kroep JR
Vorobiof D, *see* Chan S
Vose J, *see* Cheson BD
Vose JM, *see* Abou-Elella AA
— *see* Baker KS
— *see* Lazarus HM
Voulgaris Z, *see* Papadimitriou CA
Voûte PA, *see* Kremer LCM
Vredenburgh JJ, *see* Carter DL
— *see* Rizzieri DA
Vukov AM, *see* Creagan ET
Vyas V, *see* DiPaola RS

Wada H, *see* Tanaka F
Wadler S, Damle S, Haynes H, Kaleya R, Schechner R, Berkenblit R, Ladner RD, Murgo A. Phase II/Pharmacodynamic Trial of Dose-Intensive, Weekly Parental Hydroxyurea and Fluorouracil Administered With Interferon Alfa-2a in Patients With Refractory Malignancies of the Gastrointestinal Tract, 1771
Wadler S, *see* Hochster H
Wagener DJT, *see* de Jonge MJA
Wagner A, *see* Verhoog LC
Wagner DJT, *see* Tjan-Heijnen VCG
Wagner JD, Schauwecker D, Davidson D, Coleman JJ III, Saxman S, Hutchins G, Love C, Hayes JT. Prospective Study of Fluorodeoxyglucose-Positron Emission Tomography Imaging of Lymph Node Basins in Melanoma Patients Undergoing Sentinel Node Biopsy, 1508
Wagner W, *see* Schellong G
— *see* Thomas M
Wahrer DCR, *see* Nichols KE
Walde D, *see* Murray N
Waldmann V, *see* Deichmann M
Waldron D, O'Boyle CA, Kearney M, Moriarty M, Carney D. Quality-of-Life Measurement in Advanced Cancer: Assessing the Individual, 3603
Wallach R, *see* Hochster H
Waller CF, *see* Engelhardt M
Wallner KE, *see* Zelefsky MJ
Walpole E, *see* Bishop JF
— *see* Chan S
Walsh W, *see* Moore MJ
Walter AW, Mulhern RK, Gajjar A, Heideman RL, Reardon D, Sanford RA, Xiong X, Kun LE. Survival and Neurodevelopmental Outcome of Young Children With Medulloblastoma at St. Jude Children's Research Hospital, 3720
Walter AW, *see* Fouladi M
— *see* Furman WL
— *see* Gajjar A
Walters RS, *see* Valero V
Wang B, *see* Woo MH
Wang H-J, *see* Bostick PJ
Wang X, *see* Tang S-C
Wara WM, *see* Packer RJ
Ward B, *see* Turner BC
Ward FT, *see* Byrd JC
Warren L, *see* American College of Radiology Task Force on Breast Cancer
Waselenko JK, *see* Byrd JC
Wasserman E, Cuvier C, Lokiec F, Goldwasser G, Kalla S, Méry-Mignard D, Ouldkaci M, Besmaine A, Dupont-André G, Mahjoubi M, Marty M, Misset J-L, Cvitkovic E. Combination of Oxaliplatin Plus Irinotecan in Patients With Gastrointestinal Tumors: Results of Two Independent Phase I Studies With Pharmacokinetics, 1751
Wasserman TH, *see* Hensley ML
Watanabe A, *see* Maehara Y
Watanabe K, *see* Okamoto H
Watanuki Y, *see* Shoji A
Watelet LFM, *see* Rapoport AP
Wawroschek F, *see* Weckermann D
Weaver AL, *see* Neumann RM
Weaver CH, *see* Schulman KA
Weaver R, *see* Davis TA
Webb RT, *see* Hesketh PJ
Weber DC, Bieri S, Kurtz JM, Miralbell R. Prospective Pilot Study of Sildenafil for Treatment of Postradiotherapy Erectile Dysfunction in Patients With Prostate Cancer, 3444
Weber T, *see* Heller B
Webster K, *see* Markman M
Weckermann D, Müller P, Wawroschek F, Krawczak G, Riethmüller G, Schlimok G. Micrometastases of Bone Marrow in Localized Prostate Cancer: Correlation With Established Risk Factors, 3438
Weeks JA, *see* Bennett CL
Weeks JC, *see* Ng AK
Weetman R, *see* Marina NM
Weichselbaum RR, *see* Haraf DJ
Weil C, *see* Fokkema E
Weimann A, *see* Schlitt HJ
Wein A, *see* D'Amico AV
Weinländer G, *see* Scheithauer W
Weinstein HJ, *see* Parson SK
Weisberg M, *see* O'Day SJ
Weiselberg L, *see* Hudis C
Weisenburger DD, *see* Abou-Elella AA
Weiss G, *see* Atkins MB
— *see* Eckhardt SG
Weiss GR, *see* Hammond LA
— *see* Villalona-Calero MA
Weiss RB, *see* Costanza ME
Weissbach G, *see* Schellong G
Weller E, *see* Sehn LH
Wendtner C-M, *see* Bornhövd EC
— *see* Schmid-Wendtner M-H
Wenig B, *see* Haraf DJ
Wessalowski R, *see* Schneider DT
West Japan Lung Cancer Group, *see* Furuse K
Westin T, *see* Bjordal K
Wexler LH, *see* Ginsberg JP
Whaley F, *see* Jones S
Whang W, *see* Grann VR
Wharam MD, *see* Pappo AS
Wharam MD Jr, *see* Wolden SL
Wharton JT, *see* Brewer M
Wheeler C, *see* Elias A
Wheeler TM, *see* Kattan MW
Whelan J, *see* Bramwell VHC

Whelan T, Levine M, Gafni A, Sanders K, Willan A, Mirsky D, Schnider D, McCready D, Reid S, Kobylecky A, Reed K. Mastectomy or Lumpectomy? Helping Women Make Informed Choices, 1727
White CA, *see* Byrd JC
— *see* Czuczman MS
— *see* Davis TA
— *see* Witzig TE
White DE, *see* Rosenberg SA
White E, *see* DiPaola RS
White P Jr, *see* Groeger JS
Whitney CW, Sause W, Bundy BN, Malfetano JH, Hannigan EV, Fowler WC Jr, Clarke-Pearson DL, Liao S-Y. Randomized Comparison of Fluorouracil Plus Cisplatin Versus Hydroxyurea as an Adjunct to Radiation Therapy in Stage IIB-IVA Carcinoma of the Cervix With Negative Para-Aortic Lymph Nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study, 1339
Whittington R, *see* D'Amico AV
Wickerham DL, *see* Day R
— *see* Fisher B
— *see* Wolmark N
Widmer B, *see* Fossa SD
Wieand S, *see* Wolmark N
Wielenga JJ, *see* Nouwen JL
Wienand S, *see* Mamounas E
Wiener ES, *see* Wolden SL
Wienski D, *see* Adkins D
Wilding G, *see* Bubley GJ
— *see* Robins HI
Wiley J, *see* Valero V
Wilhelm HH, *see* Stuschke M
Wilke H, *see* Stuschke M
— *see* Vanhoefer U
Wilking N, *see* Nabholtz JM
Willan A, *see* Whelan T
Willemze R, *see* Bekkenk MW
Williams MA, *see* Ellis GK
Williams ME, *see* Davis TA
Williams NJ, *see* Mokbel K
Williams SD, *see* Einhorn LH
Willich N, *see* Thomas M
Wils JA, Bliss JM, Marty M, Coombes G, Fontaine C, Morvan F, Olmos T, Pérez-López FR, Vassilopoulos P, Woods E, Coombes RC for the International Collaborative Cancer Group. Epirubicin Plus Tamoxifen Versus Tamoxifen Alone in Node-Positive Postmenopausal Patients With Breast Cancer: A Randomized Trial of the International Collaborative Cancer Group, 1988
Wilson MP, *see* Foran JM
Wilson WH, *see* Bishop PC
Wilwerding MB, *see* Loprinzi CL
Windle JJ, *see* Rowinsky EK
Winer E, *see* Costanza ME
Winer EP, *see* Bluman LG
— *see* Goss PE
— *see* Hensley ML
— *see* Kantoff PW
— *see* Parmigiani G
Wingard JR, *see* Fogarty LA
Winkler K, *see* Bielack SS
Winn R, *see* Royce ME
Winograd B, *see* Gill PS
Winquist EW, *see* Moore MJ
Wirth A, Chao M, Corry J, Laidlaw C, Yuen K, Ryan G, Byram D, Davis S, Kiffer G, Quong G, Liew K. Mantle Irradiation Alone for Clinical Stage I-II Hodgkin's Disease: Long-Term Follow-Up and Analysis of Prognostic Factors in 261 Patients, 230
Wiseman GA, *see* Witzig TE
Wisenburger DD, *see* Nathwani BN
Wisoff JH, *see* Zeltzer PM
Witt ME, *see* Haraf DJ
Witzig TE, *see* Gertz MA
— *see* Rajkumar SV
Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, Janakiraman N, Gutheil J, Schilder RJ, Spies S, Silverman DHS, Parker E, Grillo-López AJ. Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20$^+$ B-Cell, 3793
Wolden SL, Anderson JR, Crist WM, Breneman JC, Wharam MD Jr, Wiener ES, Qualman SJ, Donaldson SS. Indications for Radiotherapy and Chemotherapy After Complete Resection in Rhabdomyosarcoma: A Report From the Intergroup Rhabdomyosarcoma Studies I to III, 3468
Wolfe J, Fairclough DL, Clarridge BR, Daniels ER, Emanuel EJ. Stability of Attitudes Regarding Physician-Assisted Suicide and Euthanasia Among Oncology Patients, Physicians, and the General Public, 1274
Wolfe T, *see* Zelefsky MJ
Wolff AC, *see* Sparano JA
Wolff G, *see* Sturm I
Wolmark N, Rockette H, Mamounas E, Jones J, Wieand S, Wickerham DL, Bear HD, Atkins JN, Dimitrov NV, Glass AG, Fisher ER, Fisher B. Clinical Trial to Assess the Relative Efficacy of Fluorouracil and Leucovorin, Fluorouracil and Levamisole, and Fluorouracil, Leucovorin, and Levamisole in Patients With Dukes' B and C Carcinoma of the Colon: Results From National Surgical Adjuvant Breast and Bowel Project C-04, 3553
Wolmark N, *see* Fisher B
— *see* Mamounas E
Wolter JM, *see* Cobleigh MA
Womer RB, *see* Ginsberg JP
— *see* Pappo AS
Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WKA. Outcomes and Prognostic Factors in Recurrent Glioma Patients Enrolled Onto Phase II Clinical Trials, 2572
Wong GC, *see* Beran M
Wong JH, Severino R, Honnebier MB, Tom P, Namiki TS. Number of Nodes Examined and Staging Accuracy in Colorectal Carcinoma, 2896
Wong LC, Ngan HYS, Cheung ANY, Cheng DKL, Ng TY, Choy DTK. Chemoradiation and Adjuvant Chemotherapy in Cervical Cancer, 2055
Woo MH, Hak LJ, Storm MC, Gajjar AJ, Sandlund JT, Harrison PL, Wnag B, Pui C-H, Relling MV. Cerebrospinal Fluid Asparagine Concentrations After *Escherichia coli* Asparaginase in Children With Acute Lymphoblastic Leukemia, 1568
Wood CM, *see* Sun L
Wood WC, *see* Costanza ME
— *see* Sparano JA
Woodroffe CM, *see* Cullen MH
Woods E, *see* Wils JA

Wörmann B, *see* Hiddemann W
Wozniak AJ. In reply (correspondence), 730
Wright CD, *see* Thomas CR Jr
Wright EP, *see* Velikova G
Wunder JS, *see* Ginsberg JP
Wymenga ANM, Eriksson B, Salmela PI, Jacobsen MB, Van Cutsem EJDG, Fiasse RH, Välimäki MJ, Renstrup J, de Vries EGE, Öberg KE. Efficacy and Safety of Prolonged-Release Lanreotide in Patients With Gastrointestinal Neuroendocrine Tumors and Hormone-Related Symptoms, 1111

Xiong X, *see* Walter AW

Yahalom J, *see* Moskowitz CH
Yamamoto K, *see* Kawa K
Yamato K, *see* Kawa K
Yanagihara K, *see* Tanaka F
Yang J, *see* Henson JW
Yang JC, *see* Rosenberg SA
Yao K-S, *see* Stevenson JP
Yao TJ, *see* Hudis C
Yasko AW, *see* Fleming JB
Yassa L, *see* Esserman L
Yasukawa T, *see* Fujisawa T
Yau J, *see* Gelmon K
Yaya-Tur R, *see* Yung WKA
Yaziji H, *see* Jacobs TW
Ychou M, *see* Ducreux M
Yeager AM, *see* Parson SK
Yelle L, *see* Chan S
Yeo W, Tong MMS, Chan YL. Complications of Chemotherapy: 2. Multifocal Cerebral Demyelination Secondary to Fluorouracil and Levamisole Therapy, 430
Yeung H, *see* Sabbatini P
Yilmaz U, *see* Andrieu JM
Ying Y, *see* Ayoub J
Yokoyama J, *see* Kawa K
Yosef H, *see* Fosså SD
Yoshida S, *see* Ohtsu A
Yoshiike Y, *see* Shoji A
Yoshizawa J, *see* Kawa K
Young L, *see* Tolcher AW
Yu F, Venzon DJ, Serrano J, Goebel SU, Doppman JL, Gibril F, Jensen RT. Prospective Study of the Clinical Course, Prognostic Factors, Causes of Death, and Survival in Patients With Long-Standing Zollinger-Ellison Syndrome, 615
Yu R, *see* Stevenson JP
Yu Z-X, *see* Herman EH
Yue N, *see* Yung WKA
Yuen K, *see* Wirth A
Yung WKA, Prados MD, Yaya-Tur R, Rosenfeld SS, Brada M, Friedman HS, Albright R, Olson J, Chang SM, O'Neill AM, Friedman AH, Bruner J, Yue N, Dugan M, Zaknoen S, Levin VA, Temodal Brain Tumor Group. Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse, 2762
Yung WKA, *see* Wong ET

Zaccaria A, *see* Zinzani PL
Zach O, Kasparu H, Krieger O, Hehenwarter W, Girschikofsky M, Lutz D, Detection of Circulating Mammary Carcinoma Cells in the Peripheral Blood of Breast Cancer Patients Via a Nested Reverse Transcriptase Polymerase Chain Reaction Assay for Mammaglobin mRNA, 2015
Zacharski D, *see* Belani CP
Zagars G, *see* Fleming JB
Zagars GK, *see* Ballo MT
Zaja F, *see* Zinzani PL
Zaknoen S, *see* Yung WKA
Zamboni WC, *see* Furman WL
Zamek R, *see* DiPaola RS
Zandbelt L, *see* de Wit R
Zecca M, Pession A, Messina C, Bonetti F, Favre C, Prete A, Cesaro S, Porta F, Mazzarino I, Giorgiani G, Rondelli R, Locatelli F. Total Body Irradiation, Thiotepa, and Cyclophosphamide as a Conditioning Regiment for Children With Acute Lymphoblastic Leukemia in First or Second Remission Undergoing Bone Marrow Transplantation With HLA-Identical Siblings, 1838
Zecca M, *see* Bonetti F
Zee B, *see* Gelmon K
— *see* Murray N
Zei T, *see* Aversa F
Zelefsky MJ, Leibel SA. In reply (correspondence), 1326
Zelefsky MJ, Wallner KE, Ling CC, Raben A, Hollister T, Wolfe T, Grann A, Gaudin P, Fuks Z, Leibel SA. Comparison of the 5-Year Outcome and Morbidity of Three-Dimensional Conformal Radiotherapy Versus Transperineal Permanent Iodine-125 Implantation for Early-Stage Prostatic Cancer, 517
Zelenetz AD, *see* Moskowitz CH
Zeltzer PM, Boyett JM, Finlay JL, Albright AL, Rorke LB, Milstein JM, Allen JC, Stevens KR, Stanley P, Li H, Wisoff JH, Geyer R, McGuire-Cullen P, Stehbens JA, Shurin SB, Packer RJ. Metastasis Stage, Adjuvant Treatment, and Residual Tumor Are Prognostic Factors for Medulloblastoma in Children: Conclusions From the Children's Cancer Group 921 Randomized Phase III Study, 832
Zeltzer PM, *see* Reaman GH
Zevon MA, *see* Green DM
Zhang C, *see* DiPaola RS
Zhang H, *see* Sun X-F
Zhang J, *see* Herman EH
Zhang M-J, *see* Lazarus HM
Zhang-Salomons JY, *see* Boyd C
Zhang Z-F, *see* Sabbatini P
Zhen B, *see* Schulman KA
— *see* Marshall JL
Zhu Z, Friess H, diMola FF, Zimmermann A, Graber HU, Korc M, Büchler MW. Nerve Growth Factor Expression Correlates With Perineural Invasion and Pain in Human Pancreatic Cancer, 2419
Ziegler BL, *see* Brugger W
Zimmermann A, *see* Zhu Z
Zinzani PL, Magagnoli M, Galieni P, Martelli M, Poletti V, Zaja F, Molica S, Zaccaria A, Cantonetti AM, Gentilini P, Guardigni L, Gherlinzoni F, Ribersani M, Bendandi M, Albertini P, Tura S. Nongastrointestinal Low-Grade Mucosa-Associated Lymphoid Tissue Lymphoma: Analysis of 75 Patients, 1254
Zippe C, *see* Jhaveri FM
Zoubek A, *see* Ginsberg JP
— *see* Schneider DT
Zuech N, *see* Petrylak DP
Zuhowski EG, *see* Belani CP

SUBJECT INDEX

Abdomen, Burkitt's lymphoma of, 726-727
Abdominal wall, dendritic cell tumor of, 2290-2292
Acquired immunodeficiency syndrome
  Kaposi's sarcoma in, paclitaxel therapy for, 1876-1883
  primary CNS lymphoma in, diagnosis of, 554-560
Acrometastases, non-small-cell lung carcinoma and, 2998-3001
Acute leukemia, depleted T-cell-depleted BMT for, 1545-1550
Acute lymphoblastic leukemia
  Burkitt's type adult, hyper-CVAD program in, 2461-2470
  childhood, 438-440
    allogeneic BMT *vs.* chemotherapy in second remission, 197-207
    conditioning regimen prior to BMT with HLA-identical siblings, 1838-1846
    CSF asparagine levels after *E. coli* asparaginase in, 1568-1573
    Ikaros gene abnormalities in, 3753-3766
    isolated CNS relapse in, improved survival of, 3745-3752
    MLL-ENL fusion in, 191-196
    treatment outcome and prognostic factors in infants, 445-455
  sex differences in, 818-824
Acute myelogenous leukemia, childhood, after treatment for malignant germ cell tumors, 3226-3233
Acute myeloid leukemia
  childhood
    conditioning regimen for autologous BMT, 3729-3735
    Q-TWiST analysis in, 2144-2152
  cytarabine-daunorubicin-etoposide therapy with or without PSC-833 for, 2831-2839
  in elderly, management of, 3569-3576
  high-dose cytarabine for, 3767-3775
Acute myelomonocytic leukemia, diffuse muscle infiltration by granulocytic sarcoma after, 1642-1643
Acute promyelocytic leukemia, CD56 expression in, 293-297
Adenocarcinoma
  colorectal, *DCC* expression in, 1745-1750
  large bowel metastases presenting as appendicitis, 2623-2624
  of lung, *p*120 expression in, 2721-2727
  medullary-type poorly differentiated, of large bowel, 2429-2438
Adjuvant chemotherapy
  for cervical cancer, 1334-1335 (editorial), 1339-1348
    chemoradiation and, 2055-2060
  for colon cancer
    Dukes' B verus Dukes' C, 1349-1355, 3553-3559
    Dukes' B2, 1356-1363
  for colorectal cancer in elderly, 2412-2418
  for gastric cancer, 3810-3815
  for medulloblastoma in children, 2127-2136
  and menopause risk after breast cancer diagnosis, 2365-2370
  in surgically resected pediatric nonrhabdosarcomatous soft tissue sarcomas, 1219-1226
  systemic, in node-negative breast cancer, 1458-1464
  as weight gain predictor after breast cancer diagnosis, 120-129
Adjuvant endocrine therapy, in breast cancer, outcome prediction methods for, 1474-1481
Adolescents
  autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in, 825-831
  cancer in, postradiation osteosarcoma after, 2789-2795
  cardiac mortality in cancer survivors, 3207-3215
  resected nonrhabdomyosarcoma soft tissue sarcoma in, prognostic factors, 3697-3705
  with rhabdomyosarcoma, survival after relapse in, 3487-3493
Advanced cancer/malignancies. *See also* Refractory *and* Relapsed *entries*
  hospitalized patients with, reliability of symptom ratings in, 3621-3630
  immunotherapy for, 3313-3323
  intravenous thymidine and carboplatin in, 2922-2931
  ISIS 3521 evaluation in, phase I trial, 3586-3595
  quality-of-life measurement in, 3603-3611
  13-*cis*-retinoic acid, interferon alfa, and paclitaxel in, phase I trial, 2213-2218
AGO. *See* Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group
Alkylating agents, multiple, for treatment of primary systemic amyloidosis, 262-267
ALL. *See* Acute lymphoblastic leukemia
Allogeneic stem-cell transplantation. *See* Stem-cell transplantation, allogeneic
ALVAC-CEA recombinant vaccine, in cancer patients, phase I trial, 332-337
American Society of Clinical Oncology
  antiemetics guidelines, 2971-2994
  breast cancer risk reduction strategies assessment, 1939-1955
  breast cancer surveillance guidelines of 1998, update on, 1080-1082
  chemotherapy and radiotherapy protectants, guidelines for use of, 3333-3355
  colony-stimulating factors, guidelines for use of, 3360-3361 (correspondence), 3676-3681 (special article)
  colorectal cancer surveillance guidelines, 1312-1321
  conference papers, 3005-3006 (correspondence)
Amifostine, paclitaxel with or without, for metastatic breast cancer, phase II study, 3038-3047
9-Aminocamptothecin
  in adult patients with solid tumors, 2219-2226
  continuous infusion, for advanced solid tumors, phase I and pharmacokinetic study, 1906-1914
AML. *See* Acute myelogenous leukemia
Amyloidosis, treatment of, 262-267
Anaplastic astrocytoma
  procarbazine, lomustine, and vincristine chemotherapy regimen for, 3389-3395
  temozolomide in, 2762-2771
Anaplastic glioma, temozolomide in, 2762-2771
Androgen blockade, bicalutamide *vs.*, in prostate cancer, 2027-2038
Anemia, after chemotherapy, risk model for, 2840-2846
Angiogenesis
  inhibition in metastatic renal carcinoma, 2541-2545
  prognostic significance in endometrial cancer, 1382-1390
Anorexia/cachexia, cancer-associated, treatments compared, 3299-3306
Anthracite cardiotoxicity, in children, 1208-1211
Anthracycline-resistant breast cancer, cost analysis of chemotherapy for, 3082-3090
Anti-apoptosis gene, as prognosis marker in non-small-cell lung cancer, 2100-2104
^{131}I-Anti-CD20 therapy, for non-Hodgkin's lymphoma, CD20-negative relapse after, 3692-3693 (correspondence)

Anti-HER2 monoclonal antibody, in metastatic breast cancer, 2639-2647
Anti-idiotype vaccine, for resected colon cancer, 2889-2895
Anticancer drugs, current status in Japan, 3362-3365 (correspondence)
Antiemetics
  ASCO guidelines, 2971-2994
  studies on, 1960-1962 (correspondence)
Antifolate
  LY231514, for advanced non-small-cell lung cancer, 1194-1199
  multitargeted, combined with cisplatin, phase I and pharmacokinetic study, 3009-3016
Antitubulin agents, mechanisms of action and resistance, 1061-1070
Anxiety, strategy for reducing, 371-379
Apoptosis
  and anti-apoptosis gene in non-small-cell lung cancer, 2100-2104
  dysregulation of, 2941-2953
  factors related to, in advanced ovarian cancer, 2061-2068
Apoptotic index, in non-small-cell lung cancer, 2728-2736
Appendicitis, large bowel adenocarcinoma metastases presenting as, 2623-2624
ara-C. *See* Cytarabine
Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group, ET-Carbo chemotherapy in advanced ovarian cancer, phase I/II trial, 46-51
ASCT. *See* Stem-cell transplantation, autologous
Ashkenazi Jewish women, *BRCA1/2* gene in, benefits and costs of screening, 494-500
Asparagine, in pediatric cerebrospinal fluid, after *E. coli* asparaginase, 1568-1573
Astrocytoma, anaplastic
  procarbazine, lomustine, and vincristine chemotherapy regimen for, 3389-3395
  temozolomide in, 2762-2771
Ataxia-telangiectasia gene, and secondary malignancy in Hodgkin's disease, 1259-1266
ATM mutations, and secondary malignancy in Hodgkin's disease, 1259-1266
Autoimmunity, and survival in metastatic renal cell cancer, 529-533, 1330 (erratum)
Autologous Blood and Marrow Transplant Registry, autotransplant in refractory Hodgkin's disease, 534-545
Autologous bone marrow transplantation. *See* Bone marrow transplantation, autologous
Autologous stem-cell transplantation. *See* Stem-cell transplantation, autologous
Autotransplants, in refractory Hodgkin's disease, 534-545
Axillary lymph node dissection, in breast cancer
  avoiding, 1720-1726
  decision analysis, 1465-1473
  physical and psychological morbidity after, 143-149
Axillary lymph node metastasis, in breast cancer, 2334-2340, 3365 (erratum)
  response to doxorubicin-based neoadjuvant chemotherapy, 460-469

B-ALL. *See* Burkitt's type adult acute lymphoblastic leukemia
B-cell chronic lymphocytic leukemia
  biologic advances in, 399-408
  oral fludarabine phosphate pharmacokinetics in, 1574-1579
B-cell disorders, unusual manifestations in
  chronic lymphocytic leukemia with cutaneous lesions, 1084-1095
  multiple myeloma with predominant phalangeal involvement, 1083-1084
B-cell lymphoma
  multifocal cutaneous, treatment of, 2471-2478
  non-Hodgkin's, Rituxan and CHOP treatment for, 268-276
  primary mediastinal large, CNS involvement in, 2479-2485
BAG-1 expression, in invasive breast carcinomas, 1710-1719
BAX, prognostic value in resected hepatic metastases of colorectal cancer, 1364-1374
Bcl-2, in advanced ovarian cancer, 2061-2068
Beta-tubulin gene mutations, altering paclitaxel resistance in non-small-cell lung cancer, 1786-1793
Bicalutamide, *vs.* maximal androgen blockade in prostate cancer, 2027-2038
Biochemotherapy, for metastatic melanoma, 2752-2761
Biologic predictors, of breast cancer outcome, 3058-3063
Biomodulation, of fluorouracil
  in advanced colorectal cancer, 3276-3282
  in tumors, normal tissue, and plasma, 1580-1588
Biphosphonates
  in childhood cancer-associated hypercalcemia, 1960 (correspondence)
  and flare phenomenon, 1328-1329
Bladder carcinoma, stage T1, cancer progression in, 3182-3187
Bladder preservation, 1327-1328 (correspondence)
Blood stem-cell transplant recipients
  allogeneic peripheral, long-term follow-up in, 806-812
  pneumonia in, 796-805, 3856 (correspondence)
BMT. *See* Bone marrow transplantation
Bone
  lesions in breast cancer, pamidronate and, 846-854
  localized primary non-Hodgkin's lymphoma in children, 456-459
  malignant fibrous histiocytoma of, 3260-3269
  metastatic disease in breast cancer, 2381-2389
Bone marrow
  micrometastases in prostate cancer, 3438-3443
  MUC-1 epitopes expression on, 1535-1544
  signet ring lymphoma of, 728-729
Bone marrow transplantation
  allogeneic
    Hodgkin's disease incidence after, 3122-3127
    vs. chemotherapy in childhood ALL in second remission, 197-207
  autologous
    for childhood AML, conditioning regimens for, 3729-3735
    for follicular lymphoma, recurrence after, 216-221
    for non-Hodgkin's lymphoma, myelodysplastic syndrome after, 3128-3135
  for chronic myelogenous leukemia, impact of donor lymphocyte infusion on, 561-568
  depleted T-cell-depleted, for acute leukemia, 1545-1550
  ethics of life support in, 298-303
  for hepatitis B carriers, 394-398
  with HLA-identical siblings in childhood ALL, conditioning regimen prior to, 1838-1846
  outpatient-based, costs in, 2811-2818
  pneumonia after, 796-805, 3856 (correspondence)
Bone scan index, for androgen-independent prostate cancer, 948-957
BR96-doxorubicin conjugate, in metastatic breast cancer, 478-484
Brain tumors, children with, leptomeningeal disease detection in, 1825-1828

BRCA1 and *BRC2* genes
in Ashkenazi Jewish women, benefits and costs of screening in, 494-500
breast cancer in carriers of mutations, 3367-3370 (editorial)
prognostic differences, 3653-3663 (review)
in breast-conserving therapy, 3689 (correspondence)
mutations in locally recurrent breast cancer, 3007-3008 (editorial), 3017-3024, 3689 (correspondence)
BRCA1 gene testing
benefits re-evaluated, 1962
in breast and ovarian cancer, 1040-1046
patients' moral concerns in, 1595-1600
BRCA2 gene testing
benefits re-evaluated, 1962
in breast and ovarian cancer, 1040-1046
patients' moral concerns in, 1595-1600
BrDu. *See* Bromodeoxyuridine
Breast, nevoid malignant melanoma of, 3850-3852
Breast cancer
advanced
consolidation radiotherapy in, 887-893
docetaxel *vs.* mitomycin-vinblastine in, 1413-1424
megestrol acetate for
dose-response trial, 64-73
letrozole *vs.*, in postmenopausal women, 3859-3860 (correspondence)
vorozole *vs.*, in postmenopausal patients, 52-63
neoadjuvant chemotherapy for, quality of life and, 441-444
paclitaxel and doxorubicin dose-escalation study in, 880-886
in postmenopausal patients, vorozole *vs.* megestrol acetate therapy in, 52-63
anthracycline-resistant, cost analysis of chemotherapy for, 3082-3090
ASCO surveillance guidelines of 1998, update on, 1080-1082
axillary lymph node dissection in. *See* Axillary lymph node dissection, in breast cancer
biologic predictors of outcome for, 3058-3063
BRCA1 and *BRCA2* in. *See BRCA1* and *BRC2* genes
cellular proliferation in, 470-477
clinical course of, doxorubicin-based neoadjuvant chemotherapy and, 460-469
combination *vs.* sequential primary chemotherapy in, 3033-3037
diagnosis of
choroidal metastases, 3356-3358
in premenopausal women, 2365-2370
sexual health predictors after, 2371-2380
weight gain after, 120-129
dissemination risk index in, 3048-3057
epirubicin metabolism in, 1132-1140
estrogen receptor status in, evaluation methods compared, 1474-1481
gene therapy for, phase I trial, 2180-2189
HER-2/neu in
FISH and immunohistochemistry evaluation of, 1974-1982, 3690-3692 (correspondence)
HercepTest specificity, 1983-1987
hereditary, *BRC2* germline mutations in, 3396-3402
high-dose chemotherapy for
clinical research on, 1965-1966 (editorial)
cyclophosphamide, 3374-3388
multicycle, in poor-prognosis cancer, 82-92
paclitaxel, 3-hour *vs.* 24-hour infusion, 3403-3411
high-risk
multicycle high-dose chemotherapy, 82-92
node-positive, adjuvant chemotherapy for, 1118-1126
resectable, ATC therapy for, 93-100
inflammatory stage IIIB, high-dose chemotherapy in, 2006-2014
invasive, *BAG-1* expression in, 1710-1719
local failure in, survival and, 101-109
localized
advanced, neoadjuvant chemotherapy for, 441-444
estrogen replacement therapy after, 1482-1487
recurrent, *BRCA1* and *BRC2* germline mutations in, 3007-3008 (editorial), 3017-3024, 3689 (correspondence)
lumpectomy in. *See* Lumpectomy
lymph node-positive, low-dose chemotherapy and tamoxifen trial in, 1701-1709
mammaglobin mRNA detection and, 2015-2019
mastectomy in. *See* Mastectomy
metastatic. *See* Metastatic breast cancer
metastatic bone disease and F-18 positron emission tomography in, 2381-2389
MRI for preoperative staging in, 110-119
node-negative, systemic adjuvant therapy in, 1458-1464
node-positive, in postmenopausal patients, treatments compared, 1988-1998
paclitaxel *vs.* combination neoadjuvant therapy in, 3412-3417
pamidronate and bone lesions in, 846-854
PIXY321 evaluation in, 3025-3032
poor-prognosis, multicycle high-dose chemotherapy, 82-92
in postmenopausal patients
defining clinical benefit and quality of life in, 1672-1679
effect of HRT on diagnosis and outcome in, 1680-1688
during pregnancy, management of, 855-861
preoperative
doxorubicin and docetaxel in, 1999-2005
MRI for staging of, 110-119
pretreated metastatic, docetaxel dose in, 1127-1131
prevention of
health-related quality of life and tamoxifen in, 2659-2669
tamoxifen clinical trial, commentary on, 1632-1639
primary
axillary lymph node metastasis in, 2334-2340, 3365 (erratum)
high-dose chemotherapy for, 25—29(Supp.), 30—34(Supp.)
pulmonary function after combined treatment for, 3091-3100
receptor-positive, low-dose chemotherapy and tamoxifen trial in, 1701-1709
sequencing of treatment in, first metastatic events and, 2649-2658
stage I, sector resection in, 2326-2333
stage IIIB, high-dose chemotherapy in, 2006-2014
survivors, hormone replacement therapy in, 130-142
tamoxifen for
clinical prevention trial, commentary on, 1632-1639
effect on sexual functioning, 1488-1492, 3689-3690 (correspondence)
health-related quality of life and, 2659-2669
screening for endometrial cancer in patient receiving, 1967-1968 (editorial), 2050-2054
telomerase activity and, 3075-3081
tubular and mucinous, 1442-1448
weight gain after diagnosis of, 120-129

Breast-conserving therapy
BRCA1 and *BRC2* genes in, 3689 (correspondence)
and distant metastases after local recurrence, 1449-1457
Breast lesions, telomerase activity in fine-needle aspirates of, 2020-2026, 3856-3857 (correspondence)
Bromodeoxyuridine
labeling of cellular proliferation in breast cancer, 470-477
with radiation therapy in advanced cervical cancer, 31-40
Bulky non-Hodgkin's lymphoma, rituximab phase II trial in, 1851-1857
Burkitt-like lymphoma, cytogenetics and outcome prediction in, 1558-1567
Burkitt's lymphoma, abdominal, 726-727
Burkitt's type adult acute lymphoblastic leukemia, hyper-CVAD program in, 2461-2470

CA-125, response to platinum or paclitaxel in epithelial ovarian cancer, 501-508
Cancer
advanced. *See* Advanced cancer/malignancies
Cancer anorexia/cachexia, treatments compared, 3299-3306
Cancer control, in susceptible groups, 719-725
Cancer patients/survivors
with breast cancer, informed consent for HRT in, 130-142
and cardiac mortality following childhood diagnosis, 3207-3215
chronic pain in, pain treatment evaluation measures, 1280-1287
with Hodgkin's disease, fatigue among, 253-261
of *MYCN*-amplified neuroblastoma, 3216-3220
and physician communication in clinical trials, 3324-3332
quality-of-care outcomes in, measurement of, 2614-2622, 3859 (correspondence)
reproductive issues for, 2631-2632 (editorial)
venous access ports in, 1267-1273
views on physician-assisted suicide and euthanasia, 1274-1279
Cancer therapy
Complementary and alternative, 44—52(Supp.)
unifying vision for the 21st Century, 13—21(Supp.)
Cancer trials, recruiting minorities into, pilot project, 1029-1039
Capecitabine, in paclitaxel-refractory metastatic breast cancer patients, 485-493
Carbogen, with accelerated radiotherapy and nicotinamide in glioblastoma multiforme, 3143-3149
Carboplatin
in advanced cancer, intravenous thymidine and, 2922-2931
for advanced ovarian cancer, with epirubicin and paclitaxel, phase I/II trial, 46-51
and cisplatin compared, pharmacology and clinical activity of, 409-422
hypersensitivity reactions to, 1141-1145
for non-small-cell lung cancer
advanced, with docetaxel and gemcitabine, phase II study, 3816-3821
combined with paclitaxel, 676-684
radiosensitization with, 4-11
Carcinoembryonic antigen, in ALVAC-CEA recombinant vaccine, phase I trial, 332-337
Carcinoid syndrome, malignant, octreotide acetate long-acting formulation in, 600-606
Carcinoma-in-situ, testicular, 173-179
Cardiotoxicity
anthracite, in children, 1208-1211
of epirubicin and paclitaxel-containing regimens, 3596-3602
paclitaxel and trastuzumab combination therapy, 1647-1648 (correspondence)
Castrate men, glucocorticoids and prostate cancer in, 2506-2513, 3858-3859 (correspondence)
Catabolism deficiency, prediction in advanced colorectal cancer patients, 1105-1110
Catheters, Hickman-type, infections in neutropenic patients, 1304-1311
CAV (cyclophosphamide-doxorubicin-vincristine) regimen, in recurrent small-cell lung cancer, topotecan *vs.*, 658-667
CAV/EP (cyclophosphamide-doxorubicin-vincristine/etoposide-cisplatin) regimen, for small-cell lung cancer, CODE *vs.*, 2300-2308
CD8+ tumor-infiltrating lymphocytes, in metastatic renal cell cancer, 2521-2529
CD34+ cell dose, effect on resource utilization after high-dose chemotherapy with peripheral-blood stem-cell support, 1227-1233
CD44v6, in preoperative thyroid nodule evaluation, 3494-3502
CD56 expression, in acute promyelocytic leukemia, 293-297
CDDP. *See* Cisplatin *entries*
CEA. *See* Carcinoembryonic antigen
Central nervous system
germ cell tumors of, chemotherapy and radiation for, 933-940
involvement in primary mediastinal large B-cell lymphoma, 2479-2485
isolated relapse in childhood ALL, survival and, 3745-3752
lymphoma of, primary methotrexate-based chemotherapy for, 1329 (correspondence)
Cerebellar tumor in infancy, neurocognitive development after, 3476-3486
Cerebrospinal fluid
lumbar and shunt, leptomeningeal disease detection in children with brain tumors, 1825-1828
vs. spinal MRI in detection of pediatric leptomeningeal disease, 3234-3237
Cervical cancer
advanced
BrDu and radiation therapy for, 31-40
para-aortic nodal metastasis evaluation with PET in, 31-40
chemoradiation and adjuvant chemotherapy in, 2055-2060
cisplatin and vinorelbine chemotherapy in, 756-760
concurrent chemotherapy and radiation, 1334-1335 (editorial), 1339-1348
HPV16/18mRNA detection in, 1391-1396
irinotecan in, phase II study, 3136-3142
metastatic and recurrent, paclitaxel and cisplatin chemotherapy in, 761-766
paclitaxel and cisplatin chemotherapy for, 2676-2680
in metastatic and recurrent cancer, 761-766
Cervical-thoracic Hodgkin's disease, variability in detection of, 2153-2159
CGP 69846A, phase I trial, 2227-2236
Chemoimmunotherapy, for metastatic melanoma, 651-657
Chemoprevention, National Cancer Instituted-supported research, 53—63(Supp.)
Chemoradiotherapy
for cervical cancer, adjuvant chemotherapy and, 2055-2060
for head and neck cancer, quality of life and performance of, 1020-1028
Chemotherapy
adjuvant. *See* Adjuvant chemotherapy

for advanced Hodgkin's disease, meta-analysis of, 730-734 (correspondence)
allogeneic BMT *vs.*, in childhood ALL in second remission, 197-207
anemia risk after, 2840-2846
ASCO guidelines for use of, 3333-3355
for cervical carcinoma, 2676-2680
combination. *See* Combination chemotherapy; *specific regimens*
complications of
hemialopecia, 430-433
nausea and vomiting, cost of treating, 344-351
cost of
in anthracycline-resistant breast cancer, 3082-3090
in management of nausea and vomiting related to, 344-351
cytotoxic, testicular function after, 1493-1498
dose-intensive
in limited-stage small-cell lung cancer, 1175-1184
in pediatric patients, 180-190
first-line
for advanced ovarian cancer, 46-51
in metastatic breast cancer, 74-81
prognostic factors in soft tissue sarcoma, 150-157
for germ cell tumors
advanced, high-dose *vs.* standard-dose, 3450-3456
of central nervous system, 933-940
for head and neck cancer, with concomitant radiation, 638-644
for hepatitis B carriers, with BMT, 394-398
high-dose
for breast cancer, clinical research on, 1965-1966 (editorial)
and induction therapy in metastatic breast cancer, prognostic factors for, 3064-3074
primary breast cancer, 25—29(Supp.), 30—34(Supp.)
multicycle
in high-risk breast cancer, 82-92
with peripheral-blood progenitor cell support, phase I trial, 2198-2207
with peripheral-blood stem-cell support, effect of CD34+ cell dose after, 1227-1233
for small-cell lung cancer, 3531-3539
for stage IIIB inflammatory breast cancer, 2006-2014
and stem-cell transplantation
for Hodgkin's disease, 222-229
for non-Hodgkin's lymphomas, 423-429
for locally advanced prostate cancer, 3664-3675 (review)
low-dose, for childhood desmoid tumor, 1086 (correspondence)
for metastatic melanoma, 968-975
methotrexate-based, for primary CNS lymphoma, 1329 (correspondence)
multicycle
high-dose, in high-risk breast cancer, 82-92
with peripheral-blood progenitor cell support, phase I trial, 2198-2207
for non-Hodgkin's lymphoma
B-cell type, 268-276
in transplant-eligible patients with, 3776-3785
for non-small-cell lung cancer
in advanced cancer, 734-735 (correspondence)
concurrent *vs.* sequential chemotherapy, 2692-2699
for ovarian dysgerminoma, reproductive function after, 2670-2675
preoperative
for gastric carcinoma, 2403-2411
for locally advanced breast cancer, quality of life and, 441-444
priming, GM-CSF treatment prior to, in breast cancer patients, 3426-3430
radiotherapy with
in advanced squamous cell carcinomas of head and neck, 2390-2395
after resection in rhabdomyosarcoma, 3468-3475
selection by *in vitro* drug sensitivity testing, efficacy of (review), 1625-1631
for small-cell lung cancer
in elderly patients, phase II trial, 3540-3545
high-dose, 3531-3539
venous access ports for, 1267-1273
Chest X-ray, computed tomography *vs.*, in mediastinal bulk assessment in Hodgkin's disease, 2493-2498
Childhood cancer
cardiac mortality in survivors of, 3207-3215
postradiation osteosarcoma after, 2789-2795
Children. *See also* Adolescents; Infants
acute leukemias in. *See* Acute lymphoblastic leukemia, childhood; Acute myelogenous leukemia, childhood; Acute myeloid leukemia, childhood
anthracite cardiotoxicity in, 1208-1211
autologous hematopoietic stem-cell transplantation for relapsed or refractory Hodgkin's disease in, 825-831
biphosphonates use in cancer-associated hypercalcemia, 1960 (correspondence)
with brain tumors, leptomeningeal disease detection in, 1825-1828
chemotherapy dose-intensification in, 180-190
conditioning regimen prior to BMT with HLA-identical siblings in ALL, 1838-1846
desmoid tumor in, low-dose chemotherapy for, 1086 (correspondence)
high cure rates in Hodgkin's disease, 3736-3744
idarubicin response in extraocular retinoblastoma, 1847-1850
irinotecan schedule in, phase I study, 1815-1824
localized primary non-Hodgkin's lymphoma of bone in, 456-459
malignant germ cell tumors in, prognostic factors, 1212-1218
medulloblastoma in
prognostic factors for, 832-845
reduced-dose radiotherapy in, 2127-2136
neuroblastoma in, treatment research protocols for, institutional review board and, 2625-2626 (correspondence)
nonrhabdosarcomatous soft tissue sarcomas in, 1219-1226
resection of Immature teratomas in, 2137-2143
with rhabdomyosarcoma, survival after relapse in, 3487-3493
rhabdomyosarcoma of genital tract in girls, 2117-2122
soft tissue sarcoma in
resected nonrhabdosarcomatous
—prognostic factors, 3697-3705
—role of adjuvant chemotherapy in, 1219-1226
treatment results in, 3706-3719
CHOP (cyclophosphamide-doxorubicin-vincristine-prednisone) chemotherapy, for B-cell non-Hodgkin's lymphomas, 268-276
Choroidal metastases, diagnosis of
in breast cancer, 3356-3358
in lung cancer, 3358-3359
Chronic lymphocytic leukemia
B-cell
with cutaneous lesions, 1084-1095
oral fludarabine phosphate pharmacokinetics in, 1574-1579

review of biologic advances in, 399-408
in elderly patient, rituximab for, 1962-1963 (correspondence)
Chronic lymphoid leukemia, nucleoside analog therapy in, 2454-2460
Chronic myelogenous leukemia
donor lymphocyte infusion in, 561-568
Philadelphia chromosome-positive, treatment of, 284-292
Chronic myeloid leukemia, monitoring treatment and survival in, 1858-1868
Chronic myelomonocytic leukemia, topotecan and cytarabine in, 2819-2830
Chronic pain, in cancer patients, treatment evaluation measures, 1280-1287
Cisplatin-dacarbazine-carmustine regimen, for malignant melanoma, with or without tamoxifen, 1884-1890
Cisplatin-dacarbazine-tamoxifen regimen, for metastatic melanoma, 968-975
Cisplatin-etoposide-paclitaxel regimen, for extensive-stage small-cell lung cancer, 2309-2315
Cisplatin-gemcitabine-paclitaxel regimen, in advanced non-small-cell lung cancer, phase I/II study, 2316-2325
Cisplatin-gemcitabine-vinorelbine regimen, in non-small-cell lung cancer, phase II study, 1526-1534
Cisplatin therapy
for advanced epithelial ovarian cancer, docetaxel with, 2069-2080
for cervical cancer, vinorelbine with, 756-760
emesis induced by, CJ-11,974 for, 338-343
multitargeted antifolate combined with, phase I and pharmacokinetic study, 3009-3016
for non-small-cell lung cancer, irinotecan with, 2710-2720
pharmacology and clinical activity of, compared with carboplatin, 409-422
for urothelial cancer, gemcitabine with, 2876-2881
Cisplatin-vincristine-doxorubicin-etoposide (CODE) regimen, *vs.* CAV/EP for small-cell lung cancer, 2300-2308
CJ-11,974, for cisplatin-induced emesis, 338-343
Clinical trials. *See also different* Phase *trials*
ethics of, impact of therapeutic research on, 1601-1617
meta-analyses, 1336-1338 (editorial)
recruiting minorities into, pilot project, 1029-1039
strategic physician communication and, 3324-3332
CLL. *See* Chronic lymphocytic leukemia
CMFP (cyclophosphamide-methotrexate-fluorouracil-prednisone) regimen, for untreated metastatic breast cancer, paclitaxel *vs.*, 2355-2364
CML. *See* Chronic myelogenous leukemia
CNS. *See* Central nervous system
CODE (cisplatin-vincristine-doxorubicin-etoposide), *vs.* CAV/EP for small-cell lung cancer, 2300-2308
Colon, primary follicular lymphoma of, 3684-3688
Colon cancer. *See also* Colorectal cancer
adjuvant chemotherapy for
Dukes' B *vs.* Dukes' C, 1349-1355, 3553-3559
Dukes' B2, 1356-1363
advanced pretreated, irinotecan and oxaliplatin in, 902-906
resected, anti-idiotype vaccine for, 2889-2895
Colony-stimulating factors, ASCO guidelines for use of, 3360-3361 (correspondence), 3676-3681
Colorectal cancer
advanced
fluorouracil sequential biomodulation in, 3276-3282
5FU catabolism deficiency in, 1105-1110
irinotecan, leucovorin, and fluorouracil in, 907-913
quality of life in, 1644 (correspondence)
ASCO surveillance guidelines, 1312-1321
DCC expression in, 1745-1750
in elderly, adjuvant or palliative chemotherapy for, 2412-2418
FU-based chemotherapy for, thymidylate synthase predicting outcome in, 1760-1770
metastatic, therapeutic regimens compared in, 2901-2908
p53 in
and BAX pathway, 1364-1374
genetic changes, 593-599
and K-*ras* mutations, 1375-1381
pretreated, FOLFOX3/4 for, phase II study, 3560-3568
recurrent, whole-body FDG-PET in, 894-901
staging accuracy in, 2896-2900
Colorectal tumors, dihydropyrimidine dehydrogenase inactivation in, 2439-2445
Combination chemotherapy. *See also specific agents and regimens*
for hormone-refractory prostate cancer, phase II trial, 1664-1671
for metastatic breast cancer, using single agent or phase II agent before, 1397-1406
vs. sequential chemotherapy in breast cancer, 3033-3037
Combined-modality treatment, of extensive-stage small-cell lung cancer, 2092-2099
Compassion, patient anxiety and, 371-379
Computed tomography
in cervical-thoracic Hodgkin's disease, detection variability of, 2153-2159
high-resolution, for pneumonia detection in neutropenic patients, 796-805, 3856 (correspondence)
in mediastinal bulk assessment in Hodgkin's disease, chest radiography *vs.*, 2493-2498
in supraglottic carcinoma, prior to radiotherapy, 631-637
Conditioning regimens
for bone marrow transplantation
autologous, in childhood AML, 3729-3735
with HLA-identical siblings in childhood ALL, 1838-1846
purine analog, prior to allogeneic transplantation, 1958-1960 (correspondence)
Consolidation radiotherapy, in advanced breast cancer, 887-893
Consolidation, high-dose, versus standard therapy in metastatic breast cancer, 22—24(Supp.)
Cost, of chemotherapy
for anthracycline-resistant breast cancer, 3082-3090
of managing nausea and vomiting related to, 344-351
CPT-11. *See* Irinotecan
Cranial irradiation, prophylactic, in non-small-cell lung cancer after multimodality treatment, 2700-2709
CSF. *See* Cerebrospinal fluid
Cutaneous lesions
chronic lymphocytic leukemia with, 1084-1095
in multifocal B-cell lymphoma, treatment for, 2471-2478
T-cell lymphoma with, pentostatin therapy for, 3117-3121
Cyclophosphamide, high-dose
for breast cancer, 3374-3388
effects of cytokine regimens after, comparative effects, 1296-1303
Cyclophosphamide-doxorubicin-vincristine (CAV) regimen, in recurrent small-cell lung cancer, topotecan *vs.*, 658-667
Cyclophosphamide-doxorubicin-vincristine/etoposide-cisplatin (CAV/EP) regimen, CODE *vs.*, for small-cell lung cancer, 2300-2308

Cyclophosphamide-doxorubicin-vincristine-prednisone (CHOP) chemotherapy, for B-cell non-Hodgkin's lymphomas, 268-276
Cyclophosphamide-methotrexate-fluorouracil-prednisone (CMFP) regimen, for untreated metastatic breast cancer, paclitaxel *vs.*, 2355-2364
Cyclophosphamide-paclitaxel-doxorubicin regimen, for resectable high-risk breast cancer, 93-100
Cytarabine
high-dose, for patients with t(8;21)(q22;q22) karyotype and AML, 3767-3775
low-dose, for Philadelphia chromosome-positive early chronic CML, 284-292
for lymphomatous meningitis, slow-release *vs.* standard formulation, 3110-3116
for myelodysplastic syndromes and CML, 2819-2830
for pediatric leukemia, 2804-2810
Cytarabine-daunorubicin-etoposide regimen, with or without PSC-833 for acute myeloid leukemia, 2831-2839
Cytogenetics, and outcome prediction in small noncleaved non-Burkitt's lymphoma, 1558-1567
Cytokine therapy
after high-dose cyclophosphamide, comparative effects, 1296-1303
for metastatic renal cancer
autoimmunity and, 529-533, 1330 (erratum)
switching between, 2039-2043
Cytotoxic chemotherapy, testicular function after, 1493-1498

Dacarbazine, for metastatic melanoma, Dartmouth regimen *vs.*, 2745-2751
Dartmouth regimen, *vs.* dacarbazine for metastatic melanoma, 2745-2751
DCC expression, in colorectal cancer, 1745-1750
Decision analysis
axillary lymph node dissection in breast cancer, 1465-1473
early-stage Hodgkin's disease treatment alternatives, 3577-3585
excision of early low rectal cancer, 312-318
laparotomy in early-stage Hodgkin's disease, 241-252
mastectomy *vs.* lumpectomy, 1727-1735
Delayed-emesis studies, placebo use in, 1648-1649 (correspondence)
Deleted in colorectal cancer gene, 1745-1750
Dendritic cell tumor, of abdominal wall, 2290-2292
Desmoid tumor
childhood, low-dose chemotherapy for, 1086 (correspondence)
prognostic factors and outcome after treatment, 158-167
Desmoplastic small round-cell tumors, pediatric, dose-intensification for, 180-190
Dexamethasone, for cancer anorexia/cachexia, megestrol acetate *vs.*, 3299-3306
Diet, and insulin-like growth factor 1 in healthy adults, 3291-3298
Dihydropyrimidine dehydrogenase, inactivation in colorectal tumors, 2439-2445
Dissemination risk index, in breast cancer, 3048-3057
DLIs (donor leukocyte infusions), graft-*vs.*-tumor induction with, for malignancies, 1234-1243
Docetaxel
cisplatin, fluorouracil, and leucovorin chemotherapy, for squamous cell carcinoma of head and neck, phase II trial, 3503-3511
and cisplatin for advanced epithelial ovarian cancer, 2069-2080
cost analysis in advanced breast cancer, 3081-3090
and doxorubicin in preoperative breast cancer, 1999-2005
effects on epirubicin metabolism in breast cancer, 1132-1140
and G-CSF for pancreatic cancer, multicenter phase II study, 1779-1785
in pretreated metastatic breast cancer, 1127-1131
vs. doxorubicin, in metastatic breast cancer, 2341-2354
vs. mitomycin-vinblastine in advanced breast cancer, 1413-1424
Docetaxel-estramustine regimen, for androgen-independent prostate cancer, 958-967
Docetaxel-gemcitabine regimen, in advanced non-small-cell lung cancer, 914-920
Docetaxel-mitoxantrone regimen, dose-escalation study in metastatic breast cancer, 862-869
Donor leukocyte infusions, graft-*vs.*-tumor induction with, for malignancies, 1234-1243
Donor lymphocyte infusions, in chronic myelogenous leukemia, 561-568
Doxorubicin
for breast cancer
BR96 conjugate, 478-484
high-dose liposome-encapsulated, with G-CSF, phase II study, 1435-1441
high-risk node-positive, and cyclophosphamide sequential adjuvant chemotherapy for, 1118-1126
metastatic
docetaxel *vs.*, 2341-2354
N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and, phase II trial, 3431-3437
in neoadjuvant chemotherapy, 460-469
with paclitaxel with G-CSF, phase II trial, 3828-3834
preoperative, docetaxel with, 1999-2005
liposomal, for head and neck cancer and non-small-cell cancer, 3512-3521
Doxorubicin and cisplatin, for malignant fibrous histiocytoma of bone, 3260-3269
Doxorubicin-cyclophosphamide-fluorouracil regimen, liposome-encapsulated, in metastatic breast cancer phase II study, 1425-1434
Doxorubicin-paclitaxel-cyclophosphamide regimen, for resectable high-risk breast cancer, 93-100
Doxorubicin toxicity
importance of, 2294-2296 (correspondence)
serum troponin-T levels in, 2237-2243
Drug sensitivity testing, efficacy of individualized chemotherapy selection by (review), 1625-1631
Dukes' B colon cancer, adjuvant chemotherapy in, 1349-1355, 3553-3559
Dukes' C colon cancer, adjuvant chemotherapy in, 1349-1355, 3553-3559

Eastern Cooperative Oncology Group
carboplatin radiosensitization in stage III unresectable non-small-cell lung cancer, phase III trial, 4-11
doxorubicin and paclitaxel plus G-CSF in metastatic breast cancer, phase II trial, 3828-3834
locoregional failure after mastectomy, 1689-1700
minority recruitment into clinical trial, pilot project, 1029-1039
eIF4E molecular marker, for surgical margin analysis in head and neck cancer, 2909-2914
Elderly
acute myeloid leukemia in, management of, 3569-3576
chronic lymphocytic leukemia in, rituximab for, 1962-1963 (correspondence)
colorectal cancer in, adjuvant or palliative chemotherapy for, 2412-2418

Emesis
cisplatin-induced
CJ-11,974 for, 338-343
oral morphine and 5-HT_3 receptor agonists in patients with, 1926-1930
drugs to prevent, studies on, 1960-1962 (correspondence)
Endocrine therapy, in postmenopausal breast cancer patients, 1672-1679
Endometrial cancer
advanced or recurrent, oral medroxyprogesterone acetate for, 1736-1744
prognostic significance of tumor biomarkers in, 1382-1390
screening in patient receiving tamoxifen for breast cancer, 1967-1968 (editorial), 2050-2054
Eniluracil, for DPD inactivation in colorectal tumors, 2439-2445
EORTC. *See* European Organization for Research and Treatment of Cancer
Epipodophyllotoxins, secondary leukemia or myelodysplastic syndrome after, 569-577
Epirubicin, for breast cancer
metabolism, 1132-1140
node-positive, in postmenopausal patients, 1988-1998
Epirubicin-paclitaxel-carboplatin regimen, for advanced ovarian cancer, phase I/II trial, 46-51
Epirubicin-paclitaxel-cisplatin regimen, compared with EPO added to G-CSF, 1288-1295
Epirubicin/paclitaxel-containing regimens, cardiotoxicity of, 3596-3602
Epithelial ovarian cancer
advanced, docetaxel and cisplatin for, 2069-2080
measuring CA-125 response to platinum or paclitaxel in, 501-508
stage IV, natural history of, 767-775, 3361-3362 (correspondence)
EPO. *See* Erythropoietin
Epstein-Barr virus DNA polymerase chain reaction, in diagnosis of AIDS-related primary CNS lymphoma, 554-560
*erb*B-2 expression, osteosarcoma survival and, 2781-2788
Erectile dysfunction, postradiotherapy, sildenafil for, 3444-3449
ERT. *See* Estrogen replacement therapy
Erythropoietin, added to G-CSF, compared with G-CSF alone, 1288-1295
Esophageal cancer
advanced, irinotecan plus cisplatin phase II trial in, 3270-3275
chemoradiotherapy for, 2915-2921
Estramustine-paclitaxel-etoposide regimen, for hormone-refractory prostate cancer, phase II trial, 1664-1671
Estramustine phosphate, for hormone-refractory prostate cancer, with vinblastine *vs.* vinblastine alone, 3160-3166
Estrogen receptor status, in breast cancer, evaluation methods compared, 1474-1481
Estrogen replacement therapy, after localized breast cancer, 1482-1487
Ethical issues
impact of therapeutic research, 1601-1617
life support in BMT patients, 298-303
Etoposide, oral, for relapsed neuroblastoma, 3221-3225
Etoposide-cisplatin regimen, gemcitabine-cisplatin *vs.*, in locally advanced non-small-cell lung cancer, 12-18
European Organization for Research and Treatment of Cancer
prognostic factors in advanced soft tissue sarcoma outcome, 150-157
quality of life questionnaire in head and neck cancer, 1008-1019
Euthanasia, views on, 1274-1279
Evidence-based medicine, case report, 1969-1973
Ewing's family of tumors, pediatric, dose-intensification for, 180-190
Ewing's sarcoma, *EWS-FLI1* and *EWS-ERG* gene fusions in, 1809-1814
EWS-ERG gene fusion product, in Ewing's sarcoma, 1809-1814
EWS-FLI1 gene fusion product, in Ewing's sarcoma, 1809-1814
Exemestane, for metastatic breast cancer, phase II trial, 3418-3425
Extensive-stage small-cell lung cancer
cisplatin-etoposide-paclitaxel chemotherapy for, 2309-2315
combined-modality treatment of, role of radiation therapy in, 2092-2099
phase III trials, 1794-1801
Extracapsular extension, after radical prostatectomy, 3167-3172
Extranodal follicular dendritic cell tumor, of abdominal wall, 2290-2292
Extraocular retinoblastoma, idarubicin response in children, 1847-1850

Fatigue, in Hodgkin's disease survivors, 253-261
FDG-PET. *See* Positron emission tomography, [^{18}F]-2-fluoro-2-deoxy-D-glucose
Femur, marrow MRI of, in myelodysplastic syndromes, 277-283
FHIT, role in human cancer, 1618-1624
Fibrolamellar carcinoma, recurrence after liver transplantation, 324-331
Fibrous histiocytoma of bone, malignant, 3260-3269
Filgrastim. *See* Granulocyte colony-stimulating factor
Fine-needle aspirates, of breast lesions, telomerase activity in, 2020-2026, 3856-3857 (correspondence)
Flare phenomenon, biphosphonates and, 1328-1329
Fludarabine phosphate
for lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma, 546-553
pharmacokinetics in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia, 1574-1579
Fluorescence in situ hybridization
evaluation of *HER-2/neu* in breast cancer, 1974-1982, 3690-3692 (correspondence)
vs. immunohistochemistry, 3690-3692 (correspondence)
Fluorodeoxyglucose-positron-emission tomography. *See* Positron emission tomography, [^{18}F]-2-fluoro-2-deoxy-D-glucose
Fluoropyrimidine capecitabine, and paclitaxel for malignant solid tumors, phase I and pharmacokinetic study, 1915-1925
Fluorouracil-cisplatin regimen, as adjunct to radiation therapy in cervical cancer, 1339-1348
Fluorouracil therapy
biomodulation of
sequential, in advanced colorectal cancer, 3276-3282
in tumors, normal tissue, and plasma, 1580-1588
for colorectal cancer
catabolism deficiency prediction, 1105-1110
pretreated metastatic, 2901-2908
sequential biomodulation, 3276-3282
thymidylate synthase predicting outcome in, 1760-1770
for Dukes' B2 colon cancer, folinic acid with, 1356-1363
for head and neck cancer, concomitant radiation with, 638-644
for pancreatic cancer, 585-592
FOLFOX3/4, for pretreated colorectal cancer, phase II study, 3560-3568
Folinic acid
fluorouracil with, in Dukes' B2 colon cancer, 1356-1363
plasma fluorouracil biomodulation with, 1580-1588
Follicular lymphoma
colonic, 3684-3688
Hodgkin's disease and, common precursor cell of, 3804-3809

recurrence after autologous BMT for, 216-221
stage III-IV, prognostic factors in, 2499-2505
5-FU therapy. *See* Fluorouracil therapy
Function-sparing surgery, soft tissue sarcomas of extremities and trunk, 3252-3259

G-CSF. *See* Granulocyte colony-stimulating factor
G-CSF (filgrastim). *See* Granulocyte colony-stimulating factor
Gabapentin, for taxane-induced myalgias, 434 (correspondence)
Galectin-3, in preoperative evaluation of thyroid nodules, 3494-3502
Gastric cancer
adjuvant chemotherapy in, 3810-3815
metastatic, irinotecan and cisplatin against, 319-323
preoperative chemotherapy for, 2403-2411
TGF-β1 in, 607-614
Gastrointestinal cancer
hydroxyurea-fluorouracil-interferon alfa-2a for, phase II/pharmacodynamic trial, 1771-1778
oxaliplatin with irinotecan for, phase I studies with pharmacokinetics, 1751-1759
Gastrointestinal neuroendocrine tumors, prolonged-release lanreotide for, 1111-1117
Gemcitabine
for advanced non-small-cell lung cancer
and combination chemotherapy regimens compared, phase III trial, 3522-3530
phase II trial, 2081-2085
for non-small-cell lung cancer, paclitaxel pharmacologic interactions and, 2190-2197
for pancreatic cancer, 585-592
advanced, concurrent radiation with, 2208-2212, 3692 (correspondence)
for refractory germ cell tumors, 509-511
for relapsed Hodgkin's disease, 2627-2628 (correspondence)
for relapsed or cisplatin-refractory testicular cancer, 512-516
for relapsed or refractory aggressive non-Hodgkin's lymphoma, 3786-3792
Gemcitabine-carboplatin regimen, for non-small-cell lung cancer, 921-926
Gemcitabine-cisplatin regimen
for malignant pleural mesothelioma, 25-30, 2626-2627 (correspondence)
for urothelial cancer, 2876-2881
vs. etoposide-cisplatin, in locally advanced non-small-cell lung cancer, 12-18
Gene therapy
for advanced malignancy, phase I/II trial, 3313-3323
for breast cancer, phase I trial, 2180-2189
Genetic markers, in high risk population, placebo-controlled trial, 3546-3552
Genetics, of melanoma, consensus statement on, 3245-3251
Genital tract, rhabdomyosarcoma in girls, 2117-2122
Germ cell tumors
advanced, high-dose *vs.* standard-dose chemotherapy for, 3450-3456
CNS, chemotherapy and radiation for, 933-940
malignant, in children
AML after treatment for, 3226-3233
nonseminomatous, prognostic factors, 1212-1218
refractory, gemcitabine in, 509-511
testicular, Leydig cell function in, 173-179
Germinoma
intracranial, prospective radiation therapy trial, 2585-2592
and ovarian dysgerminoma, reproductive function after chemotherapy for, 2670-2675
Glioblastoma, recurrent, procarbazine and tamoxifen in, 645-650
Glioblastoma multiforme
accelerated radiotherapy, carbogen, and nicotinamide in, 3143-3149
RSR13 in, phase I trial, 2593-2603
Glioma
anaplastic, temozolomide in, 2762-2771
recurrent, outcome and prognostic factors in, phase II trial, 2572-2578
recurrent high-grade, KRN8602 in, 2579-2584
recurrent malignant, phenylacetate for, 984-990
Recurrent or progressing malignant, irinotecan therapy for, 1516-1525
GM-CSF. *See* Granulocyte-macrophage colony-stimulating factor
Gonadal function, before orchiectomy in testicular cancer patients, 941-947
Graft-*vs.*-tumor effect, in posttransplant metastatic renal cell carcinoma, 2044-2049
Granulocyte colony-stimulating factor
for advanced pretreated colon cancer, 902-906
after high-dose cyclophosphamide, 1296-1303
for breast cancer
before chemotherapy priming, 3426-3430
with doxorubicin and paclitaxel, phase II trial, 3828-3834
effect on neutropenia and thrombocytopenia, 3025-3032
metastatic, high-dose liposome-encapsulated doxorubicin with, phase II study, 1435-1441
erythropoietin added to, compared with G-CSF alone, 1288-1295
mobilizing peripheral-blood progenitor cell support
high- *vs.* standard-dose, 2160-2172
in high-risk breast cancer, 82-92
for neutropenic fever, 1644-1645 (correspondence)
for pancreatic cancer, docetaxel with, multicenter phase II study, 1779-1785
prechemotherapy administration, detrimental effects of, 1088-1090 (correspondence)
Granulocyte-macrophage colony-stimulating factor
after high-dose cyclophosphamide, 1296-1303
in established febrile neutropenia, 3002 (correspondence)
Granulocytic sarcoma, diffuse muscle infiltration by, 1642-1643
Granuloma, midline, and nasal NK cell lymphoma diagnosis, 1322-1325
Groupe d'Etude des Lymphomes de l'Adulte, prognostic factors in follicular lymphoma, 2499-2505
Gynecologic Oncology Group, chemotherapy with radiation therapy in cervical cancer, 1339-1348
Gynecomastia, in lung cancer patient, 1956-1957

Head and neck cancer
chemotherapy with concomitant radiation in, 638-644
eIF4E analysis of surgical margins in, 2909-2914
liposomal doxorubicin and radiotherapy for, 3512-3521
quality of life in, 352-360
chemoradiotherapy, 1008-1019
questionnaire assessment, 1008-1019
Health-related quality of life. *See* Quality of life
Heart
anthracite cardiotoxicity in children, 1208-1211

cardiac disease in childhood and adolescent cancer survivors, 3207-3215
doxorubicin-induced cardiomyopathy, 2237-2243
Hematologic malignancies
outpatient-based BMT for, 2811-2818
rituximab therapy in, 791-795
uncommon sites
diffuse muscle infiltration by granulocytic sarcoma, 1642-1643
localized primary non-Hodgkin's lymphoma of the patella, 1640-1642
WHO classification of, 3835-3849
Hematopoietic cells, autologous and allogeneic transplantation, role in multiple myeloma remissions, 208-215
Hemialopecia, as chemotherapy complication, 430-433
Hepatitis B, in cancer patients, chemotherapy and BMT for, 394-398
Hepatocellular carcinoma, recurrence after liver transplantation, 324-331
HER-2/neu, in breast cancer
FISH and immunohistochemistry evaluation of, 1974-1982, 3690-3692 (correspondence)
HercepTest specificity, 1983-1987
HER2 oncogene
FDA-approved antibody and, 434 (correspondence)
overexpression, immunohistochemical assays for, 1650
HercepTest assay
HER-2/neu status in breast cancers, 1983-1987
HER2, 2293-2294 (correspondence)
FDA-approved antibody and, 434 (correspondence)
Hereditary breast cancer, survival and *BRC2* germline mutations in, 3396-3402
Hereditary retinoblastoma, associated with primary ectopic intracranial retinoblastomas, 1829-1837
Hickman catheters, infections in neutropenic patients, 1304-1311
High-resolution computed tomography, for pneumonia detection in neutropenic patients, 796-805, 3856 (correspondence)
High-risk breast cancer
multicycle high-dose chemotherapy, 82-92
node-positive, adjuvant chemotherapy for, 1118-1126
resectable, ATC therapy for, 93-100
High risk population, genetic markers in, placebo-controlled trial, 3546-3552
Hodgkin's disease
ATM mutations and secondary malignancy in, 1259-1266
cervical-thoracic, variability in detection of, 2153-2159
chemotherapy for
meta-analysis of regimens, 730-734 (correspondence)
and stem-cell transplantation, 222-229
early-stage
decision analysis for laparotomy in, 241-252
treatment alternatives for, 3577-3585
and follicular lymphoma, common precursor cell of, 3804-3809
incidence after allogeneic BMT, 3122-3127
lymphocyte-predominant
clinical features of, 776-783
therapeutic efforts in, 744-746
lymphocyte-rich classical, clinical features of, 776-783
mantle radiotherapy for, 230-240
mediastinal bulk in, CT *vs.* chest radiography assessment, 2493-2498
pediatric, high cure rates in, 3736-3744
refractory, autologous stem-cell transplantation for, 534-545, 3101-3109
in children and adolescents, 825-831
relapsed
autologous hematopoietic stem-cell transplantation in children and adolescents, 825-831
gemcitabine in, 2627-2628 (correspondence)
survivors, fatigue among, 253-261
Hoosier Oncology Group
combination *vs.* sequential chemotherapy in breast cancer, 3033-3037
vinblastine *vs.* vinblastine plus estramustine phosphate in hormone-refractory prostate cancer, phase III trial, 3160-3166
Hormone-refractory prostate cancer
combination chemotherapy for, phase II trial, 1664-1671
hydrocortisone with or without mitoxantrone, 2506-2513, 3858-3859 (correspondence)
PSA doubling time as surrogate end point in, 1645-1646 (correspondence)
vinblastine *vs.* vinblastine plus estramustine phosphate in, phase III trial, 3160-3166
Hormone replacement therapy
in breast cancer survivors, 130-142
postmenopausal, effect on outcome and diagnosis of early-stage breast cancer, 1680-1688
Human papillomavirus, detection in peripheral blood of cervical cancer patients, 1391-1396
Hydrocortisone, with or without mitoxantrone in hormone-refractory prostate cancer, 2506-2513, 3858-3859 (correspondence)
5-Hydroxytryptamine-3 receptor agonists, and oral morphine in patients with cisplatin-induced emesis, 1926-1930
Hydroxyurea
as adjunct to radiation therapy in cervical cancer, 1339-1348
with concomitant radiation in head and neck cancer, 638-644
Hydroxyurea-fluorouracil-interferon alfa-2a, for gastrointestinal cancer, phase II/pharmacodynamic trial, 1771-1778
Hyper-CVAD program, in Burkitt's type adult acute lymphoblastic leukemia, 2461-2470
Hypercalcemia, cancer-associated, biphosphonates use in children, 1960 (correspondence)
Hypersensitivity reactions, to carboplatin, 1141-1145

Idarubicin, response in pediatric extraocular retinoblastoma, 1847-1850
IDEC-Y2B8 radioimmunotherapy, for relapsed or refractory non-Hodgkin's lymphoma, phase I/II trial, 3793-3803
IFN-α. *See* Interferon-α
Ifosfamide, for invasive thymoma, 2737-2744
Ifosfamide-carboplatin-etoposide regimen
for small-cell lung cancer, 3531-3539
for transplant-eligible patients with non-Hodgkin's lymphoma, 3776-3785
IGF-BP3 (insulin-like growth factor-binding protein 3), predictors of, 813-817
Immature teratomas, resection in children, 2137-2143
Immunocytoma, retrospective analysis (1972-1996), 2847-2853
Immunohistochemistry
determining estrogen receptor status in breast cancer, 1474-1481
evaluation of *HER-2/neu* in breast cancer, 1974-1982, 3690-3692 (correspondence)
fluorescence in situ hybridization *vs.*, 3690-3692 (correspondence)
HER2 overexpression and, 1650 (correspondence)
thymidylate synthase quantitation, and outcome prediction in colorectal cancer treated by FU-based chemotherapy, 1760-1770
Immunoproliferative small intestinal disease, 3682-3684

Immunotherapy
of advanced malignancy, 3313-3323
with chemotherapy for metastatic melanoma, 651-657
lymphoma, 7—13(Supp.)
inhaled interleukin-2, quality of life during, 3612-3620
in malignant melanoma, 1963 (correspondence)
in sarcomatoid renal cell carcinoma, 523-528
IMPACT B2, adjuvant chemotherapy, 1356-1363
Implantation, iodine-125, for early-stage prostatic cancer, 517-522
In Memoriam
C. Gordon Zubrod, 1331-1333
Emmanuel van der Schueren, 437
Indium-111-antimyosin scintigraphy, for anthracite cardiotoxicity detection in children, 1208-1211
Induction therapy, and high-dose chemotherapy in metastatic breast cancer, prognostic factors for, 3064-3074
Infants
acute lymphoblastic leukemia in, 438-440
treatment outcome and prognostic factors in, 445-455
cerebellar tumor in, neurocognitive development after, 3476-3486
neuroblastoma screening at 1 year, 1200-1207
Infections, Hickman catheter-related, in neutropenic patients, 1304-1311
Inflammatory breast cancer, stage IIIB, high-dose chemotherapy in, 2006-2014
Informed consent
for HRT in breast cancer survivors, 130-142
impact of therapeutic research on, 1601-1617
Insulin-like growth factor-1
and diet in healthy adults, 3291-3298
predictors of, 813-817
Insulin-like growth factor-binding protein 3, predictors of, 813-817
Integrin adhesion molecules, expression in non-Hodgkin's lymphoma, 1869-1875
Interferon-α therapy
for advanced renal cell cancer, with vinblastine, *vs.* vinblastine alone in, 2859-2867
for metastatic melanoma, 651-657
with chemotherapy, 968-975
for Philadelphia chromosome-positive early chronic CML, 284-292
plasma fluorouracil biomodulation with, 1580-1588
Interferon therapy, for metastatic renal cancer, 2039-2043
Interleukin-2 DNA/DMRIE/DOPE lipid complex, in advanced malignancy phase I/II trial, 3313-3323
Interleukin-2 therapy
inhaled, quality of life during, 3612-3620
for metastatic melanoma, 651-657
with chemotherapy, 968-975
high-dose therapy, 2105-2116
for metastatic renal cell cancer, 2039-2043
CD8+ tumor-infiltrating lymphocytes with, 2521-2529
Interleukin-3, plus GM-CSF, effect after high-dose cyclophosphamide, 1296-1303
International Collaborative Cancer Group, node-positive breast cancer in postmenopausal patients, treatments compared, 1988-1998
International Consensus Conference on Intensive Chemotherapy Plus Hematopoietic Stem Cell Transplantation in Malignancies, jury results, 423-429
International Multicentre Pooled Analysis of B2 Colon Cancer Trials, adjuvant chemotherapy, 1356-1363
International Society of Pediatric Oncology, rhabdomyosarcoma of genital tract in girls, 2117-2122
Intestines, primary low-grade lymphomas of, 3682-3688
Intracranial germinoma, prospective radiation therapy trial, 2585-2592
Invasive breast carcinomas, *BAG-1* expression in, 1710-1719
Invasive thymoma, ifosfamide for, 2737-2744
Irinotecan and cisplatin, for advanced esophageal cancer, phase II trial, 3270-3275
Irinotecan and cisplatin regimen
against metastatic gastric cancer, 319-323
in non-small-cell lung cancer, 2710-2720
Irinotecan and oxaliplatin regimen, in advanced pretreated colon cancer, 902-906
Irinotecan-fluorouracil-leucovorin regimen, for colorectal cancer
advanced form, 907-913
metastatic form, 2901-2908
Irinotecan therapy
for cervical cancer, phase II study, 3136-3142
for malignant solid tumors, continuous infusion phase I and pharmacokinetic study, 1897-1905
oral, in patients with solid tumors, 685-696
pediatric administration schedule, phase I study, 1815-1824
for recurrent or progressing malignant glioma, 1516-1525
Irradiation
prophylactic cranial, in non-small-cell lung cancer after multimodality treatment, 2700-2709
thoracic, for small-cell lung cancer, 2681-2691
total-body, for autologous BMT in childhood AML, 3729-3735
ISIS 3521, phase I evaluation in advanced cancer, 3586-3595
ISIS 5132, phase I trial, 2227-2236

Japan, status of anticancer drugs in, 3362-3365 (correspondence)
JM216, for small-cell lung cancer, phase II study, 3822-3827

K-*ras* gene mutations
in colorectal cancer, 1375-1381
in DNA from plasma of pancreatic cancer patients, 578-584
in resected non-small-cell lung cancer, 668-675
Kaposi's sarcoma, paclitaxel in, 1876-1883
Ki-67, prognostic significance in endometrial cancer, 1382-1390
KRN8602, in recurrent high-grade glioma, 2579-2584

Lactate dehydrogenase, monitoring in AJCC stage IV melanoma, 1891-1896
Lanreotide, prolonged-release, for gastrointestinal neuroendocrine tumors, 1111-1117
Laparotomy, for early-stage Hodgkin's disease, decision analysis in, 241-252
Large bowel
adenocarcinoma metastases presenting as appendicitis, 2623-2624
medullary-type poorly-differentiated adenocarcinoma of, 2429-2438
Laryngeal squamous cell carcinoma, p21 and p27 protein expression in, 3150-3159
Leptomeningeal disease, detection in children
with brain tumors, 1825-1828
with medulloblastoma or PNET, 3234-3237
Letrozole, for advanced breast cancer in postmenopausal women, 3859-3860 (correspondence)

Leucovorin
and fluorouracil therapy, with irinotecan in pretreated metastatic colorectal carcinoma, 2901-2908
for methotrexate toxicity, 1589-1594
Leukemia(s)
acute forms
depleted T-cell-depleted BMT for, 1545-1550
lymphoblastic. *See* Acute lymphoblastic leukemia
myeloid. *See* Acute myeloid leukemia
myelomonocytic, diffuse muscle infiltration by granulocytic sarcoma after, 1642-1643
promyelocytic, CD56 expression in, 293-297
chronic forms
lymphocytic. *See* Chronic lymphocytic leukemia
lymphoid, nucleoside analog therapy in, secondary malignancies and, 2454-2460
myelogenous. *See* Chronic myelogenous leukemia
myeloid, monitoring treatment and survival in, 1858-1868
myelomonocytic, topotecan and cytarabine in, 2819-2830
pediatric, ara-C in, 2804-2810
RAS signaling pathways and, 1071-1079
secondary, after epipodophyllotoxin treatment, 569-577
Leydig cell function
after cytotoxic chemotherapy, 1493
in testicular germ cell cancer, 173-179
Life support, in BMT patients, ethical issues concerning, 298-303
Liposomal doxorubicin, and radiotherapy for head and neck cancer and non-small-cell cancer, 3512-3521
Liposomal vincristine, phase I study of, 697-705
Liver metastases, resected, *p53/BAX* pathway analysis in colorectal cancer, 1364-1374
Liver transplantation, hepatocellular and fibrolamellar carcinoma recurrence patterns after, 324-331
Local failure, in breast cancer, survival and, 101-109
Locoregional failure, after mastectomy, risk factors affecting, 1689-1700
Low-dose chemotherapy, and tamoxifen trial, in receptor-positive and lymph node-positive breast cancer, 1701-1709
Lumpectomy
BRCA1 and *BRC2* germline mutations in locally recurrent breast cancer after, 3007-3008 (editorial), 3017-3024, 3689 (correspondence)
mastectomy *vs.*, informed choices by patients, 1727-1735
Lung cancer
diagnosis of, choroidal metastases in, 3358-3359
gynecomastia in, 1956-1957
malignant mesothelioma, cisplatin and gemcitabine phase II study in, 25-30, 2626-2627 (correspondence)
non-small-cell. *See* Non-small-cell lung cancer
*p*120 expression in, 2721-2727
small-cell. *See* Small-cell lung cancer
with solitary bone metastases
acrometastases, 2998-3001
to patella, 2995-2997
Lymph node dissection, axillary. *See* Axillary lymph node dissection
Lymph node-positive breast cancer, low-dose chemotherapy and tamoxifen trial in, 1701-1709
Lymph nodes
disseminated tumor cells in, non-small-cell lung cancer survival and, 19-24
sentinel node status, in melanoma, 976-983
Lymphadenectomy, sentinel, occult melanoma metastases detection by, 3238-3244
Lymphocyte-predominant Hodgkin's disease
clinical features of, 776-783
therapeutic efforts in, 744-746
Lymphocyte-rich classical Hodgkin's disease, clinical features of, 776-783
Lymphocytes, CD8+ tumor-infiltrating, in metastatic renal cell cancer, 2521-2529
Lymphoepithelioma-like carcinoma, of the skin, 3853-3855
Lymphoma(s)
abdominal Burkitt's, 726-727
B-cell. *See* B-cell lymphoma
Burkitt-like, cytogenetics and outcome prediction in, 1558-1567
diffuse large-cell, of testis, 2854-2858
fludarabine phosphate for, 546-553
follicular
recurrence after autologous BMT for, 216-221
stage III-IV, prognostic factors in, 2499-2505
immunotherapy of, 7—13(Supp.)
intestinal low-grade, 3682-3688
mediastinal large B-cell, 784-790
mucosa-associated lymphoid tissue. *See* Mucosa-associated lymphoid tissue lymphoma
nasal NK cell, 1322-1325
nodal marginal zone, 2486-2492
non-Hodgkin's. *See* Non-Hodgkin's lymphoma
primary CNS
AIDS-related, diagnosis of, 554-560
methotrexate-based chemotherapy for, 1329 (correspondence)
pulmonary function after combined treatment for, 3091-3100
signet ring, of bone marrow, 728-729
T-cell, pentostatin therapy for, 3117-3121
Lymphomatous meningitis, slow-release *vs.* standard formulation of cytarabine for, 3110-3116
Lymphoplasmacytoid lymphoma, fludarabine phosphate for, 546-553

Magnetic resonance imaging
in children receiving ara-C, 2804-2810
of femoral marrow, in myelodysplastic syndromes, 277-283
for preoperative staging in breast cancer, 110-119
spinal, *vs.* CSF cytology in detection of pediatric leptomeningeal disease, 3234-3237
Malignancy(ies). *See also specific forms*
advanced. *See* Advanced cancer/malignancies
graft-*vs.*-tumor induction with donor leukocyte infusion therapy for, 1234-1243
hematologic. *See* Hematologic malignancies
Malignant carcinoid syndrome, octreotide acetate long-acting formulation in, 600-606
Malignant fibrous histiocytoma, of bone, 3260-3269
Malignant germ cell tumors, in children
AML after treatment for, 3226-3233
nonseminomatous, prognostic factors for, 1212-1218
Malignant glioma, recurrent, phenylacetate for, 984-990
Malignant melanoma
AJCC stage IV, discriminating progressive from nonprogressive disease, 1891-1896
chemoimmunotherapy for, 651-657
cisplatin-dacarbazine-carmustine with or without tamoxifen for, phase III trial, 1884-1890

concurrent biochemotherapy for, 2752-2761
Dartmouth regimen *vs.* dacarbazine in, 2745-2751
FDG-PET imaging of sentinel nodes in, 1508-1515
genetics of, consensus statement on, 3245-3251
immunotherapy in, 1963 (correspondence)
metastatic
chemoimmunotherapy for, 651-657
chemotherapy for, 968-975
survival in, psychosocial predictors of, 2256-2263, 3857-3858 (correspondence)
nevoid, of breast, 3850-3852
PCR with tyrosinase and with MART-1 in, 2562-2571
RT-PCR detection of circulating melanoma cells as marker for, 304-311
sentinel lymph node status in, 976-983
Malignant mesothelioma, pleural, cisplatin and gemcitabine treatment for, 25-30, 2626-2627 (correspondence)
MALT (mucosa-associated lymphoid tissue) lymphoma, nongastrointestinal low-grade, 1254-1258
Mammaglobin mRNA, reverse transcriptase PCR detection of, 2015-2019
Mammography, risk-based, 735-738 (correspondence)
Mantle-cell lymphoma, fludarabine phosphate for, 546-553
Mantle radiotherapy, for Hodgkin's disease, 230-240
MART-1, PCR with, in melanoma, 2562-2571
Mastectomy
locoregional failure after, risk factors affecting, 1689-1700
vs. lumpectomy, informed choices by patients, 1727-1735
Mdm2, in advanced ovarian cancer, 2061-2068
Mechanical ventilation, outcome of, 991-997
Mediastinal bulk, in Hodgkin's disease, CT *vs.* chest radiography assessment, 2493-2498
Mediastinal large B-cell lymphoma, 784-790
Medroxyprogesterone acetate, for advanced or recurrent endometrial cancer, 1736-1744
Medullary-type adenocarcinoma, of large bowel, 2429-2438
Medulloblastoma, in children
leptomeningeal disease and, 3234-3237
prognostic factors for, 832-845
reduced-dose radiotherapy and, 2127-2136
survival and neurodevelopmental outcome, 3720-3728
Megestrol acetate therapy
for advanced breast cancer
dose-response trial, 64-73
vorozole therapy *vs.*, in postmenopausal patients, 52-63
for cancer anorexia/cachexia, *vs.* dexamethasone, 3299-3306
low-dose, PSA decline after withdrawal, 1087-1088 (correspondence)
Melanoma. *See* Malignant melanoma
Melanoma Genetic Consortium, consensus statement of, 3245-3251
Melanoma-inhibiting activity, monitoring in AJCC stage IV melanoma, 1891-1896
Melphalan therapy
for autologous BMT in childhood AML, 3729-3735
with autotransplantation for refractory multiple myeloma, 2173-2179
high-dose, for metastatic rhabdomyosarcoma, 2796-2803
with prednisolone, for primary systemic amyloidosis, 262-267
Meningitis, lymphomatous, slow-release *vs.* standard formulation of cytarabine for, 3110-3116
Menopause
risk after breast cancer diagnosis, 2365-2370
time of onset as predictor of weight gain after breast cancer diagnosis, 120-129
Mesothelioma, malignant pleural, cisplatin and gemcitabine treatment for, 25-30, 2626-2627 (correspondence)
Meta-analysis(es)
hereditary retinoblastoma associated with primary ectopic intracranial retinoblastomas, 1829-1837
reliability of, 1646-1647 (correspondence)
separate clinical trials, 1336-1338 (editorial)
Metalloproteinases, in small-cell lung cancer, expression and prognostic significance of, 1802-1808
Metaplasia, myeloid, myelofibrosis with, 2954-2970
Metastasis(es)
in breast cancer. *See also* Metastatic breast cancer
frequency of first events, 2649-2658
local failure contributing to, 101-109
choroidal
breast cancer, 3356-3358
lung cancer, 3358-3359
gastric cancer, TGF-β1 in, 607-614
occult melanoma, detection of, 3238-3244
risk after local breast cancer recurrence, 1449-1457
sentinel lymph node biopsy with, in breast cancer patients, 1720-1726
Metastatic bone disease, in breast cancer, F-18 positron emission tomography detection, 2381-2389
Metastatic breast cancer
anti-HER2 monoclonal antibody in, 2639-2647
axillary lymph nodes, 2334-2340, 3365 (erratum)
BR96-doxorubicin conjugate in, 478-484
docetaxel and mitoxantrone dose-escalation study in, 862-869
docetaxel *vs.* doxorubicin, prospective study, 2341-2354
first-line chemotherapy in, 74-81
high-dose consolidation versus standard therapy, 22—24(Supp.)
infusional paclitaxel, weekly vinorelbine and concurrent filgrastim in, 1407-1412
megestrol acetate for
dose-response, 64-73
vorozole *vs.*, in postmenopausal patients, 52-63
paclitaxel-refractory, capecitabine in, 485-493
phase II trials
doxorubicin and paclitaxel plus G-CSF for, 3828-3834
exemestane for, 3418-3425
liposome-encapsulated doxorubicin for
with cyclophosphamide and fluorouracil, 1425-1434
high-dose, with G-CSF, 1435-1441
N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin for, 3431-3437
paclitaxel with or without amifostine for, 3038-3047
pretreated, docetaxel dose in, 1127-1131
prognostic factors for induction therapy and high-dose chemotherapy in, 3064-3074
qualitative PCR for detection of micrometastases, 870-879, 1330 (erratum)
untreated, paclitaxel *vs.* CMFP in, 2355-2364
using single agent or phase II agent before standard combination chemotherapy in, 1397-1406
Metastatic cervical cancer, paclitaxel and cisplatin chemotherapy in, 761-766
Metastatic colorectal carcinoma, pretreated, therapeutic regimens compared in, 2901-2908

Metastatic gastric cancer, irinotecan and cisplatin against, 319-323
Metastatic melanoma
chemoimmunotherapy for, 651-657
chemotherapy for, 968-975
concurrent biochemotherapy for, 2752-2761
Dartmouth regimen *vs.* dacarbazine in, 2745-2751
high-dose interleukin-2 treatment of, 2105-2116
survival in, psychosocial predictors of, 2256-2263, 3857-3858 (correspondence)
Metastatic prostate cancer, treatments for, quality of life and, 1654-1663
Metastatic renal cell cancer
autoimmunity and, 529-533, 1330 (erratum)
CD8+ tumor-infiltrating lymphocytes plus recombinant interleukin-2 in, phase III study, 2521-2529
nonmyeloablative allogeneic transplants in, 2044-2049
survival and prognostic stratification in, 2530-2540
switching between cytokine therapies in, 2039-2043
TNP-270 in, 2541-2545
Metastatic rhabdomyosarcoma, high-dose melphalan for, 2796-2803
Metastatic transitional cell carcinoma
long-term survival in, 3173-3181
surgical outcome after methotrexate-vinblastine-doxorubicin-cisplatin treatment in, 2546-2552
Methadone, and rapid switching from morphine to, in pain management, 3307-3312
Methotrexate-based chemotherapy, for primary CNS lymphoma, 1329 (correspondence)
Methotrexate toxicity, high-dose leucovorin as sole therapy for, 1589-1594
Methotrexate-vinblastine-doxorubicin-cisplatin, surgical outcome in metastatic transitional cell carcinoma after treatment with, 2546-2552
MIB-1 assays, of cellular proliferation in breast cancer, 470-477
Micrometastases
bone marrow, in prostate cancer, 3438-3443
qualitative PCR detection in breast cancer, 870-879, 1330 (erratum)
Micrometastatic tumor cells, detection in patients with solid tumors, 1535-1544
Midline granuloma, nasal NK cell lymphoma diagnosis, 1322-1325
Minorities, recruitment into clinical trials, pilot project, 1029-1039
Mitomycin-ifosfamide-cisplatin chemotherapy, for non-small-cell lung cancer
advanced, phase III trial, 3522-3530
unresectable, effects on survival and quality of life, 3188-3194
Mitomycin-vinblastine chemotherapy, for advanced breast cancer, docetaxel *vs.*, 1413-1424
Mitotic index, of cellular proliferation in breast cancer, 470-477
Mitoxantrone
for hormone-refractory prostate cancer, hydrocortisone with or without, 2506-2513, 3858-3859 (correspondence)
for metastatic prostate cancer, prednisone with, 1654-1663
MLL-ENL fusion, in childhood acute lymphoblastic leukemia, 191-196
Molecular remissions, in multiple myeloma, 208-215
Monoclonal antibody, anti-HER2, in metastatic breast cancer, 2639-2647
Moral issues, in *BRCA1/2* gene testing, 1595-1600
Morbidity
physical and psychological, after axillary lymph node dissection for breast cancer, 143-149
in prostatic cancer, conformal radiotherapy *vs.* iodine-125 implantation, 517-522
Morphine
and 5-HT_3 receptor agonists in patients with cisplatin-induced emesis, 1926-1930
and rapid switching to methadone, in pain management, 3307-3312
Mortality
and cancer control in susceptible groups, 719-725
in long-standing Zollinger-Ellison syndrome, 615-630
mRNA, human papillomavirus-specific, detection in peripheral blood of cervical cancer patients, 1391-1396
MUC-1 epitopes, expression on normal bone marrow, 1535-1544
Mucinous breast carcinoma, tumor characteristics and clinical outcome of, 1442-1448
Mucosa-associated lymphoid tissue lymphoma, nongastrointestinal low-grade, 1254-1258
Mucositis, stem-cell transplant-associated, 2446-2453
Multicycle high-dose chemotherapy, in high-risk breast cancer, 82-92
Multiple myeloma
molecular and clinical remissions in, 208-215
plasmablastic, survival prediction and, 1551-1557
with predominant phalangeal involvement, 1083-1084
refractory, autotransplantation for, 2173-2179
Multitargeted antifolate, combined with cisplatin, phase I and pharmacokinetic study, 3009-3016
Muscle, diffuse infiltration by granulocytic sarcoma, 1642-1643
Mutations, *BRCA1* and *BRC2* germline
breast cancer in carriers of, 3367-3370
prognostic differences, 3653-3663 (review)
hereditary breast cancer survival and, 3396-3402
in locally recurrent breast cancer, 3007-3008 (editorial), 3017-3024, 3689 (correspondence)
MX2-hydrochloride, in recurrent high-grade glioma, 2579-2584
Myalgias, taxane-induced, gabapentin for, 434 (correspondence)
MYCN-amplified neuroblastoma, long-term survivors of, 3216-3220
Myelodysplastic syndrome
after autologous BMT for non-Hodgkin's lymphoma, 3128-3135
after epipodophyllotoxin treatment, 569-577
marrow MRI in, 277-283
topotecan and cytarabine in, 2819-2830
Myelofibrosis, with myeloid metaplasia, 2954-2970
Myeloid metaplasia, myelofibrosis with, 2954-2970
Myoablative therapy, for follicular lymphoma, recurrence after, 216-221

Nasal NK cell lymphoma, 1322-1325
National Cancer Institute, cancer chemoprevention research, 53—62(Supp.)
National Cancer Institute of Canada Clinical Trials Group, CODE *vs.* CAV/EP for small-cell lung cancer, 2300-2308
National Coalition for Cancer Survivorship, 730 (correspondence)
National Surgical Adjuvant Breast and Bowel Project, adjuvant chemotherapy studies, Dukes' B *vs.* Dukes' C colon cancer, 1349-1355, 3553-3559
Nausea, chemotherapy-related, treatment costs, 344-351
Navelbine. *See* Vinorelbine *entries*
Neck cancer. *See* Head and neck cancer
Neoadjuvant androgen ablation therapy, and 3-D conformal radiotherapy for prostate cancer, 1326-1327 (correspondence)
Neoadjuvant chemotherapy
doxorubicin-based, in breast cancer patients, 460-469
for locally advanced breast cancer, quality of life and, 441-444
for malignant fibrous histiocytoma of bone, 3260-3269

Neoplasia
biology of
neuroblastoma, 2264-2279
Ras protein farnesyltransferase and, 3631-3652
role of *FHIT* in human cancer, 1618-1624
and cancer vaccines, 1047-1060
and dysregulation of apoptosis, 2941-2953
Nephron-sparing surgery, for renal cell carcinoma, 2868-2875
Nerve growth factor, expression in pancreatic cancer, 2419-2428
Neuroblastoma
molecular biology of, 2264-2279
MYCN-amplified, long-term survivors of, 3216-3220
pediatric, treatment research protocols for, institutional review board and, 2625-2626 (correspondence)
refractory and relapsed, oral etoposide for, 3221-3225
screening in infants at 1 year, 1200-1207
Neurocognitive development, after cerebellar tumor in infancy, 3476-3486
Neurodevelopmental outcome, in pediatric medulloblastoma, 3720-3728
Neuroendocrine tumors, gastrointestinal, prolonged-release lanreotide for, 1111-1117
Neutropenia
in breast cancer, granulocyte colony-stimulating factor effect on, 3025-3032
erythropoietin added to G-CSF abrogates for, 1288-1295
febrile
GM-CSF in, 3002 (correspondence)
pneumonia in, 796-805, 3856 (correspondence)
Hickman catheter-related infections in, 1304-1311
Nevoid malignant melanoma, of breast, 3850-3852
Nicotinamide, with accelerated radiotherapy and carbogen in glioblastoma multiforme, 3143-3149
Non-Burkitt's lymphoma, small noncleaved, cytogenetics and outcome prediction in, 1558-1567
Non-Hodgkin's lymphoma
autologous stem-cell transplantation in, 3003 (correspondence)
B-cell, Rituxan and CHOP treatment for, 268-276
bulky, rituximab phase II trial in, 1851-1857
CD20-negative relapse after ^{131}I-anti-CD20 therapy for, 3692-3693 (correspondence)
combination chemotherapy for transplant-eligible patients with, 3776-3785
expression of beta-integrin adhesion molecules in, 1869-1875
high-dose chemotherapy with stem cell transplantation in, 423-429
localized primary
of bone in children, 456-459
of the patella, 1640-1642
myelodysplastic syndrome after autologous BMT for, 3128-3135
oral fludarabine phosphate pharmacokinetics in, 1574-1579
relapsed or refractory
gemcitabine therapy for, 3786-3792
IDEC-Y2B8 radioimmunotherapy for, phase I/II trial, 3793-3803
response criteria for, standardization of, 1244-1253
Non-small-cell lung cancer
acrometastases and, 2998-3001
advanced, chemotherapy for, 734-735 (correspondence)
carboplatin-docetaxel-gemcitabine, phase II study, 3816-3821
cisplatin-gemcitabine-paclitaxel, phase I/II study, 2316-2325
docetaxel-gemcitabine, 914-920
gemcitabine, phase II trial, 2081-2085
multitargeted antifolate LY231514, 1194-1199
regimens compared, phase III trial, 3522-3530
apoptotic index in, 2728-2736
combined paclitaxel and carboplatin in, 676-684
FDG-PET prognostic significance in, 3201-3206
gemcitabine-carboplatin therapy in, 921-926
gemcitabine/paclitaxel pharmacologic interactions in, 2190-2197
irinotecan plus cisplatin in, 2710-2720
liposomal doxorubicin and radiotherapy for, 3512-3521
locally advanced, gemcitabine-cisplatin *vs.* etoposide-cisplatin treatment in, 12-18
prophylactic cranial irradiation in, after multimodality treatment, 2700-2709
radiotherapy and chemotherapy in, 2692-2699
stage I
resected, K-*ras* mutations in, 668-675
smoking and survival in, 2086-2091
stage II, resected, K-*ras* mutations in, 668-675
stage III
trimodality therapeutic approach in, 1185-1193
unresectable, radiosensitization with carboplatin for, 4-11
stage IIIB or IV, maximum-tolerated doses in, phase I/II study, 3195-3200
surgically resected
K-*ras* mutations in, 668-675
lymphatic tumor cell dissemination in, 19-24
survivin as prognosis marker in, 2100-2104
tubulin mutations altering paclitaxel resistance in, 1786-1793
unresectable, survival and quality of life in, 3188-3194
Nonmyeloablative allogeneic transplants, in metastatic renal cell carcinoma, 2044-2049
Nonrhabdomyosarcoma soft tissue sarcoma, pediatric resected, prognostic factors in, 3697-3705
Nuclear morphometry, in Wilms' tumor, 2123-2126
Nucleoside analogs, and secondary malignancies, 2454-2460

Obituary. *See In Memoriam*
Octreotide acetate, long-acting formulation *vs.* subcutaneous administration, in malignant carcinoid syndrome, 600-606
Oligoastrocytoma, anaplastic, temozolomide in, 2762-2771
Oncogenes. *See HER2* oncogene; Proto-oncogene
Oncology care, alternative and complementary therapies, 35—37(Supp.), 38—43(Supp.)
Oncology patients. *See* Cancer patients/survivors
Operating theater, Hickman catheter-related infections in neutropenic patients, 1304-1311
Orchiectomy, gonadal function in testicular cancer patients before, 941-947
Osteosarcoma
*erb*B-2 expression in, 2781-2788
secondary, combined modality treatment for, 1164-1174
Outcome(s)
in acute lymphoblastic leukemia in infants, 445-455
in breast cancer
biologic predictors of, 3058-3063
postmenopausal women undergoing hormone replacement therapy, 1680-1688
prediction methods for, 1474-1481
stage IIIB inflammatory, 2006-2014
telomerase activity and, 3075-3081
tubular type, 1442-1448

in colorectal cancer, thymidylate synthase predicting, 1760-1770
of desmoid tumor after radiotherapy, 158-167
of mechanical ventilation, 991-997
in metastatic transitional cell carcinoma, 2546-2552, 3173-3181
in pediatric patients
after treatment for soft tissue sarcoma, 3706-3719
with medulloblastoma, 3720-3728
of prolonged-release lanreotide for gastrointestinal neuroendocrine tumors, 1111-1117
quality-of-care, in oncology practice, measurement of, 2614-2622, 3859 (correspondence)
in recurrent glioma, phase II trial, 2572-2578
in small noncleaved non-Burkitt's lymphoma, 1558-1567
in soft tissue sarcoma, 150-157
involving extremities and trunk, 3252-3259
stage IIB, 2772-2780
surgical, after methotrexate-vinblastine-doxorubicin-cisplatin treatment in metastatic transitional cell carcinoma, 2546-2552
Ovarian cancer
advanced
apoptosis-related factors in, 2061-2068
docetaxel and cisplatin for, 2069-2080
ET-Carbo chemotherapy trial in, 46-51
BRCA1 and *BRCA2* testing in, 1040-1046
combination chemotherapy in, 741-743 (editorial)
paclitaxel, cisplatin, and topotecan regimen, 747-755
cytoreduction in, 3003-3004 (correspondence)
epithelial
docetaxel and cisplatin for, 2069-2080
measuring CA-125 response to platinum or paclitaxel in, 501-508
stage IV, natural history of, 767-775, 3361-3362 (correspondence)
pretreated, topotecan infusion in, 2553-2561
Ovarian dysgerminoma, reproductive function after chemotherapy for, 2670-2675
Oxaliplatin with irinotecan, for gastrointestinal cancer, phase I studies with pharmacokinetics, 1751-1759
Oxycodone, controlled-release, 738 (correspondence)

p21, prognostic significance in endometrial cancer, 1382-1390
P21 and P27 protein expression, in laryngeal squamous cell carcinoma, 3150-3159
p53
in advanced ovarian cancer, 2061-2068
genetic changes in colorectal cancer, 593-599
prognostic significance of
in endometrial cancer, 1382-1390
in resected hepatic metastases of colorectal cancer, 1364-1374
and tumor aggressiveness in colorectal cancer, 1375-1381
*p*120 expression, in lung adenocarcinoma, 2721-2727
Paclitaxel-carboplatin regimen
in non-small-cell lung cancer, 676-684
in resistant small-cell lung cancer, 927-932
Paclitaxel-cisplatin regimen
for cervical carcinoma, 2676-2680
for metastatic and recurrent cervical cancer, 761-766
Paclitaxel-cisplatin-topotecan regimen, for ovarian cancer, 747-755
Paclitaxel-doxorubicin-cyclophosphamide regimen, for resectable high-risk breast cancer, 93-100
Paclitaxel-doxorubicin regimen, for breast cancer
dose-escalation study, 880-886
with G-CSF, phase II trial, 3828-3834
Paclitaxel-epirubicin-carboplatin regimen, for advanced ovarian cancer, phase I/II trial, 46-51
Paclitaxel resistance, in non-small-cell lung cancer, 1786-1793
Paclitaxel therapy
for breast cancer
cost analysis in, 3081-3090
effects on epirubicin metabolism in, 1132-1140
3-hour *vs.* 24-hour high-dose infusion in, 3403-3411
vs. combination neoadjuvant therapy, 3412-3417
for epithelial ovarian cancer, measuring CA-125 response to, 501-508
for Kaposi's sarcoma, 1876-1883
for malignant solid tumors, fluoropyrimidine capecitabine with, phase I and pharmacokinetic study, 1897-1905
for non-small-cell lung cancer, and gemcitabine pharmacologic interactions, 2190-2197
with or without amifostine for metastatic breast cancer, phase II study, 3038-3047
vs. CMFP in untreated metastatic breast cancer, 2355-2364
Paclitaxel-vinorelbine regimen, for metastatic breast cancer, 74-81
with G-CSF, 1407-1412
Pain management
evaluation measures in cancer patients, 1280-1287
guidelines for, 361-370
in pancreatic cancer, nerve growth factor and *TrkA* and, 2419-2428
rapid switching from morphine to methadone in, 3307-3312
Palliative chemotherapy, for colorectal cancer in elderly, 2412-2418
Pamidronate, and bone lesions in breast cancer, 846-854
Pancreatic cancer
advanced, gemcitabine and concurrent radiation in, 2208-2212, 3692 (correspondence)
gemcitabine-fluorouracil chemotherapy for, 585-592
mutant DNA in plasma of patients with, 578-584
nerve growth factor and *TrkA* in, 2419-2428
Patella
localized primary non-Hodgkin's lymphoma of, 1640-1642
metastatic lung adenocarcinoma to, 2995-2997
Patient anxiety, strategy for reducing, 371-379
Patient satisfaction, questionnaire measuring, 1931-1938
PBSC. *See* Peripheral-blood stem-cell transplantation
PCR. *See* Polymerase chain reaction
PDGF-R. *See* Platelet-derived growth factor receptor, inhibition of
Pediatric Oncology Group
isolated CNS relapse of ALL, improved survival of, 3745-3754
localized primary non-Hodgkin's lymphoma of bone, 456-459
nonrhabdosarcomatous soft tissue sarcomas, 1219-1226
Q-TWiST analysis in acute myeloid leukemia, 2144-2152
resection for children with immature teratomas, 2137-2143
Pediatric patients. *See* Children
PEG-1000, in adult patients with solid tumors, 2219-2226
Pentoxifylline, for radiation-induced fibrosis, regression and, 3283-3290
Peripheral-blood progenitor cell support
filgrastim-mobilized
high- *vs.* standard-dose, 2160-2172
in high-risk breast cancer, 82-92
in metastatic renal cell carcinoma, 2044-2049
multiple cycles of high-dose chemotherapy with, phase I trial, 2198-2207
Peripheral-blood stem-cell transplantation
allogeneic, long-term follow-up in, 806-812

high-dose chemotherapy with, effect of CD34+ cell dose after, 1227-1233
PET. *See* Positron emission tomography
Phalangeal involvement, multiple myeloma with, 1083-1084
Pharmacodynamics
c-*raf*-1 antisense oligonucleotide, 2227-2236
combined paclitaxel and carboplatin in non-small-cell lung cancer, 676-684
gemcitabine/paclitaxel interactions in non-small-cell lung cancer, 2190-2197
hydroxyurea-fluorouracil-interferon alfa-2a for gastrointestinal cancer, phase II trial, 1771-1778
RSR13 in glioblastoma multiforme, phase I trial, 2593-2603
topotecan infusion in pretreated ovarian cancer, 2553-2561
Pharmacokinetics
c-*raf*-1 antisense oligonucleotide, 2227-2236
combined paclitaxel and carboplatin in non-small-cell lung cancer, 676-684
continuous infusion
of 9-aminocamptothecin for advanced solid tumors, 1897-1905
of irinotecan for malignant solid tumors, 1897-1905
fludarabine phosphate oral doses, in non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia, 1574-1579
fluoropyrimidine capecitabine and paclitaxel for malignant solid tumors, 1897-1905
fluorouracil biomodulation in tumors, normal tissue, and plasma, 1580-1588
gemcitabine/paclitaxel interactions in non-small-cell lung cancer, 2190-2197
multitargeted antifolate combined with cisplatin, 3009-3016
oral irinotecan in patients with solid tumors, 685-696
oxaliplatin with irinotecan for gastrointestinal cancer, phase I studies, 1751-1759
RSR13 in glioblastoma multiforme, phase I trial, 2593-2603
temozolomide in advanced solid malignancies, 2604-2613
Pharmacology
cisplatin and carboplatin compared, 409-422
oral 9-aminocamptothecin in adult patients with solid tumors, 2219-2226
13-*cis*-retinoic acid, interferon alfa, and paclitaxel in advanced malignancy, 2213-2218
Phase I trials
avipox recombinant vaccine in cancer patients, 332-337
c-*raf*-1 antisense oligonucleotide, 2227-2236
combined paclitaxel and carboplatin in non-small-cell lung cancer, 676-684
continuous infusion
of 9-aminocamptothecin for advanced solid tumors, 1897-1905
of irinotecan for malignant solid tumors, 1897-1905
fluoropyrimidine capecitabine and paclitaxel for malignant solid tumors, 1897-1905
gene therapy for breast cancer, 2180-2189
ISIS 3521 evaluation in advanced cancer, 3586-3595
liposomal vincristine, 697-705
multiple cycles of high-dose chemotherapy with peripheral-blood progenitor cell support, 2198-2207
multitargeted antifolate combined with cisplatin, 3009-3016
oral 9-aminocamptothecin in adult patients with solid tumors, 2219-2226
oral irinotecan in patients with solid tumors, 685-696
13-*cis*-retinoic acid, interferon alfa, and paclitaxel in advanced malignancy, 2213-2218
RSR13 in glioblastoma multiforme, 2593-2603
temozolomide in advanced solid malignancies, 2604-2613
Phase I/II trials
cisplatin-gemcitabine-paclitaxel in advanced non-small-cell lung cancer, 2316-2325
ET-Carbo chemotherapy in advanced ovarian cancer, 46-51
gemcitabine and fluorouracil in pancreatic cancer, 585-592
gene transfer therapy in advanced malignancy, 3313-3323
IDEC-Y2B8 radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma, 3793-3803
in non-small-cell lung cancer, maximum-tolerated doses in, 3195-3200
radiation with chemotherapy in advanced squamous cell carcinomas of head and neck, 2390-2395
Phase II trials
carboplatin-docetaxel- gemcitabine chemotherapy in advanced non-small-cell lung cancer, 3816-3821
chemotherapy for small-cell lung cancer in elderly patients, 3540-3545
cisplatin and gemcitabine for malignant mesothelioma, 25-30, 2626-2627 (correspondence)
cisplatin-gemcitabine-vinorelbine in non-small-cell lung cancer, 1526-1534
CJ-11,974 for cisplatin-induced emesis, 338-343
combination chemotherapy for hormone-refractory prostate cancer, 1664-1671
docetaxel and G-CSF for pancreatic cancer, 1779-1785
doxorubicin and paclitaxel plus G-CSF in metastatic breast cancer, 3828-3834
exemestane for metastatic breast cancer, 3418-3425
fludarabine phosphate, 546-553
FOLFOX3/4 for pretreated colorectal cancer, 3560-3568
gemcitabine
for advanced non-small-cell lung cancer, 2081-2085
for refractory germ cell tumors, 509-511
hydroxyurea-fluorouracil-interferon alfa-2a for gastrointestinal cancer, 1771-1778
irinotecan and cisplatin
for advanced esophageal cancer, 3270-3275
against metastatic gastric cancer, 319-323
irinotecan in cervical cancer, 3136-3142
metastatic breast cancer
BR96-doxorubicin conjugate, 478-484
high-dose liposome-encapsulated doxorubicin with G-CSF, 1435-1441
liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil, 1425-1434
paclitaxel-refractory, capecitabine in, 485-493
N,N-diethyl-2-[4-(phenylmethyl)phenoxy]ethanamine.HCl and doxorubicin in metastatic breast cancer, 3431-3437
oral platinum drug JM216 for small-cell lung cancer, 3822-3827
outcome and prognostic factors in recurrent glioma, 2572-2578
paclitaxel with or without amifostine for metastatic breast cancer, 3038-3047
prostate-specific antigen in androgen independent prostate cancer, 3461-3467
rituximab efficacy in bulky non-Hodgkin's lymphoma, 1851-1857
squamous cell carcinoma of head and neck, phase II trial, 3503-3511

Phase III trials
carboplatin radiosensitization in stage III unresectable non-small-cell lung cancer, 4-11
CD8+ tumor-infiltrating lymphocytes plus recombinant interleukin-2 in metastatic renal cell cancer, 2521-2529
cisplatin-dacarbazine-carmustine with or without tamoxifen in malignant melanoma, 1884-1890
extensive-stage small-cell lung cancer, 1794-1801
megestrol acetate for advanced breast cancer
dose-response, 64-73
vorozole *vs.*, in postmenopausal patients, 52-63
vinblastine *vs.* vinblastine plus estramustine phosphate in hormone-refractory prostate cancer, 3160-3166
Phenylacetate, for recurrent malignant glioma, 984-990
Philadelphia chromosome, early chronic CML positive for, treatment of, 284-292
N-Phosphonacetyl-L-aspartate, plasma fluorouracil biomodulation with, 1580-1588
Physician-assisted suicide, views on, 1274-1279
Physicians
communication with patient in clinical trials, 3324-3332
views on physician-assisted suicide and euthanasia, 1274-1279
Pilot study
combination *vs.* sequential chemotherapy in breast cancer, 3033-3037
minority recruitment into ECOG clinical trial, 1029-1039
PIXY321. *See* Granulocyte colony-stimulating factor
Placebo-controlled trial, of genetic markers in high risk population, 3546-3552
Plasmablastic multiple myeloma, survival prediction in, 1551-1557
Platelet-derived growth factor receptor, inhibition of, 1093-1094 (editorial)
Platinum, for epithelial ovarian cancer, measuring CA-125 response to, 501-508
PNET (primitive neuroectodermal tumor), pediatric, leptomeningeal disease in, 3234-3237
Pneumonia, in febrile neutropenia, 796-805, 3856 (correspondence)
POG. *See* Pediatric Oncology Group
Polymerase chain reaction. *See also* Qualitative polymerase chain reaction; Reverse transcriptase polymerase chain reaction
Epstein-Barr virus DNA, in diagnosis of AIDS-related primary CNS lymphoma, 554-560
with tyrosinase and MART-1 in melanoma, 2562-2571
Pooled analyses, separate clinical trials, 1336-1338 (editorial)
Positron emission tomography
[^{18}F]-2-fluoro-2-deoxy-D-glucose
for metastatic bone disease detection in breast cancer, 2381-2389
nodal metastasis evaluation in locally advanced cervical cancer, 31-40
prognostic importance in non-small-cell lung cancer, 3201-3206
of recurrent colorectal cancer, 894-901
of sentinel nodes in melanoma, 1508-1515
in seminoma patients, 3457-3460
Postmenopausal women, advanced breast cancer in
letrozole *vs.* megestrol acetate, 3859-3860 (correspondence)
vorozole *vs.* megestrol acetate therapy for, 52-63
Prednisone, for metastatic prostate cancer, quality of life and, 1654-1663
Pregnancy, management of breast cancer during, 855-861
Preoperative chemotherapy. *See* Neoadjuvant chemotherapy
Prevention, breast cancer, commentary on clinical trial, 1632-1639
Primary breast cancer, axillary lymph node metastasis in, 2334-2340, 3365 (erratum)
Primary CNS lymphoma, methotrexate-based chemotherapy for, 1329 (correspondence)
Primary ectopic intracranial retinoblastomas, hereditary retinoblastoma associated with, 1829-1837
Primitive neuroectodermal tumor, pediatric, leptomeningeal disease in, 3234-3237
Princess Margaret Hospital, patient satisfaction questionnaire from, 1931-1938
Procarbazine and tamoxifen, in recurrent glioblastoma, 645-650
Procarbazine-lomustine-vincristine regimen, for anaplastic astrocytoma, 3389-3395
Prognostic factors
in desmoid tumor, 158-167
FDG-PET uptake in non-small-cell lung cancer, 3201-3206
in Hodgkin's disease
early-stage, 3577-3585
laparotomy and, 241-252
mantle radiotherapy and, 230-240
for induction therapy and high-dose chemotherapy in metastatic breast cancer, 3064-3074
in infant ALL, 445-455
in long-standing Zollinger-Ellison syndrome, 615-630
for medulloblastoma in children, 832-845
in metastatic renal cell cancer, 2530-2540
in metastatic transitional cell carcinoma, 3173-3181
mutant DNA in plasma of pancreatic cancer patients, 578-584
in myelodysplastic syndromes, femoral marrow MRI and, 277-283
in occult melanoma metastases detection, 3238-3244
p53 genetic changes in colorectal cancer, 593-599
in recurrent glioma, phase II trial, 2572-2578
in soft tissue sarcoma, 150-157
resected nonrhabdomyosarcomatous, in children, 3697-3705
survivin in non-small-cell lung cancer, 2100-2104
in Wilms' tumor, 2123-2126
Prostate cancer
androgen-independent
bone scan index for, 948-957
docetaxel-estramustine therapy for, 958-967
androgen independent, prostate-specific antigen in, phase II trial, 3461-3467
bicalutamide *vs.* maximal androgen patient blockade in, 2027-2038
bone marrow micrometastases in, 3438-3443
early-stage, conformal radiotherapy *vs.* transperineal permanent iodine-123 implantation for, 517-522
extracapsular extension in, 3167-3172
hormone-refractory
combination chemotherapy for, phase II trial, 1664-1671
hydrocortisone with or without mitoxantrone, 2506-2513, 3858-3859 (correspondence)
PSA doubling time as surrogate end point in, 1645-1646 (correspondence)
vinblastine *vs.* vinblastine plus estramustine phosphate in, phase III trial, 3160-3166
locally advanced, treatment of, 3664-3675 (review)
management methods, 3371-3373 (editorial)
metastatic, treatments for, 1654-1663
Neoadjuvant androgen ablation therapy and 3-D conformal radiotherapy for, 1326-1327 (correspondence)
postoperative nomogram for disease recurrence in, 1499-1507

PSA recurrence prediction after treatment for, 168-172
quality of life in, 1654-1663, 2882-2888
radiation therapy guidelines in, 1155-1163
13-*cis*-retinoic acid, interferon alfa, and paclitaxel in, phase I trial, 2213-2218
salvage cryotherapy in, patient selection for, 2514-2520
Prostate-specific antigen
after radical prostatectomy
predicting recurrence, 168-172
radiation therapy guidelines and, 1155-1163
in androgen independent prostate cancer, phase II trial, 3461-3467
decline after low-dose megestrol acetate withdrawal, 1087-1088 (correspondence)
doubling time as surrogate end point in hormone- refractory prostate cancer, 1645-1646 (correspondence)
Prostatectomy, radical
extracapsular extension after, 3167-3172
prostate cancer recurrence after, 1499-1507
radiation therapy guidelines after, 1155-1163
Proteases, as risk factor after local breast cancer recurrence, 1449-1457
Proto-oncogene, *RET*, in human cancer development, 380-393
PSA. *See* Prostate-specific antigen
PSC-833, for acute myeloid leukemia, cytarabine-daunorubicin-etoposide regimen and, 2831-2839
Psychosocial predictors, of survival in metastatic melanoma, 2256-2263, 3857-3858 (correspondence)
Pulmonary function, after combined treatment for breast cancer and lymphoma, 3091-3100
Purine analog conditioning regimens, prior to allogeneic transplantation, 1958-1960 (correspondence)

Q-PCR. *See* Qualitative polymerase chain reaction
QOL. *See* Quality of life
Qualitative polymerase chain reaction, for micrometastases detection in breast cancer, 870-879, 1330 (erratum)
Quality-of-care outcomes, in oncology practice, 2614-2622, 3859 (correspondence)
Quality of life
in advanced cancer
colorectal, 1644 (correspondence)
measurement of, 3603-3611
assessment instruments, 738-740 (correspondence)
in advanced cancer, 3603-3611
comparisons, 2932-2940
paper *vs.* touch-screen questionnaires, 998-1007
in breast cancer
locally advanced, neoadjuvant chemotherapy for, 441-444
in postmenopausal women undergoing endocrine therapy, 1672-1679
tamoxifen for prevention and, 2659-2669
in head and neck cancer, 352-360
chemoradiotherapy and, 1020-1028
questionnaire validation, 1008-1019
during inhaled interleukin-2 immunotherapy, 3612-3620
in prolonged-release lanreotide for gastrointestinal neuroendocrine tumors, 1111-1117
in prostate cancer, 1654-1663, 2882-2888
metastatic, treatments for, 1654-1663
science, language, intuition, and, 1651-1653 (editorial), 2293 (correspondence)
and stem-cell transplantation, 706-718
in unresectable non-small-cell lung cancer, 3188-3194
venous access ports in cancer patients, 1267-1273
Questionnaire(s)
on patient satisfaction, 1931-1938
in quality of life assessment, 998-1007
in head and neck cancer, 1008-1019

Radiation-induced fibrosis, pentoxifylline and tocopherol treatment of, 3283-3290
Radiation therapy. *See* Radiotherapy
Radical prostatectomy
extracapsular extension after, 3167-3172
prostate cancer recurrence after, 1499-1507
radiation therapy guidelines after, 1155-1163
Radioimmunotherapy, for relapsed or refractory non-Hodgkin's lymphoma, phase I/II trial, 3793-3803
Radiology suite, Hickman catheter-related infections in neutropenic patients, 1304-1311
Radiosensitization
with BrDu in advanced cervical cancer, 31-40
with carboplatin in non-small-cell lung cancer, 4-11
clinical trials in, 1-3 (editorial)
Radiotherapy. *See also* Radiosensitization
for advanced breast cancer, 887-893
ASCO guidelines for use of, 3333-3355
associated with malignancy after Hodgkin's disease, *ATM* gene and, 1259-1266
BRCA1 and *BRC2* germline mutations in locally recurrent breast cancer after, 3007-3008 (editorial), 3017-3024, 3689 (correspondence)
with chemotherapy
for advanced squamous cell carcinomas of head and neck, 2390-2395
after resection in rhabdomyosarcoma, 3468-3475
for cervical cancer, 1334-1335 (editorial), 1339-1348
for head and neck cancer, 638-644
for CNS germ cell tumors, 933-940
desmoid tumor after, prognostic factors and outcome for, 158-167
erectile dysfunction after, sildenafil for, 3444-3449
for extensive-stage small-cell lung cancer, in combined-modality treatment of, 2092-2099
for glioblastoma multiforme, with carbogen and nicotinamide in, 3143-3149
for head and neck cancer
and liposomal doxorubicin, 3512-3521
for Hodgkin's disease, 230-240
for intracranial germinoma, prospective trial, 2585-2592
for medulloblastoma in children, 2127-2136
for non-small-cell lung cancer
concurrent *vs.* sequential, 2692-2699
and liposomal doxorubicin, 3512-3521
for pancreatic cancer, concurrent with gemcitabine, 2208-2212, 3692 (correspondence)
for prostate cancer
early stage, 517-522
guidelines for use of, 1155-1163
PSA recurrence prediction after, 168-172
for rectal cancer, 2398-2402
for seminoma, optimal field size in, 1146-1154
for supraglottic carcinoma, computed tomography prior to, 631-637
c-*raf*-1 antisense oligonucleotide, phase I trial, 2227-2236

Raloxifene, for breast cancer, ASCO risk reduction assessment, 1939-1955
Ras protein farnesyltransferase, in biology of neoplasia, 3631-3652
RAS signaling pathways, and leukemia, 1071-1079
Receptor-positive breast cancer, low-dose chemotherapy and tamoxifen trial in, 1701-1709
Rectal cancer
  early low, decision analysis for management of, 312-318
  preoperative radiotherapy in, 2398-2402
Recurrent breast cancer, *BRCA1* and *BRC2* germline mutations in, 3007-3008 (editorial), 3017-3024, 3689 (correspondence)
Recurrent cervical cancer, paclitaxel and cisplatin chemotherapy in, 761-766
Recurrent colorectal cancer, whole-body FDG-PET in, 894-901
Recurrent endometrial cancer, oral medroxyprogesterone acetate for, 1736-1744
Recurrent glioma
  high-grade, KRN8602 in, 2579-2584
  outcome and prognostic factors in, phase II trial, 2572-2578
Recurrent malignant glioma
  irinotecan therapy for, 1516-1525
  phenylacetate for, 984-990
Recurrent prostate cancer, salvage cryotherapy in, patient selection for, 2514-2520
Refractory cancer/malignancies. *See* Advanced cancer/malignancies
Refractory germ cell tumors, gemcitabine in, 509-511
Refractory Hodgkin's disease, autologous stem-cell transplantation for, 534-545, 3101-3109
  in children and adolescents, 825-831
Refractory multiple myeloma, autotransplantation for, 2173-2179
Refractory neuroblastoma, oral etoposide for, 3221-3225
Refractory testicular cancer, gemcitabine in, 512-516
Relapsed Hodgkin's disease
  autologous hematopoietic stem-cell transplantation in children and adolescents, 825-831
  gemcitabine in, 2627-2628 (correspondence)
Relapsed neuroblastoma, oral etoposide for, 3221-3225
Relapsed non-Hodgkin's lymphoma, gemcitabine in treatment of, 3786-3792
Relapsed testicular cancer, gemcitabine in, 512-516
Remission(s)
  in childhood ALL, allogeneic BMT *vs.* chemotherapy in, 197-207
  In chronic myelogenous leukemia, donor lymphocyte infusion for, 561-568
  in multiple myeloma, molecular and clinical, 208-215
Renal cell cancer
  advanced, treatment options for, 2859-2867
  metastatic
    autoimmunity and, 529-533, 1330 (erratum)
    CD8+ tumor-infiltrating lymphocytes plus recombinant interleukin-2 in, phase III study, 2521-2529
    nonmyeloablative allogeneic transplants in, 2044-2049
    survival and prognostic stratification in, 2530-2540
    switching between cytokine therapies in, 2039-2043
    TNP-270 in, 2541-2545
  sarcomatoid, immunotherapy in, 523-528
Reproductive function
  after chemotherapy for ovarian dysgerminoma, 2670-2675
  in cancer patients/survivors, 2631-2632 (editorial)
Research protocols, in neuroblastoma treatment, institutional review board and, 2625-2626 (correspondence)
Resection
  of immature teratomas in children, 2137-2143
  in rhabdomyosarcoma, radiotherapy and chemotherapy after, 3468-3475
  in stage I breast cancer, 2326-2333
Residual disease, in multiple myeloma, 208-215
Response criteria, for non-Hodgkin's lymphoma, standardization of, 1244-1253
RET proto-oncogene, in human cancer development, 380-393
Retinoblastoma
  extraocular, idarubicin response in children, 1847-1850
  trilateral, meta-analysis of, 1829-1837
Reverse transcriptase polymerase chain reaction
  detection of circulating melanoma cells, as marker for tumor progression, 304-311
  for mammaglobin mRNA detection, 2015-2019
  occult melanoma metastases detection by, 3238-3244
Rhabdomyosarcoma
  in children and adolescents, survival after relapse in, 3487-3493
  of genital tract in girls, 2117-2122
  high-dose melphalan for, 2796-2803
Rituxan, for B-cell non-Hodgkin's lymphomas, 268-276
Rituximab therapy
  for bulky non-Hodgkin's lymphoma, phase II trial in, 1851-1857
  for chronic lymphocytic leukemia in elderly, 1962-1963 (correspondence)
  for hematologic malignancy, 791-795
RSR13, in glioblastoma multiforme, phase I trial, 2593-2603
RT-PCR. *See* Reverse transcriptase polymerase chain reaction

S100-beta, monitoring in AJCC stage IV melanoma, 1891-1896
Salvage cryotherapy, in prostate cancer, patient selection for, 2514-2520
Sarcoma
  *erb*B-2 expression in osteosarcoma, 2781-2788
  Ewing's. *See* Ewing's sarcoma
  granulocytic, diffuse muscle infiltration by, 1642-1643
  soft tissue. *See* Soft tissue sarcoma
Sarcomatoid renal cell carcinoma, immunotherapy in, 523-528
Scintigraphy, for anthracite cardiotoxicity detection in children, 1208-1211
SCLC. *See* Small-cell lung cancer
Screening
  for endometrial cancer in patient receiving tamoxifen for breast cancer, 1967-1968 (editorial), 2050-2054
  neuroblastoma in infants, 1200-1207
  protocols for *BRCA1/2* in Ashkenazi Jewish women, benefits and costs of, 494-500
  risk-based mammography, 735-738 (correspondence)
Secondary leukemia, after epipodophyllotoxin treatment, 569-577
Secondary malignancy
  in Hodgkin's disease, *ATM* gene and, 1259-1266
  nucleoside analogs and, 2454-2460
Secondary osteosarcoma, combined modality treatment for, 1164-1174
Sector resection, in stage I breast cancer, 2326-2333
Semen quality, before orchiectomy in testicular cancer patients, 941-947
Seminoma
  positron emission tomography scans in, 3457-3460
  radiation therapies compared, 3004-3005 (correspondence)
  optimal field size for, 1146-1154
Sentinel lymph node status, in melanoma, 976-983

Sentinel lymphadenectomy, occult melanoma metastases detection by, 3238-3244
Sentinel nodes
biopsy with metastasis, in breast cancer patients, 1720-1726
FDG-PET imaging in melanoma, 1508-1515
Sex differences, in acute lymphoblastic leukemia, 818-824
Sexual functioning, in breast cancer, effects of tamoxifen on, 1488-1492, 3689-3690 (correspondence)
Sexual health, predictors after breast cancer diagnosis, 2371-2380
Sexuality, tamoxifen and, 3689-3690 (correspondence)
Signaling pathways, delineation of, 1093-1094
Signet ring lymphoma, of bone marrow, 728-729
Sildenafil, for postradiotherapy erectile dysfunction, 3444-3449
Single-photon emission computed tomography
in children receiving ara-C, 2804-2810
in diagnosis of AIDS-related primary CNS lymphoma, 554-560
Skin. *See also* Malignant melanoma
in chronic lymphocytic leukemia, 1084-1095
malignant lesions of, 3850-3855
lymphoepithelioma-like carcinoma, 3853-3855
nevoid malignant melanoma, 3850-3852
multifocal B-cell lymphoma of, treatment for, 2471-2478
T-cell lymphoma and, pentostatin therapy for, 3117-3121
Small-cell lung cancer
chemotherapy for
dose-intensity increases in, 2297-2299 (editorial)
in elderly patients, phase II trial, 3540-3545
high-dose, 3531-3539
extensive-stage
cisplatin-etoposide-paclitaxel for, 2309-2315
CODE *vs.* CAV/EP for, 2300-2308
combined-modality treatment of, role of radiation therapy in, 2092-2099
phase III trials, 1794-1801
limited-stage, dose-intensive therapy for, 1175-1184
metalloproteinases and their tissue inhibitors in, expression and prognostic significance of, 1802-1808
oral platinum drug JM216, phase II study, 3822-3827
recurrent, topotecan *vs.* cyclophosphamide-doxorubicin-vincristine for, 658-667
resistant, paclitaxel-carboplatin regimen in, 927-932
twice-daily split-course *vs.* once-daily thoracic irradiation for, 2681-2691
Small intestinal disease, immunoproliferative, 3682-3684
Small noncleaved non-Burkitt's lymphoma, cytogenetics and outcome prediction in, 1558-1567
Socioeconomic status, and cancer survival, 2244-2255
Soft tissue sarcoma, 3695-3696
advanced, prognostic factors in, 150-157
long-term outcomes in
involving extremities and trunk, 3252-3259
stage IIB, 2772-2780
pediatric
nonrhabdosarcomatous
prognostic factors in, 3697-3705
role of adjuvant chemotherapy in, 1219-1226
treatment results in, 3706-3719
Solid tumors
advanced
continuous infusion 9-aminocamptothecin for, phase I and pharmacokinetic study, 1906-1914
SU101 tyrosine inhibitor phase I trial, 1095-1104
9-aminocamptothecin in adult patients with, phase I study, 2219-2226
irinotecan in patients with, 685-696
malignant
continuous infusion irinotecan for, phase I and pharmacokinetic study, 1897-1905
oral fluoropyrimidine capecitabine and paclitaxel for, phase I and pharmacokinetic study, 1915-1925
temozolomide in phase I and pharmacokinetic study, 2604-2613
micrometastatic tumor cell detection in patients with, 1535-1544
venous access ports for chemotherapy in patients with, 1267-1273
Solitary bone metastases, lung cancer presenting with
acrometastases, 2998-3001
patella, 2995-2997
Southern Italy Cooperative Oncology Group, cisplatin-gemcitabine-vinorelbine combination therapy in non-small-cell lung cancer, 1526-1534
Southwest Oncology Group
chemotherapy with radiation therapy in cervical cancer, 1339-1348
CODE *vs.* CAV/EP for small-cell lung cancer, 2300-2308
melphalan with autotransplantation for refractory multiple myeloma, 2173-2179
SPECT. *See* Single-photon emission computed tomography
Squamous cell carcinoma(s)
cervical, irinotecan in, phase II study, 3136-3142
of head and neck
advanced, radiation with chemotherapy in, 2390-2395
combination chemotherapy for, phase II trial, 3503-3511
laryngeal, p21 and p27 protein expression in, 3150-3159
Staging
in colorectal carcinoma, accuracy of, 2896-2900
in preoperative breast cancer, MRI for, 110-119
TNM system, for renal cell carcinoma, 2868-2875
Standardization, of response criteria for non-Hodgkin's lymphoma, 1244-1253
Stem-cell transplantation
allogeneic
mucositis following, 2446-2453
purine analog conditioning regimens prior to, 1958-1960 (correspondence)
autologous
for aggressive non-Hodgkin's lymphoma, 3003 (correspondence)
mucositis following, 2446-2453
for multiple myeloma, plasmablastic morphology and, 1551-1557
for relapsed or refractory Hodgkin's disease, 3101-3109
in children and adolescents, 825-831
for stage IIIB inflammatory breast cancer, 2006-2014
autologous hematopoietic, for relapsed or refractory Hodgkin's disease in children and adolescents, 825-831
health-related quality of life after, 706-718
and high-dose chemotherapy
for Hodgkin's disease, 222-229
in non-Hodgkin's lymphomas, 423-429
Strategic physician communication, and clinical trials, 3324-3332
SU0020, as signaling inhibitor, 1093-1094 (editorial)
SU101 tyrosine inhibitor
in advanced solid tumors, phase I trial, 1095-1104
and signaling pathway delineation, 1093-1094 (editorial)
Suicide, physician-assisted, views on, 1274-1279

Supraglottic carcinoma, preradiotherapy computed tomography in, 631-637
Surgery
  function-sparing, in soft tissue sarcomas of extremities and trunk, 3252-3259
  local failure in breast cancer following, survival and, 101-109
  MRI for preoperative staging in breast cancer, 110-119
  nephron-sparing, for renal cell carcinoma, 2868-2875
  outcome after methotrexate-vinblastine-doxorubicin-cisplatin treatment in metastatic transitional cell carcinoma, 2546-2552
  prognostic factors and outcome for desmoid tumor after, 158-167
  for prostate cancer, PSA recurrence prediction after, 168-172
  in sarcomatoid renal cell carcinoma, 523-528
Surveillance
  ASCO breast cancer guidelines of 1998, update on, 1080-1082
  colorectal cancer, ASCO guidelines, 1312-1321
Survival. *See also* Cancer patients/survivors
  after relapse in children and adolescents with rhabdomyosarcoma, 3487-3493
  and autoimmunity in metastatic renal cell cancer, 529-533, 1330 (erratum)
  in breast cancer
    hereditary form, *BRC2* germline mutations and, 3396-3402
    and local failure, 101-109
  in chronic myeloid leukemia, 1858-1868
  in limited-stage small-cell lung cancer, 1175-1184
  in long-standing Zollinger-Ellison syndrome, 615-630
  long-term, in metastatic transitional cell carcinoma, 3173-3181
  in metastatic melanoma, psychosocial predictors of, 2256-2263, 3857-3858 (correspondence)
  in metastatic renal cell cancer, 2530-2540
  National Coalition for Cancer Survivorship, 730 (correspondence)
  in non-small-cell lung cancer, 19-24
    stage I, smoking and, 2086-2091
    stage III, effect of trimodality therapeutic approach for, 1185-1193
    unresectable, 3188-3194
  in patients with t(8;21)(q22;q22) karyotype and AML, 3767-3775
  in pediatric medulloblastoma, 3720-3728
  quality-adjusted, after treatment for acute myeloid leukemia in children, 2144-2152
  socioeconomic status and, 2244-2255
Survivin, as prognosis marker in non-small-cell lung cancer, 2100-2104
Susceptibility, and cancer control, 719-725
Symptom management, guidelines for, 361-370
Symptom ratings, in hospitalized advanced cancer patients, reliability of, 3621-3630
Systemic adjuvant therapy, in node-negative breast cancer, 1458-1464

T-cell lymphomas, with cutaneous manifestations, pentostatin therapy for, 3117-3121
t(8;21)(q22;q22) karyotype, high-dose cytarabine for, 3767-3775
Tamoxifen
  bioactivity in low concentrations of, 2633-2638
  for breast cancer
    ASCO risk reduction assessment, 1939-1955
    commentary on clinical prevention trial, 1632-1639
    and effects on sexual functioning, 1488-1492, 3689-3690 (correspondence)
    epirubicin added to, in postmenopausal node-positive breast cancer, 1988-1998
    receptor-positive and lymph node-positive, low-dose therapy for, 1701-1709
    screening for endometrial cancer in patient receiving, 1967-1968 (editorial), 2050-2054
  cisplatin-dacarbazine-carmustine with or without, for malignant melanoma, 1884-1890
  clinical trials with, 2629-2630 (editorial)
    breast cancer prevention, commentary on, 1632-1639
  health related quality of life and, 2659-2669
  and procarbazine in recurrent glioblastoma, 645-650
  and sexuality, 1488-1492, 3689-3690 (correspondence)
Taxane
  effects on epirubicin metabolism in breast cancer, 1132-1140
  myalgias induced by, gabapentin for, 434 (correspondence)
Taxol. *See* Paclitaxel *entries*
TBI (total-body irradiation), for autologous BMT in childhood AML, 3729-3735
Telomerase activity
  and breast cancer outcome, 3075-3081
  in fine-needle aspirates of breast lesions, 2020-2026, 3856-3857 (correspondence)
Temozolomide
  in advanced solid malignancies, phase I and pharmacokinetic study, 2604-2613
  in anaplastic glioma, 2762-2771
Teratomas, immature, resection in children, 2137-2143
Testicular cancer
  carcinoma-in-situ, 173-179
  Leydig cell function in, 173-179
  relapsed or cisplatin-refractory, gemcitabine in, 512-516
Testicular function, after cytotoxic chemotherapy, 1493-1498
Testis
  cancer of. *See* Testicular cancer
  diffuse large-cell lymphoma of, 2854-2858
  seminoma of. *See* Seminoma
TGF-β1. *See* Transforming growth factor-β1
Thoracic irradiation, twice-daily split-course *vs.* once-daily, for small-cell lung cancer, 658-667
Three-dimensional conformal radiotherapy, and neoadjuvant androgen ablation therapy for prostate cancer, 1326-1327 (correspondence)
Thrombocytopenia, in breast cancer, granulocyte colony-stimulating factor effect on, 3025-3032
Thymidine, and intravenous carboplatin in advanced cancer, 2922-2931
Thymidylate synthase, predicting outcome in colorectal cancer treated by FU-based chemotherapy, 1760-1770
Thymoma, 2280-2289 (review article)
  invasive, ifosfamide in, 2737-2744
Thyroid nodules, preoperative evaluation of, 3494-3502
Tissue inhibitors, of metalloproteinases, in small-cell lung cancer, expression and prognostic significance of, 1802-1808
TNM staging system. *See* Tumor-node-metastasis staging system
Tocopherol, for radiation-induced fibrosis, regression and, 3283-3290
Topotecan
  infusion in pretreated ovarian cancer, 2553-2561
  in myelodysplastic syndromes and chronic myelomonocytic leukemia, 2819-2830
  vs. cyclophosphamide-doxorubicin-vincristine in recurrent small-cell lung cancer, 658-667
Total-body irradiation, for autologous BMT in childhood AML, 3729-3735
Transforming growth factor-β1, in gastric cancer, 607-614

Transitional cell carcinoma, metastatic
long-term survival in, 3173-3181
surgical outcome after methotrexate-vinblastine-doxorubicin-cisplatin treatment in, 2546-2552
Transplantation
bone marrow. *See* Bone marrow transplantation
hematopoietic cells, autologous and allogeneic, role in multiple myeloma remissions, 208-215
stem cells. *See* Stem-cell transplantation
Trilateral retinoblastoma, 1829-1837
TrkA, in pancreatic cancer, 2419-2428
Troponin-T levels, in doxorubicin toxicity, 2237-2243
Tubular breast carcinoma, tumor characteristics and clinical outcome of, 1442-1448
Tubulin-binding agents, 1061-1070
Tumor cells, micrometastatic, detection in patients with solid tumors, 1535-1544
Tumor markers. *See also specific markers*
circulating melanoma cells as, 304-311
prognostic significance in endometrial cancer, 1382-1390
Tumor-node-metastasis staging system, for renal cell carcinoma, 2868-2875
Tyrosinase, PCR with, in melanoma, 2562-2571
Tyrosine kinase inhibitors, SU101. *See* SU101 tyrosine inhibitor

Urothelial cancer, gemcitabine plus cisplatin in, 2876-2881
Uterine cervical cancer. *See* Cervical cancer

Vaccine(s)
ALVAC-CEA recombinant, in cancer patients, phase I trial, 332-337
anti-idiotype, for resected colon cancer, 2889-2895
biology of neoplasia and, 1047-1060
van der Schueren, Emmanuel *(In Memoriam)*, 437
Venous access ports, in cancer patients, 1267-1273
Vinblastine therapy
with interferon-alfa-2a, *vs.* vinblastine alone in advanced renal cell cancer, 2859-2867
with methotrexate, in low-dose chemotherapy for childhood desmoid tumor, 1086 (correspondence)
vs. vinblastine plus estramustine phosphate in hormone-refractory prostate cancer, 3160-3166
Vincristine, liposomal, phase I study of, 697-705
Vinorelbine-mitomycin-cisplatin regimen, in non-small-cell lung cancer, 3195-3200
Vinorelbine-paclitaxel regimen, in metastatic breast cancer, 74-81
Vinorelbine therapy, cost analysis in advanced breast cancer, 3081-3090
Vomiting, chemotherapy-related, treatment costs, 344-351
Vorozole, *vs.* megestrol acetate therapy in postmenopausal advanced breast cancer patients, 52-63

Waldenström's macroglobulinemia, fludarabine phosphate for, 546-553
Weight gain, after breast cancer diagnosis, 120-129
WHO (World Health Organization), hematologic malignancies classification by, 3835-3849
Wilms' tumor, nuclear morphometry in, 2123-2126
World Health Organization, hematologic malignancies classification by, 3835-3849

Zollinger-Ellison syndrome, long-standing, natural history of, 615-630
Zubrod, C. Gordon *(In Memoriam)*, 1331-1333